Corporate_JJ
responsibility_NOMZ
Product_NN
Contributing_VBG [WZPRES]
to_PIN
society_NN
highlights_VPRT
GlaxoSmithKline_NN
is_VPRT [PASS]
committed_VBN
to_TO
enhancing_VBG
its_PIT
position_NOMZ
as_IN
Ten_CD
major_JJ
products_NN
,_,
accounting_VBG [PRESP]
for_PIN
7.6_CD
billion_CD
of_PIN
turnover_NN
,_,
a_DT
responsible_JJ
corporate_JJ
citizen_NN
and_CC
to_TO
building_VBG
community_NOMZ
grew_VBD
in_PIN
strong_JJ
double_JJ
digits_NN
,_,
including_VBG
Seretide_NN
Advair_NN
for_PIN
partnerships_NN
._.
We_FPP1
also_RB
know_VPRT [PRIV]
that_THVC
people_NN
want_VPRT
to_TO
be_VB [PASS]
reassured_VBN
asthma_NN
and_CC
chronic_JJ
obstructive_JJ
pulmonary_JJ
disease_NN
COPD_NN
about_IN
the_DT
sound_JJ
ethical_JJ
basis_NN
of_PIN
our_FPP1
business_NOMZ
._.
and_ANDC
Avandia_NN
Avandamet_NN
for_PIN
diabetes_NN
._.
Corporate_JJ
responsibility_NOMZ
We_FPP1
continued_VBD
our_FPP1
support_NN
for_PIN
two_CD
organizations_NOMZ
Top_JJ
pharmaceutical_JJ
products_NN
Product_NN
turnover_NN
breakdown_NN
GSK_NN
is_VPRT [PASS]
committed_VBN
to_TO
connecting_VBG
business_NOMZ
in_PIN
Ireland_NN
and_PHC
France_NN
that_TSUB
provide_VPRT
therapeutic_JJ
decisions_NN
to_PIN
ethical_JJ
,_,
social_JJ
and_PHC
environmental_JJ
recreation_NOMZ
for_PIN
children_NN
with_PIN
cancer_NN
or_CC
serious_JJ
concerns_NN
._.
Solid_JJ
financial_JJ
performance_NN
is_VPRT
closely_RB
illnesses_NOMZ
,_,
and_ANDC
started_VBD
a_DT
three-year_JJ
program_NN
in_PIN
Turnover_NN
Top_NN
5_CD
pharmaceutical_JJ
Top_NN
5_CD
Consumer_NN
Healthcare_NN
connected_VBD
to_PIN
ethical_JJ
business_NOMZ
practices_NN
._.
It_PIT
is_VPRT [BEMA]
not_XX0
five_CD
European_JJ
countries_NN
that_TOBJ
partners_NN
with_PIN
young_JJ
products_NN
total_VPRT
turnover_NN
products_NN
total_VPRT
turnover_NN
just_EMPH
how_RB
much_QUAN
profit_NN
GSK_NN
makes_VPRT
that_DEMO
matters_NN
._.
people_NN
living_VBG [WZPRES]
with_PIN
HIV_NN
AIDS_NN
to_TO
help_VB
alleviate_VB
HIV_NN
-_:
15_CD
%_NN
People_NN
want_VPRT
to_TO
know_VB [PRIV]
how_RB [WHCL]
that_DEMO
profit_NN
is_VPRT [PASS]
made_VBN
._.
Consumer_NN
1_CD
Seretide_NN
Advair_NN
2,214_CD
m_NN [BEMA]
1_CD
Aquafresh_NN
332m_CD
Healthcare_NN
2_CD
Seroxat_NN
Paxil_NN
1,877_CD
m_NN [BEMA]
2_CD
Smoking_VBG
control_NN
325m_CD
3.2_CD
billion_CD
GSK_NN
reports_NN
on_PIN
corporate_JJ
responsibility_NOMZ
issues_NN
In_PIN
the_DT
UK_NN
and_CC
in_PIN
Philadelphia_NN
,_,
our_FPP1
IMPACT_NN
3_CD
Wellbutrin_NN
953m_CD
3_CD
Lucozade_NN
252m_CD
and_ANDC
how_RB
we_FPP1
manage_VPRT
them_TPP3
in_PIN
a_DT
separate_JJ
Awards_NN
rewarded_VBD
the_DT
work_NN
of_PIN
voluntary_JJ
Corporate_JJ
Responsibility_NOMZ
Report_NN
._.
To_TO
guide_VB
community-based_JJ
organizations_NOMZ
tackling_VBG [WZPRES]
issues_NN
4_CD
Avandia_NN
Avandamet_NN
931m_CD
4_CD
Sensodyne_NN
210m_CD
employees_NN
on_PIN
the_DT
standards_NN
to_PIN
which_WDT [PIRE]
the_DT
such_JJ
as_IN
sexual_JJ
abuse_NN
,_,
mental_JJ
health_NN
,_,
elderly_JJ
day_NN
5_CD
Augmentin_NN
825m_CD
5_CD
Ribena_NN
195m_CD
company_NN
is_VPRT [PASS]
committed_VBN
,_,
in_PIN
2003_CD
we_FPP1
developed_VBD
care_NN
and_PHC
disability_NOMZ
._.
In_CONJ
addition_NULL
,_,
we_FPP1
supported_VBD
a_DT
set_NN
of_PIN
corporate_JJ
responsibility_NOMZ
principles_NN
for_PIN
medical_JJ
research_NN
charities_NOMZ
in_PIN
the_DT
UK_NN
focused_VBD
on_PIN
85_CD
%_NN
GSK_NN
which_WDT [WHSUB]
are_VPRT [PASS]
published_VBN
in_PIN
the_DT
Report_NN
._.
neonatal_JJ
care_NN
,_,
epilepsy_NN
,_,
spinal_JJ
and_CC
osteoporosis_NN
Pharmaceutical_NN
research_NN
._.
18.2_CD
billion_CD
The_DT
principles_NN
set_VBN [WZPAST]
out_PIN
the_DT
approach_NN
to_TO
ten_VB
areas_NN
:_:
standards_NN
of_PIN
ethical_JJ
conduct_NN
:_:
leadership_NN
In_PIN
2003_CD
,_,
GSK_NN
donated_VBD
and_CC
advocacy_NN
:_:
research_NN
and_PHC
innovation_NOMZ
:_:
products_NN
Vaccines_NN
New_NN
product_NN
performance_NN
medicines_NN
valued_VBN [WZPAST]
at_PIN
and_CC
customers_NN
:_:
access_NN
to_PIN
medicines_NN
:_:
employment_NOMZ
practices_NN
:_:
human_JJ
rights_NN
:_:
community_NOMZ
investment_NOMZ
:_:
105_CD
million_CD
to_TO
support_VB
caring_NN
for_PIN
the_DT
environment_NOMZ
:_:
and_ANDC
engagement_NOMZ
with_PIN
stakeholders_NN
._.
relief_NN
efforts_NN
in_PIN
over_IN
80_CD
4.6_CD
billion_CD
countries_NN
We_FPP1
continue_VPRT
to_TO
work_VB
towards_PIN
developing_VBG
simple_JJ
ways_NN
to_TO
measure_VB
the_DT
progress_NN
we_FPP1
are_VPRT
making_VBG
in_PIN
39_CD
%_NN
24_CD
%_NN
Turnover_NN
of_PIN
new_JJ
each_QUAN
of_PIN
these_DEMO
areas_NN
._.
The_DT
largest_JJ
part_NN
of_PIN
our_FPP1
community_NOMZ
investment_NOMZ
sales_NN
growth_NN
sales_NN
growth_NN
is_VPRT [BEMA]
the_DT
donation_NOMZ
of_PIN
essential_JJ
medicines_NN
for_PIN
products_NN
,_,
those_DEMO
2,214_CD
m_NN [BEMA]
931m_CD
Community_NOMZ
investment_NOMZ
humanitarian_JJ
relief_NN
efforts_NN
._.
In_PIN
2003_CD
,_,
we_FPP1
SERETIDE_VPRT
ADVAIR_NN
AVANDIA_NN
AVANDAMET_NN
launched_VBD
in_PIN
the_DT
Working_GER
as_IN
partners_NN
with_PIN
under-served_JJ
donated_VBN
medicines_NN
such_JJ
as_IN
antibiotics_NN
valued_VBN
Sales_NN
in_PIN
the_DT
USA_NN
were_VBD
up_RB
GSK_NN
is_VPRT
building_VBG
a_DT
strong_JJ
communities_NOMZ
in_PIN
both_DT
the_DT
developed_VBN
and_CC
the_DT
at_PIN
105_CD
million_CD
to_TO
support_VB
relief_NN
efforts_NN
in_PIN
over_IN
54_CD
%_NN
to_PIN
1,235_CD
million_CD
._.
franchise_NN
in_PIN
the_DT
treatment_NOMZ
last_JJ
five_CD
years_NN
,_,
developing_VBG
world_NN
is_VPRT [BEMA]
an_DT
integral_JJ
activity_NOMZ
that_TOBJ
80_CD
countries_NN
._.
Donations_NOMZ
are_VPRT [PASS]
made_VBN
at_PIN
the_DT
request_NN
Europe_NN
and_PHC
International_NN
of_PIN
diabetes_NN
which_WDT [WHSUB]
affects_VPRT
supports_NN
GSKs_NN
mission_NN
of_PIN
improving_VBG
the_DT
quality_NOMZ
of_PIN
governments_NOMZ
and_CC
major_JJ
charities_NOMZ
._.
Our_FPP1
sales_NN
rose_VBD
18_CD
%_NN
and_CC
37_CD
%_NN
over_IN
175_CD
million_CD
people_NN
increased_VBN [WZPAST]
by_PIN
29_CD
%_NN
._.
GSKs_NN
global_JJ
community_NOMZ
investment_NOMZ
products_NN
were_VBD [BEMA]
among_PIN
the_DT
first_JJ
to_TO
be_VB [PASS]
airlifted_VBN
respectively_RB
._.
activities_NOMZ
in_PIN
2003_CD
were_VBD [PASS]
valued_VBN
at_PIN
338_CD
million_CD
._.
This_DEMO
into_PIN
Iraq_NN
following_VBG [WZPRES]
the_DT
start_NN
of_PIN
the_DT
conflict_NN
._.
of_PIN
the_DT
top_JJ
ten_NN
selling_VBG [WZPRES]
Top_NN
Kenya_NN
AIDS_NN
group_NN
GSKs_NN
pioneering_JJ
Positive_NN
Action_NOMZ
program_NN
has_VPRT [PEAS]
included_VBN
125_CD
million_CD
for_PIN
the_DT
Patient_NN
Assistance_NN
pharmaceutical_JJ
products_NN
supported_VBD
some_QUAN
28_CD
organizations_NOMZ
in_PIN
34_CD
countries_NN
in_PIN
Program_NN
and_CC
other_JJ
medicine_NN
donations_NOMZ
for_PIN
low_JJ
GSKs_NN
science_NN
education_NOMZ
program_NN
aims_VPRT
to_TO
give_VB
worldwide_NN
._.
2003_CD
,_,
such_JJ
as_IN
the_DT
Movement_NOMZ
of_PIN
Men_NN
Against_PIN
AIDS_NN
in_PIN
income_NN
groups_NN
in_PIN
the_DT
USA_NN
see_VB [PRIV]
page_NN
9_CD
,_,
plus_PIN
105_CD
science_NN
context_NN
and_CC
enhance_VB
science_NN
teaching_GER
._.
Community-based_JJ
organizations_NOMZ
are_VPRT [BEMA]
frequently_RB
the_DT
sole_JJ
source_NN
of_PIN
education_NOMZ
,_,
support_NN
,_,
homemillion_NN
of_PIN
humanitarian_JJ
product_NN
donations_NOMZ
._.
We_FPP1
continued_VBD
our_FPP1
INSPIRE_NN
INnovative_NN
Scheme_NN
based_VBN
care_NN
and_PHC
treatment_NOMZ
for_PIN
people_NN
living_VBG [WZPRES]
with_PIN
HIV_NN
AIDS_NN
for_PIN
Post-doctorates_NN
In_PIN
Research_NN
and_PHC
Education_NOMZ
Top_NN
Consumer_NN
Healthcare_NN
products_NN
in_PIN
developing_VBG
countries_NN
._.
New_NN
product_NN
launches_VPRT
Our_FPP1
programs_NN
reach_VPRT
over_IN
100_CD
countries_NN
and_PHC
partnership_NN
to_TO
support_VB
specialist_NN
science_NN
schools_NN
Left_VBN
PHASE_NN
in_PIN
Nicaragua_NN
focus_NN
on_PIN
improving_VBG
health_NN
and_PHC
education_NOMZ
._.
We_FPP1
also_RB
supported_VBD
Science_NN
Across_PLACE
the_DT
GSKs_NN
Personal_NN
Hygiene_NN
And_PHC
Sanitation_NOMZ
Education_NOMZ
our_FPP1
three_CD
major_JJ
public_JJ
health_NN
programs_NN
are_VPRT
World_NN
,_,
a_DT
web-based_JJ
educational_JJ
resource_NN
PHASE_NN
is_VPRT [BEMA]
a_DT
simple_JJ
handwashing_GER
program_NN
that_DEMO
During_PIN
2003_CD
,_,
GSK_NN
Wellbutrin_NN
XL_NN
Excellent_NN
uptake_NN
continues_VPRT
with_PIN
the_DT
new_JJ
in_PIN
lymphatic_JJ
filariasis_NN
,_,
HIV_NN
AIDS_NN
and_PHC
malaria_NN
see_VPRT [PRIV]
program_NN
that_TSUB
promotes_VPRT
discussion_NN
of_PIN
science_NN
reduces_VPRT
diarrhoea-related_JJ
disease_NN
and_PHC
deaths_NN
in_PIN
school_NN
formulation_NOMZ
accounting_GER
for_PIN
40_CD
%_NN
of_PIN
new_JJ
children_NN
._.
It_PIT
has_VPRT [SPAU] [PEAS]
now_TIME
expanded_VBN
from_PIN
Kenya_NN
,_,
Nicaragua_NN
obtained_VBD
regulatory_JJ
page_NN
11_CD
,_,
our_FPP1
businesses_NOMZ
are_VPRT [SPAU] [PASS]
actively_RB
involved_VBN
in_PIN
issues_NN
within_PIN
and_CC
between_PIN
schools_NN
in_PIN
almost_DWNT
100_CD
Wellbutrin_NN
prescriptions_NOMZ
._.
and_ANDC
Peru_NN
to_TO
include_VB
Zambia_NN
and_CC
is_VPRT [PASS]
incorporated_VBN
into_PIN
the_DT
numerous_JJ
activities_NOMZ
that_TSUB
help_VPRT
build_VB
healthy_JJ
countries_NN
._.
In_PIN
the_DT
USA_NN
,_,
our_FPP1
support_NN
for_PIN
the_DT
awardapproval_NN
for_PIN
ten_NN
important_JJ
school_NN
curriculum_NN
in_PIN
some_QUAN
countries_NN
._.
winning_VBG
Science_NN
in_PIN
the_DT
Summer_NN
initiative_NN
entered_VBD
Levitra_NN
Launched_NN
in_PIN
the_DT
USA_NN
in_PIN
August_NN
2003_CD
and_CC
in_PIN
new_JJ
products_NN
and_CC
new_JJ
Europe_NN
in_PIN
the_DT
first_JJ
half_NN
of_PIN
the_DT
year_NN
,_,
Levitra_NN
is_VPRT
Right_RB
IMPACT_NN
SHARE_VPRT
its_PIT
17th_JJ
year_NN
with_PIN
more_EMPH
than_PIN
60,000_CD
children_NN
GSKs_NN
IMPACT_NN
Awards_NN
in_PIN
the_DT
UK_NN
and_CC
the_DT
USA_NN
and_CC
the_DT
making_VBG
strong_JJ
market_NN
share_NN
gains_NN
._.
indications_NOMZ
including_VBG [WZPRES]
Levitra_NN
In_PIN
healthcare_NN
,_,
many_QUAN
of_PIN
our_FPP1
grants_NN
target_NN
voluntary_JJ
experiencing_VBG
this_DEMO
free_JJ
,_,
library-based_JJ
science_NN
2003_CD
SHARE_NN
Awards_NN
in_PIN
the_DT
USA_NN
reward_NN
excellence_NN
in_PIN
community-based_JJ
organizations_NOMZ
working_VBG [WZPRES]
in_PIN
health_NN
education_NOMZ
program_NN
._.
for_PIN
erectile_JJ
dysfunction_NOMZ
,_,
healthcare_NN
,_,
enabling_VBG
community-based_JJ
organizations_NOMZ
to_PIN
Lexiva_NN
A_NN
new_JJ
protease_NN
inhibitor_NN
launched_VBN [WZPAST]
in_PIN
December_NN
continue_VPRT
their_TPP3
valuable_JJ
work_NN
and_PHC
access_NN
ongoing_JJ
education_NOMZ
and_CC
often_RB
with_PIN
children_NN
._.
In_PIN
2003_CD
,_,
these_DEMO
2003_CD
for_PIN
the_DT
treatment_NOMZ
of_PIN
HIV_NN
._.
ranged_VBD
from_PIN
a_DT
sexual_JJ
health_NN
awareness_NOMZ
program_NN
GSKs_NN
commitment_NOMZ
to_PIN
communities_NOMZ
increases_NN
Lexiva_NN
for_PIN
HIV_NN
AIDS_NN
and_CC
for_PIN
street_NN
children_NN
in_PIN
Panama_NN
to_PIN
a_DT
scheme_NN
that_TOBJ
the_DT
number_NN
of_PIN
people_NN
who_WP [WHSUB]
benefit_VPRT
from_PIN
the_DT
Advair_NN
FDA_NN
approval_NN
for_PIN
use_NN
in_PIN
the_DT
treatment_NOMZ
of_PIN
ensures_VPRT [SUAV] [PRIV]
continuity_NOMZ
of_PIN
care_NN
for_PIN
medically_RB
under_IN
companys_NN
success_NN
and_CC
ensures_VPRT [SUAV] [PRIV]
that_THVC
the_DT
spirit_NN
Advair_NN
for_PIN
COPD_NN
COPD_NN
which_WDT [WHSUB]
is_VPRT [BEMA]
the_DT
fourth_JJ
leading_VBG
cause_NN
of_PIN
served_VBN
,_,
high-risk_JJ
children_NN
in_PIN
the_DT
USA_NN
._.
of_PIN
do_VPRT
more_EMPH
,_,
feel_VB [PRIV]
better_RB
,_,
live_VPRT
longer_RB
means_VPRT [PRIV]
death_NN
worldwide_NN
._.
14_CD
Annual_JJ
Review_NN
2003_CD
Annual_JJ
Review_NN
2003_CD
15_CD
The_DT
Board_NN
The_DT
Corporate_NN
Executive_NN
Team_NN
The_NN
Board_NN
of_PIN
Directors_NN
is_VPRT [BEMA]
ultimately_RB
accountable_PRED
for_PIN
the_DT
Groups_NN
activities_NOMZ
,_,
strategy_NN
The_DT
executive_NN
management_NOMZ
of_PIN
the_DT
Group_NN
is_VPRT [BEMA]
through_PIN
the_DT
Corporate_NN
Executive_NN
Team_NN
CET_NN
,_,
and_ANDC
financial_JJ
performance_NN
._.
comprising_VBG [PRESP]
the_DT
Chief_NN
Executive_NN
Officer_NN
,_,
the_DT
Chief_NN
Financial_NN
Officer_NN
and_CC
other_JJ
senior_JJ
managers_NN
._.
Sir_NN
Christopher_NN
Hogg_NN
Jean-Pierre_NN
Garnier_NN
John_NN
Coombe_NN
Michle_NN
Barzach_NN
Lawrence_NN
Culp_NN
Crispin_NN
Davis_NN
Sir_NN
Peter_NN
Job_NN
`_``
Jean-Pierre_NN
Garnier_NN
Rupert_NN
Bondy_NN
Ford_NN
Calhoun_NN
John_NN
Coombe_NN
Marc_NN
Dunoyer_NN
Russell_NN
Greig_NN
Dan_NN
Phelan_NN
John_NN
McArthur_NN
Donald_NN
McHenry_NN
Sir_NN
Ian_NN
Prosser_NN
Ronaldo_NN
Schmitz_NN
Lucy_NN
Shapiro_NN
Sir_NN
Robert_NN
Wilson_NN
Tachi_NN
Yamada_NN
David_NN
Pulman_NN
David_NN
Stout_NN
Chris_NN
Viehbacher_NN
Andrew_NN
Witty_NN
Tachi_NN
Yamada_NN
Jennie_NN
Younger_NN
Jack_NN
Ziegler_NN
Sir_NN
Christopher_NN
Hogg_NN
Aged_VBD
67_CD
Michle_NN
Barzach_NN
Aged_VBD
60_CD
Sir_NN
Peter_NN
Job_NN
Aged_VBD
62_CD
Lucy_NN
Shapiro_NN
Aged_VBD
63_CD
Jean-Pierre_NN
Garnier_NN
Marc_NN
Dunoyer_NN
David_NN
Stout_NN
Jennie_NN
Younger_NN
Appointed_VBN [WZPAST]
on_PIN
23rd_JJ
May_POMD
2000_CD
Appointed_VBN
on_PIN
23rd_JJ
May_POMD
2000_CD
Appointed_VBN
on_PIN
23rd_JJ
May_POMD
2000_CD
Appointed_VBN
on_PIN
23rd_JJ
May_POMD
2000_CD
Chief_NN
Executive_NN
Officer_NN
President_NN
President_NN
Senior_NN
Vice_NN
President_NN
Non-Executive_NN
Chairman_NN
._.
Sir_NN
Peter_NN
was_VBD [BEMA]
Non-Executive_JJ
Director_NN
._.
Lucy_NN
Shapiro_NN
As_IN
Chief_NN
Executive_NN
Officer_NN
,_,
JP_NN
is_VPRT
Pharmaceuticals_NN
Japan_NN
Pharmaceutical_NN
Operations_NOMZ
Corporate_NN
Communications_NOMZ
was_VBD [BEMA]
formerly_TIME
a_DT
Non-Executive_JJ
Director_NN
was_VBD [BEMA]
formerly_TIME
a_DT
Non-Executive_JJ
Director_NN
formerly_TIME
a_DT
Non-Executive_JJ
Director_NN
of_PIN
Glaxo_NN
was_VBD [BEMA]
formerly_TIME
a_DT
Non-Executive_JJ
Director_NN
of_PIN
responsible_JJ
for_PIN
the_DT
management_NOMZ
of_PIN
Marc_NN
was_VBD [PASS]
appointed_VBN
President_NN
,_,
David_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
the_DT
global_JJ
&_CC
Community_NOMZ
Partnerships_NN
of_PIN
SmithKline_NN
Beecham_NN
plc._NN
._.
He_TPP3
is_VPRT
Nonof_NN
Glaxo_NN
Wellcome_NN
plc._NN
._.
She_TPP3
is_VPRT [BEMA]
a_DT
member_NN
Wellcome_NN
plc._NN
._.
He_TPP3
is_VPRT [BEMA]
a_DT
Non-Executive_JJ
SmithKline_NN
Beecham_NN
plc._NN
._.
He_TPP3
oversees_VPRT
all_QUAN
operational_JJ
Pharmaceuticals_NN
Japan_NN
in_PIN
March_NN
2003_CD
._.
He_TPP3
pharmaceuticals_NN
and_PHC
vaccines_NN
businesses_NOMZ
._.
Jennie_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
the_DT
Groups_NN
Executive_NN
Chairman_NN
of_PIN
Reuters_NN
Group_NN
of_PIN
the_DT
International_NN
Cooperation_NOMZ
High_NN
Director_NN
of_PIN
Schroders_NN
plc_NN
,_,
Shell_NN
Transport_NN
Professor_NN
of_PIN
Cancer_NN
Research_NN
in_PIN
the_DT
aspects_NN
including_VBG [WZPRES]
establishing_VBG [PRIV]
policies_NN
,_,
joined_VBD
the_DT
Group_NN
in_PIN
1999_CD
and_CC
was_VBD [BEMA]
Senior_PRED
He_TPP3
joined_VBD
SmithKline_NN
Beecham_NN
in_PIN
1996_CD
internal_JJ
and_PHC
external_JJ
communications_NOMZ
,_,
PLC_NN
and_CC
a_DT
member_NN
of_PIN
the_DT
Supervisory_NN
Council_NN
,_,
Chairman_NN
of_PIN
the_DT
Board_NN
of_PIN
and_CC
Trading_GER
Company_NN
plc_NN
,_,
TIBCO_NN
Software_NN
Department_NOMZ
of_PIN
Developmental_NN
Biology_NN
objectives_NN
and_PHC
initiatives_NN
,_,
and_ANDC
directs_VPRT
Vice_NN
President_NN
and_PHC
Regional_NN
Director_NN
,_,
as_IN
head_NN
of_PIN
US_FPP1
Sales_NN
and_PHC
Marketing_GER
,_,
its_PIT
image_NN
and_PHC
partnerships_NN
with_PIN
global_JJ
Board_NN
of_PIN
Air_NN
Liquide_NN
S._NN
A._NN
and_PHC
Chairman_NN
Equilibres_NN
et_NN
Populations_NOMZ
and_PHC
Director_NN
of_PIN
Inc._NN
and_PHC
Instinet_NN
Group_NN
Inc._NN
._.
He_TPP3
is_VPRT [BEMA]
also_RB
a_DT
and_CC
Director_NN
of_PIN
the_DT
Beckman_NN
Center_NN
for_PIN
long-term_JJ
strategy_NN
._.
He_TPP3
was_VBD
formerly_TIME
Japan_NN
,_,
until_IN
his_TPP3
current_JJ
appointment_NOMZ
._.
and_ANDC
was_VBD
President_NN
,_,
US_FPP1
Pharmaceuticals_NN
communities_NOMZ
._.
She_TPP3
joined_VBD
Glaxo_NN
of_PIN
The_DT
Royal_NN
National_NN
Theatre_NN
._.
the_DT
Board_NN
of_PIN
Project_NN
Hope_NN
._.
International_NN
member_NN
of_PIN
the_DT
Supervisory_NN
Boards_NN
of_PIN
Molecular_JJ
and_PHC
Genetic_JJ
Medicine_NN
at_PIN
the_DT
Chief_NN
Executive_NN
Officer_NN
of_PIN
SmithKline_NN
until_IN
his_TPP3
current_JJ
appointment_NOMZ
in_PIN
Wellcome_NN
in_PIN
1996_CD
as_IN
Director_NN
consultant_NN
in_PIN
health_NN
strategy_NN
,_,
she_TPP3
was_VBD
Deutsche_NN
Bank_NN
AG_NN
and_PHC
Bertelsmann_NN
AG_NN
._.
Stanford_NN
University_NOMZ
School_NN
of_PIN
Medicine_NN
Russell_NN
Greig_NN
Jean-Pierre_NN
Garnier_NN
Aged_VBD
56_CD
Beecham_NN
,_,
having_VBG [PEAS]
joined_VBN
the_DT
Group_NN
January_NN
2003_CD
._.
of_PIN
Investor_NN
Relations_NOMZ
._.
formerly_TIME
French_NN
Minister_NN
of_PIN
Health_NN
and_CC
and_CC
a_DT
Non-Executive_JJ
Director_NN
of_PIN
Anacor_NN
President_NN
Appointed_VBN [WZPAST]
on_PIN
23rd_JJ
May_POMD
2000_CD
John_NN
McArthur_NN
Aged_VBD
69_CD
in_PIN
1990_CD
._.
Pharmaceuticals_NN
Inc._NN
._.
She_TPP3
holds_VPRT [PRIV]
a_DT
PhD_NN
in_PIN
Pharmaceuticals_NN
International_NN
Chris_NN
Viehbacher_NN
Jack_NN
Ziegler_NN
Chief_NN
Executive_NN
Officer_NN
._.
JP_NN
Garnier_NN
was_VBD [PASS]
Appointed_VBN
on_PIN
23rd_JJ
May_POMD
2000_CD
molecular_JJ
biology_NN
from_PIN
the_DT
Albert_NN
Rupert_NN
Bondy_NN
Russell_NN
leads_VPRT
the_DT
pharmaceutical_JJ
President_NN
President_NN
appointed_VBD
an_DT
Executive_NN
Director_NN
of_PIN
Lawrence_NN
Culp_NN
Aged_VBD
40_CD
Non-Executive_JJ
Director_NN
._.
John_NN
McArthur_NN
Einstein_NN
College_NN
of_PIN
Medicine_NN
._.
Senior_JJ
Vice_NN
President_NN
and_PHC
General_NN
operations_NOMZ
outside_PLACE
the_DT
USA_NN
and_CC
most_EMPH
US_FPP1
Pharmaceuticals_NN
Consumer_NN
Healthcare_NN
SmithKline_NN
Beecham_NN
plc_NN
in_PIN
1992_CD
,_,
and_ANDC
Appointed_VBN
on_PIN
1st_CD
July_NN
2003_CD
was_VBD [BEMA]
formerly_TIME
a_DT
Non-Executive_JJ
Director_NN
of_PIN
Counsel_NN
of_PIN
Europe_NN
,_,
covering_VBG
more_EMPH
than_PIN
100_CD
Chris_NN
has_VPRT [PEAS]
been_VBN [BEMA]
responsible_PRED
for_PIN
US_FPP1
Jack_NN
is_VPRT
head_NN
of_PIN
the_DT
global_JJ
Consumer_NN
became_VBD
Chief_NN
Executive_NN
Officer_NN
in_PIN
April_NN
Non-Executive_NN
Director_NN
._.
Lawrence_NN
Culp_NN
Glaxo_NN
Wellcome_NN
plc._NN
._.
He_TPP3
is_VPRT [BEMA]
a_DT
Non-Executive_JJ
Sir_NN
Robert_NN
Wilson_NN
Aged_VBD
60_CD
Rupert_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
legal_JJ
matters_NN
countries_NN
._.
He_TPP3
joined_VBD
the_DT
Group_NN
in_PIN
1980_CD
Pharmaceuticals_NN
since_OSUB
January_NN
2003_CD
._.
Healthcare_NN
business_NOMZ
,_,
which_WDT [SERE]
produces_VPRT
oral_JJ
2000_CD
._.
He_TPP3
is_VPRT [BEMA]
a_DT
Non-Executive_JJ
Director_NN
of_PIN
is_VPRT
President_NN
and_PHC
CEO_NN
of_PIN
Danaher_NN
Director_NN
of_PIN
BCE_NN
Inc._NN
._.
BCE_NN
Emergis_NN
Inc._NN
._.
Appointed_VBN [PASTP]
on_PIN
1st_CD
November_NN
2003_CD
across_PLACE
the_DT
Group_NN
,_,
together_RB
with_PIN
and_CC
was_VBD [BEMA]
Senior_JJ
Vice_NN
President_NN
,_,
He_TPP3
joined_VBD
Wellcome_NN
in_PIN
1988_CD
and_CC
healthcare_NN
,_,
over-the-counter_JJ
medicines_NN
United_NN
Technologies_NN
Corporation_NOMZ
and_CC
a_DT
Corporation_NOMZ
._.
Prior_RB
to_TO
joining_VBG
Danaher_NN
,_,
Cabot_NN
Corporation_NOMZ
,_,
HCA_NN
Corporation_NOMZ
,_,
Koc_NN
Non-Executive_NN
Director_NN
._.
Sir_NN
Robert_NN
is_VPRT [BEMA]
Nonenvironmental_PRED
,_,
health_NN
and_PHC
safety_NN
issues_NN
,_,
Worldwide_NN
Business_NOMZ
Development_NOMZ
for_PIN
became_VBD
Director_NN
,_,
Continental_NN
Europe_NN
,_,
and_ANDC
nutritional_JJ
healthcare_NN
products_NN
._.
He_TPP3
member_NN
of_PIN
the_DT
Board_NN
of_PIN
Trustees_NN
of_PIN
the_DT
he_TPP3
held_VBD [PRIV]
positions_NOMZ
in_PIN
Accenture_NN
,_,
Holdings_GER
A._NN
S._NN
Rohm_NN
and_PHC
Haas_NN
Company_NN
,_,
Executive_NN
Chairman_NN
of_PIN
BG_NN
Group_NN
plc_NN
and_PHC
insurance_NN
and_PHC
security_NOMZ
._.
He_TPP3
was_VBD [BEMA]
a_DT
lawyer_NN
R&D_NN
prior_RB
to_PIN
his_TPP3
current_JJ
appointment_NOMZ
at_PIN
Glaxo_NN
Wellcome_NN
in_PIN
1999_CD
._.
He_TPP3
was_VBD [PASS]
joined_VBN
SmithKline_NN
Beecham_NN
in_PIN
1991_CD
and_CC
Eisenhower_NN
Exchange_NN
Fellowships_NN
._.
Telsat_NN
Canada_NN
and_CC
The_DT
AES_NN
Corporation_NOMZ
._.
the_DT
Economist_NN
Group_NN
and_CC
was_VBD [BEMA]
previously_TIME
in_PIN
private_JJ
practice_NN
before_IN
joining_VBG
in_PIN
March_NN
2003_CD
._.
responsible_JJ
for_PIN
GlaxoSmithKlines_NN
in_PIN
1998_CD
was_VBD [PASS]
appointed_VBN
President_NN
of_PIN
the_DT
holds_VPRT [PRIV]
a_DT
PhD_NN
in_PIN
pharmacology_NN
from_PIN
the_DT
He_TPP3
is_VPRT [BEMA]
also_RB
Senior_JJ
Advisor_NN
to_PIN
the_DT
President_NN
Executive_NN
Chairman_NN
of_PIN
Rio_NN
Tinto_NN
plc._NN
._.
Crispin_NN
Davis_NN
Aged_VBD
54_CD
SmithKline_NN
Beecham_NN
in_PIN
1995_CD
._.
European_JJ
Pharmaceuticals_NN
business_NOMZ
Consumer_NN
Healthcare_NN
business_NOMZ
._.
University_NOMZ
of_PIN
Louis_NN
Pasteur_NN
in_PIN
France_NN
and_CC
an_DT
of_PIN
the_DT
World_NN
Bank_NN
._.
Dan_NN
Phelan_NN
Appointed_VBN [WZPAST]
on_PIN
1st_CD
July_NN
2003_CD
Tachi_NN
Yamada_NN
Aged_VBD
58_CD
before_IN
his_TPP3
current_JJ
appointment_NOMZ
._.
MBA_NN
from_PIN
Stanford_NN
University_NOMZ
in_PIN
the_DT
USA_NN
._.
Ford_NN
Calhoun_NN
Senior_NN
Vice_NN
President_NN
Other_JJ
members_NN
Non-Executive_JJ
Director_NN
._.
Crispin_NN
Davis_NN
is_VPRT
Donald_NN
McHenry_NN
Aged_VBD
67_CD
Appointed_VBN
on_PIN
1st_CD
January_NN
2004_CD
Chief_NN
Information_NOMZ
Officer_NN
Human_NN
Resources_NN
Andrew_NN
Witty_NN
Howard_NN
Pien_NN
left_VBD
the_DT
Group_NN
on_PIN
31st_CD
John_NN
Coombe_NN
Aged_VBD
58_CD
Chief_NN
Executive_NN
of_PIN
Reed_NN
Elsevier_NN
PLC._NN
._.
Appointed_VBN [PASTP]
on_PIN
23rd_JJ
May_POMD
2000_CD
Chairman_NN
,_,
Research_NN
&_CC
Development_NOMZ
._.
Ford_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
information_NOMZ
Dan_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
benefits_NN
,_,
President_NN
March_NN
2003_CD
to_TO
pursue_VB
another_DT
role_NN
in_PIN
Appointed_VBN
on_PIN
23rd_JJ
May_POMD
2000_CD
Prior_RB
to_PIN
that_DEMP
,_,
he_TPP3
was_VBD
Chief_NN
Executive_NN
of_PIN
Non-Executive_NN
Director_NN
._.
Donald_NN
McHenry_NN
Tachi_NN
Yamada_NN
was_VBD [BEMA]
formerly_TIME
a_DT
Nontechnology_NN
,_,
a_DT
global_JJ
function_NOMZ
that_DEMO
compensation_NOMZ
,_,
recruitment_NOMZ
,_,
organization_NOMZ
Pharmaceuticals_NN
Europe_NN
the_DT
pharmaceutical_JJ
industry_NN
._.
Bob_NN
Ingram_NN
Chief_NN
Financial_NN
Officer_NN
._.
John_NN
Coombe_NN
was_VBD
Aegis_NN
Group_NN
plc_NN
,_,
which_WDT [SERE]
he_TPP3
joined_VBD
from_PIN
was_VBD [BEMA]
formerly_TIME
a_DT
Non-Executive_JJ
Director_NN
Executive_NN
Director_NN
,_,
and_ANDC
subsequently_TIME
enables_VPRT
key_JJ
business_NOMZ
processes_VPRT
across_PLACE
all_QUAN
development_NOMZ
,_,
leadership_NN
development_NOMZ
Andrew_NN
has_VPRT [PEAS]
been_VBN [BEMA]
responsible_PRED
for_PIN
the_DT
continues_VPRT
to_TO
work_VB
part-time_JJ
as_IN
Vice_NN
formerly_TIME
an_DT
Executive_NN
Director_NN
of_PIN
Glaxo_NN
Guinness_NOMZ
plc_NN
,_,
where_RB
he_TPP3
was_VBD
Group_NN
of_PIN
SmithKline_NN
Beecham_NN
plc._NN
._.
His_TPP3
other_JJ
an_DT
Executive_NN
Director_NN
,_,
of_PIN
SmithKline_NN
parts_NN
of_PIN
the_DT
Group_NN
._.
With_PIN
doctoral_JJ
and_CC
and_CC
succession_NN
planning_GER
,_,
human_JJ
Groups_NN
pharmaceuticals_NN
operations_NOMZ
in_PIN
Chairman_NN
of_PIN
Pharmaceuticals_NN
,_,
acting_VBG
Wellcome_NN
plc_NN
where_RB
he_TPP3
was_VBD [BEMA]
responsible_PRED
Managing_VBG
Director_NN
of_PIN
United_NN
Distillers_NN
Non-Executive_JJ
directorships_NN
include_VPRT
Beecham_NN
plc._NN
._.
Prior_RB
to_TO
joining_VBG
SmithKline_NN
post-doctoral_JJ
training_GER
in_PIN
microbiology_NN
,_,
resource_NN
information_NOMZ
systems_NN
and_PHC
Europe_NN
since_OSUB
January_NN
2003_CD
._.
He_TPP3
joined_VBD
as_IN
special_JJ
advisor_NN
to_PIN
the_DT
Group_NN
and_CC
for_PIN
Finance_NN
and_PHC
Investor_NN
Relations_NOMZ
._.
He_TPP3
is_VPRT
and_CC
a_DT
member_NN
of_PIN
the_DT
main_JJ
board_NN
of_PIN
The_DT
Coca-Cola_NN
Company_NN
,_,
FleetBoston_NN
Beecham_NN
he_TPP3
was_VBD
Chairman_NN
of_PIN
the_DT
genetics_NN
,_,
biomathematics_NN
and_PHC
computer_NN
employee_NN
health_NN
management_NOMZ
._.
He_TPP3
Glaxo_NN
in_PIN
1985_CD
and_CC
at_PIN
GlaxoSmithKline_NN
attending_VBG [WZPRES]
CET_NN
meetings_GER
in_PIN
that_DEMO
capacity_NOMZ
._.
a_DT
member_NN
of_PIN
the_DT
Supervisory_NN
Board_NN
of_PIN
Guinness_NOMZ
plc._NN
._.
He_TPP3
spent_VBD
his_TPP3
early_TIME
career_NN
Financial_NN
Corporation_NOMZ
,_,
International_NN
Department_NOMZ
of_PIN
Internal_NN
Medicine_NN
at_PIN
the_DT
science_NN
,_,
Ford_NN
joined_VBD
Smith_NN
Kline_NN
&_CC
French_NN
was_VBD [BEMA]
a_DT
lawyer_NN
in_PIN
private_JJ
practice_NN
before_IN
was_VBD [BEMA]
Senior_JJ
Vice_NN
President_NN
,_,
Asia_NN
Pacific_NN
,_,
Siemens_NN
AG_NN
and_CC
the_DT
Code_NN
Committee_NN
of_PIN
with_PIN
Procter_NN
&_CC
Gamble_NN
._.
Paper_NN
Company_NN
and_PHC
AT&T_NN
Corporation_NOMZ
._.
University_NOMZ
of_PIN
Michigan_NN
Medical_NN
School_NN
in_PIN
1984_CD
._.
joining_VBG
Smith_NN
Kline_NN
&_CC
French_NN
in_PIN
1981_CD
until_IN
his_TPP3
current_JJ
appointment_NOMZ
._.
and_ANDC
Physician-in-Chief_NN
of_PIN
the_DT
University_NOMZ
Sir_NN
Ian_NN
Prosser_NN
Aged_VBD
60_CD
and_CC
in_PIN
1994_CD
was_VBD [PASS]
appointed_VBN
Senior_NN
of_PIN
Michigan_NN
Medical_NN
Center_NN
._.
He_TPP3
is_VPRT [BEMA]
a_DT
John_NN
Coombe_NN
Tachi_NN
Yamada_NN
Appointed_VBN [WZPAST]
on_PIN
23rd_JJ
May_POMD
2000_CD
Vice_NN
President_NN
and_PHC
Director_NN
,_,
Human_NN
member_NN
of_PIN
the_DT
Board_NN
of_PIN
diaDexus_NN
,_,
Inc._NN
._.
Chief_NN
Financial_NN
Officer_NN
Chairman_NN
Non-Executive_NN
Director_NN
._.
Sir_NN
Ian_NN
was_VBD
Resources_NN
,_,
SmithKline_NN
Beecham_NN
._.
and_ANDC
is_VPRT [BEMA]
a_DT
Trustee_NN
of_PIN
the_DT
Rockefeller_NN
As_IN
head_NN
of_PIN
the_DT
finance_NN
function_NOMZ
,_,
John_NN
is_VPRT
Research_NN
&_CC
Development_NOMZ
formerly_TIME
a_DT
Non-Executive_JJ
Director_NN
Brothers_NN
Fund_NN
._.
responsible_JJ
for_PIN
activities_NOMZ
such_JJ
as_IN
financial_JJ
David_NN
Pulman_NN
Tachi_NN
leads_VPRT
the_DT
Groups_NN
complex_JJ
business_NOMZ
of_PIN
SmithKline_NN
Beecham_NN
plc._NN
._.
He_TPP3
was_VBD
reporting_VBG [PUBV]
and_CC
control_NN
,_,
tax_NN
and_PHC
treasury_NN
,_,
President_NN
of_PIN
drug_NN
discovery_NN
and_PHC
development_NOMZ
,_,
Membership_NN
of_PIN
Board_NN
Committees_NN
is_VPRT [PASS]
indicated_VBN [PRIV]
in_PIN
the_DT
following_VBG
table_NN
:_:
Chairman_NN
of_PIN
Six_CD
Continents_NN
PLC_NN
and_CC
Other_JJ
Directors_NN
investor_NN
relations_NOMZ
,_,
finance_NN
systems_NN
,_,
Global_JJ
Manufacturing_GER
&_CC
Supply_NN
creating_VBG [WZPRES]
new_JJ
medicines_NN
through_PIN
the_DT
World_NN
Travel_NN
&_CC
Tourism_NN
Council_NN
and_PHC
Sir_NN
Roger_NN
Hurn_NN
,_,
Non-Executive_NN
Deputy_NN
internal_JJ
audit_NN
and_CC
real_JJ
estate_NN
._.
He_TPP3
joined_VBD
David_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
the_DT
global_JJ
research_NN
._.
He_TPP3
joined_VBD
SmithKline_NN
Beecham_NN
is_VPRT [BEMA]
Non-Executive_JJ
Deputy_NN
Chairman_NN
of_PIN
BP_NN
Chairman_NN
and_PHC
Paul_NN
Allaire_NN
,_,
NonGlaxo_NN
in_PIN
1986_CD
as_IN
Group_NN
Financial_NN
manufacturing_GER
and_PHC
supply_NN
chain_NN
in_PIN
1994_CD
as_IN
a_DT
Non-Executive_JJ
member_NN
of_PIN
plc._NN
._.
He_TPP3
is_VPRT [BEMA]
a_DT
member_NN
of_PIN
the_DT
CBI_NN
Executive_NN
Director_NN
,_,
both_DT
retired_VBN
from_PIN
Controller_NN
and_CC
was_VBD [PASS]
appointed_VBN
Group_NN
network_NN
._.
He_TPP3
joined_VBD
Glaxo_NN
in_PIN
1978_CD
and_CC
the_DT
Board_NN
and_CC
became_VBD
Chairman_NN
,_,
R&D_NN
,_,
Presidents_NN
Committee_NN
._.
Finance_NN
Director_NN
in_PIN
1992_CD
._.
was_VBD [BEMA]
responsible_PRED
for_PIN
the_DT
North_PLACE
American_JJ
Pharmaceuticals_NN
in_PIN
1999_CD
._.
He_TPP3
was_VBD
Audit_NN
M_NN
M_NN
C_NN
M_NN
supply_NN
network_NN
,_,
manufacturing_VBG
strategy_NN
appointed_VBN [WZPAST]
to_PIN
the_DT
Board_NN
of_PIN
Directors_NN
Corporate_JJ
Administration_NOMZ
M_NN
M_NN
M_NN
M_NN
M_NN
M_NN
M_NN
M_NN
M_NN
M_NN
M_NN
M_NN
M_NN
M_NN
Ronaldo_NN
Schmitz_NN
Aged_VBD
65_CD
&_CC
Transactions_NOMZ
and_PHC
logistics_NN
until_IN
his_TPP3
current_JJ
on_PIN
1st_CD
January_NN
2004_CD
._.
Appointed_VBN [PASTP]
on_PIN
23rd_JJ
May_POMD
2000_CD
Corporate_JJ
Responsibility_NOMZ
M_NN
M_NN
C_NN
M_NN
appointment_NOMZ
in_PIN
2002_CD
._.
Ronaldo_NN
Schmitz_NN
Financial_NN
Results_NN
M_NN
M_NN
M_NN
M_NN
M_NN
M_NN
M_NN
M_NN
M_NN
M_NN
M_NN
M_NN
M_NN [PASS]
M_NN [PASS]
was_VBD [BEMA]
formerly_TIME
a_DT
Non-Executive_JJ
Director_NN
Nominations_NOMZ
C_NN
M_NN
M_NN [BEMA]
of_PIN
Glaxo_NN
Wellcome_NN
plc._NN
._.
He_TPP3
is_VPRT [BEMA]
a_DT
NonRemuneration_NOMZ
M_NN
M_NN
M_NN
C_NN
M_NN
Executive_NN
Director_NN
of_PIN
Legal_NN
&_CC
General_NN
Key_NN
:_:
C_NN
Chairman_NN
M_NN
Member_NN
Group_NN
plc_NN
and_CC
a_DT
member_NN
of_PIN
the_DT
Board_NN
Details_NN
of_PIN
the_DT
terms_NN
of_PIN
reference_NN
of_PIN
the_DT
Board_NN
Committees_NN
may_POMD
be_VB [PASS]
found_VBN [PRIV]
on_PIN
page_NN
21_CD
._.
of_PIN
Directors_NN
of_PIN
Rohm_NN
and_PHC
Haas_NN
Company_NN
and_PHC
Cabot_NN
Corporation_NOMZ
._.
16_CD
Annual_JJ
Review_NN
2003_CD
Annual_JJ
Review_NN
2003_CD
17_CD
Hogg_NN
Garnier_NN
Coombe_NN
Barzach_NN
Culp_NN
Davis_NN
Job_NN
McArthur_NN
McHenry_NN
Prosser_NN
Schmitz_NN
Shapiro_NN
Wilson_NN
Yamada_NN
Summary_NN
Remuneration_NOMZ
Report_NN
FOR_PIN
THE_DT
YEAR_NN
TO_PIN
31ST_CD
DECEMBER_NN
2003_CD
Summary_NN
Remuneration_NOMZ
Report_NN
FOR_PIN
THE_DT
YEAR_NN
TO_PIN
31ST_CD
DECEMBER_NN
2003_CD
a_DT
commitment_NOMZ
to_TO
be_VB [BEMA]
a_DT
leader_NN
of_PIN
good_JJ
remuneration_NOMZ
practice_NN
in_PIN
the_DT
Annual_JJ
bonus_NN
The_DT
Committee_NN
has_VPRT [PEAS]
decided_VBN [SUAV] [PRIV]
for_PIN
the_DT
2003_CD
grant_NN
that_THVC
if_COND
the_DT
performance_NN
Introduction_NOMZ
pharmaceutical_JJ
industry_NN
._.
All_QUAN
bonuses_NN
are_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
on_PIN
the_DT
basis_NN
of_PIN
a_DT
formal_JJ
review_NN
of_PIN
annual_JJ
condition_NOMZ
is_VPRT [PASS]
not_XX0
met_VBN
in_PIN
full_JJ
after_IN
the_DT
three_CD
year_NN
period_NN
,_,
performance_NN
will_PRMD
performance_NN
against_PIN
stretching_VBG
financial_JJ
targets_NN
based_VBN [WZPAST]
on_PIN
business_NOMZ
be_VB [PASS]
measured_VBN
again_TIME
over_IN
the_DT
four_CD
financial_JJ
years_NN
following_VBG [WZPRES]
the_DT
date_NN
of_PIN
The_DT
Summary_NN
Remuneration_NOMZ
Report_NN
sets_VPRT
out_PIN
the_DT
annual_JJ
remuneration_NOMZ
In_PIN
formulating_VBG
the_DT
policy_NN
,_,
the_DT
Committee_NN
also_RB
decided_VBD [SUAV] [PRIV] [THATD]
that_DEMP
:_:
performance_NN
profit_NN
before_IN
interest_NN
and_PHC
tax_NN
and_CC
are_VPRT [BEMA]
subject_PRED
to_PIN
detailed_JJ
grant_NN
of_PIN
the_DT
option_NOMZ
._.
To_PIN
the_DT
extent_NN
the_DT
option_NOMZ
performance_NN
conditions_NOMZ
earned_VBN [WZPAST]
in_PIN
2003_CD
together_RB
with_PIN
any_QUAN
gains_NN
under_IN
long-term_JJ
incentive_NN
the_DT
remuneration_NOMZ
structure_NN
must_NEMD
support_VB
the_DT
business_NOMZ
by_PIN
securing_VBG
,_,
assessment_NOMZ
of_PIN
individual_JJ
,_,
business_NOMZ
unit_NN
and_PHC
group_NN
achievements_NOMZ
against_PIN
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
met_VBN
at_PIN
the_DT
end_NN
of_PIN
four_CD
years_NN
,_,
the_DT
option_NOMZ
will_PRMD
lapse_NN
._.
It_PIT
also_RB
describes_VPRT
the_DT
background_NN
and_CC
outlines_VPRT
the_DT
Groups_NN
retaining_VBG [WZPRES]
and_PHC
motivating_VBG
key_JJ
talent_NN
in_PIN
a_DT
very_AMP
competitive_JJ
market_NN
objectives_NN
._.
The_DT
Committee_NN
considers_VPRT [PRIV]
re-measurement_NOMZ
to_TO
be_VB [BEMA]
an_DT
important_JJ
feature_NN
remuneration_NOMZ
policy_NN
together_RB
with_PIN
the_DT
performance_NN
graph_NN
as_IN
required_VBN [SUAV]
by_PIN
place_NN
:_:
for_PIN
the_DT
2003_CD
grant_NN
in_PIN
the_DT
light_NN
of_PIN
the_DT
imposition_NOMZ
of_PIN
performance_NN
the_DT
Directors_NN
Remuneration_NOMZ
Report_NN
Regulations_NOMZ
2002_CD
the_DT
Regulations_NOMZ
._.
UK_NN
shareholder_NN
guidelines_NN
would_PRMD
be_VB [PASS]
followed_VBN
to_PIN
the_DT
maximum_NN
extent_NN
Bonus_NN
awards_NN
for_PIN
2003_CD
reflected_VBD [PRIV]
the_DT
Committees_NN
belief_NN
that_TOBJ
the_DT
company_NN
conditions_NOMZ
in_PIN
an_DT
industry_NN
where_RB
most_EMPH
of_PIN
the_DT
major_JJ
competitors_NN
do_VPRT
not_XX0
consistent_JJ
with_PIN
the_DT
needs_NN
of_PIN
the_DT
business_NOMZ
and_CC
the_DT
company_NN
would_PRMD
produced_VBD
superior_JJ
results_NN
during_PIN
the_DT
year_NN
,_,
after_IN
taking_VBG
account_NN
of_PIN
factors_NN
apply_VPRT
them_TPP3
to_PIN
options_NOMZ
._.
The_DT
Committee_NN
will_PRMD
consider_VB [PRIV]
prior_RB
to_PIN
each_QUAN
annual_JJ
The_DT
Remuneration_NOMZ
Committee_NN
the_DT
Committee_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
making_VBG
maintain_VB [PUBV]
a_DT
regular_JJ
dialogue_NN
with_PIN
shareholders_NN
:_:
outside_PLACE
the_DT
control_NN
of_PIN
management_NOMZ
,_,
notably_RB
exchange_NN
rates_NN
and_CC
the_DT
grant_NN
of_PIN
options_NOMZ
whether_IN
a_DT
re-measurement_NOMZ
will_PRMD
be_VB [PASS]
permitted_VBN
._.
recommendations_NOMZ
to_PIN
the_DT
Board_NN
on_PIN
the_DT
companys_NN
remuneration_VPRT
policy_NN
global_JJ
pharmaceutical_JJ
companies_NN
are_VPRT [BEMA]
the_DT
primary_JJ
pay_NN
comparator_NN
group_NN
:_:
launch_NN
of_PIN
generic_JJ
competition_NOMZ
to_PIN
Paxil_NN
in_PIN
the_DT
USA_NN
._.
and_ANDC
,_,
within_PIN
the_DT
terms_NN
of_PIN
the_DT
agreed_JJ
policy_NN
,_,
determining_VBG [SUAV] [PRIV] [PRESP]
the_DT
total_JJ
performance_NN
conditions_NOMZ
would_PRMD
be_VB [PASS]
based_VBN
on_PIN
the_DT
measurable_JJ
delivery_NN
The_DT
performance_NN
condition_NOMZ
for_PIN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
prior_RB
to_PIN
2003_CD
was_VBD [BEMA]
individual_JJ
remuneration_NOMZ
packages_NN
of_PIN
the_DT
Executive_NN
Directors_NN
and_PHC
members_NN
of_PIN
strong_JJ
financial_JJ
performance_NN
and_CC
the_DT
delivery_NN
of_PIN
superior_JJ
returns_NN
Long-term_JJ
incentives_NN
that_DEMP
,_,
for_PIN
the_DT
options_NOMZ
to_PIN
vest_NN
in_PIN
full_JJ
,_,
Business_NOMZ
Performance_NN
EPS_NN
growth_NN
,_,
of_PIN
the_DT
CET_NN
Executives_NN
._.
The_DT
members_NN
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
to_PIN
shareholders_NN
as_IN
compared_VBN
with_PIN
other_JJ
pharmaceutical_JJ
companies_NN
:_:
The_DT
remuneration_NOMZ
policy_NN
provides_VPRT
that_DEMO
annual_JJ
long-term_JJ
incentive_NN
awards_NN
excluding_VBG [WZPRES]
currency_NN
and_CC
exceptional_JJ
items_NN
,_,
had_VBD
on_PIN
average_NN
to_TO
be_VB [BEMA]
at_PIN
least_JJ
are_VPRT [PASS]
set_VBN
out_PIN
on_PIN
page_NN
16_CD
._.
a_DT
high_JJ
proportion_NOMZ
of_PIN
the_DT
total_JJ
remuneration_NOMZ
opportunity_NOMZ
would_PRMD
be_VB
will_PRMD [SPAU]
normally_RB
be_VB [PASS]
made_VBN
up_IN
of_PIN
a_DT
performance_NN
share_NN
award_NN
and_CC
a_DT
share_NN
three_CD
percentage_NN
points_NN
per_PIN
annum_NN
more_EMPH
than_PIN
the_DT
increase_NN
in_PIN
RPI_NN
over_IN
based_VBN
on_PIN
performance-related_JJ
remuneration_NOMZ
which_WDT [WHSUB]
will_PRMD
be_VB [PASS]
delivered_VBN
option_NOMZ
award_NN
._.
The_DT
new_JJ
remuneration_NOMZ
policy_NN
increases_VPRT
the_DT
emphasis_NN
on_PIN
any_QUAN
three-year_JJ
performance_NN
period_NN
._.
During_PIN
2003_CD
the_DT
Committee_NN
reviewed_VBN
and_PHC
developed_VBN
the_DT
remuneration_NOMZ
over_IN
the_DT
medium_NN
to_PIN
long-term_JJ
:_:
and_ANDC
the_DT
use_NN
of_PIN
performance_NN
shares_NN
._.
policy_NN
to_TO
align_VB
executive_JJ
remuneration_NOMZ
with_PIN
the_DT
interests_NN
of_PIN
shareholders_NN
no_SYNE
ex-gratia_NN
payments_NOMZ
would_PRMD
be_VB [PASS]
made_VBN
._.
Pensions_NN
whilst_OSUB
meeting_VBG
the_DT
imperative_NN
of_PIN
recruiting_GER
and_CC
retaining_VBG
the_DT
executive_NN
As_IN
part_NN
of_PIN
the_DT
review_NN
process_NN
,_,
the_DT
Committee_NN
considered_VBN [PRIV]
which_WDT [WHCL]
The_DT
Executives_NN
participate_VB
in_PIN
GlaxoSmithKline_NN
senior_JJ
executive_NN
pension_NN
talent_NN
essential_JJ
to_PIN
the_DT
leadership_NN
of_PIN
the_DT
company_NN
._.
Overall_RB
the_DT
policy_NN
is_VPRT [PASS]
intended_VBN [SUAV]
to_TO
provide_VB
median_JJ
total_JJ
remuneration_NOMZ
for_PIN
performance_NN
conditions_NOMZ
should_NEMD
be_VB [PASS]
applied_VBN
to_PIN
the_DT
long-term_JJ
incentives_NN
._.
The_DT
pension_NN
arrangements_NOMZ
are_VPRT [PASS]
structured_VBN
in_PIN
accordance_NN
with_PIN
the_DT
median_JJ
performance_NN
._.
Poor_NN
performance_NN
will_PRMD
result_VB
in_PIN
total_JJ
remuneration_NOMZ
The_DT
Committee_NN
concluded_VBD [PRIV]
that_THVC
it_PIT
was_VBD [BEMA]
appropriate_PRED
to_TO
measure_VB
plans_NN
operated_VBN [WZPAST]
for_PIN
Executives_NN
in_PIN
the_DT
country_NN
in_PIN
which_WDT [PIRE]
the_DT
Executives_NN
are_VPRT [BEMA]
The_DT
new_JJ
remuneration_NOMZ
policy_NN
was_VBD [PASS]
finalized_VBN
after_IN
undertaking_VBG
an_DT
extensive_JJ
significantly_RB
below_PLACE
the_DT
pay_NN
comparator_NN
group_NN
median_NN
,_,
with_PIN
the_DT
opportunity_NOMZ
performance_NN
using_VBG [WZPRES]
a_DT
combination_NOMZ
of_PIN
absolute_JJ
financial_JJ
results_NN
based_VBN
likely_JJ
to_TO
retire_VB
._.
Benefits_NN
are_VPRT [BEMA]
normally_RB
payable_PRED
at_PIN
age_NN
60_CD
._.
consultation_NOMZ
process_NN
with_PIN
shareholders_NN
and_CC
institutional_JJ
bodies_NN
during_PIN
the_DT
to_TO
earn_VB
upper_JJ
quartile_JJ
total_JJ
remuneration_NOMZ
for_PIN
exceptional_JJ
performance_NN
._.
on_PIN
earnings_GER
per_PIN
share_NN
-_:
EPS_NN
and_CC
the_DT
delivery_NN
of_PIN
superior_JJ
value_NN
to_PIN
course_NN
of_PIN
2003_CD
._.
During_PIN
the_DT
year_NN
the_DT
Chairman_NN
of_PIN
GlaxoSmithKline_NN
and_PHC
shareholders_NN
based_VBN [WZPAST]
on_PIN
Total_JJ
Shareholder_NN
Return_NN
-_:
TSR_NN
._.
the_DT
Chairman_NN
of_PIN
the_DT
Committee_NN
met_VBD
shareholders_NN
,_,
representing_VBG [PRESP]
nearly_DWNT
Executive_NN
Director_NN
terms_NN
and_PHC
conditions_NOMZ
This_DEMO
strong_JJ
alignment_NOMZ
with_PIN
performance_NN
is_VPRT [BEMA]
demonstrably_RB
in_PIN
the_DT
interests_NN
half_NN
of_PIN
GlaxoSmithKlines_NN
share_NN
capital_NN
,_,
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
the_DT
Committee_NN
of_PIN
shareholders_NN
and_CC
provides_VPRT
the_DT
Executives_NN
with_PIN
unambiguous_JJ
signals_NN
For_PIN
the_DT
Executives_NN
,_,
the_DT
level_NN
of_PIN
performance_NN
shares_NN
vesting_VBG [WZPRES]
is_VPRT [PASS]
based_VBN
on_PIN
obtained_VBN
a_DT
clear_JJ
understanding_GER
of_PIN
shareholder_NN
expectations_NOMZ
and_CC
to_PIN
The_DT
policy_NN
regarding_VBG [WZPRES]
the_DT
Executive_NN
Directors_NN
contracts_NN
was_VBD [BEMA]
the_DT
subject_NN
of_PIN
about_IN
the_DT
importance_NN
of_PIN
delivering_VBG
success_NN
to_PIN
the_DT
companys_NN
the_DT
companys_NN
TSR_NN
relative_JJ
to_PIN
the_DT
performance_NN
comparator_NN
group_NN
over_IN
communicate_VPRT
the_DT
competitive_JJ
issues_NN
facing_VBG [WZPRES]
the_DT
company_NN
._.
extensive_JJ
review_NN
and_PHC
change_NN
during_PIN
2003_CD
._.
The_DT
new_JJ
policy_NN
provides_VPRT
the_DT
shareholders_NN
._.
If_COND
GlaxoSmithKline_NN
is_VPRT [PASS]
ranked_VBN
at_PIN
the_DT
framework_NN
for_PIN
contracts_NN
for_PIN
Executive_NN
Directors_NN
appointed_VBN [WZPAST]
in_PIN
the_DT
future_NN
._.
median_NN
of_PIN
the_DT
performance_NN
comparator_NN
group_NN
,_,
35_CD
%_NN
of_PIN
the_DT
shares_NN
will_PRMD
The_DT
revised_VBN
remuneration_NOMZ
policy_NN
is_VPRT [PASS]
designed_VBN
to_TO
establish_VB [PRIV]
a_DT
framework_NN
for_PIN
Commitment_NOMZ
vest_NN
._.
Only_DWNT
if_COND
GlaxoSmithKline_NN
is_VPRT [BEMA]
one_CD
of_PIN
the_DT
top_JJ
two_CD
companies_NN
will_PRMD
all_QUAN
of_PIN
remuneration_NOMZ
which_WDT [WHSUB]
is_VPRT [BEMA]
consistent_PRED
with_PIN
the_DT
companys_NN
scale_NN
and_PHC
scope_NN
of_PIN
Dr_NN
Garnier_NN
and_PHC
Mr_NN
Coombe_NN
have_VPRT [PEAS]
agreed_VBN [SUAV] [PUBV]
to_PIN
changes_NN
in_PIN
their_TPP3
own_JJ
The_DT
Committee_NN
will_PRMD
apply_VB
this_DEMO
policy_NN
on_PIN
a_DT
consistent_JJ
and_PHC
transparent_JJ
the_DT
shares_NN
vest_NN
._.
When_RB
determining_VBG [SUAV] [PRIV]
vesting_GER
levels_NN
,_,
the_DT
Committee_NN
will_PRMD
operations_NOMZ
,_,
meets_VPRT
the_DT
recruitment_NOMZ
needs_NN
of_PIN
the_DT
business_NOMZ
and_CC
is_VPRT [BEMA]
closely_RB
contractual_JJ
terms_NN
without_PIN
compensation_NOMZ
to_TO
bring_VB
their_TPP3
contractual_JJ
basis_NN
._.
Any_QUAN
significant_JJ
change_NN
will_PRMD
be_VB [PASS]
discussed_VBN
with_PIN
shareholders_NN
in_PIN
have_VPRT
regard_NN
for_PIN
the_DT
companys_NN
underlying_VBG [WZPRES]
financial_JJ
performance_NN
._.
aligned_VBN [PASTP]
with_PIN
the_DT
shareholder_NN
guidelines_NN
._.
terms_NN
broadly_RB
in_PIN
line_NN
with_PIN
the_DT
new_JJ
contractual_JJ
framework_NN
,_,
including_VBG [PRESP]
the_DT
advance_NN
of_PIN
implementation_NOMZ
._.
reduction_NOMZ
of_PIN
contractual_JJ
notice_NN
period_NN
from_PIN
24_CD
to_PIN
12_CD
calendar_NN
months_NN
._.
Prior_RB
to_PIN
2003_CD
,_,
performance_NN
share_NN
awards_NN
were_VBD [BEMA]
in_PIN
two_CD
parts_NN
:_:
half_NN
could_POMD
2003_CD
Independent_NN
review_NN
of_PIN
executive_NN
remuneration_NOMZ
However_CONJ
,_,
to_TO
honor_VB
certain_JJ
aspects_NN
of_PIN
their_TPP3
old_JJ
contractual_JJ
terms_NN
there_RB
Pay_VB
and_CC
performance_NN
comparators_NN
be_VB [BYPA]
earned_VBN
by_PIN
reference_NN
to_PIN
GlaxoSmithKline_NN
's_POS
TSR_NN
performance_NN
compared_VBN
As_IN
indicated_VBN [PRIV]
in_PIN
the_DT
2002_CD
Remuneration_NOMZ
Report_NN
,_,
the_DT
Committee_NN
appointed_VBN [WZPAST]
are_VPRT [BEMA]
a_DT
number_NN
of_PIN
individual_JJ
features_NN
which_WDT [WHSUB]
will_PRMD
be_VB [PASS]
retained_VBN
._.
In_PIN
the_DT
event_NN
The_DT
following_JJ
table_NN
sets_VPRT
out_PIN
the_DT
companies_NN
used_VBN [WZPAST]
for_PIN
pay_NN
and_PHC
performance_NN
with_PIN
the_DT
FTSE_NN
100_CD
and_CC
the_DT
other_JJ
half_NN
of_PIN
the_DT
award_NN
was_VBD [BEMA]
dependent_PRED
upon_PIN
Deloitte_NN
&_CC
Touche_NN
LLP_NN
Deloitte_NN
to_TO
conduct_VB
a_DT
comprehensive_JJ
independent_JJ
of_PIN
early_TIME
termination_NOMZ
by_PIN
the_DT
company_NN
,_,
Dr_NN
Garnier_NN
and_PHC
Mr_NN
Coombe_NN
would_PRMD
comparison_NN
:_:
the_DT
companys_NN
business_NOMZ
performance_NN
EPS_NN
growth_NN
._.
review_NN
of_PIN
the_DT
remuneration_NOMZ
of_PIN
the_DT
Executives_NN
of_PIN
GlaxoSmithKline_NN
._.
Deloitte_NN
receive_VB
,_,
in_PIN
respect_NN
of_PIN
that_DEMO
12_CD
months_NN
notice_NN
,_,
a_DT
cash_NN
sum_NN
representing_VBG [WZPRES]
Market_NN
Cap_NN
reported_VBD [PUBV]
exclusively_RB
to_PIN
the_DT
Committee_NN
and_CC
the_DT
Chairman_NN
of_PIN
the_DT
company_NN
._.
annual_JJ
salary_NN
,_,
on_PIN
target_NN
bonus_NN
and_PHC
pension_NN
contributions_NOMZ
._.
31.12.03_CD
The_DT
share_NN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
in_PIN
2003_CD
to_PIN
the_DT
Executives_NN
are_VPRT [PASS]
linked_VBN
to_PIN
the_DT
Deloitte_NN
reviewed_VBD
all_QUAN
aspects_NN
of_PIN
the_DT
remuneration_NOMZ
policy_NN
,_,
each_QUAN
element_NOMZ
of_PIN
Company_NN
Country_NN
m_NN
achievement_NOMZ
of_PIN
compound_JJ
annual_JJ
EPS_NN
growth_NN
over_IN
the_DT
performance_NN
remuneration_NOMZ
,_,
the_DT
performance_NN
measures_NN
used_VBN
and_CC
the_DT
terms_NN
and_PHC
TSR_NN
performance_NN
graph_NN
Abbott_NN
Laboratories_NN
USA_NN
40,700_CD
period_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
the_DT
three_CD
years_NN
following_VBG [WZPRES]
the_DT
grant_NN
of_PIN
an_DT
option_NOMZ
._.
conditions_NOMZ
of_PIN
the_DT
Executives_NN
contracts_NN
._.
The_DT
following_JJ
graph_NN
sets_VPRT
out_PIN
the_DT
performance_NN
of_PIN
the_DT
company_NN
relative_JJ
AstraZeneca_NN
UK_NN
45,465_CD
to_PIN
the_DT
FTSE_NN
100_CD
index_NN
of_PIN
which_WDT [PIRE]
the_DT
company_NN
is_VPRT [BEMA]
a_DT
constituent_NN
and_CC
,_,
for_PIN
Aventis_NN
France_NN
29,593_CD
When_RB
setting_VBG
EPS_NN
targets_VPRT
the_DT
Committee_NN
will_PRMD
consider_VB [PRIV]
the_DT
companys_NN
Their_TPP3
review_NN
also_RB
included_VBD
consideration_NOMZ
of_PIN
the_DT
relevant_JJ
comparator_NN
information_NOMZ
,_,
to_PIN
the_DT
median_NN
of_PIN
the_DT
performance_NN
comparator_NN
group_NN
since_OSUB
Bristol-Myers_NN
Squibb_NN
USA_NN
30,985_CD
internal_JJ
projections_NOMZ
and_PHC
analysts_NN
forecasts_NN
for_PIN
GlaxoSmithKlines_NN
EPS_NN
companies_NN
for_PIN
performance_NN
measurement_NOMZ
and_CC
pay_VB
benchmarking_VBG
for_PIN
the_DT
merger_NN
on_PIN
27th_JJ
December_NN
2000_CD
._.
The_DT
graph_NN
has_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
in_PIN
Eli_NN
Lilly_NN
USA_NN
44,119_CD
performance_NN
as_RB
well_RB
as_IN
analysts_NN
forecasts_NN
for_PIN
the_DT
pharmaceutical_JJ
industry_NN
._.
accordance_NN
with_PIN
the_DT
Regulations_NOMZ
and_CC
is_VPRT [BEMA]
not_XX0
an_DT
indication_NOMZ
of_PIN
the_DT
likely_JJ
GlaxoSmithKline_NN
UK_NN
76,153_CD
vesting_GER
of_PIN
awards_NN
granted_VBN [SUAV]
under_IN
any_QUAN
of_PIN
the_DT
companys_NN
incentive_NN
plans_NN
._.
Johnson_NN
&_CC
Johnson_NN
USA_NN
85,661_CD
For_PIN
the_DT
2003_CD
grant_NN
,_,
vesting_VBG
increases_NN
on_PIN
a_DT
straight_JJ
line_NN
basis_NN
for_PIN
EPS_NN
Deloittes_NN
independent_JJ
review_NN
produced_VBD
the_DT
following_VBG
key_JJ
findings_GER
:_:
Merck_NN
USA_NN
57,427_CD
performance_NN
between_PIN
the_DT
hurdles_NN
set_VBN [WZPAST]
out_PIN
in_PIN
the_DT
table_NN
below_PLACE
._.
the_DT
link_NN
between_PIN
pay_NN
and_PHC
performance_NN
needed_VBN
strengthening_GER
:_:
Novartis_NN
Switzerland_NN
68,457_CD
100_CD
the_DT
potential_NN
for_PIN
payment_NOMZ
for_PIN
failure_NN
needed_VBN
addressing_VBG
:_:
Annualised_NN
Percentage_NN
of_PIN
Pfizer_NN
USA_NN
150,627_CD
stronger_JJ
alignment_NOMZ
to_PIN
UK_NN
best_JJ
practice_NN
and_PHC
shareholder_NN
guidelines_NN
growth_NN
in_PIN
EPS_NN
._.
award_NN
vesting_GER
90_CD
Roche_NN
Holdings_GER
Switzerland_NN
39,658_CD
was_VBD [PASS]
needed_VBN
:_:
Sanofi-Synthelabo_NN
France_NN
30,811_CD
RPI_NN
5_CD
%_NN
100_CD
%_NN
80_CD
other_JJ
global_JJ
pharmaceutical_JJ
companies_NN
are_VPRT [BEMA]
the_DT
primary_JJ
market_NN
Schering-Plough_NN
USA_NN
14,276_CD
RPI_NN
4_CD
%_NN
75_CD
%_NN
for_PIN
talent_NN
:_:
and_ANDC
Takeda_NN
Chemical_NN
Industries_NN
Japan_NN
19,684_CD
RPI_NN
3_CD
%_NN
50_CD
%_NN
70_CD
the_DT
long-term_JJ
incentive_NN
opportunity_NOMZ
was_VBD [BEMA]
uncompetitive_PRED
._.
Wyeth_NN
USA_NN
31,584_CD
RPI_NN
3_CD
%_NN
0_CD
%_NN
60_CD
31_CD
12_CD
00_CD
31_CD
12_CD
01_CD
31_CD
12_CD
02_CD
31_CD
12_CD
03_CD
Remuneration_NOMZ
policy_NN
GSK_NN
Total_NN
Return_NN
FTSE_NN
100_CD
Total_JJ
Return_NN
Index_NN
GSK_NN
Performance_NN
Comparator_NN
Group_NN
GlaxoSmithKlines_NN
Executive_NN
remuneration_NOMZ
consists_VPRT
of_PIN
the_DT
This_DEMO
performance_NN
condition_NOMZ
is_VPRT [BEMA]
substantially_RB
consistent_PRED
with_PIN
UK_NN
shareholder_NN
following_VBG [WZPRES]
components_NN
:_:
guidelines_NN
and_PHC
expectations_NOMZ
and_CC
is_VPRT [SPAU]
considerably_RB
more_EMPH
demanding_VBG [SUAV]
than_PIN
Principles_NN
any_QUAN
operated_VBN
by_PIN
other_JJ
global_JJ
pharmaceutical_JJ
companies_NN
._.
This_DEMO
change_NN
is_VPRT [BEMA]
The_DT
Committee_NN
considered_VBD [PRIV]
the_DT
findings_GER
and_CC
established_VBN [PRIV]
three_CD
core_NN
Base_NN
salary_NN
consistent_JJ
with_PIN
the_DT
new_JJ
policy_NN
of_PIN
providing_VBG
pay_NN
for_PIN
performance_NN
and_CC
only_DWNT
principles_NN
which_WDT [WHSUB]
underpin_VPRT
the_DT
new_JJ
remuneration_NOMZ
policy_NN
for_PIN
Base_NN
salaries_NN
will_PRMD
be_VB [BYPA]
set_VBN
by_PIN
reference_NN
to_PIN
the_DT
median_NN
for_PIN
the_DT
relevant_JJ
for_PIN
performance_NN
._.
For_PIN
Executives_NN
this_DEMP
is_VPRT [BEMA]
the_DT
pharmaceutical_JJ
pay_NN
comparator_NN
group_NN
._.
pay_NN
for_PIN
performance_NN
and_CC
only_DWNT
for_PIN
performance_NN
:_:
Base_NN
salary_NN
is_VPRT [BEMA]
the_DT
only_DWNT
element_NOMZ
of_PIN
remuneration_NOMZ
that_DEMP
is_VPRT [PASS]
fixed_VBN
._.
robust_JJ
and_PHC
transparent_JJ
governance_NN
structures_NN
:_:
and_ANDC
18_CD
Annual_JJ
Review_NN
2003_CD
Annual_JJ
Review_NN
2003_CD
19_CD
Summary_NN
Remuneration_NOMZ
Report_NN
FOR_PIN
THE_DT
YEAR_NN
TO_PIN
31ST_CD
DECEMBER_NN
2003_CD
Corporate_JJ
governance_NN
Annual_JJ
remuneration_NOMZ
Board_NN
committees_NN
Governance_NN
and_PHC
policy_NN
2003_CD
2002_CD
Audit_NN
Committee_NN
Total_NN
Total_NN
The_NN
Board_NN
and_PHC
Executive_NN
Fees_NN
and_CC
Other_JJ
Annual_JJ
annual_JJ
annual_JJ
The_DT
Audit_NN
Committee_NN
reviews_VPRT
the_DT
financial_JJ
and_PHC
internal_JJ
reporting_GER
process_NN
,_,
salary_NN
benefits_NN
bonus_NN
remuneration_NOMZ
remuneration_NOMZ
The_DT
Directors_NN
are_VPRT [PASS]
listed_VBN
under_IN
The_DT
Board_NN
on_PIN
page_NN
16_CD
._.
the_DT
system_NN
of_PIN
internal_JJ
control_NN
and_PHC
management_NOMZ
of_PIN
risks_NN
and_CC
the_DT
external_JJ
Directors_NN
of_PIN
GlaxoSmithKline_NN
000 000 000 000_CD
000_CD
and_CC
internal_JJ
audit_NN
process_NN
._.
The_DT
Committee_NN
also_RB
proposes_VPRT [SUAV]
to_PIN
the_DT
Executive_NN
Directors_NN
The_DT
Board_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
the_DT
Groups_NN
system_NN
of_PIN
corporate_JJ
governance_NN
shareholders_NN
the_DT
appointment_NOMZ
of_PIN
the_DT
external_JJ
auditors_NN
and_CC
is_VPRT [BEMA]
directly_RB
Dr_JJ
J_NN
P_NN
Garnier_NN
916_CD
386_CD
1,485_CD
2,787_CD
2,452_CD
and_CC
is_VPRT [BEMA]
ultimately_RB
accountable_PRED
for_PIN
the_DT
Groups_NN
activities_NOMZ
,_,
strategy_NN
and_CC
responsible_JJ
for_PIN
their_TPP3
remuneration_NOMZ
and_PHC
oversight_NN
of_PIN
their_TPP3
work_NN
._.
The_DT
Mr_NN
J_NN
D_NN
Coombe_NN
490_CD
17_CD
730_CD
1,237_CD
947_CD
financial_JJ
performance_NN
._.
Committee_NN
consists_VPRT
entirely_AMP
of_PIN
independent_JJ
Non-Executive_JJ
Directors_NN
._.
The_DT
Board_NN
comprises_VPRT
three_CD
Executive_NN
and_CC
11_CD
Non-Executive_JJ
Directors_NN
._.
Current_JJ
Non-Executive_JJ
Directors_NN
Whilst_OSUB
the_DT
Board_NN
considers_VPRT [PRIV]
all_QUAN
of_PIN
its_PIT
Non-Executive_JJ
Directors_NN
to_TO
be_VB
Sir_NN
Christopher_NN
Hogg_NN
374 374 252_CD
Remuneration_NOMZ
Committee_NN
independent_JJ
in_PIN
character_NN
and_PHC
judgement_NOMZ
,_,
in_PIN
accordance_NN
with_PIN
the_DT
Dr_NN
M_NN
Barzach_NN
107 107 100_CD
The_DT
Remuneration_NOMZ
Committee_NN
determines_VPRT [SUAV] [PRIV]
the_DT
terms_NN
of_PIN
service_NN
and_CC
1998_CD
Code_NN
,_,
it_PIT
has_VPRT [PEAS]
determined_VBN [SUAV] [PRIV]
that_THVC
four_CD
Non-Executive_JJ
Directors_NN
-_:
Mr_NN
L_NN
Culp_NN
29_CD
29_CD
remuneration_NOMZ
of_PIN
the_DT
Executive_NN
Directors_NN
and_PHC
members_NN
of_PIN
the_DT
CET_NN
and_CC
,_,
the_DT
Chairman_NN
,_,
Dr_NN
Barzach_NN
,_,
Mr_NN
McHenry_NN
and_PHC
Dr_NN
Shapiro_NN
-_:
should_NEMD
not_XX0
Mr_NN
C_NN
Davis_NN
29_CD
29_CD
with_PIN
the_DT
assistance_NN
of_PIN
external_JJ
independent_JJ
advisors_NN
,_,
it_PIT
evaluates_VPRT
and_PHC
be_VB [PASS]
considered_VBN [PRIV]
as_IN
independent_JJ
under_IN
the_DT
2003_CD
Code_NN
._.
In_PIN
the_DT
case_NN
of_PIN
Sir_NN
Peter_NN
Job_NN
57_CD
57_CD
59_CD
makes_VPRT
recommendations_NOMZ
to_PIN
the_DT
Board_NN
on_PIN
overall_JJ
executive_NN
remuneration_NOMZ
the_DT
Chairman_NN
and_PHC
Mr_NN
McHenry_NN
this_DEMP
is_VPRT [BEMA]
due_PRED
to_PIN
their_TPP3
length_NN
of_PIN
service_NN
with_PIN
Mr_NN
J_NN
H_NN
McArthur_NN
62_CD
62_CD
62_CD
policy_NN
._.
The_DT
Committee_NN
consists_VPRT
entirely_AMP
of_PIN
independent_JJ
Non-Executive_JJ
GlaxoSmithKline_NN
and_CC
its_PIT
predecessor_NN
companies_NN
and_CC
,_,
in_PIN
the_DT
case_NN
of_PIN
Drs_NN
Mr_NN
D_NN
F_NN
McHenry_NN
65_CD
65_CD
62_CD
Directors_NN
._.
It_PIT
meets_VPRT
at_PIN
least_JJ
four_CD
times_NN
a_DT
year_NN
and_ANDC
otherwise_CONJ
as_RB
necessary_JJ
._.
Barzach_NN
and_PHC
Shapiro_NN
,_,
due_JJ
to_TO
remuneration_VB
that_DEMO
they_TPP3
have_VPRT [PEAS]
received_VBN
from_PIN
Sir_NN
Ian_NN
Prosser_NN
66_CD
66_CD
59_CD
the_DT
Group_NN
in_PIN
other_JJ
capacities_NOMZ
._.
These_DEMO
four_CD
Non-Executive_JJ
Directors_NN
have_VPRT [PEAS]
Dr_VBN
R_NN
Schmitz_NN
67_CD
67_CD
69_CD
Nominations_NOMZ
Committee_NN
resigned_VBD
their_TPP3
positions_NOMZ
on_PIN
Board_NN
Committees_NN
where_RB
independence_NN
is_VPRT
Dr_NN
L_NN
Shapiro_NN
109 109 118_CD
The_DT
Nominations_NOMZ
Committee_NN
reviews_VPRT
the_DT
structure_NN
,_,
size_NN
and_PHC
composition_NOMZ
required_VBN [SUAV]
under_IN
the_DT
2003_CD
Code_NN
._.
Sir_NN
Robert_NN
Wilson_NN
10_CD
10_CD
of_PIN
the_DT
Board_NN
and_CC
the_DT
appointment_NOMZ
of_PIN
members_NN
of_PIN
the_DT
Board_NN
and_CC
the_DT
CET_NN
,_,
and_ANDC
makes_VPRT
recommendations_NOMZ
to_PIN
the_DT
Board_NN
as_IN
appropriate_JJ
._.
The_DT
975 975 781_CD
The_NN
Board_NN
considers_VPRT [PRIV]
that_THVC
Mr_NN
McArthur_NN
,_,
Dr_NN
Schmitz_NN
,_,
Mr_NN
Culp_NN
,_,
Mr_NN
Davis_NN
,_,
Committee_NN
also_RB
monitors_VPRT
the_DT
planning_GER
of_PIN
succession_NN
to_PIN
the_DT
Board_NN
and_PHC
Former_NN
Non-Executive_NN
Directors_NN
Sir_NN
Peter_NN
Job_NN
,_,
Sir_NN
Ian_NN
Prosser_NN
and_PHC
Sir_NN
Robert_NN
Wilson_NN
are_VPRT [BEMA]
independent_PRED
under_IN
Senior_NN
Management_NOMZ
._.
The_DT
Committee_NN
consists_VPRT
entirely_AMP
of_PIN
Non-Executive_JJ
Sir_NN
Richard_NN
Sykes_NN
958 958 162_CD
the_DT
2003_CD
Code_NN
._.
The_DT
Board_NN
noted_VBD [PRIV]
that_THVC
Dr_NN
Schmitz_NN
and_PHC
Mr_NN
McArthur_NN
are_VPRT
Directors_NN
of_PIN
whom_WP [PIRE]
a_DT
majority_NOMZ
are_VPRT [BEMA]
independent_PRED
and_CC
meets_VPRT
at_PIN
least_JJ
once_TIME
Sir_NN
Roger_NN
Hurn_NN
50_CD
50_CD
121_CD
associated_VBN
as_IN
non-executive_JJ
directors_NN
of_PIN
other_JJ
public_JJ
companies_NN
-_:
Rohm_NN
a_DT
year_NN
to_TO
consider_VB [PRIV]
succession_NN
planning_GER
and_ANDC
otherwise_CONJ
as_RB
necessary_JJ
._.
Sir_NN
Peter_NN
Walters_NN
53_CD
and_CC
Haas_NN
Company_NN
and_PHC
Cabot_NN
Corporation_NOMZ
-_:
but_CC
do_VPRT
not_XX0
consider_VB [PRIV]
the_DT
Mr_NN
P_NN
A_NN
Allaire_NN
28_CD
28_CD
68_CD
associations_NOMZ
to_TO
be_VB [BEMA]
of_PIN
sufficient_JJ
economic_JJ
significance_NN
to_TO
compromise_VB
Financial_NN
Results_NN
Committee_NN
Mr_NN
D_NN
C_NN
Bonham_NN
5_CD
their_TPP3
independence_NN
._.
The_DT
Financial_NN
Results_NN
Committee_NN
reviews_VPRT
and_PHC
approves_VPRT
,_,
on_PIN
behalf_NN
of_PIN
Mr_NN
J_NN
A_NN
Young_NN
31_CD
the_DT
Board_NN
,_,
the_DT
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_NN
,_,
the_DT
Annual_JJ
Review_NN
and_CC
At_PIN
the_DT
date_NN
of_PIN
publication_NOMZ
,_,
a_DT
majority_NOMZ
of_PIN
the_DT
Board_NN
members_NN
,_,
excluding_VBG [PRESP]
78_CD
958_CD
1,036_CD
440_CD
the_DT
convening_VBG
of_PIN
the_DT
AGM_NN
,_,
together_RB
with_PIN
the_DT
preliminary_JJ
and_PHC
quarterly_JJ
the_DT
Chairman_NN
,_,
were_VBD [BEMA]
independent_JJ
Non-Executive_JJ
Directors_NN
,_,
in_PIN
accordance_NN
Total_JJ
Non-Executive_JJ
Directors_NN
1,053_CD
958_CD
2,011_CD
1,221_CD
statements_NOMZ
of_PIN
trading_GER
results_NN
._.
Each_QUAN
Director_NN
is_VPRT [BEMA]
a_DT
member_NN
of_PIN
the_DT
with_PIN
the_DT
recommendations_NOMZ
of_PIN
the_DT
2003_CD
Code_NN
._.
Committee_NN
and_CC
the_DT
quorum_NN
for_PIN
a_DT
meeting_GER
is_VPRT [BEMA]
any_QUAN
three_CD
members_NN
._.
To_TO
be_VB [BEMA]
Total_JJ
remuneration_NOMZ
2,459_CD
1,361_CD
2,215_CD
6,035_CD
4,620_CD
quorate_NN
,_,
each_QUAN
meeting_GER
must_NEMD
include_VB
the_DT
Chairman_NN
or_CC
the_DT
Chairman_NN
of_PIN
Dr_NN
Barzach_NN
,_,
Mr_NN
McArthur_NN
and_PHC
Mr_NN
McHenry_NN
will_PRMD
be_VB
retiring_VBG
from_PIN
the_DT
Board_NN
the_DT
Audit_NN
Committee_NN
and_CC
the_DT
CEO_NN
or_CC
the_DT
CFO_NN
._.
The_DT
Committee_NN
meets_VPRT
at_PIN
the_DT
conclusion_NN
of_PIN
the_DT
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
AGM_NN
on_PIN
17th_JJ
May_POMD
Following_VBG [WZPRES]
the_DT
merger_NN
,_,
those_DEMO
participants_NN
in_PIN
the_DT
legacy_NN
schemes_NN
who_WP [WHSUB]
elected_VBD
to_TO
exchange_VB
their_TPP3
legacy_NN
options_NOMZ
for_PIN
options_NOMZ
over_IN
GlaxoSmithKline_NN
as_RB
necessary_JJ
._.
Following_VBG [PRESP]
their_TPP3
retirement_NOMZ
and_CC
assuming_VBG [PRIV]
that_THVC
the_DT
other_JJ
Directors_NN
shares_NN
were_VBD [PASS]
granted_VBN [SUAV]
an_DT
additional_JJ
cash_NN
benefit_NN
equal_JJ
to_PIN
10_CD
per_PIN
cent_NN
of_PIN
the_DT
grant_NN
price_NN
of_PIN
the_DT
original_JJ
option_NOMZ
._.
This_DEMO
additional_JJ
benefit_NN
is_VPRT [PASS]
known_VBN [PRIV]
seeking_VBG
re-election_NOMZ
at_PIN
the_DT
AGM_NN
are_VPRT [PASS]
elected_VBN
or_CC
re-elected_VBN
,_,
the_DT
Board_NN
will_PRMD
as_IN
the_DT
Exchange_NN
Offer_NN
Incentive_NN
EOI_NN
and_CC
is_VPRT [BEMA]
only_DWNT
payable_PRED
when_RB
the_DT
new_JJ
option_NOMZ
is_VPRT [PASS]
exercised_VBN
or_CC
lapses_NN
above_PLACE
market_NN
value_NN
._.
To_TO
qualify_VB
for_PIN
this_DEMO
Corporate_JJ
Responsibility_NOMZ
Committee_NN
comprise_VPRT
three_CD
Executive_NN
Directors_NN
and_CC
eight_CD
Non-Executive_JJ
Directors_NN
with_PIN
additional_JJ
cash_NN
benefit_NN
,_,
participants_NN
had_VBD
to_TO
retain_VB
these_DEMO
options_NOMZ
until_IN
at_PIN
least_JJ
the_DT
second_JJ
anniversary_NN
of_PIN
the_DT
effective_JJ
date_NN
of_PIN
the_DT
merger_NN
._.
During_PIN
The_DT
Corporate_JJ
Responsibility_NOMZ
Committee_NN
formerly_TIME
the_DT
Corporate_JJ
Social_NN
a_DT
majority_NOMZ
of_PIN
the_DT
Board_NN
,_,
excluding_VBG [PRESP]
the_DT
Chairman_NN
,_,
being_VBG [BEMA]
independent_PRED
the_DT
year_NN
Dr_NN
J_NN
P_NN
Garnier_NN
received_VBD
182,478_CD
relating_VBG
to_PIN
options_NOMZ
exercised_VBN
and_CC
Sir_NN
Richard_NN
Sykes_NN
received_VBD
940,499_CD
,_,
under_IN
the_DT
EOI_NN
,_,
as_CONJ
a_NULL
result_NULL
of_PIN
Responsibility_NOMZ
Committee_NN
consists_VPRT
entirely_AMP
of_PIN
Non-Executive_JJ
Directors_NN
and_CC
Non-Executive_JJ
Directors_NN
._.
Sir_NN
Ian_NN
Prosser_NN
is_VPRT [BEMA]
the_DT
Senior_JJ
Independent_NN
Director_NN
._.
his_TPP3
options_NOMZ
lapsing_GER
above_PLACE
market_NN
value_NN
._.
Those_DEMO
amounts_NN
are_VPRT [PASS]
included_VBN
in_PIN
other_JJ
benefits_NN
in_PIN
the_DT
table_NN
above_PLACE
._.
provides_VPRT
a_DT
Board_NN
level_NN
forum_NN
for_PIN
the_DT
regular_JJ
review_NN
of_PIN
external_JJ
issues_NN
that_TSUB
have_VPRT
the_DT
potential_NN
for_PIN
serious_JJ
impact_NN
upon_PIN
the_DT
Groups_NN
business_NOMZ
and_CC
From_PIN
1st_CD
June_NN
2002_CD
Sir_NN
Richard_NN
Sykes_NN
was_VBD [PASS]
appointed_VBN
Senior_JJ
Advisor_NN
to_PIN
the_DT
company_NN
,_,
at_PIN
a_DT
salary_NN
of_PIN
49,000_CD
per_PIN
annum_NN
which_WDT [WHOBJ]
he_TPP3
received_VBD
in_PIN
Board_NN
process_NN
reputation_NOMZ
._.
The_DT
Committee_NN
is_VPRT [BEMA]
also_RB
responsible_PRED
for_PIN
annual_JJ
governance_NN
,_,
addition_NOMZ
to_PIN
the_DT
fees_NN
and_PHC
salary_NN
above_PLACE
which_WDT
he_TPP3
received_VBD
as_IN
a_DT
former_JJ
director_NN
._.
The_DT
Board_NN
meets_VPRT
at_PIN
least_JJ
six_CD
times_NN
a_DT
year_NN
._.
It_PIT
has_VPRT
a_DT
formal_JJ
schedule_NN
oversight_NN
of_PIN
the_DT
Groups_NN
worldwide_JJ
donations_NOMZ
and_PHC
community_NOMZ
support_NN
._.
of_PIN
matters_NN
reserved_VBN [WZPAST]
to_PIN
it_PIT
for_PIN
decision_NN
but_CC
otherwise_CONJ
delegates_NN
specific_JJ
The_DT
Committee_NN
meets_VPRT
formally_RB
twice_RB
a_DT
year_NN
and_CC
has_VPRT
further_JJ
meetings_GER
Non-Executive_JJ
Directors_NN
are_VPRT [PASS]
required_VBN [SUAV]
to_TO
receive_VB
a_DT
significant_JJ
part_NN
of_PIN
their_TPP3
fees_NN
in_PIN
the_DT
form_NN
of_PIN
shares_NN
and_PHC
ADSs_NN
and_CC
may_POMD [SPAU]
also_RB
elect_VB
to_TO
invest_VB
part_NN
responsibilities_NOMZ
to_PIN
Board_NN
committees_NN
,_,
as_IN
described_VBN
below_PLACE
._.
The_DT
Board_NN
and_PHC
consultations_NOMZ
as_IN
required_VBN [SUAV]
._.
or_CC
all_QUAN
of_PIN
the_DT
balance_NN
of_PIN
their_TPP3
fees_NN
in_PIN
the_DT
form_NN
of_PIN
shares_NN
and_PHC
ADSs_NN
._.
The_DT
value_NN
of_PIN
these_DEMO
shares_NN
and_PHC
ADSs_NN
at_PIN
the_DT
dates_NN
of_PIN
award_NN
are_VPRT [PASS]
included_VBN
in_PIN
fees_NN
works_VPRT
to_PIN
an_DT
agreed_NN
business_NOMZ
agenda_NN
in_PIN
reviewing_VBG
the_DT
key_JJ
activities_NOMZ
of_PIN
and_CC
salary_NN
above_PLACE
._.
These_DEMO
shares_NN
and_PHC
ADSs_NN
are_VPRT [PASS]
not_XX0
paid_VBN
out_PIN
until_IN
the_DT
Directors_NN
retirement_NOMZ
from_PIN
the_DT
Board_NN
._.
the_DT
business_NOMZ
,_,
and_ANDC
receives_VPRT
papers_NN
and_PHC
presentations_NOMZ
to_TO
enable_VB
it_PIT
to_TO
do_VB [PROD]
Corporate_JJ
Administration_NOMZ
&_CC
Transactions_NOMZ
Committee_NN
so_RB
effectively_RB
._.
The_DT
Board_NN
considers_VPRT [PRIV]
and_PHC
reviews_VPRT
the_DT
work_NN
undertaken_VBN [WZPAST]
by_PIN
Following_VBG
their_TPP3
retirement_NOMZ
on_PIN
5th_JJ
June_NN
2003_CD
,_,
Sir_NN
Roger_NN
Hurn_NN
and_PHC
Mr_NN
Allaire_NN
received_VBD
the_DT
then_RB
value_NN
of_PIN
their_TPP3
shares_NN
and_PHC
ADSs_NN
as_IN
awarded_VBN
under_IN
The_DT
Corporate_JJ
Administration_NOMZ
&_CC
Transactions_NOMZ
Committee_NN
reviews_VPRT
and_CC
its_PIT
Committees_NN
._.
the_DT
Non-Executive_NN
Directors_NN
share_VPRT
arrangements_NOMZ
and_CC
equivalent_JJ
SmithKline_NN
Beecham_NN
arrangements_NOMZ
._.
Sir_NN
Roger_NN
Hurn_NN
elected_VBD
to_TO
receive_VB
his_TPP3
approves_VPRT
matters_NN
in_PIN
connection_NOMZ
with_PIN
the_DT
administration_NOMZ
of_PIN
the_DT
Groups_NN
entitlement_NOMZ
in_PIN
instalments_NOMZ
and_PHC
Mr_NN
Allaire_NN
elected_VBD
to_TO
receive_VB
his_TPP3
full_JJ
entitlement_NOMZ
immediately_TIME
._.
business_NOMZ
,_,
and_ANDC
of_PIN
certain_JJ
corporate_JJ
transactions_NOMZ
._.
The_DT
Committee_NN
consists_VPRT
The_DT
Company_NN
Secretary_NN
is_VPRT [BEMA]
responsible_PRED
to_PIN
the_DT
Board_NN
and_CC
is_VPRT [BEMA]
available_PRED
of_PIN
the_DT
Directors_NN
,_,
Corporate_NN
Executive_NN
Team_NN
members_NN
and_CC
the_DT
Company_NN
to_PIN
individual_JJ
Directors_NN
in_PIN
respect_NN
of_PIN
Board_NN
procedures_NN
._.
The_DT
Company_NN
In_CONJ
addition_NULL
to_PIN
annual_JJ
compensation_NOMZ
,_,
GlaxoSmithKline_NN
operates_VPRT
share_NN
plans_NN
to_TO
provide_VB
incentives_NN
to_PIN
Executive_NN
Directors_NN
to_TO
achieve_VB
longer-term_JJ
Secretary_NN
._.
The_DT
Committee_NN
meets_VPRT
as_RB
necessary_JJ
._.
Secretary_NN
is_VPRT
Simon_NN
Bicknell_NN
who_WP [WHSUB]
was_VBD [PASS]
appointed_VBN
in_PIN
May_POMD
2000_CD
._.
He_TPP3
is_VPRT [BEMA]
a_DT
growth_NN
in_PIN
shareholder_NN
value_NN
._.
Gains_NN
under_IN
such_JJ
plans_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
on_PIN
exercise_NN
or_CC
award_NN
,_,
but_CC
reflect_VPRT [PRIV] [THATD]
value_NN
earned_VBN
over_IN
a_DT
period_NN
of_PIN
years_NN
._.
The_DT
timing_NN
of_PIN
exercise_NN
is_VPRT [BEMA]
normally_RB
at_PIN
the_DT
discretion_NOMZ
of_PIN
the_DT
Director_NN
._.
Gains_NN
in_PIN
2003_CD
on_PIN
exercise_NN
of_PIN
options_NOMZ
were_VBD
:_:
share_NN
option_NOMZ
plans_VPRT
3,097,260_CD
2002_CD
barrister_NN
and_CC
joined_VBD
the_DT
Group_NN
in_PIN
1984_CD
._.
He_TPP3
is_VPRT
secretary_NN
to_PIN
all_QUAN
the_DT
Board_NN
Corporate_NN
Executive_NN
Team_NN
nil_NN
:_:
long-term_JJ
incentive_NN
plan_NN
256,134_CD
2002_CD
293,370_CD
._.
Full_JJ
details_NN
of_PIN
the_DT
awards_NN
granted_VBN [SUAV]
under_IN
the_DT
companys_NN
share_NN
plans_VPRT
during_PIN
2003_CD
Committees_NN
._.
The_DT
Corporate_NN
Executive_NN
Team_NN
CET_NN
assists_VPRT
the_DT
CEO_NN
in_PIN
the_DT
executive_NN
can_POMD
be_VB [PASS]
found_VBN [PRIV]
in_PIN
the_DT
Annual_JJ
Report_NN
2003_CD
-_:
refer_VPRT
to_PIN
Shareholder_NN
information_NOMZ
._.
The_DT
CET_NN
meets_VPRT
11_CD
times_NN
a_DT
year_NN
._.
The_DT
members_NN
and_CC
their_TPP3
responsibilities_NOMZ
are_VPRT [PASS]
given_VBN
on_PIN
page_NN
17_CD
._.
The_DT
accrued_VBN
annual_JJ
benefits_NN
under_IN
the_DT
defined_VBN
benefit_NN
schemes_NN
operated_VBN [WZPAST]
by_PIN
the_DT
Group_NN
were_VBD
:_:
Dr_VB
J_NN
P_NN
Garnier_NN
565,294_CD
:_:
Mr_NN
J_NN
D_NN
Coombe_NN
317,211_CD
._.
In_CONJ
addition_NULL
,_,
Dr_NN
J_NN
P_NN
Garnier_NN
is_VPRT [BEMA]
also_RB
a_DT
member_NN
of_PIN
a_DT
money_NN
purchase_NN
scheme_NN
into_PIN
which_WDT [PIRE]
contributions_NOMZ
of_PIN
88,609_CD
were_VBD [PASS]
paid_VBN
._.
Remuneration_NOMZ
of_PIN
Directors_NN
None_INPR
of_PIN
the_DT
above_PLACE
Directors_NN
received_VBD
expenses_NN
during_PIN
the_DT
year_NN
requiring_VBG [SUAV] [WZPRES]
separate_JJ
disclosure_NN
as_IN
defined_VBN
by_PIN
the_DT
Regulations_NOMZ
._.
Information_NOMZ
on_PIN
the_DT
remuneration_NOMZ
of_PIN
Directors_NN
is_VPRT [PASS]
given_VBN
in_PIN
the_DT
Summary_NN
Remuneration_NOMZ
Report_NN
on_PIN
pages_NN
18_CD
to_PIN
20_CD
._.
20_CD
Annual_JJ
Review_NN
2003_CD
Annual_JJ
Review_NN
2003_CD
21_CD
Business_NOMZ
operating_GER
review_NN
Business_NOMZ
operating_VBG [WZPRES]
review_NN
Products_NN
drive_VPRT
growth_NN
Total_JJ
pharmaceutical_JJ
turnover_NN
grew_VBD
five_CD
per_PIN
cent_NN
in_PIN
2003_CD
to_TO
just_EMPH
over_IN
18_CD
billion_CD
-_:
a_DT
good_JJ
performance_NN
given_VBN
the_DT
generic_JJ
erosion_NN
Pharmaceutical_NN
turnover_NN
by_PIN
therapeutic_JJ
area_NN
Consumer_NN
Healthcare_NN
2003_CD
2002_CD
%_NN
CER_NN
of_PIN
two_CD
of_PIN
GSKs_NN
biggest_JJ
products_NN
,_,
Augmentin_NN
and_PHC
Paxil_NN
._.
Excluding_VBG
m_FW
m_FW
Growth_NN
Total_JJ
Consumer_NN
Healthcare_NN
sales_NN
grew_VBD
four_CD
per_PIN
cent_NN
in_PIN
2003_CD
to_PIN
3.3_CD
billion_CD
._.
CNS_NN
4,455_CD
4,511_CD
4_CD
sales_NN
of_PIN
these_DEMO
products_NN
,_,
pharmaceutical_JJ
turnover_NN
grew_VBD
9_CD
per_PIN
cent_NN
._.
Respiratory_NN
4,417_CD
3,987_CD
14_CD
Over-the-counter_NN
medicine_NN
sales_NN
were_VBD [BEMA]
1.6_CD
billion_CD
,_,
up_RB
two_CD
per_PIN
cent_NN
._.
Anti-virals_NN
2,349_CD
2,299_CD
5_CD
Sales_NN
of_PIN
smoking_GER
control_NN
and_CC
gastro-intestinal_JJ
products_NN
were_VBD [BEMA]
down_RB
Anti-bacterials_PRED
1,815_CD
2,210_CD
16_CD
significantly_RB
in_PIN
the_DT
USA_NN
,_,
primarily_RB
due_JJ
to_PIN
flat_JJ
market_NN
conditions_NOMZ
and_CC
Within_PIN
anti-virals_NN
,_,
HIV_NN
medicines_NN
grew_VBD
across_PLACE
all_QUAN
regions_NN
and_CC
totalled_VBD
Pharmaceuticals_NN
Vaccines_NN
1,123_CD
1,080_CD
2_CD
private_JJ
label_NN
competition_NOMZ
._.
Growth_NN
from_PIN
smoking_GER
control_NN
products_NN
1.5_CD
billion_CD
in_PIN
sales_NN
,_,
up_RB
six_CD
per_PIN
cent_NN
._.
Sales_NN
of_PIN
Trizivir_NN
,_,
GSKs_NN
triple_JJ
Oncology_NN
and_PHC
emesis_NN
1,001_CD
977_CD
9_CD
recently_TIME
launched_VBN
in_PIN
Europe_NN
and_PHC
sales_NN
of_PIN
dermatological_JJ
products_NN
combination_NOMZ
therapy_NN
,_,
grew_VBD
22_CD
per_PIN
cent_NN
._.
Global_JJ
sales_NN
of_PIN
Valtrex_NN
,_,
which_WDT [SERE]
In_PIN
the_DT
central_JJ
nervous_JJ
system_NN
therapy_NN
area_NN
,_,
sales_NN
grew_VBD
four_CD
per_PIN
cent_NN
._.
Sales_NN
Metabolic_NN
1,079_CD
960_CD
20_CD
acquired_VBN
earlier_TIME
this_DEMO
year_NN
helped_VBD
to_TO
offset_VB
these_DEMO
declines_NN
._.
Oral_JJ
care_NN
sales_NN
received_VBD
FDA_NN
approval_NN
in_PIN
August_NN
2003_CD
to_TO
reduce_VB
the_DT
risk_NN
of_PIN
transmission_NN
of_PIN
Seroxat_NN
Paxil_NN
,_,
a_DT
leading_VBG
product_NN
for_PIN
depression_NN
and_PHC
anxiety_NN
disorders_NN
,_,
Cardiovascular_NN
and_CC
urogenital_JJ
771_CD
661_CD
22_CD
were_VBD [BEMA]
1.1_CD
billion_CD
,_,
up_RB
three_CD
per_PIN
cent_NN
._.
GSKs_NN
Sensodyne_NN
brand_NN
continues_VPRT
of_PIN
genital_JJ
herpes_NN
,_,
rose_VBD
23_CD
per_PIN
cent_NN
._.
US_FPP1
sales_NN
declined_VBD
nine_CD
per_PIN
cent_NN
to_PIN
1,179_CD
million_CD
Other_JJ
1,171_CD
1,310_CD
8_CD
to_TO
grow_VB
in_PIN
all_QUAN
regions_NN
._.
Nutritional_NN
healthcare_NN
products_NN
grew_VBD
nine_CD
per_PIN
following_VBG
the_DT
launch_NN
of_PIN
a_DT
generic_JJ
paroxetine_NN
in_PIN
September_NN
2003_CD
._.
Lucozade_NN
Sport_NN
and_PHC
Lucozade_NN
Hydroactive_NN
a_DT
sustained_VBN
release_NN
formulation_NOMZ
,_,
increased_VBD
its_PIT
share_NN
of_PIN
total_JJ
prescriptions_NOMZ
continued_VBD
to_TO
drive_VB
growth_NN
in_PIN
this_DEMO
category_NN
._.
Several_QUAN
significant_JJ
product_NN
launches_NN
and_PHC
filings_GER
planned_VBN [WZPAST]
for_PIN
since_OSUB
the_DT
generic_JJ
paroxetine_JJ
launch_NN
from_PIN
33_CD
per_PIN
cent_NN
to_PIN
37_CD
per_PIN
cent_NN
._.
Paxil_NN
2004_CD
include_VPRT
:_:
CR_NN
sales_NN
in_PIN
2003_CD
were_VBD [BEMA]
387_CD
million_CD
._.
European_JJ
sales_NN
declined_VBD
eight_CD
per_PIN
Legal_JJ
proceedings_GER
cent_NN
but_CC
International_JJ
sales_NN
grew_VBD
25_CD
per_PIN
cent_NN
led_VBN [WZPAST]
by_PIN
continued_VBN
strong_JJ
Solifenacin_NN
for_PIN
over-active_JJ
bladder_NN
Trading_GER
profit_NN
and_PHC
EPS_NN
growth_NN
in_PIN
Japan_NN
._.
Sales_NN
of_PIN
Wellbutrin_NN
,_,
for_PIN
depression_NN
,_,
grew_VBD
18_CD
per_PIN
cent_NN
to_PIN
The_DT
Group_NN
is_VPRT [PASS]
involved_VBN
in_PIN
patent_NN
litigation_NOMZ
with_PIN
manufacturers_NN
seeking_VBG [WZPRES]
to_PIN
Avandaryl_NN
,_,
a_DT
fixed-dose_JJ
combination_NOMZ
treatment_NOMZ
for_PIN
type_NN
2_CD
953_CD
million_CD
._.
Wellbutrin_NN
XL_NN
,_,
a_DT
new_JJ
improved_VBN
formulation_NOMZ
,_,
was_VBD [PASS]
launched_VBN
market_NN
generic_JJ
versions_NN
of_PIN
many_QUAN
of_PIN
the_DT
Groups_NN
most_EMPH
important_JJ
products_NN
,_,
diabetes_NN
Business_NOMZ
performance_NN
trading_GER
profit_NN
was_VBD [BEMA]
6.9_CD
billion_CD
with_PIN
a_DT
growth_NN
in_PIN
2003_CD
and_CC
now_TIME
accounts_VPRT
for_PIN
40_CD
per_PIN
cent_NN
of_PIN
branded_JJ
Wellbutrin_NN
including_VBG [WZPRES]
Wellbutrin_NN
,_,
Seretide_NN
,_,
Avandia_NN
,_,
Imitrex_NN
,_,
Valtrex_NN
,_,
Lamictal_NN
and_CC
of_PIN
nine_CD
per_PIN
cent_NN
,_,
stronger_JJ
than_PIN
turnover_NN
growth_NN
of_PIN
five_CD
per_PIN
cent_NN
,_,
prescriptions_NOMZ
and_CC
7_CD
per_PIN
cent_NN
of_PIN
sales_NN
in_PIN
2003_CD
._.
Limited_JJ
generic_JJ
competition_NOMZ
Epivir_NN
Ziagen_NN
,_,
the_DT
first_JJ
once-daily_JJ
combination_NOMZ
HIV_NN
AIDS_NN
Zofran_NN
,_,
prior_RB
to_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
Groups_NN
patents_NN
._.
The_DT
Group_NN
is_VPRT
demonstrating_VBG [PRIV]
an_DT
improved_JJ
trading_GER
margin_NN
of_PIN
0.7_CD
points_NN
to_PIN
32.3_CD
per_PIN
cent_NN
to_PIN
Wellbutrin_NN
began_VBD
in_PIN
the_DT
USA_NN
in_PIN
January_NN
2004_CD
for_PIN
the_DT
100_CD
mg_NN
dose_NN
._.
currently_RB
a_DT
defendant_NN
in_PIN
a_DT
number_NN
of_PIN
product_NN
liability_NOMZ
lawsuits_NN
,_,
including_VBG
compared_VBN
with_PIN
2002_CD
._.
This_DEMP
was_VBD [BEMA]
principally_RB
due_PRED
to_TO
cost_VB
savings_GER
derived_VBN
Generic_JJ
competition_NOMZ
across_PLACE
all_QUAN
dose_NN
forms_NN
of_PIN
Wellbutrin_NN
SR_NN
is_VPRT [PASS]
expected_VBN [PRIV]
at_PIN
class_NN
actions_NOMZ
,_,
that_DEMP
involve_VPRT
substantial_JJ
claims_NN
for_PIN
damages_NN
related_VBN [WZPAST]
to_PIN
the_DT
from_PIN
merger_NN
integration_NOMZ
,_,
manufacturing_GER
and_CC
other_JJ
initiatives_NN
,_,
partly_DWNT
offset_VBN
any_QUAN
time_NN
._.
Lamictal_NN
,_,
for_PIN
epilepsy_NN
,_,
continued_VBD
to_TO
grow_VB
across_PLACE
all_QUAN
regions_NN
with_PIN
Groups_NN
pharmaceutical_JJ
products_NN
._.
The_DT
Group_NN
is_VPRT [BEMA]
also_RB
a_DT
defendant_NN
in_PIN
by_PIN
charges_NN
relating_VBG [WZPRES]
to_PIN
operational_JJ
excellence_NN
cost_NN
saving_VBG [WZPRES]
programs_NN
and_PHC
sales_NN
up_IN
31_CD
per_PIN
cent_NN
driven_VBN [WZPAST]
by_PIN
the_DT
FDA-approved_JJ
long_JJ
term_NN
maintenance_NN
anti-trust_JJ
actions_NOMZ
filed_VBN
following_VBG
adverse_JJ
outcomes_NN
in_PIN
prosecution_NOMZ
of_PIN
Anti-bacterial_JJ
sales_NN
declined_VBD
16_CD
per_PIN
cent_NN
worldwide_NN
and_CC
41_CD
per_PIN
cent_NN
in_PIN
higher_JJ
pension_NN
costs_NN
._.
Further_RB
,_,
the_DT
Group_NN
is_VPRT
responding_VBG
to_PIN
federal_JJ
the_DT
USA_NN
._.
Augmentins_NN
US_FPP1
sales_NN
were_VBD [BEMA]
down_RB
51_CD
per_PIN
cent_NN
in_PIN
the_DT
year_NN
as_IN
a_DT
and_CC
state_NN
governmental_JJ
investigations_NOMZ
in_PIN
the_DT
USA_NN
into_PIN
pricing_GER
,_,
marketing_GER
result_NN
of_PIN
generic_JJ
competition_NOMZ
that_TSUB
began_VBD
in_PIN
the_DT
third_JJ
quarter_NN
of_PIN
2002_CD
._.
Full_JJ
year_NN
business_NOMZ
performance_NN
earnings_GER
per_PIN
share_NN
EPS_NN
of_PIN
82.1_CD
pence_NN
In_PIN
respiratory_JJ
,_,
GSK_NN
continues_VPRT
to_TO
be_VB [BEMA]
the_DT
global_JJ
leader_NN
in_PIN
respiratory_JJ
and_CC
reimbursement_NOMZ
of_PIN
a_DT
number_NN
of_PIN
prescription_NOMZ
drug_NN
products_NN
._.
See_VB [PRIV]
Note_VB [PRIV]
In_PIN
the_DT
USA_NN
,_,
GSKs_NN
two_CD
new_JJ
antibiotics_NN
,_,
Augmentin_NN
ES_NN
for_PIN
children_NN
and_CC
increased_VBD
10_CD
per_PIN
cent_NN
,_,
and_ANDC
five_CD
per_PIN
cent_NN
in_PIN
sterling_GER
terms_NN
,_,
reflecting_VBG [PRIV] [PRESP]
a_DT
pharmaceuticals_NN
with_PIN
sales_NN
of_PIN
its_PIT
three_CD
key_JJ
products_NN
Seretide_NN
Advair_NN
,_,
30_CD
to_PIN
the_DT
Financial_NN
statements_NOMZ
Legal_JJ
proceedings_GER
in_PIN
the_DT
Annual_JJ
Report_NN
Augmentin_NN
XR_NN
for_PIN
adults_NN
,_,
recorded_VBN
sales_NN
of_PIN
237_CD
million_CD
in_PIN
2003_CD
in_PIN
spite_NN
weakening_GER
of_PIN
the_DT
US_FPP1
dollar_NN
._.
Full_JJ
year_NN
statutory_JJ
EPS_NN
was_VBD [BEMA]
77.2_CD
p_NN
,_,
an_DT
increase_NN
Flixotide_NN
Flovent_NN
and_PHC
Serevent_NN
amounting_VBG [WZPRES]
to_PIN
3.4_CD
billion_CD
,_,
up_IN
17_CD
per_PIN
cent_NN
._.
2003_CD
for_PIN
a_DT
discussion_NN
of_PIN
proceedings_GER
and_CC
governmental_JJ
investigations_NOMZ
of_PIN
generic_JJ
competition_NOMZ
._.
Sales_NN
of_PIN
Seretide_NN
Advair_NN
,_,
GSKs_NN
largest_JJ
product_NN
,_,
grew_VBD
39_CD
per_PIN
cent_NN
to_PIN
in_PIN
which_WDT [PIRE]
the_DT
Group_NN
is_VPRT [SPAU] [PASS]
currently_RB
involved_VBN
._.
2.2_CD
billion_CD
although_CONC
this_DEMP
contributed_VBD
to_PIN
declines_NN
in_PIN
Serevent_NN
and_PHC
Flixotide_NN
,_,
Within_PIN
vaccines_NN
,_,
Infanrix_NN
Pediarix_NN
grew_VBD
32_CD
per_PIN
cent_NN
to_PIN
336_CD
million_CD
._.
The_DT
growth_NN
prospects_NN
for_PIN
Advair_NN
were_VBD [BEMA]
further_JJ
GSK_NN
delivered_VBD
business_NOMZ
performance_NN
Pediarix_NN
adds_VPRT [PUBV]
protection_NOMZ
against_PIN
hepatitis_NN
B_NN
and_PHC
poliomyelitis_NN
to_PIN
the_DT
strengthened_VBN
with_PIN
an_DT
FDA_NN
approval_NN
for_PIN
use_NN
in_PIN
the_DT
treatment_NOMZ
of_PIN
Chronic_NN
EPS_NN
growth_NN
of_PIN
10_CD
per_PIN
cent_NN
in_PIN
line_NN
Infanrix_NN
combination_NOMZ
and_PHC
results_NN
in_PIN
up_RB
to_PIN
six_CD
fewer_JJ
injections_NOMZ
for_PIN
infants_NN
._.
Obstructive_NN
Pulmonary_NN
Disease_NN
COPD_NN
in_PIN
the_DT
fourth_JJ
quarter_NN
of_PIN
2003_CD
._.
Business_NOMZ
performance_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
the_DT
primary_JJ
performance_NN
measure_NN
The_DT
hepatitis_NN
franchise_NN
declined_VBD
13_CD
per_PIN
cent_NN
reflecting_VBG [PRIV] [WZPRES]
competitive_JJ
with_PIN
guidance_NN
._.
used_VBN [PASTP]
by_PIN
management_NOMZ
,_,
is_VPRT [PASS]
presented_VBN
after_IN
excluding_VBG
merger_NN
items_NN
,_,
pressure_NN
in_PIN
the_DT
USA_NN
and_PHC
Europe_NN
._.
integration_NOMZ
and_PHC
restructuring_GER
costs_NN
and_PHC
disposal_NN
of_PIN
businesses_NOMZ
._.
Management_NOMZ
believes_VPRT [PRIV]
that_THVC
exclusion_NN
of_PIN
these_DEMO
items_NN
provides_VPRT
a_DT
better_JJ
Taxation_NOMZ
In_PIN
oncology_NN
,_,
sales_NN
of_PIN
Zofran_NN
grew_VBD
16_CD
per_PIN
cent_NN
to_PIN
774_CD
million_CD
,_,
driven_VBN [PASTP]
by_PIN
GSKs_NN
underlying_VBG [WZPRES]
growth_NN
driven_VBN [WZPAST]
by_PIN
a_DT
broad_JJ
portfolio_NN
of_PIN
fast_JJ
reflection_NOMZ
of_PIN
the_DT
way_NN
in_PIN
which_WDT [PIRE]
the_DT
business_NOMZ
is_VPRT [PASS]
managed_VBN
and_PHC
gives_VPRT
an_DT
a_DT
strong_JJ
US_FPP1
performance_NN
,_,
up_RB
20_CD
per_PIN
cent_NN
to_PIN
575_CD
million_CD
._.
growing_VBG
,_,
high_JJ
value_NN
products_NN
:_:
indication_NOMZ
of_PIN
the_DT
performance_NN
of_PIN
the_DT
Group_NN
in_PIN
terms_NN
of_PIN
those_DEMO
GSK_NN
has_VPRT
open_JJ
tax_NN
issues_NN
with_PIN
the_DT
revenue_NN
authorities_NOMZ
in_PIN
the_DT
USA_NN
,_,
UK_NN
,_,
elements_NOMZ
of_PIN
revenue_NN
and_PHC
expenditure_NN
which_WDT [WHOBJ]
local_JJ
management_NOMZ
is_VPRT
Seretide_NN
Advair_NN
2.2_CD
billion_CD
up_IN
39_CD
%_NN
Japan_NN
and_PHC
Canada_NN
,_,
but_CC
by_PIN
far_PLACE
the_DT
largest_JJ
relates_VPRT
to_PIN
Glaxo_NN
heritage_NN
In_PIN
metabolic_JJ
,_,
the_DT
Avandia_NN
franchise_NN
Avandia_NN
and_PHC
Avandamet_NN
grew_VBD
24_CD
able_JJ
to_TO
influence_VB
._.
This_DEMO
information_NOMZ
,_,
which_WDT [SERE]
is_VPRT [PASS]
provided_VBN
in_CONJ
addition_NULL
to_PIN
products_NN
in_PIN
the_DT
USA_NN
._.
The_DT
Group_NN
has_VPRT [SPAU] [PEAS]
now_TIME
received_VBN
a_DT
claim_NN
for_PIN
additional_JJ
per_PIN
cent_NN
for_PIN
the_DT
year_NN
._.
Avandamet_NN
,_,
a_DT
combination_NOMZ
of_PIN
Avandia_NN
and_PHC
Avandia_NN
Avandamet_NN
0.9_CD
billion_CD
up_IN
24_CD
%_NN
the_DT
statutory_JJ
results_NN
prepared_VBN
under_IN
UK_NN
GAAP_NN
,_,
is_VPRT [PASS]
given_VBN
to_TO
assist_VB
taxes_NN
that_TOBJ
the_DT
IRS_NN
asserts_VPRT [PUBV]
legacy_NN
company_NN
Glaxo_NN
Wellcome_NN
owes_VPRT
for_PIN
the_DT
metformin_NN
HCI_NN
,_,
expanded_VBD
the_DT
Avandia_NN
metabolic_JJ
franchise_NN
with_PIN
its_PIT
US_FPP1
Wellbutrin_NN
0.9_CD
billion_CD
up_IN
18_CD
%_NN
shareholders_NN
to_TO
gain_VB
a_DT
clearer_JJ
understanding_GER
of_PIN
the_DT
underlying_VBG
years_NN
1989_CD
to_PIN
1996_CD
._.
This_DEMO
statutory_JJ
notice_NN
of_PIN
deficiency_NN
for_PIN
$_$
2.7_CD
billion_CD
launch_NN
in_PIN
the_DT
fourth_JJ
quarter_NN
of_PIN
2002_CD
._.
In_PIN
Europe_NN
,_,
the_DT
franchise_NN
should_NEMD
performance_NN
of_PIN
the_DT
business_NOMZ
and_CC
to_TO
increase_VB
comparability_NOMZ
for_PIN
the_DT
1.5_CD
billion_CD
in_PIN
tax_NN
principally_RB
relates_VPRT
to_PIN
the_DT
allocation_NOMZ
of_PIN
profits_NN
for_PIN
Glaxo_NN
benefit_NN
further_RB
from_PIN
the_DT
EU_NN
approval_NN
of_PIN
Avandamet_NN
in_PIN
December_NN
2003_CD
._.
Zofran_NN
0.8_CD
billion_CD
up_IN
16_CD
%_NN
periods_NN
presented_VBN
._.
heritage_NN
products_NN
between_PIN
the_DT
USA_NN
and_CC
other_JJ
countries_NN
._.
To_PIN
the_DT
extent_NN
Avandia_NN
also_RB
did_VBD
very_AMP
well_RB
in_PIN
International_JJ
markets_NN
with_PIN
sales_NN
of_PIN
106_CD
Lamictal_JJ
0.6_CD
billion_CD
up_IN
31_CD
%_NN
that_TOBJ
the_DT
IRS_NN
was_VBD [BEMA]
successful_PRED
in_PIN
its_PIT
claim_NN
,_,
interest_NN
would_PRMD
be_VB [BEMA]
payable_PRED
._.
In_PIN
order_NN
to_TO
illustrate_VB
underlying_VBG
performance_NN
,_,
it_PIT
is_VPRT [BEMA]
the_DT
Groups_NN
estimates_VPRT [PRIV]
the_DT
interest_NN
on_PIN
the_DT
full_JJ
claim_NN
to_PIN
date_NN
would_PRMD
be_VB
approximately_RB
Valtrex_NN
0.5_CD
billion_CD
up_IN
23_CD
%_NN
practice_NN
to_TO
discuss_VB
the_DT
results_NN
in_PIN
terms_NN
of_PIN
constant_JJ
exchange_NN
rates_NN
$_$
2.5_CD
billion_CD
1.4_CD
billion_CD
,_,
net_NN
of_PIN
federal_JJ
tax_NN
relief_NN
._.
However_CONJ
,_,
there_EX
In_PIN
cardiovascular_JJ
and_PHC
urogenital_JJ
,_,
Coreg_NN
sales_NN
grew_VBD
28_CD
per_PIN
cent_NN
benefiting_VBG [WZPRES]
Trizivir_NN
0.4_CD
billion_CD
up_IN
22_CD
%_NN
CER_NN
growth_NN
._.
This_DEMP
represents_VPRT
growth_NN
calculated_VBN [PRIV]
as_IN
if_COND
the_DT
exchange_NN
continues_VPRT
to_TO
be_VB [BEMA]
a_DT
wide_JJ
difference_NN
of_PIN
views_NN
between_PIN
the_DT
Group_NN
and_CC
the_DT
from_PIN
recent_JJ
data_NN
that_TSUB
showed_VBD [PRIV]
a_DT
highly_AMP
significant_JJ
statistical_JJ
difference_NN
in_PIN
rates_NN
used_VBN
to_TO
determine_VB [SUAV] [PRIV]
the_DT
results_NN
of_PIN
overseas_PLACE
companies_NN
in_PIN
sterling_GER
Coreg_NN
0.4_CD
billion_CD
up_IN
28_CD
%_NN
IRS_NN
._.
The_DT
ultimate_JJ
liability_NOMZ
for_PIN
such_JJ
matters_NN
may_POMD
vary_VB
significantly_RB
from_PIN
survival_NN
between_PIN
Coreg_NN
and_PHC
metopropol_NN
in_PIN
patients_NN
with_PIN
heart_NN
failure_NN
._.
had_VBD [PEAS]
remained_VBN
unchanged_JJ
from_PIN
those_DEMP
used_VBN
in_PIN
the_DT
previous_JJ
period_NN
._.
amounts_NN
provided_VBD
and_PHC
is_VPRT [BEMA]
dependent_PRED
upon_PIN
the_DT
outcome_NN
of_PIN
litigation_NOMZ
Levitra_NN
vardenafil_NN
,_,
a_DT
new_JJ
agent_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
erectile_JJ
dysfunction_NOMZ
,_,
Infanrix_NN
Pediarix_NN
0.3_CD
billion_CD
up_IN
32_CD
%_NN
Growth_NN
rates_NN
are_VPRT [BEMA]
therefore_CONJ
at_PIN
CER_NN
unless_COND
otherwise_CONJ
stated_VBN [PUBV]
._.
proceedings_GER
and_PHC
negotiations_NOMZ
with_PIN
the_DT
relevant_JJ
tax_NN
authorities_NOMZ
._.
was_VBD [PASS]
launched_VBN
in_PIN
the_DT
USA_NN
in_PIN
August_NN
2003_CD
and_CC
in_PIN
Europe_NN
in_PIN
the_DT
first_JJ
half_NN
of_PIN
the_DT
year_NN
._.
22_CD
Annual_JJ
Review_NN
2003_CD
Annual_JJ
Review_NN
2003_CD
23_CD
Responsibility_NOMZ
statements_NOMZ
Summary_NN
financial_JJ
statements_NOMZ
FOR_PIN
THE_DT
YEAR_NN
TO_PIN
31ST_CD
DECEMBER_NN
2003_CD
Summary_NN
consolidated_JJ
profit_NN
and_PHC
loss_NN
account_NN
Annual_JJ
Review_NN
Corporate_NN
governance_NN
Merger_NN
,_,
restructuring_GER
and_PHC
Business_NOMZ
performance_NN
disposal_NN
of_PIN
subsidiaries_NN
Statutory_JJ
2003_CD
2002_CD
Growth_NN
2003 2002 2003 2002_CD
The_DT
Annual_JJ
Review_NN
is_VPRT [BEMA]
a_DT
summary_NN
report_NN
and_CC
does_VPRT
not_XX0
contain_VB
sufficient_JJ
The_DT
Combined_NN
Code_NN
Principles_NN
of_PIN
Good_JJ
Governance_NN
and_PHC
Code_NN
of_PIN
Best_JJ
m_FW
m_FW [BEMA]
CER_CD
%_NN
m_NN
m_FW
m_FW
m_FW
information_NOMZ
to_TO
allow_VB [SUAV]
as_IN
full_JJ
an_DT
understanding_GER
of_PIN
the_DT
results_NN
and_PHC
state_NN
Practice_NN
is_VPRT [BYPA]
specified_VBN
by_PIN
the_DT
Listing_GER
Rules_NN
of_PIN
the_DT
Financial_NN
Services_NN
Authority_NOMZ
of_PIN
affairs_NN
of_PIN
the_DT
Group_NN
as_IN
is_VPRT [BYPA]
provided_VBN
by_PIN
the_DT
Annual_JJ
Report_NN
2003_CD
._.
for_PIN
the_DT
guidance_NN
of_PIN
listed_VBN
companies_NN
1998_CD
Combined_NN
Code_NN
._.
The_DT
Board_NN
Turnover_NN
Shareholders_NN
requiring_VBG [SUAV] [WZPRES]
more_EMPH
detailed_JJ
information_NOMZ
may_POMD
obtain_VB
,_,
free_JJ
of_PIN
considers_VPRT [PRIV]
that_THVC
throughout_PIN
2003_CD
and_CC
up_RB
to_PIN
the_DT
date_NN
of_PIN
approval_NN
of_PIN
this_DEMO
Pharmaceuticals_NN
18,181_CD
17,995_CD
5_CD
18,181_CD
17,995_CD
charge_NN
,_,
a_DT
copy_NN
of_PIN
the_DT
Annual_JJ
Report_NN
2003_CD
and_CC
may_POMD [SPAU]
also_RB
elect_VB
to_TO
receive_VB
review_NN
,_,
GlaxoSmithKline_NN
plc_NN
applied_VBD
the_DT
principles_NN
of_PIN
the_DT
1998_CD
Combined_VBN
Consumer_NN
Healthcare_NN
3,260_CD
3,217_CD
4_CD
3,260_CD
3,217_CD
a_DT
copy_NN
of_PIN
the_DT
Annual_JJ
Report_NN
in_PIN
future_JJ
years_NN
refer_VPRT
to_PIN
Shareholder_NN
Code_NN
and_CC
,_,
with_PIN
the_DT
exception_NOMZ
of_PIN
matters_NN
where_RB
the_DT
companys_NN
position_NOMZ
Total_JJ
turnover_NN
21,441_CD
21,212_CD
5_CD
21,441_CD
21,212_CD
information_NOMZ
._.
is_VPRT [PASS]
described_VBN
in_PIN
the_DT
Annual_JJ
Report_NN
,_,
complied_VBN [PASTP]
with_PIN
the_DT
provisions_NN
of_PIN
the_DT
Combined_NN
Code_NN
,_,
and_ANDC
the_DT
guidance_NN
on_PIN
internal_JJ
control_NN
issued_VBN [WZPAST]
by_PIN
the_DT
Cost_NN
of_PIN
sales_NN
4,188_CD
4,243_CD
356_CD
366_CD
4,544_CD
4,609_CD
The_DT
Independent_NN
Auditors_NN
report_VPRT [PUBV]
on_PIN
the_DT
full_JJ
financial_JJ
statements_NOMZ
of_PIN
the_DT
1998_CD
Turnbull_NN
Committee_NN
._.
Selling_VBG
,_,
general_JJ
and_PHC
administrative_JJ
expenditure_NN
7,563_CD
7,543_CD
4_CD
18_CD
498_CD
7,581_CD
8,041_CD
Research_NN
and_PHC
development_NOMZ
expenditure_NN
2,770_CD
2,732_CD
4_CD
21_CD
168_CD
2,791_CD
2,900_CD
Group_NN
for_PIN
the_DT
year_NN
ended_VBD
31st_CD
December_NN
2003_CD
is_VPRT [BEMA]
unqualified_PRED
and_CC
does_VPRT
not_XX0
contain_VB
any_QUAN
statement_NOMZ
concerning_VBG [WZPRES]
inadequate_JJ
accounting_GER
records_NN
The_DT
Annual_JJ
Review_NN
,_,
including_VBG
Summary_NN
financial_JJ
statements_NOMZ
,_,
has_VPRT [PEAS]
been_VBN
Trading_GER
profit_NN
6,920_CD
6,694_CD
9_CD
395_CD
1,032_CD
6,525_CD
5,662_CD
or_CC
failure_NN
to_TO
obtain_VB
necessary_JJ
information_NOMZ
and_PHC
explanations_NOMZ
._.
approved_VBN [PASTP]
by_PIN
the_DT
Board_NN
of_PIN
Directors_NN
and_CC
signed_VBN
on_PIN
its_PIT
behalf_NN
by_PIN
Other_JJ
operating_GER
income_NN
expenses_NN
133 111 133 111_CD
Sir_NN
Christopher_NN
Hogg_NN
Profits_NN
of_PIN
associates_NN
93_CD
75_CD
93_CD
75_CD
Chairman_NN
Profit_NN
on_PIN
disposal_NN
of_PIN
products_NN
and_PHC
businesses_NOMZ
-_:
5_CD
21_CD
5_CD
21_CD
Summary_NN
financial_JJ
statements_NOMZ
3rd_VPRT
March_NN
2004_CD
Net_JJ
interest_NN
payable_JJ
161 141 161 141_CD
A_DT
columnar_NN
presentation_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
adopted_VBN
in_PIN
the_DT
Summary_NN
consolidated_JJ
Profit_NN
before_IN
taxation_NOMZ
6,719_CD
6,517_CD
8_CD
390_CD
1,011_CD
6,329_CD
5,506_CD
profit_NN
and_PHC
loss_NN
account_NN
in_PIN
order_NN
to_TO
illustrate_VB
business_NOMZ
performance_NN
which_WDT [WHSUB]
is_VPRT [BEMA]
Independent_JJ
auditors_NN
statement_NOMZ
to_PIN
the_DT
Taxation_NOMZ
1,848_CD
1,760_CD
109_CD
299_CD
1,739_CD
1,461_CD
the_DT
primary_JJ
measure_NN
used_VBN [WZPAST]
by_PIN
management_NOMZ
._.
For_PIN
this_DEMO
purpose_NN
certain_JJ
items_NN
members_NN
of_PIN
GlaxoSmithKline_NN
plc_NN
are_VPRT [PASS]
identified_VBN
separately_RB
and_CC
are_VPRT [PASS]
excluded_VBN
from_PIN
business_NOMZ
performance_NN
._.
Profit_NN
after_IN
taxation_NOMZ
4,871_CD
4,757_CD
281_CD
712_CD
4,590_CD
4,045_CD
These_DEMP
comprise_VPRT
merger_NN
items_NN
,_,
including_VBG
merger_NN
related_VBN
product_NN
Minority_NOMZ
interests_NN
94_CD
110_CD
94_CD
110_CD
We_FPP1
have_VPRT [PEAS]
examined_VBN
the_DT
Summary_NN
financial_JJ
statements_NOMZ
which_WDT [WHSUB]
comprise_VPRT
divestments_NOMZ
,_,
costs_NN
relating_VBG [WZPRES]
to_TO [SPIN]
previously_TIME
announced_VBN [PUBV]
manufacturing_GER
and_PHC
Preference_NN
share_NN
dividends_NN
12_CD
20_CD
12_CD
20_CD
the_DT
Summary_NN
consolidated_JJ
profit_NN
and_PHC
loss_NN
account_NN
,_,
Summary_NN
consolidated_VBD
other_JJ
restructuring_GER
,_,
and_ANDC
disposal_NN
of_PIN
businesses_NOMZ
._.
Management_NOMZ
believes_VPRT [PRIV]
that_THVC
Earnings_GER
4,765_CD
4,627_CD
8_CD
281_CD
712_CD
4,484_CD
3,915_CD
balance_NN
sheet_NN
and_PHC
Summary_NN
consolidated_JJ
cash_NN
flow_NN
statement_NOMZ
and_CC
the_DT
exclusion_NN
of_PIN
these_DEMO
non-recurring_JJ
items_NN
provides_VPRT
a_DT
better_JJ
reflection_NOMZ
of_PIN
the_DT
Summary_NN
Report_NN
of_PIN
the_DT
Directors_NN
including_VBG [WZPRES]
the_DT
Summary_NN
Remuneration_NOMZ
Earnings_GER
per_PIN
share_NN
82.1_CD
p_NN
78.3_CD
p_NN
10_CD
77.2_CD
p_NN
66.2_CD
p_NN
way_NN
the_DT
business_NOMZ
is_VPRT [PASS]
managed_VBN
and_PHC
gives_VPRT
an_DT
indication_NOMZ
of_PIN
the_DT
performance_NN
Report_NN
._.
of_PIN
the_DT
Group_NN
in_PIN
terms_NN
of_PIN
those_DEMO
elements_NOMZ
of_PIN
revenue_NN
and_PHC
expenditure_NN
Dividends_NN
2,374_CD
2,346_CD
which_WDT
local_JJ
management_NOMZ
is_VPRT [BEMA]
able_PRED
to_TO
influence_VB
._.
Business_NOMZ
performance_NN
is_VPRT [BEMA]
Respective_JJ
responsibilities_NOMZ
of_PIN
Directors_NN
and_PHC
Auditors_NN
To_TO
illustrate_VB
Business_NOMZ
performance_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
the_DT
primary_JJ
measure_NN
used_VBN [WZPAST]
by_PIN
management_NOMZ
,_,
merger_NN
items_NN
,_,
integration_NOMZ
and_PHC
restructuring_GER
costs_NN
and_PHC
disposal_NN
of_PIN
businesses_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
excluded_VBN
and_CC
an_DT
adjusted_JJ
discussed_VBN
in_PIN
the_DT
Business_NOMZ
operating_VBG [WZPRES]
review_NN
._.
Statutory_JJ
results_NN
include_VPRT
these_DEMO
items_NN
._.
Business_NOMZ
performance_NN
growth_NN
is_VPRT [BEMA]
at_PIN
constant_JJ
exchange_NN
rates_NN
CER_NN
._.
The_DT
Directors_NN
are_VPRT [BEMA]
responsible_PRED
for_PIN
preparing_VBG
the_DT
Annual_JJ
Review_NN
in_PIN
accordance_NN
with_PIN
applicable_JJ
law_NN
._.
Our_FPP1
responsibility_NOMZ
is_VPRT
to_TO
report_VB [PUBV]
to_PIN
you_SPP2
our_FPP1
Earnings_GER
and_PHC
shareholders_NN
funds_NN
are_VPRT [SPAU] [PASS]
also_RB
restated_VBN
in_PIN
accordance_NN
with_PIN
US_FPP1
opinion_NN
on_PIN
the_DT
consistency_NN
of_PIN
the_DT
Summary_NN
financial_JJ
statements_NOMZ
within_PIN
the_DT
Summary_NN
consolidated_JJ
balance_NN
sheet_NN
GAAP_NN
as_IN
additional_JJ
information_NOMZ
provided_VBN [WZPAST]
to_PIN
US_FPP1
shareholders_NN
._.
Annual_JJ
Review_NN
with_PIN
the_DT
Annual_JJ
financial_JJ
statements_NOMZ
,_,
the_DT
Report_NN
of_PIN
the_DT
2003_CD
2002_CD
Directors_NN
and_CC
the_DT
Directors_NN
Remuneration_NOMZ
Report_NN
,_,
and_ANDC
its_PIT
compliance_NN
with_PIN
m_NN
m_NN
Statement_NOMZ
by_PIN
the_DT
Directors_NN
the_DT
relevant_JJ
requirements_NOMZ
of_PIN
Section_NOMZ
251_CD
of_PIN
the_DT
United_NN
Kingdom_NN
Companies_NN
Act_NN
1985_CD
and_CC
the_DT
regulations_NOMZ
made_VBD
thereunder_RB
._.
We_FPP1
also_RB
read_VBD
the_DT
other_JJ
Fixed_JJ
assets_NN
11,350_CD
11,578_CD
The_DT
Annual_JJ
Review_NN
2003_CD
is_VPRT [BEMA]
the_DT
Summary_NN
Directors_NN
report_NN
and_CC
includes_VPRT
information_NOMZ
contained_VBN [WZPAST]
in_PIN
the_DT
Annual_JJ
Review_NN
and_CC
consider_VB [PRIV]
the_DT
implications_NOMZ
Current_JJ
assets_NN
12,625_CD
10,749_CD
Creditors_NN
:_:
amounts_NN
due_JJ
within_PIN
one_CD
year_NN
8,597_CD
8,808_CD
the_DT
Summary_NN
financial_JJ
statements_NOMZ
of_PIN
GlaxoSmithKline_NN
plc_NN
for_PIN
the_DT
year_NN
for_PIN
our_FPP1
report_NN
if_COND
we_FPP1
become_VPRT
aware_JJ
of_PIN
any_QUAN
apparent_JJ
misstatements_NOMZ
or_CC
Net_JJ
current_JJ
assets_NN
4,028_CD
1,941_CD
ended_VBD
31st_CD
December_NN
2003_CD
,_,
which_WDT [SERE]
is_VPRT [PASS]
published_VBN
in_PIN
hard-copy_JJ
printed_VBN
form_NN
material_NN
inconsistencies_NN
with_PIN
the_DT
Summary_NN
financial_JJ
statements_NOMZ
._.
Total_JJ
assets_NN
less_RB
current_JJ
liabilities_NOMZ
15,378_CD
13,519_CD
and_CC
on_PIN
the_DT
website_NN
._.
The_DT
Business_NOMZ
operating_VBG [WZPRES]
review_NN
,_,
the_DT
Summary_NN
financial_JJ
Creditors_NN
:_:
amounts_NN
due_RB
after_IN
one_CD
year_NN
3,883_CD
3,298_CD
statements_NOMZ
,_,
the_DT
Summary_NN
Remuneration_NOMZ
Report_NN
and_CC
the_DT
statement_NOMZ
on_PIN
This_DEMO
statement_NOMZ
,_,
including_VBG [PRESP]
the_DT
opinion_NN
,_,
has_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
for_PIN
and_CC
only_DWNT
Provisions_NN
for_PIN
liabilities_NOMZ
and_PHC
charges_NN
3,030_CD
2,833_CD
Corporate_JJ
governance_NN
are_VPRT
summaries_NN
of_PIN
information_NOMZ
in_PIN
the_DT
Annual_JJ
Report_NN
for_PIN
the_DT
companys_NN
members_NN
as_IN
a_DT
body_NN
in_PIN
accordance_NN
with_PIN
Section_NOMZ
251_CD
Net_JJ
assets_NN
8,465_CD
7,388_CD
2003_CD
._.
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
and_CC
for_PIN
no_SYNE
other_JJ
purpose_NN
._.
We_FPP1
do_VPRT
not_XX0
,_,
Capital_NN
and_PHC
reserves_NN
in_PIN
giving_VBG
this_DEMO
opinion_NN
,_,
accept_VB [PRIV]
or_CC
assume_VB [PRIV]
responsibility_NOMZ
for_PIN
any_QUAN
other_JJ
Equity_NOMZ
shareholders_NN
funds_NN
7,720_CD
6,581_CD
The_DT
Directors_NN
are_VPRT [BEMA]
responsible_PRED
for_PIN
the_DT
maintenance_NN
and_PHC
integrity_NOMZ
of_PIN
the_DT
purpose_NN
or_CC
to_PIN
any_QUAN
other_JJ
person_NN
to_PIN
whom_WP [PIRE]
this_DEMO
statement_NOMZ
is_VPRT [PASS]
shown_VBN [PRIV]
Minority_NOMZ
interests_NN
745_CD
807_CD
Annual_JJ
Review_NN
on_PIN
the_DT
website_NN
in_PIN
accordance_NN
with_PIN
the_DT
UK_NN
legislation_NOMZ
or_CC
into_PIN
whose_WPS [PIRE]
hands_NN
it_PIT
may_POMD
come_VB
save_IN
where_RB
expressly_RB
agreed_VBN [SUAV] [PUBV]
by_PIN
Capital_NN
employed_VBN
8,465_CD
7,388_CD
governing_VBG
the_DT
preparation_NOMZ
and_PHC
dissemination_NOMZ
of_PIN
financial_JJ
statements_NOMZ
._.
our_FPP1
prior_JJ
consent_NN
in_PIN
writing_VBG [PUBV]
._.
Access_NN
to_PIN
the_DT
website_NN
is_VPRT [BEMA]
available_PRED
from_PIN
outside_PLACE
the_DT
UK_NN
,_,
where_RB
comparable_JJ
legislation_NOMZ
may_POMD
be_VB [BEMA]
different_PRED
._.
Basis_NN
of_PIN
opinion_NN
Summary_NN
consolidated_JJ
cash_NN
flow_NN
statement_NOMZ
We_FPP1
conducted_VBD
our_FPP1
work_NN
in_PIN
accordance_NN
with_PIN
Bulletin_NN
1999_CD
6_CD
,_,
The_DT
2003_CD
2002_CD
auditors_NN
statement_NOMZ
on_PIN
the_DT
Summary_NN
financial_JJ
statement_NOMZ
issued_VBN [WZPAST]
by_PIN
the_DT
m_FW
m_FW
Auditing_GER
Practices_NN
Board_NN
for_PIN
use_NN
in_PIN
the_DT
United_NN
Kingdom_NN
._.
Net_JJ
cash_NN
inflow_NN
from_PIN
operating_VBG
activities_NOMZ
7,005_CD
7,255_CD
Opinion_NN
Dividends_NN
from_PIN
joint_JJ
ventures_NN
and_CC
associated_VBN
undertakings_GER
1_CD
2_CD
In_PIN
our_FPP1
opinion_NN
the_DT
Summary_NN
financial_JJ
statements_NOMZ
are_VPRT [BEMA]
consistent_PRED
with_PIN
Returns_NN
on_PIN
investments_NOMZ
and_PHC
servicing_GER
of_PIN
finance_NN
231_CD
237_CD
the_DT
Annual_JJ
financial_JJ
statements_NOMZ
,_,
the_DT
Report_NN
of_PIN
the_DT
Directors_NN
and_CC
the_DT
Taxation_NOMZ
paid_VBD
1,917_CD
1,633_CD
Remuneration_NOMZ
Report_NN
of_PIN
GlaxoSmithKline_NN
plc_NN
for_PIN
the_DT
year_NN
ended_VBD
31st_CD
Capital_NN
expenditure_NN
and_CC
financial_JJ
investment_NOMZ
928_CD
1,120_CD
December_NN
2003_CD
and_CC
comply_VB
with_PIN
the_DT
applicable_JJ
requirements_NOMZ
of_PIN
Section_NOMZ
Acquisitions_NOMZ
and_PHC
disposals_NN
12_CD
20_CD
251_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
and_CC
the_DT
regulations_NOMZ
made_VBD
thereunder_RB
._.
Equity_NOMZ
dividends_NN
paid_VBD
2,333_CD
2,327_CD
Management_NOMZ
of_PIN
liquid_JJ
resources_NN
and_PHC
financing_GER
1,612_CD
1,515_CD
LLP_NN
Decrease_NN
increase_NN
in_PIN
cash_NN
in_PIN
the_DT
year_NN
27_CD
405_CD
Chartered_NN
Accountants_NN
and_PHC
Registered_NN
Auditors_NN
Embankment_NOMZ
Place_NN
,_,
London_NN
,_,
England_NN
,_,
3rd_CD
March_NN
2004_CD
24_CD
Annual_JJ
Review_NN
2003_CD
Annual_JJ
Review_NN
2003_CD
25_CD
Summary_NN
information_NOMZ
under_IN
US_FPP1
GAAP_NN
FOR_PIN
THE_DT
YEAR_NN
TO_PIN
31ST_CD
DECEMBER_NN
2003_CD
Shareholder_NN
information_NOMZ
The_DT
following_GER
is_VPRT [BEMA]
a_DT
summary_NN
of_PIN
the_DT
material_NN
adjustments_NOMZ
to_TO
profit_VB
and_CC
shareholders_NN
funds_NN
which_WDT [WHSUB]
would_PRMD
be_VB [PASS]
required_VBN [SUAV]
if_COND
US_FPP1
Generally_RB
Accepted_JJ
Ordinary_NN
shares_NN
SmithKline_NN
Beecham_NN
plc_NN
Floating_VBG [WZPRES]
Rate_NN
Accounting_GER
Principles_NN
GAAP_NN
had_VBD [PEAS]
been_VBN [PASS]
applied_VBN
instead_CONJ
of_NULL
UK_NN
GAAP_NN
._.
The_DT
companys_NN
shares_NN
are_VPRT [PASS]
listed_VBN
on_PIN
the_DT
London_NN
Stock_NN
Exchange_NN
._.
Unsecured_JJ
Loan_NN
Stock_NN
1990 2010 2003 2002_CD
Profit_NN
m_NN
m_NN
Registrar_NN
Profit_NN
attributable_JJ
to_PIN
shareholders_NN
under_IN
UK_NN
GAAP_NN
4,484_CD
3,915_CD
The_DT
loan_NN
stock_NN
is_VPRT [PASS]
not_XX0
listed_VBN
on_PIN
any_QUAN
exchange_NN
but_CC
holders_NN
may_POMD
require_VB [SUAV] [THATD]
The_DT
companys_NN
share_VPRT
register_NN
is_VPRT [BYPA]
administered_VBN
by_PIN
Lloyds_NN
TSB_NN
Registrars_NN
,_,
US_FPP1
GAAP_NN
adjustments_NOMZ
:_:
SmithKline_NN
Beecham_NN
plc_NN
to_TO
redeem_VB
their_TPP3
loan_NN
stock_NN
at_PIN
par_NN
,_,
i._FW
e._FW
1_CD
for_PIN
who_WP [PIRE]
also_RB
provide_VPRT
the_DT
following_JJ
services_NN
:_:
Fixed_JJ
assets_NN
28_CD
45_CD
every_QUAN
1_CD
of_PIN
loan_NN
stock_NN
held_VBN [PRIV]
,_,
on_PIN
the_DT
first_JJ
business_NOMZ
day_NN
of_PIN
March_NN
,_,
June_NN
,_,
GlaxoSmithKline_NN
Investment_NOMZ
Plan_NN
enables_VPRT
shareholders_NN
to_TO
reinvest_VB
Product_NN
rights_NN
and_PHC
goodwill_NN
2,378_CD
4,252_CD
September_NN
and_PHC
December_NN
._.
Holders_NN
wishing_VBG [WZPRES]
to_TO
redeem_VB
all_QUAN
or_CC
part_NN
of_PIN
their_TPP3
quarterly_JJ
dividends_NN
and_CC
or_CC
make_VB
monthly_JJ
investments_NOMZ
in_PIN
the_DT
Disposal_NN
of_PIN
products_NN
7_CD
7_CD
loan_NN
stock_NN
should_NEMD
complete_VB
the_DT
notice_NN
on_PIN
the_DT
back_NN
of_PIN
their_TPP3
loan_NN
stock_NN
company_NN
's_POS
ordinary_JJ
shares_NN
using_VBG [WZPRES]
a_DT
special_JJ
dealing_GER
arrangement_NOMZ
._.
Equity_NOMZ
investments_NOMZ
31_CD
8_CD
certificate_NN
and_CC
return_VB
it_PIT
to_PIN
the_DT
registrar_NN
,_,
to_TO
arrive_VB
at_PIN
least_JJ
30_CD
days_NN
before_IN
GlaxoSmithKline_NN
Individual_NN
Savings_GER
Account_NN
is_VPRT [BEMA]
a_DT
tax-efficient_JJ
way_NN
Employee_NN
costs_NN
501_CD
469_CD
the_DT
relevant_JJ
redemption_NOMZ
date_NN
._.
to_TO
invest_VB
in_PIN
the_DT
companys_NN
ordinary_JJ
shares_NN
._.
Provision_NN
against_PIN
ESOT_NN
shares_NN
25_CD
51_CD
GlaxoSmithKline_NN
Corporate_NN
Sponsored_NN
Nominee_NN
provides_VPRT
a_DT
facility_NOMZ
Derivative_JJ
instruments_NOMZ
74_CD
8_CD
for_PIN
shareholders_NN
to_TO
hold_VB [PRIV]
shares_NN
without_PIN
the_DT
need_NN
for_PIN
share_NN
certificates_NN
._.
Share_NN
buy-back_NN
program_NN
Guarantor_NN
obligations_NOMZ
21_CD
-_:
Shareholders_NN
details_NN
will_PRMD
not_XX0
be_VB [PASS]
held_VBN [PRIV]
on_PIN
the_DT
main_JJ
share_NN
register_NN
,_,
and_ANDC
Restructuring_GER
98_CD
37_CD
so_RB
will_PRMD
remain_VB
confidential_JJ
._.
In_PIN
October_NN
2002_CD
,_,
following_VBG [PRESP]
the_DT
completion_NOMZ
of_PIN
the_DT
4_CD
billion_CD
share_NN
buy_NN
Taxation_NOMZ
783_CD
1,169_CD
Shareview_NN
service_NN
provides_VPRT
shareholders_NN
with_PIN
information_NOMZ
on_PIN
their_TPP3
back_JJ
program_NN
announced_VBN [PUBV] [WZPAST]
in_PIN
2001_CD
,_,
the_DT
company_NN
announced_VBD [PUBV]
plans_NN
investment_NOMZ
in_PIN
the_DT
company_NN
._.
Shareholders_NN
may_POMD
register_VB
for_PIN
this_DEMO
service_NN
for_PIN
a_DT
new_JJ
4_CD
billion_CD
share_NN
buy-back_JJ
program_NN
._.
The_DT
program_NN
covers_VPRT
Net_JJ
income_NN
under_IN
US_FPP1
GAAP_NN
before_IN
cumulative_JJ
changes_NN
in_PIN
accounting_GER
principles_NN
2,420_CD
503_CD
at_PIN
www_NN
._.
co._FW
uk_FW
purchases_NN
by_PIN
the_DT
company_NN
of_PIN
shares_NN
for_PIN
cancellation_NOMZ
or_CC
to_TO
be_VB [PASS]
held_VBN [PRIV]
as_IN
Cumulative_JJ
effect_NN
of_PIN
changes_NN
in_PIN
accounting_GER
principles_NN
-_:
90_CD
Treasury_NN
Shares_NN
,_,
in_PIN
accordance_NN
with_PIN
the_DT
authority_NOMZ
given_VBN [WZPAST]
by_PIN
shareholders_NN
Net_JJ
income_NN
under_IN
US_FPP1
GAAP_NN
after_IN
cumulative_JJ
effect_NN
of_PIN
changes_NN
in_PIN
accounting_GER
principles_NN
2,420_CD
413_CD
Share_NN
dealing_VBG [WZPRES]
service_NN
at_PIN
the_DT
AGM_NN
in_PIN
2003_CD
._.
In_PIN
total_JJ
980_CD
billion_CD
was_VBD [PASS]
spent_VBN
in_PIN
2003_CD
._.
Hoare_NN
Govett_NN
Limited_NN
operates_VPRT
a_DT
postal_JJ
dealing_VBG
service_NN
in_PIN
the_DT
companys_NN
Basic_JJ
income_NN
per_PIN
share_NN
under_IN
US_FPP1
GAAP_NN
:_:
ordinary_JJ
shares_NN
._.
It_PIT
enables_VPRT
investors_NN
to_TO
buy_VB
or_CC
sell_VB
shares_NN
at_PIN
competitive_JJ
Basic_JJ
net_JJ
income_NN
before_IN
cumulative_JJ
changes_NN
in_PIN
accounting_GER
principles_NN
41.7_CD
p_NN
8.5_CD
p_NN
In_PIN
May_POMD
2003_CD
the_DT
company_NN
was_VBD [PASS]
authorised_VBN
to_TO
purchase_VB
a_DT
maximum_NN
of_PIN
commission_NN
charges_NN
._.
Transactions_NOMZ
are_VPRT [PASS]
executed_VBN
and_PHC
settled_VBN
by_PIN
Pershing_GER
Changes_NN
in_PIN
accounting_GER
principles_NN
-_:
1.5_CD
p_NN
600_CD
million_CD
shares_NN
617_CD
million_CD
shares_NN
in_PIN
May_POMD
2002_CD
and_CC
81_CD
million_CD
shares_NN
Securities_NOMZ
Limited_NN
._.
Further_JJ
details_NN
of_PIN
this_DEMO
service_NN
together_RB
with_PIN
purchase_NN
Basic_JJ
net_JJ
income_NN
after_IN
changes_NN
in_PIN
accounting_GER
principles_NN
41.7_CD
p_NN
7.0_CD
p_NN
were_VBD [PASS]
purchased_VBN
for_PIN
cancellation_NOMZ
during_PIN
2003_CD
see_VPRT [PRIV]
Note_NN
to_PIN
the_DT
Financial_NN
and_PHC
sale_NN
forms_NN
may_POMD
be_VB [BYPA]
obtained_VBN
by_PIN
telephoning_VBG
44_CD
0_CD
20 7676 8300_CD
._.
statements_NOMZ
,_,
Share_NN
capital_NN
and_PHC
share_NN
premium_NN
account_NN
in_PIN
the_DT
companys_NN
Diluted_JJ
income_NN
per_PIN
share_NN
under_IN
US_FPP1
GAAP_NN
:_:
Annual_JJ
Report_NN
2003_CD
._.
The_DT
exact_JJ
amount_NN
and_PHC
timing_NN
of_PIN
future_JJ
purchases_NN
Diluted_VBN
net_JJ
income_NN
before_IN
cumulative_JJ
changes_NN
in_PIN
accounting_GER
principles_NN
41.6_CD
p_NN
8.5_CD
p_NN
Smith_NN
Barney_NN
,_,
part_NN
of_PIN
Citigroup_NN
,_,
also_RB
offers_VPRT
a_DT
share_NN
dealing_VBG [WZPRES]
service_NN
in_PIN
the_DT
will_PRMD
be_VB [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
the_DT
company_NN
and_CC
is_VPRT [BEMA]
dependent_PRED
on_PIN
market_NN
Changes_NN
in_PIN
accounting_GER
principles_NN
-_:
1.5_CD
p_NN
companys_NN
ordinary_JJ
shares_NN
and_PHC
ADSs_NN
._.
Further_JJ
details_NN
of_PIN
this_DEMO
service_NN
can_POMD
be_VB
conditions_NOMZ
and_CC
other_JJ
factors_NN
._.
Diluted_JJ
net_JJ
income_NN
after_IN
changes_NN
in_PIN
accounting_GER
principles_NN
41.6_CD
p_NN
7.0_CD
p_NN
obtained_VBN [WZPAST]
by_PIN
contacting_VBG
their_TPP3
offices_NN
in_PIN
the_DT
UK_NN
or_CC
USA_NN
see_VPRT [PRIV]
contact_NN
details_NN
2003_CD
2002_CD
on_PIN
the_DT
inside_PLACE
back_JJ
cover_NN
for_PIN
further_JJ
information_NOMZ
._.
Cautionary_JJ
statement_NOMZ
Equity_NOMZ
shareholders_NN
funds_NN
m_VPRT
m_NN
Equity_NOMZ
shareholders_NN
funds_NN
under_IN
UK_NN
GAAP_NN
7,720_CD
6,581_CD
The_DT
provision_NN
of_PIN
the_DT
details_NN
above_PLACE
are_VPRT [PASS]
not_XX0
intended_VBN [SUAV]
to_TO
be_VB [BEMA]
an_DT
invitation_NOMZ
or_CC
Under_IN
the_DT
safe_JJ
harbor_NN
provisions_NN
of_PIN
the_DT
US_FPP1
Private_NN
Securities_NOMZ
Litigation_NOMZ
US_FPP1
GAAP_NN
adjustments_NOMZ
:_:
inducement_NOMZ
to_TO
engage_VB
in_PIN
an_DT
investment_NOMZ
activity_NOMZ
._.
Advice_NN
on_PIN
share_NN
dealing_GER
,_,
Reform_NN
Act_NN
of_PIN
1995_CD
,_,
the_DT
company_NN
cautions_VPRT
investors_NN
that_TOBJ
any_QUAN
forwardFixed_JJ
assets_NN
243_CD
215_CD
should_NEMD
be_VB [PASS]
obtained_VBN
from_PIN
a_DT
stockbroker_NN
or_CC
independent_JJ
financial_JJ
adviser_NN
._.
looking_VBG
statements_NOMZ
or_CC
projections_NOMZ
made_VBN [WZPAST]
by_PIN
the_DT
company_NN
,_,
including_VBG [PRESP]
those_DEMO
Product_NN
rights_NN
and_PHC
goodwill_NN
33,638_CD
36,141_CD
made_VBN
in_PIN
this_DEMO
Annual_JJ
Review_NN
,_,
are_VPRT [BEMA]
subject_PRED
to_PIN
risks_NN
and_PHC
uncertainties_NN
that_TSUB
may_POMD
Marketable_JJ
securities_NOMZ
84_CD
113_CD
Share_NN
price_NN
information_NOMZ
cause_NN
actual_JJ
results_NN
to_TO
differ_VB
materially_RB
from_PIN
those_DEMP
projected_VBN
._.
Factors_NN
that_TOBJ
Other_JJ
investments_NOMZ
832_CD
829_CD
Share_NN
price_NN
information_NOMZ
is_VPRT [BEMA]
available_PRED
on_PIN
the_DT
website_NN
at_PIN
www_NN
._.
may_POMD
affect_VB
the_DT
Groups_NN
operations_NOMZ
are_VPRT [PASS]
described_VBN
under_IN
Risk_NN
factors_NN
in_PIN
the_DT
Employee_NN
costs_VPRT
1,574_CD
1,198_CD
Information_NOMZ
made_VBN
available_JJ
on_PIN
the_DT
website_NN
does_VPRT
not_XX0
constitute_VB
part_NN
of_PIN
this_DEMP
companys_VPRT
Annual_JJ
Report_NN
2003_CD
._.
Employee_NN
Share_NN
Ownership_NN
Trust_NN
2,775_CD
2,826_CD
Annual_JJ
Review_NN
._.
Information_NOMZ
in_PIN
the_DT
UK_NN
is_VPRT [BEMA]
also_RB
available_PRED
on_PIN
Ceefax_NN
,_,
Teletext_NN
,_,
Derivative_JJ
instruments_NOMZ
26_CD
98_CD
and_CC
from_PIN
FT_NN
Cityline_NN
by_PIN
calling_VBG
0906 003 5694_CD
or_CC
0906 843 5694_CD
calls_NN
Guarantor_NN
obligations_NOMZ
21_CD
-_:
charged_VBN [PASTP]
at_PIN
60p_CD
a_DT
minute_NN
plus_PIN
VAT_NN
at_PIN
all_QUAN
times_NN
._.
Restructuring_GER
92_CD
6_CD
Dividends_NN
808_CD
754_CD
American_JJ
Depositary_NN
Shares_NN
Deferred_NN
taxation_NOMZ
4,957_CD
5,779_CD
Shareholders_NN
equity_NOMZ
under_IN
US_FPP1
GAAP_NN
34,116_CD
34,922_CD
The_DT
companys_NN
shares_NN
are_VPRT [PASS]
listed_VBN
on_PIN
the_DT
New_NN
York_NN
Stock_NN
Exchange_NN
in_PIN
the_DT
form_NN
of_PIN
American_JJ
Depositary_NN
Shares_NN
ADSs_NN
and_CC
these_DEMP
are_VPRT [BYPA]
evidenced_VBN
by_PIN
American_JJ
Depositary_NN
Receipts_NN
ADRs_NN
,_,
each_QUAN
one_CD
of_PIN
which_WDT [PIRE]
represents_VPRT
A_DT
summary_NN
of_PIN
the_DT
material_NN
differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
GAAP_NN
that_TSUB
apply_VB
to_PIN
the_DT
Group_NN
is_VPRT [PASS]
set_VBN
out_PIN
in_PIN
the_DT
Annual_JJ
Report_NN
2003_CD
._.
two_CD
ordinary_JJ
shares_NN
._.
During_PIN
the_DT
year_NN
,_,
the_DT
Group_NN
implemented_VBD
the_DT
following_VBG
new_JJ
accounting_GER
standards_NN
and_PHC
interpretations_NOMZ
issued_VBN [WZPAST]
by_PIN
the_DT
Financial_NN
Accounting_GER
Standards_NN
Board_NN
FASB_NN
:_:
SFAS_NN
132_CD
revised_VBN
2003_CD
Employers_NN
Disclosures_NN
about_IN
Pensions_NN
and_CC
other_JJ
Postretirement_NOMZ
Benefits_NN
:_:
SFAS_NN
143_CD
Accounting_GER
for_PIN
Obligations_NOMZ
ADR_NN
program_NN
administrator_NN
Associated_NN
with_PIN
Long-Lived_NN
Assets_NN
:_:
SFAS_NN
146_CD
Accounting_GER
for_PIN
Costs_NN
Associated_NN
with_PIN
Exit_NN
or_CC
Disposal_NN
Activities_NOMZ
:_:
SFAS_NN
149_CD
Amendment_NOMZ
of_PIN
Statement_NOMZ
The_NN
ADR_NN
program_NN
is_VPRT [BYPA]
administered_VBN
by_PIN
The_DT
Bank_NN
of_PIN
New_NN
York_NN
which_WDT [WHOBJ]
133_CD
on_PIN
Derivative_JJ
Instruments_NOMZ
and_PHC
Hedging_GER
Activities_NOMZ
:_:
SFAS_NN
150_CD
Accounting_GER
for_PIN
Certain_NN
Financial_NN
Instruments_NOMZ
with_PIN
Characteristics_NN
of_PIN
both_DT
Liabilities_NOMZ
provides_VPRT
Global_JJ
BuyDIRECT_NN
,_,
a_DT
direct_JJ
ADS_NN
purchase_NN
sale_NN
and_PHC
dividend_NN
and_PHC
Equity_NOMZ
:_:
FIN_NN
45_CD
Guarantors_NN
Accounting_GER
and_PHC
Disclosure_NN
Requirements_NOMZ
for_PIN
Guarantees_NN
,_,
Including_VBG
Indirect_NN
Guarantees_NN
of_PIN
Indebtedness_NOMZ
of_PIN
Others_NN
:_:
reinvestment_NOMZ
plan_NN
for_PIN
ADR_NN
holders_NN
._.
and_ANDC
the_DT
transitional_JJ
requirements_NOMZ
of_PIN
FIN_NN
46_CD
revised_VBN
December_NN
2003_CD
Consolidation_NOMZ
of_PIN
Variable_JJ
Interest_NN
Entities_NOMZ
relating_VBG [WZPRES]
to_PIN
2003_CD
._.
In_PIN
2004_CD
,_,
the_DT
Group_NN
will_PRMD
implement_VB
the_DT
remaining_VBG
requirements_NOMZ
of_PIN
FIN_NN
46_CD
._.
The_DT
Group_NN
has_VPRT [SPAU] [PEAS]
also_RB
elected_VBN
,_,
under_IN
FASB_NN
Staff_NN
Position_NOMZ
106-1_CD
Accounting_GER
and_PHC
Disclosure_NN
Requirements_NOMZ
Related_NN
to_PIN
the_DT
Medicare_NN
Prescription_NOMZ
Drug_NN
,_,
Improvement_NOMZ
and_PHC
Modernization_NOMZ
Act_NN
of_PIN
2003_CD
,_,
to_TO
defer_VB
accounting_GER
for_PIN
the_DT
implications_NOMZ
of_PIN
this_DEMO
new_JJ
law_NN
until_IN
specific_JJ
authoritative_JJ
guidance_NN
is_VPRT [PASS]
issued_VBN
._.
Such_JJ
guidance_NN
,_,
when_RB
issued_VBN
,_,
could_POMD
require_VB [SUAV]
a_DT
change_NN
in_PIN
previously_TIME
reported_VBN [PUBV]
information_NOMZ
._.
26_CD
Annual_JJ
Review_NN
2003_CD
Annual_JJ
Review_NN
2003_CD
27_CD
Shareholder_NN
information_NOMZ
continued_VBD
Internet_NN
Our_FPP1
Reports_NN
ANNUAL_NN
REVIEW_NN
Information_NOMZ
for_PIN
investors_NN
and_CC
about_IN
the_DT
Do_VPRT
more_EMPH
,_,
feel_VB [PRIV]
better_RB
,_,
live_VPRT
longer_RB
A_DT
review_NN
of_PIN
major_JJ
company_NN
is_VPRT [BEMA]
available_PRED
on_PIN
GlaxoSmithKlines_NN
communication_NOMZ
corporate_JJ
website_NN
at_PIN
www_NN
._.
com_NN
themes_NN
for_PIN
2003_CD
and_CC
an_DT
abridged_JJ
version_NN
of_PIN
Financial_NN
reporting_VBG [PUBV] [WZPRES]
Market_NN
capitalization_NOMZ
the_DT
financial_JJ
results_NN
._.
The_DT
market_NN
capitalization_NOMZ
of_PIN
GlaxoSmithKline_NN
at_PIN
31st_CD
December_NN
2003_CD
Head_NN
Office_NN
and_PHC
Registered_NN
Office_NN
was_VBD [BEMA]
76_CD
billion_CD
._.
At_PIN
that_DEMO
date_NN
GlaxoSmithKline_NN
was_VBD [BEMA]
the_DT
fourth_JJ
largest_JJ
Financial_JJ
reporting_GER
calendar_NN
2004_CD
Improving_GER
health_NN
GlaxoSmithKline_NN
plc_NN
company_NN
by_PIN
market_NN
capitalization_NOMZ
on_PIN
the_DT
FTSE_NN
index_NN
._.
every_QUAN
day_NN
Announcement_NOMZ
of_PIN
1st_CD
Quarter_NN
Results_NN
29th_JJ
April_NN
2004_CD
980_CD
Great_NN
West_NN
Road_NN
ANNUAL_NN
REVIEW_NN
2003_CD
Announcement_NOMZ
of_PIN
2nd_CD
Quarter_NN
Results_NN
27th_JJ
July_NN
2004_CD
Brentford_NN
Dividends_NN
Announcement_NOMZ
of_PIN
3rd_CD
Quarter_NN
Results_NN
28th_JJ
October_NN
2004_CD
Middlesex_NN
TW8_NN
9GS_NN
Tel_NN
:_:
44_CD
0_CD
20 8047 5000_CD
Preliminary_JJ
Announcement_NOMZ
of_PIN
Annual_JJ
Results_NN
10th_JJ
February_NN
2005_CD
GlaxoSmithKline_NN
pays_VPRT
dividends_NN
quarterly_RB
._.
Publication_NOMZ
of_PIN
Annual_JJ
Report_NN
Review_NN
March_NN
2005_CD
ANNUAL_NN
REPORT_NN
The_NN
Board_NN
has_VPRT [PEAS]
declared_VBN [PUBV]
dividends_NN
for_PIN
2003_CD
as_IN
follows_VPRT
:_:
Do_VB
more_EMPH
,_,
feel_VB [PRIV]
better_RB
,_,
live_VPRT
longer_RB
The_DT
full_JJ
Financial_NN
Statements_NOMZ
for_PIN
the_DT
Results_NN
Announcements_NOMZ
2003_CD
2002_CD
United_NN
Kingdom_NN
United_NN
States_NN
of_PIN
America_NN
Dividends_NN
per_PIN
share_NN
pence_NN
pence_NN
year_NN
ended_VBD
31st_CD
Results_NN
Announcements_NOMZ
are_VPRT [PASS]
issued_VBN
to_PIN
the_DT
London_NN
Stock_NN
Exchange_NN
LSE_NN
,_,
Investor_NN
relations_NOMZ
Investor_NN
relations_NOMZ
December_NN
2003_CD
._.
and_ANDC
made_VBN
available_JJ
on_PIN
the_DT
LSE_NN
news_NN
service_NN
,_,
and_ANDC
at_PIN
the_DT
same_JJ
time_NN
,_,
or_CC
One_CD
Franklin_NN
Plaza_NN
First_NN
interim_JJ
paid_VBN
3rd_CD
July_NN
2003_CD
9_CD
9_CD
980_CD
Great_NN
West_NN
Road_NN
shortly_TIME
afterwards_TIME
,_,
are_VPRT [PASS]
issued_VBN
to_PIN
the_DT
media_NN
,_,
are_VPRT [PASS]
made_VBN
available_JJ
on_PIN
the_DT
PO_NN
Box_NN
7929_CD
Second_JJ
interim_JJ
paid_VBN
2nd_JJ
October_NN
2003_CD
9_CD
9_CD
Brentford_NN
Improving_GER
performance_NN
companys_VPRT
website_JJ
and_CC
in_PIN
the_DT
USA_NN
with_PIN
the_DT
Securities_NOMZ
and_PHC
Exchange_NN
Philadelphia_NN
PA_NN
19101_CD
Third_NN
interim_JJ
paid_VBN
6th_JJ
January_NN
2004_CD
9_CD
9_CD
Middlesex_NN
TW8_NN
9GS_NN
Commission_NN
and_CC
the_DT
New_NN
York_NN
Stock_NN
Exchange_NN
._.
Tel_NN
:_:
1_CD
888 825 5249_CD
toll_NN
free_JJ
Fourth_JJ
interim_JJ
payable_JJ
15th_JJ
April_NN
2004_CD
14_CD
13_CD
every_QUAN
day_NN
Tel_NN
:_:
44_CD
0_CD
20 8047 5557 5558_CD
ANNUAL_NN
REPORT_NN
2003_CD
Tel_NN
:_:
1_CD
215 751 7003_CD
outside_PLACE
the_DT
USA_NN
Total_NN
41_CD
40_CD
Fax_NN
:_:
44_CD
0_CD
20 8047 7807_CD
Financial_NN
reports_NN
Fax_NN
:_:
1_CD
215 751 3233_CD
The_DT
company_NN
publishes_VPRT
an_DT
Annual_JJ
Report_NN
and_CC
,_,
for_PIN
the_DT
investor_NN
not_XX0
In_PIN
2004_CD
,_,
GSK_NN
expects_VPRT [PRIV]
a_DT
similar_JJ
increase_NN
in_PIN
total_JJ
dividend_NN
as_IN
has_VPRT [PEAS]
been_VBN [BEMA]
Registrar_PRED
needing_VBG
the_DT
full_JJ
detail_NN
of_PIN
the_DT
Report_NN
,_,
an_DT
Annual_JJ
Review_NN
._.
These_DEMP
are_VPRT
ADR_NN
program_NN
administrator_NN
declared_VBD [PUBV]
in_PIN
2003_CD
._.
The_DT
allocation_NOMZ
of_PIN
quarterly_JJ
dividends_NN
will_PRMD
be_VB [PASS]
rebalanced_VBN
Lloyds_NN
TSB_NN
Registrars_NN
available_JJ
from_PIN
the_DT
date_NN
of_PIN
publication_NOMZ
on_PIN
the_DT
GlaxoSmithKline_NN
website_NN
._.
GSK_NN
intends_VPRT [SUAV]
to_TO
increase_VB
the_DT
first_JJ
three_CD
interim_JJ
dividends_NN
from_PIN
The_DT
Causeway_NN
CORPORATE_JJ
The_DT
Annual_JJ
Review_NN
is_VPRT [PASS]
sent_VBN
to_PIN
all_QUAN
shareholders_NN
on_PIN
the_DT
date_NN
of_PIN
publication_NOMZ
._.
Shareholder_NN
Relations_NOMZ
9p_VPRT
to_TO
10p_VB
,_,
with_PIN
the_DT
remainder_NN
of_PIN
the_DT
total_JJ
dividend_NN
for_PIN
the_DT
year_NN
being_VBG [WZPRES]
Do_VPRT
more_EMPH
,_,
feel_VB [PRIV]
better_RB
,_,
live_VPRT
longer_RB
Worthing_JJ
RESPONSIBILITY_NOMZ
Shareholders_NN
may_POMD [SPAU]
also_RB
elect_VB
to_TO
receive_VB
the_DT
Report_NN
by_PIN
writing_VBG [PUBV]
to_PIN
the_DT
PO_NN
Box_NN
11258_CD
allocated_VBN
to_PIN
the_DT
fourth_JJ
quarter_NN
dividend_NN
._.
West_NN
Sussex_NN
BN99_NN
6DA_NN
REPORT_NN
companys_VPRT
registrars_NN
._.
Alternatively_CONJ
shareholders_NN
may_POMD
elect_VB
to_TO
receive_VB
Church_NN
Street_NN
Station_NOMZ
A_NN
review_NN
of_PIN
our_FPP1
www_NN
._.
co._FW
uk_FW
notification_NOMZ
by_PIN
email_NN
of_PIN
the_DT
publication_NOMZ
of_PIN
financial_JJ
reports_NN
by_PIN
registering_VBG
New_NN
York_NN
NY_NN
10286-1258_CD
Dividends_NN
ADSs_NN
commitment_NOMZ
to_PIN
on_PIN
www_NN
._.
Copies_NN
of_PIN
previous_JJ
financial_JJ
reports_NN
are_VPRT [BEMA]
available_JJ
www_NN
._.
com_NN
As_IN
a_DT
guide_NN
to_PIN
holders_NN
of_PIN
ADRs_NN
,_,
the_DT
tables_NN
below_PLACE
set_VBN
out_PIN
the_DT
dividends_NN
paid_VBD
society_NN
and_CC
the_DT
General_NN
enquiries_NN
,_,
Annual_JJ
Report_NN
orderline_NN
on_PIN
the_DT
companys_NN
website_VPRT
._.
Printed_NN
copies_NN
can_POMD
be_VB [PASS]
obtained_VBN
from_PIN
the_DT
Tel_NN
:_:
1_CD
877 353 1154_CD
toll_NN
free_JJ
environment_NOMZ
._.
per_PIN
ADS_NN
in_PIN
US_FPP1
dollars_NN
in_PIN
the_DT
last_JJ
five_CD
years_NN
._.
The_DT
dividends_NN
are_VPRT [PASS]
adjusted_VBN
for_PIN
and_CC
Corporate_JJ
Nominee_NN
service_NN
Making_VBG [WZPRES]
a_DT
difference_NN
companys_VPRT
registrar_NN
in_PIN
the_DT
UK_NN
and_CC
from_PIN
the_DT
companys_NN
Customer_NN
Response_NN
Tel_NN
:_:
1_CD
610 382 7836_CD
outside_PLACE
the_DT
USA_NN
UK_NN
tax_NN
credit_NN
less_RB
withholding_VBG
tax_NN
,_,
where_RB
applicable_JJ
,_,
and_ANDC
are_VPRT [PASS]
translated_VBN
Tel_NN
:_:
0870 600 3991_CD
inside_PLACE
the_DT
UK_NN
every_QUAN
day_NN
Center_NN
in_PIN
the_DT
USA_NN
._.
into_PIN
US_FPP1
dollars_NN
at_PIN
applicable_JJ
exchange_NN
rates_NN
._.
Tel_NN
:_:
44_CD
0_CD
121 415 7067_CD
outside_PLACE
the_DT
UK_NN
CORPORATE_JJ
RESPONSIBILITY_NOMZ
REPORT_NN
2003_CD
Customer_NN
Response_NN
Center_NN
Since_OSUB
6th_JJ
April_NN
1999_CD
,_,
claims_VPRT [PUBV]
for_PIN
refunds_NN
of_PIN
tax_NN
credits_NN
on_PIN
dividends_NN
from_PIN
the_DT
Publications_NOMZ
Tel_NN
:_:
1_CD
888 825 5249_CD
toll_NN
free_JJ
Making_VBG
a_DT
dif_NN
Improving_GER
health_NN
,_,
every_QUAN
day_NN
ference_NN
,_,
every_QUAN
day_NN
101_CD
101_CD
Shareholder_NN
Investment_NOMZ
Plans_NN
UK_NN
tax_NN
authorities_NOMZ
are_VPRT [BEMA]
of_PIN
negligible_JJ
benefit_NN
to_PIN
US_FPP1
shareholders_NN
._.
This_DEMO
year_NN
GlaxoSmithKline_NN
has_VPRT [SPAU] [PEAS]
again_TIME
produced_VBN
a_DT
separate_JJ
report_NN
covering_VBG [WZPRES]
Dividend_NN
re-investment_NOMZ
queries_VPRT
Every_QUAN
day_NN
,_,
all_QUAN
around_PLACE
the_DT
world_NN
,_,
GlaxoSmithKline_NN
is_VPRT [BEMA]
the_DT
Groups_NN
contribution_NOMZ
to_PIN
society_NN
._.
The_DT
2003_CD
Corporate_JJ
Responsibility_NOMZ
Corporate_JJ
share_NN
dealing_VBG [WZPRES]
facility_NOMZ
Tel_NN
:_:
0870 241 3018_CD
inside_PLACE
the_DT
UK_NN
Year_NN
GSK_NN
$_$
GW_CD
$_$
SB_CD
$_$
trying_VBG
to_TO
improve_VB
peoples_NN
lives_NN
and_CC
have_VPRT
a_DT
positive_JJ
Report_NN
covers_VPRT
the_DT
issues_NN
that_TSUB
are_VPRT [BEMA]
of_PIN
primary_JJ
interest_NN
to_PIN
stakeholders_NN
,_,
Smith_NN
Barney_NN
Tel_NN
:_:
44_CD
0_CD
121 415 7067_CD
outside_PLACE
the_DT
UK_NN
impact_NN
on_PIN
all_QUAN
our_FPP1
stakeholders_NN
._.
Our_FPP1
three_CD
annual_JJ
2003_CD
1.39_CD
including_VBG
the_DT
contribution_NOMZ
to_PIN
society_NN
,_,
business_NOMZ
ethics_NN
and_PHC
integrity_NOMZ
,_,
access_NN
Attn_NN
:_:
GSK_NN
Services_NN
publications_NOMZ
for_PIN
2003_CD
emphasise_NN
this_DEMO
far-reaching_JJ
Ordinary_NN
holders_NN
2002_CD
1.24_CD
to_PIN
medicines_NN
,_,
R&D_NN
,_,
community_NOMZ
investment_NOMZ
,_,
the_DT
environment_NOMZ
and_PHC
health_NN
53_CD
State_NN
Street_NN
commitment_NOMZ
._.
The_DT
report_NN
is_VPRT [BEMA]
available_PRED
from_PIN
the_DT
Secretariat_NN
at_PIN
the_DT
companys_NN
39th_VPRT
Floor_NN
Employees_NN
2000_CD
1.10_CD
0.87_CD
head_NN
office_NN
and_CC
the_DT
website_NN
at_PIN
www_NN
._.
Boston_NN
Produced_NN
by_PIN
Corporate_NN
Communications_NOMZ
,_,
1999_CD
1.14_CD
0.86_CD
MA_NN
02109_CD
GlaxoSmithKline_NN
._.
Monthly_JJ
Savings_GER
Plan_NN
queries_VPRT
Tel_NN
:_:
1_CD
800 347 6179_CD
toll_NN
free_JJ
Tel_NN
:_:
0870 606 0268_CD
inside_PLACE
the_DT
UK_NN
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
2004_CD
Dividends_NN
paid_VBD
to_PIN
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
ADR_NN
Design_NN
consultancy_NN
by_PIN
salterbaxter_NN
._.
Tel_NN
:_:
1_CD
617 589 3341_CD
outside_PLACE
the_DT
USA_NN
Tel_NN
:_:
44_CD
0_CD
131 527 3746_CD
outside_PLACE
the_DT
UK_NN
holders_NN
are_VPRT [PASS]
expressed_VBN
as_IN
dividends_NN
per_PIN
GlaxoSmithKline_NN
ADS_NN
._.
Fax_NN
:_:
1_CD
617 589 3474_CD
Printed_NN
in_PIN
the_DT
UK_NN
by_PIN
St._NN
Ives_NN
Direct_NN
Edenbridge_NN
Ltd._NN
._.
The_DT
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
will_PRMD
be_VB [PASS]
held_VBN [PRIV]
at_PIN
the_DT
Queen_NN
Elizabeth_NN
II_NN
The_DT
paper_NN
used_VBN [WZPAST]
in_PIN
the_DT
production_NOMZ
of_PIN
this_DEMO
document_NOMZ
is_VPRT
Email_NN
:_:
TheTaylorGroup@SmithBarney_NN
._.
com_NN
ISA_NN
enquiries_VPRT
Conference_NN
Centre_NN
,_,
Broad_NN
Sanctuary_NN
,_,
Westminster_NN
,_,
London_NN
SW1P_NN
3EE_NN
on_PIN
Dividend_NN
calendar_NN
made_VBN [WZPAST]
from_PIN
pulps_NN
harvested_VBN [WZPAST]
from_PIN
sustainable_JJ
forests_NN
,_,
Tel_NN
:_:
0870 242 4244_CD
inside_PLACE
the_DT
UK_NN
also_RB
using_VBG
sawmill_NN
residues_NN
and_PHC
forest_NN
thinnings_GER
._.
Tel_NN
:_:
44_CD
0_CD
1903 854 049_CD
outside_PLACE
the_DT
UK_NN
Ex-dividend_NN
date_NN
18th_JJ
February_NN
2004_CD
Share_NN
price_NN
Product_NN
names_NN
throughout_PIN
this_DEMO
publication_NOMZ
Record_NN
date_NN
20th_JJ
February_NN
2004 2003 2002_CD
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
are_VPRT [PASS]
indicated_VBN [PRIV]
in_PIN
italics_NN
and_CC
are_VPRT
trademarks_NN
of_PIN
Share_NN
price_NN
Payable_JJ
15th_JJ
April_NN
2004_CD
corporate_JJ
PEPs_NN
GlaxoSmithKline_NN
plc_NN
,_,
its_PIT
subsidiaries_NN
or_CC
associated_VBN
companies_NN
,_,
with_PIN
the_DT
exception_NOMZ
of_PIN
Levitra_NN
,_,
a_DT
At_PIN
1st_CD
January_NN
11.92_CD
17.23_CD
The_DT
Share_NN
Centre_NN
Limited_NN
First_NN
quarter_NN
2004_CD
trademark_NN
of_PIN
Bayer_NN
,_,
and_ANDC
Nicoderm_NN
,_,
a_DT
trademark_NN
High_NN
during_PIN
the_DT
year_NN
13.90_CD
17.80_CD
Oxford_NN
House_NN
of_PIN
Aventis_NN
,_,
all_QUAN
of_PIN
which_WDT [PIRE]
are_VPRT [PASS]
used_VBN
under_IN
licence_NN
by_PIN
Ex-dividend_NN
date_NN
12th_JJ
May_POMD
2004_CD
Low_NN
during_PIN
the_DT
year_NN
10.00_CD
10.57_CD
Oxford_NN
Road_NN
the_DT
Group_NN
._.
Record_NN
date_NN
14th_JJ
May_POMD
2004_CD
At_PIN
31st_CD
December_NN
12.80_CD
11.92_CD
Aylesbury_NN
Payable_NN
1st_CD
July_NN
2004_CD
Increase_VB
Decrease_NN
over_IN
year_NN
7_CD
%_NN
31_CD
%_NN
Bucks_NN
HP21_NN
8SZ_NN
Tel_NN
:_:
44_CD
0_CD
1296 414 144_CD
Second_JJ
quarter_NN
2004_CD
The_DT
table_NN
above_PLACE
sets_NN
out_PIN
the_DT
middle_JJ
market_NN
closing_GER
prices_NN
derived_VBN [WZPAST]
from_PIN
Ex-dividend_NN
date_NN
4th_JJ
August_NN
2004_CD
the_DT
London_NN
Stock_NN
Exchange_NN
Daily_NN
Official_NN
List_NN
._.
The_DT
companys_NN
share_VPRT
price_NN
Corporate_JJ
share_NN
dealing_VBG [WZPRES]
facility_NOMZ
Record_NN
date_NN
6th_JJ
August_NN
2004_CD
increased_VBN
by_PIN
7_CD
per_PIN
cent_NN
in_PIN
2003_CD
from_PIN
a_DT
price_NN
of_PIN
11.92_CD
at_PIN
1st_CD
January_NN
Smith_NN
Barney_NN
Payable_NN
30th_JJ
September_NN
2004_CD
2003_CD
to_PIN
12.80_CD
at_PIN
31st_CD
December_NN
2003_CD
._.
This_DEMP
compares_VPRT
with_PIN
an_DT
increase_NN
Attn_NN
:_:
GSK_NN
Services_NN
in_PIN
the_DT
FTSE_NN
100_CD
index_NN
of_PIN
14_CD
per_PIN
cent_NN
during_PIN
the_DT
year_NN
._.
Citigroup_NN
Centre_NN
,_,
Level_NN
20_CD
Third_JJ
quarter_NN
2004_CD
Canada_NN
Square_NN
,_,
Canary_NN
Wharf_NN
Ex-dividend_NN
date_NN
3rd_CD
November_NN
2004_CD
London_NN
E14_NN
5LB_NN
Record_NN
date_NN
5th_JJ
November_NN
2004_CD
Tel_NN
:_:
44_CD
0_CD
20 7508 1795_CD
Payable_JJ
6th_JJ
January_NN
2005_CD
Fax_NN
:_:
44_CD
0_CD
20 7890 7281_CD
Email_NN
:_:
TheBalaesGroup@Citigroup_NN
._.
com_NN
28_CD
Annual_JJ
Review_NN
2003_CD
Do_VPRT
more_EMPH
,_,
feel_VB [PRIV]
better_RB
,_,
live_VPRT
longer_RB
Making_VBG
a_DT
difference_NN
every_QUAN
day_NN
CORPORATE_JJ
RESPONSIBILITY_NOMZ
REPORT_NN
2003_CD
Making_VBG
a_DT
dif_NN
Improving_GER
health_NN
,_,
every_QUAN
day_NN
ference_NN
,_,
every_QUAN
da_NN
101_CD
101_CD
Contents_NN
Front_NN
cover_NN
01_CD
Introduction_NOMZ
by_PIN
Chairman_NN
14_CD
Community_NOMZ
investment_NOMZ
Sri_NN
Lankan_NN
mothers_NN
and_PHC
children_NN
waiting_VBG [WZPRES]
and_CC
Chief_NN
Executive_NN
Officer_NN
18_CD
Business_NOMZ
ethics_NN
and_PHC
integrity_NOMZ
in_PIN
line_NN
to_TO
receive_VB
GSKs_NN
albendazole_RB
and_CC
02_CD
About_IN
GSK_NN
20_CD
Environment_NOMZ
,_,
health_NN
and_PHC
safety_NN
another_DT
medication_NOMZ
as_IN
part_NN
of_PIN
the_DT
global_JJ
03_CD
Managing_VBG
corporate_JJ
responsibility_NOMZ
23_CD
Valuing_GER
people_NN
program_NN
to_TO
eliminate_VB
lymphatic_JJ
05_CD
Summary_NN
of_PIN
indicators_NN
26_CD
Research_NN
and_PHC
development_NOMZ
filariasis_NN
LF_NN
._.
08_CD
Our_FPP1
contribution_NOMZ
to_PIN
society_NN
29_CD
Discussion_NN
with_PIN
others_NN
10_CD
Medicines_NN
for_PIN
the_DT
developing_VBG
world_NN
32_CD
Web_NN
references_NN
Highlights_NN
2003_CD
Humanitarian_JJ
product_NN
Community_NOMZ
investment_NOMZ
donations_NOMZ
valued_VBN [WZPAST]
at_PIN
valued_VBN
at_PIN
105_CD
million_CD
338_CD
million_CD
74_CD
%_NN
94_CD
million_CD
more_EMPH
Combivir_NN
supplied_VBD
to_TO
developing_VBG
albendazole_JJ
treatments_NOMZ
donated_VBN [WZPAST]
in_PIN
countries_NN
at_PIN
preferential_JJ
prices_NN
the_DT
fight_NN
against_PIN
lymphatic_JJ
filariasis_NN
Not-for-profit_JJ
price_NN
for_PIN
Combivir_NN
10_CD
reduced_VBN
by_PIN
corporate_JJ
responsibility_NOMZ
principles_NN
formally_RB
adopted_VBN
62_CD
%_NN
Greenhouse_NN
gas_NN
emissions_NN
9,000_CD
per_PIN
unit_NN
sales_NN
down_IN
managers_NN
certified_VBD [PUBV]
their_TPP3
compliance_NN
with_PIN
Code_NN
of_PIN
Conduct_NN
8_CD
%_NN
Today_TIME
..._:
Corporate_JJ
responsibility_NOMZ
has_VPRT
particular_JJ
resonance_NN
for_PIN
the_DT
pharmaceutical_JJ
sector_NN
._.
Our_FPP1
business_NOMZ
is_VPRT
creating_VBG
medicines_NN
to_TO
treat_VB
and_PHC
prevent_VB
disease_NN
something_QUPR
that_DEMO
society_NN
needs_NN
and_PHC
values_NN
._.
At_PIN
the_DT
same_JJ
time_NN
healthcare_NN
,_,
its_PIT
financing_GER
and_CC
the_DT
way_NN
it_PIT
is_VPRT [PASS]
delivered_VBN
provokes_NN
much_QUAN
debate_NN
._.
This_DEMO
report_NN
deals_NN
with_PIN
important_JJ
issues_NN
We_FPP1
have_VPRT [PEAS]
embarked_VBN
on_PIN
a_DT
program_NN
of_PIN
continual_JJ
for_PIN
our_FPP1
business_NOMZ
and_CC
explains_VPRT [PUBV]
what_WP [WHCL]
we_FPP1
improvement_NOMZ
in_PIN
environment_NOMZ
,_,
health_NN
and_PHC
safety_NN
performance_NN
._.
Our_FPP1
ten-year_JJ
Plan_NN
for_PIN
Excellence_NN
are_VPRT
doing_VBG [PROD]
._.
Where_RB
possible_JJ
we_FPP1
have_VPRT
includes_VPRT
detailed_JJ
measures_NN
and_PHC
targets_NN
in_PIN
this_DEMO
area_NN
._.
included_VBD
performance_NN
measures_NN
to_PIN
We_FPP1
are_VPRT
already_RB
well_RB
on_PIN
the_DT
way_NN
to_TO
meeting_VBG
our_FPP1
show_NN
our_FPP1
progress_NN
._.
targets_NN
for_PIN
the_DT
first_JJ
five_CD
years_NN
._.
Significant_JJ
achievements_NOMZ
this_DEMO
year_NN
include_VPRT
our_FPP1
In_PIN
2003_CD
we_FPP1
introduced_VBD
new_JJ
marketing_GER
codes_NN
programs_NN
for_PIN
the_DT
developing_VBG
world_NN
._.
For_PIN
that_DEMP
are_VPRT [PASS]
backed_VBN
at_PIN
the_DT
highest_JJ
level_NN
by_PIN
the_DT
Board_NN
example_NN
,_,
lymphatic_JJ
filariasis_NN
LF_NN
or_CC
elephantiasis_NN
and_CC
the_DT
heads_NN
of_PIN
each_QUAN
of_PIN
our_FPP1
business_NOMZ
divisions_NN
._.
is_VPRT [BEMA]
a_DT
debilitating_VBG
disease_NN
affecting_VBG [WZPRES]
120_CD
million_CD
Our_FPP1
efforts_NN
to_TO
reinforce_VB
these_DEMO
codes_NN
leave_VPRT
no_SYNE
people_NN
._.
Our_FPP1
medicine_NN
,_,
albendazole_NN
,_,
helps_VPRT
prevent_VB
doubt_NN
about_IN
what_WP
is_VPRT
and_PHC
is_VPRT [BEMA]
not_XX0
acceptable_PRED
,_,
and_ANDC
transmission_NN
of_PIN
LF_NN
and_CC
in_PIN
partnership_NN
with_PIN
the_DT
the_DT
seriousness_NOMZ
of_PIN
contravening_VBG
our_FPP1
codes_NN
._.
World_NN
Health_NN
Organization_NOMZ
WHO_WP [WHOBJ]
we_FPP1
donated_VBD
94_CD
million_CD
treatments_NOMZ
in_PIN
2003_CD
._.
The_DT
WHO_WP
target_NN
is_VPRT
GSK_NN
has_VPRT [SPAU] [PEAS]
always_RB
been_VBN [PASS]
committed_VBN
to_TO
achieving_VBG
to_TO
eliminate_VB
LF_NN
by_PIN
2020_CD
,_,
by_PIN
which_WDT [PIRE]
time_NN
we_FPP1
expect_VPRT [PRIV]
performance_NN
with_PIN
integrity_NOMZ
profits_NN
without_PIN
to_TO
have_VB [PEAS]
donated_VBN
6_CD
billion_CD
treatments_NOMZ
worth_JJ
around_PLACE
principles_NN
are_VPRT [BEMA]
not_XX0
sustainable_PRED
._.
This_DEMP
will_PRMD
be_VB [BEMA]
one_CD
of_PIN
the_DT
pharmaceutical_JJ
about_IN
what_WP
this_DEMP
means_VPRT [PRIV] [THATD]
we_FPP1
have_VPRT [PEAS]
adopted_VBN
new_JJ
industry_NN
's_POS
largest_JJ
donation_NOMZ
programs_NN
._.
We_FPP1
expect_VPRT [PRIV]
everyone_QUPR
in_PIN
GSK_NN
to_TO
consider_VB [PRIV]
how_RB [WHCL]
they_TPP3
apply_VPRT
We_FPP1
will_PRMD
continue_VB
our_FPP1
research_NN
and_PHC
development_NOMZ
to_PIN
their_TPP3
work_NN
._.
into_PIN
treatments_NOMZ
for_PIN
diseases_NN
of_PIN
the_DT
developing_VBG
world_NN
._.
This_DEMO
effort_NN
is_VPRT [BYPA]
complemented_VBN
by_PIN
our_FPP1
access_NN
We_FPP1
look_VPRT
forward_RB
to_TO
reporting_VBG [PUBV]
our_FPP1
progress_NN
to_PIN
initiatives_NN
,_,
particularly_RB
for_PIN
AIDS_NN
in_PIN
Africa_NN
and_CC
all_QUAN
you_SPP2
again_TIME
next_JJ
year_NN
._.
least_JJ
developed_JJ
countries_NN
where_RB
our_FPP1
preferential_JJ
pricing_GER
agreements_NOMZ
are_VPRT [SPAU] [PASS]
now_TIME
well_RB
established_VBN [PRIV]
._.
However_CONJ
,_,
real_JJ
progress_NN
in_PIN
addressing_VBG
disease_NN
and_PHC
suffering_GER
in_PIN
poor_JJ
countries_NN
will_PRMD [SPAU]
only_DWNT
occur_VB
if_COND
responsibility_NOMZ
is_VPRT [BYPA]
shared_VBN
by_PIN
all_QUAN
sectors_NN
of_PIN
global_JJ
society_NN
-_:
governments_NOMZ
,_,
international_JJ
agencies_NN
Sir_NN
Christopher_NN
Hogg_NN
JP_NN
Garnier_NN
and_PHC
companies_NN
such_JJ
as_IN
GSK_NN
._.
Chairman_NN
Chief_NN
Executive_NN
Officer_NN
Corporate_NN
Responsibility_NOMZ
Report_NN
2003_CD
01_CD
About_IN
GSK_NN
GlaxoSmithKline_NN
GSK_NN
is_VPRT [BEMA]
a_DT
leading_VBG
research-based_JJ
pharmaceutical_JJ
company_NN
._.
We_FPP1
make_VPRT
prescription_NOMZ
medicines_NN
,_,
vaccines_NN
,_,
over-the-counter_JJ
medicines_NN
,_,
and_ANDC
oral_JJ
care_NN
and_CC
nutritional_JJ
healthcare_NN
products_NN
._.
We_FPP1
are_VPRT [BEMA]
a_DT
global_JJ
company_NN
headquartered_VBD
in_PIN
the_DT
UK_NN
,_,
with_PIN
major_JJ
operations_NOMZ
in_PIN
the_DT
US_FPP1
._.
Our_FPP1
business_NOMZ
accounts_NN
for_PIN
seven_CD
per_PIN
cent_NN
of_PIN
the_DT
world_NN
's_POS
pharmaceutical_JJ
market_NN
._.
We_FPP1
have_VPRT
particularly_RB
strong_JJ
positions_NOMZ
in_PIN
several_QUAN
therapeutic_JJ
areas_NN
including_VBG [WZPRES]
respiratory_JJ
,_,
anti-viral_JJ
,_,
central_JJ
nervous_JJ
system_NN
,_,
diabetes_NN
and_PHC
vaccines_NN
._.
Further_JJ
information_NOMZ
on_PIN
all_QUAN
the_DT
issues_NN
covered_VBN [WZPAST]
in_PIN
this_DEMO
report_NN
is_VPRT [BEMA]
available_PRED
on_PIN
our_FPP1
website_NN
,_,
www_NN
._.
com_NN
02_CD
Corporate_JJ
Responsibility_NOMZ
Report_NN
2003_CD
Managing_VBG
Corporate_JJ
Responsibility_NOMZ
During_PIN
2003_CD
GSK_NN
formally_RB
adopted_VBD
Corporate_JJ
Responsibility_NOMZ
Principles_NN
._.
These_DEMO
clearly_RB
identify_VB
our_FPP1
key_JJ
corporate_JJ
responsibility_NOMZ
CR_NN
issues_NN
,_,
and_ANDC
provide_VB
guidance_NN
for_PIN
employees_NN
on_PIN
the_DT
standards_NN
to_PIN
which_WDT [PIRE]
the_DT
company_NN
is_VPRT [PASS]
committed_VBN
._.
7_CD
Standards_NN
of_PIN
ethical_JJ
Corporate_JJ
Responsibility_NOMZ
Principles_NN
conduct_VPRT
The_DT
mission_NN
of_PIN
our_FPP1
business_NOMZ
to_TO
improve_VB
the_DT
quality_NOMZ
of_PIN
human_JJ
life_NN
to_TO
enable_VB
people_NN
to_TO
do_VB
more_EMPH
,_,
feel_VB [PRIV]
better_JJ
and_CC
live_VPRT
We_FPP1
expect_VPRT [PRIV]
employees_NN
to_TO
meet_VB
high_JJ
ethical_JJ
standards_NN
in_PIN
all_QUAN
aspects_NN
of_PIN
our_FPP1
business_NOMZ
,_,
by_PIN
longer_JJ
focuses_VPRT
on_PIN
the_DT
needs_NN
of_PIN
patients_NN
._.
We_FPP1
will_PRMD
achieve_VB
conducting_VBG
our_FPP1
activities_NOMZ
with_PIN
honesty_NN
and_CC
this_DEMO
mission_NN
through_PIN
our_FPP1
products_NN
and_PHC
activities_NOMZ
,_,
while_OSUB
integrity_NOMZ
,_,
adhering_VBG [PRESP]
to_PIN
our_FPP1
CR_NN
principles_NN
,_,
and_ANDC
complying_VBG
with_PIN
applicable_JJ
laws_NN
and_PHC
regulations_NOMZ
._.
enhancing_VBG [PRESP]
the_DT
contribution_NOMZ
we_FPP1
make_VPRT
to_PIN
society_NN
,_,
sustaining_VBG
economic_JJ
performance_NN
and_PHC
operating_GER
in_PIN
an_DT
environmentally_RB
responsible_JJ
manner_NN
._.
1_CD
Employment_NOMZ
practices_NN
4_CD
Leadership_NN
and_PHC
advocacy_NN
8_CD
Research_NN
and_PHC
innovation_NOMZ
We_FPP1
will_PRMD
treat_VB
our_FPP1
employees_NN
with_PIN
respect_NN
and_CC
We_FPP1
will_PRMD
establish_VB [PRIV]
our_FPP1
own_JJ
challenging_JJ
standards_NN
In_PIN
undertaking_VBG
our_FPP1
research_NN
and_CC
in_PIN
innovating_GER
:_:
dignity_NOMZ
,_,
encourage_VPRT
diversity_NOMZ
and_CC
ensure_VB [SUAV] [PRIV]
fair_JJ
in_PIN
corporate_JJ
responsibility_NOMZ
,_,
appropriate_JJ
to_PIN
the_DT
We_FPP1
may_POMD
explore_VB
and_PHC
apply_VB
new_JJ
technologies_NN
._.
treatment_NOMZ
through_PIN
all_QUAN
phases_NN
of_PIN
employment_NOMZ
._.
complexities_NOMZ
and_CC
specific_JJ
needs_NN
of_PIN
our_FPP1
business_NOMZ
,_,
We_FPP1
will_PRMD [SPAU]
constructively_RB
engage_VB
stakeholders_NN
on_PIN
We_FPP1
will_PRMD
provide_VB
a_DT
safe_JJ
and_PHC
healthy_JJ
working_VBG
building_GER
on_PIN
external_JJ
guidelines_NN
and_PHC
experience_NN
._.
any_QUAN
concerns_NN
that_TSUB
may_POMD
arise_VB
._.
environment_NOMZ
,_,
support_NN
employees_NN
to_TO
perform_VB
to_PIN
We_FPP1
will_PRMD
share_VB
best_JJ
practice_NN
and_CC
seek_VB
to_TO
influence_VB
We_FPP1
will_PRMD
ensure_VB [SUAV] [PRIV]
that_THVC
our_FPP1
products_NN
are_VPRT [BEMA]
subject_PRED
their_TPP3
full_JJ
potential_NN
and_CC
to_TO
take_VB
responsibility_NOMZ
for_PIN
others_NN
,_,
while_OSUB
remaining_VBG
competitive_JJ
in_PIN
order_NN
to_TO
to_PIN
rigorous_JJ
scientific_JJ
evaluation_NOMZ
and_PHC
testing_GER
for_PIN
the_DT
performance_NN
and_PHC
reputation_NOMZ
of_PIN
the_DT
business_NOMZ
._.
We_FPP1
will_PRMD
comply_VB
with_PIN
or_CC
exceed_VB
all_QUAN
regulations_NOMZ
and_CC
legal_JJ
standards_NN
applicable_JJ
to_PIN
the_DT
research_NN
and_PHC
development_NOMZ
of_PIN
our_FPP1
products_NN
._.
9_CD
Products_NN
and_PHC
customers_NN
2_CD
Human_JJ
rights_NN
5_CD
Community_NOMZ
investment_NOMZ
We_FPP1
will_PRMD
promote_VB
our_FPP1
products_NN
in_PIN
line_NN
with_PIN
high_JJ
We_FPP1
are_VPRT [PASS]
committed_VBN
to_TO
upholding_VBG
the_DT
UN_NN
We_FPP1
will_PRMD
make_VB
a_DT
positive_JJ
contribution_NOMZ
to_PIN
the_DT
1_CD
ethical_JJ
,_,
medical_JJ
and_PHC
scientific_JJ
standards_NN
and_CC
will_PRMD
Universal_NN
Declaration_NOMZ
of_PIN
Human_NN
Rights_NN
,_,
the_DT
communities_NOMZ
in_PIN
which_WDT [PIRE]
we_FPP1
operate_VPRT
,_,
and_ANDC
will_PRMD
2_CD
comply_VPRT
with_PIN
all_QUAN
applicable_JJ
laws_NN
and_PHC
regulations_NOMZ
._.
OECD_NN
guidelines_NN
for_PIN
MNEs_NN
and_CC
the_DT
core_NN
labor_NN
invest_VPRT
in_PIN
health_NN
and_PHC
education_NOMZ
programs_NN
standards_NN
set_VBN [WZPAST]
out_PIN
by_PIN
the_DT
International_NN
Labor_NN
and_PHC
partnerships_NN
that_TSUB
aim_VPRT
to_TO
bring_VB
sustainable_JJ
3_CD
Organisation_NOMZ
._.
We_FPP1
expect_VPRT [PRIV]
the_DT
same_JJ
standards_NN
improvements_NOMZ
to_PIN
under-served_JJ
people_NN
in_PIN
the_DT
of_PIN
our_FPP1
suppliers_NN
,_,
contractors_NN
and_PHC
business_NOMZ
developed_VBD
and_PHC
developing_VBG
world_NN
._.
partners_NN
working_VBG [WZPRES]
on_PIN
GSKs_NN
behalf_NN
._.
6_CD
Engagement_NOMZ
with_PIN
10_CD
Caring_NN
for_PIN
the_DT
3_CD
Access_NN
to_PIN
medicines_NN
stakeholders_NN
environment_NOMZ
We_FPP1
will_PRMD
continue_VB
to_PIN
research_NN
and_CC
develop_VB
medicines_NN
to_TO
treat_VB
diseases_NN
of_PIN
the_DT
developing_VBG
We_FPP1
want_VPRT
to_TO
understand_VB [PRIV]
the_DT
concerns_NN
of_PIN
those_DEMO
We_FPP1
will_PRMD
operate_VB
in_PIN
an_DT
environmentally_RB
responsible_JJ
world_NN
._.
We_FPP1
will_PRMD
find_VB [PRIV]
sustainable_JJ
ways_NN
to_TO
improve_VB
with_PIN
an_DT
interest_NN
in_PIN
corporate_JJ
responsibility_NOMZ
manner_NN
through_PIN
systematic_JJ
management_NOMZ
of_PIN
our_FPP1
access_NN
to_PIN
medicines_NN
for_PIN
disadvantaged_JJ
people_NN
,_,
issues_NN
._.
We_FPP1
will_PRMD
engage_VB
with_PIN
a_DT
range_NN
of_PIN
environmental_JJ
impacts_NN
,_,
measurement_NOMZ
of_PIN
our_FPP1
and_CC
will_PRMD
seek_VB
partnerships_NN
to_TO
support_VB
this_DEMO
activity_NOMZ
._.
stakeholders_NN
and_CC
will_PRMD
communicate_VB
openly_RB
performance_NN
and_CC
setting_VBG
challenging_JJ
performance_NN
about_IN
how_RB
we_FPP1
are_VPRT
addressing_VBG
CR_NN
issues_NN
,_,
in_PIN
targets_NN
._.
We_FPP1
will_PRMD
improve_VB
the_DT
efficiency_NN
of_PIN
all_QUAN
our_FPP1
ways_NN
that_TSUB
aim_VPRT
to_TO
meet_VB
the_DT
needs_NN
of_PIN
different_JJ
activities_NOMZ
to_TO
minimize_VB
material_NN
and_PHC
energy_NN
use_NN
and_PHC
groups_NN
while_OSUB
allowing_VBG [SUAV]
us_FPP1
to_TO
pursue_VB
legitimate_JJ
waste_NN
generated_VBD
._.
We_FPP1
aim_VPRT
to_TO
find_VB [PRIV]
opportunities_NOMZ
to_PIN
business_NOMZ
goals_NN
._.
use_NN
renewable_JJ
materials_NN
and_CC
to_TO
recycle_VB
our_FPP1
waste_NN
._.
Corporate_JJ
Responsibility_NOMZ
Report_NN
2003_CD
03_CD
The_DT
pharmaceutical_JJ
sector_NN
needs_VPRT
to_TO
demonstrate_VB [PRIV]
responsibility_NOMZ
across_PLACE
a_DT
very_AMP
wide_JJ
range_NN
of_PIN
issues_NN
._.
GSK_NN
has_VPRT [PEAS]
shown_VBN [PRIV] [THATD]
it_PIT
is_VPRT [BEMA]
aware_PRED
of_PIN
its_PIT
key_JJ
CR_NN
issues_NN
and_CC
has_VPRT
clear_JJ
structures_NN
for_PIN
managing_VBG
them_TPP3
._.
GSK_NN
management_NOMZ
keeps_VPRT
the_DT
CR_NN
Committee_NN
informed_VBD
of_PIN
its_PIT
activities_NOMZ
and_CC
is_VPRT [BEMA]
responsive_PRED
to_PIN
the_DT
Committees_NN
suggestions_NOMZ
._.
Donald_NN
McHenry_NN
Chairman_NN
,_,
Corporate_NN
Responsibility_NOMZ
Committee_NN
Corporate_NN
Responsibility_NOMZ
Committee_NN
GSKs_NN
Corporate_NN
Responsibility_NOMZ
Committee_NN
consists_VPRT
of_PIN
four_CD
non-executive_JJ
Directors_NN
and_PHC
reports_NN
to_PIN
the_DT
Board_NN
._.
During_PIN
2003_CD
the_DT
Committee_NN
met_VBD
three_CD
times_NN
and_CC
reviewed_VBN
our_FPP1
activity_NOMZ
in_PIN
a_DT
number_NN
of_PIN
areas_NN
including_VBG [WZPRES]
donations_NOMZ
and_PHC
community_NOMZ
investment_NOMZ
,_,
consumer_NN
advertising_GER
,_,
corporate_JJ
responsibility_NOMZ
management_NOMZ
and_PHC
reporting_GER
,_,
political_JJ
activity_NOMZ
and_PHC
programs_NN
for_PIN
diseases_NN
of_PIN
the_DT
developing_VBG
world_NN
._.
Donald_NN
McHenry_NN
Dr_NN
Michle_NN
Barzach_NN
Sir_NN
Christopher_NN
Hogg_NN
Dr_NN
Lucy_NN
Shapiro_NN
Chairman_NN
of_PIN
the_DT
Corporate_JJ
Dr_NN
Barzach_NN
is_VPRT [BEMA]
a_DT
member_NN
of_PIN
the_DT
Sir_NN
Christopher_NN
is_VPRT [BEMA]
Non-Executive_JJ
Dr_NN
Shapiro_NN
is_VPRT
Ludwig_NN
Professor_NN
of_PIN
Responsibility_NOMZ
Committee_NN
._.
Mr_NN
International_NN
Cooperation_NOMZ
High_NN
Chairman_NN
of_PIN
Reuters_NN
Group_NN
PLC_NN
,_,
Cancer_NN
Research_NN
in_PIN
the_DT
Department_NOMZ
McHenry_NN
is_VPRT [BEMA]
a_DT
Distinguished_NN
Professor_NN
Council_NN
,_,
Chairman_NN
of_PIN
the_DT
Board_NN
of_PIN
a_DT
member_NN
of_PIN
the_DT
Supervisory_NN
Board_NN
of_PIN
Developmental_NN
Biology_NN
and_PHC
Director_NN
in_PIN
the_DT
Practice_NN
of_PIN
Diplomacy_NN
at_PIN
the_DT
Equilibres_NN
et_FW
Populations_NOMZ
and_PHC
Director_NN
of_PIN
Air_NN
Liquide_NN
S._NN
A._NN
and_PHC
Chairman_NN
of_PIN
of_PIN
the_DT
Beckman_NN
Centre_NN
for_PIN
Molecular_NN
School_NN
of_PIN
Foreign_NN
Service_NN
at_PIN
of_PIN
the_DT
Board_NN
of_PIN
Project_NN
Hope_NN
._.
The_DT
Royal_NN
National_NN
Theatre_NN
,_,
as_RB
well_RB
and_CC
Genetic_NN
Medicine_NN
at_PIN
the_DT
Stanford_NN
Georgetown_NN
University_NOMZ
and_CC
is_VPRT
International_NN
consultant_NN
in_PIN
health_NN
as_IN
being_VBG [BEMA]
Non-Executive_JJ
Chairman_NN
University_NOMZ
School_NN
of_PIN
Medicine_NN
._.
President_NN
of_PIN
the_DT
IRC_NN
Group_NN
,_,
LLC_NN
._.
strategy_NN
,_,
she_TPP3
was_VBD [BEMA]
formerly_TIME
French_PRED
of_PIN
GSK_NN
._.
Minister_NN
of_PIN
Health_NN
and_PHC
Family_NN
._.
MANAGEMENT_NOMZ
OF_PIN
CORPORATE_JJ
RESPONSIBILITY_NOMZ
We_FPP1
believe_VPRT [PRIV]
that_THVC
corporate_JJ
responsibility_NOMZ
is_VPRT [SPAU] [PASS]
most_EMPH
effectively_RB
managed_VBN
within_PIN
our_FPP1
business_NOMZ
operations_NOMZ
,_,
where_RB
experts_NN
on_PIN
Corporate_JJ
all_QUAN
our_FPP1
CR_NN
issues_NN
are_VPRT [PASS]
employed_VBN
._.
We_FPP1
GSK_NN
Board_NN
Responsibility_NOMZ
have_VPRT
a_DT
small_JJ
corporate_JJ
team_NN
that_TOBJ
Committee_NN
Ethics_NN
and_PHC
co-ordinates_NN
policy_NN
development_NOMZ
,_,
integrity_NOMZ
reporting_GER
,_,
and_ANDC
communication_NOMZ
with_PIN
socially_RB
responsible_JJ
investors_NN
._.
CEO_NN
Access_NN
to_PIN
medicines_NN
Research_NN
and_PHC
GSK_NN
innovation_NOMZ
Corporate_NN
Executive_NN
Stakeholder_NN
Team_NN
engagement_NOMZ
Human_NN
rights_NN
Corporate_JJ
responsibility_NOMZ
strategy_NN
and_PHC
Community_NOMZ
reporting_VBG [PUBV] [WZPRES]
investment_NOMZ
Employment_NOMZ
practices_NN
Environment_NOMZ
Products_NN
and_PHC
Advocacy_NN
customers_NN
04_CD
Corporate_JJ
Responsibility_NOMZ
Report_NN
2003_CD
Key_NN
impact_NN
areas_NN
1_CD
Medicines_NN
for_PIN
the_DT
Summary_NN
of_PIN
indicators_NN
developing_VBG [WZPRES]
world_NN
Below_NN
are_VPRT [BEMA]
the_DT
main_JJ
indicators_NN
we_FPP1
are_VPRT
using_VBG
to_TO
track_VB
our_FPP1
Resear_NN
Resear_NN
ch_VPRT
to_TO
find_VB [PRIV]
tr_NN
ch_NN
to_TO
find_VB [PRIV]
tr_NN
eatments_NOMZ
for_PIN
diseases_NN
of_PIN
eatments_NOMZ
for_PIN
diseases_NN
the_DT
developing_VBG
world_NN
._.
Pr_NN
of_PIN
the_DT
developing_VBG
world_NN
._.
Pr_NN
oviding_VBG [WZPRES]
vaccines_NN
oviding_VBG [WZPRES]
performance_NN
on_PIN
a_DT
range_NN
of_PIN
corporate_JJ
responsibility_NOMZ
issues_NN
._.
and_ANDC
medicines_NN
for_PIN
the_DT
poor_JJ
vaccines_NN
and_PHC
medicines_NN
for_PIN
the_DT
poor_JJ
est_NN
countries_NN
at_PIN
est_NN
prefercountries_NN
at_PIN
pr_NN
ential_JJ
prices_NN
._.
PAGE_NN
10_CD
PAGE_NN
10_CD
Issue_NN
2002_CD
2003_CD
Medicines_NN
for_PIN
the_DT
developing_VBG
world_NN
2_CD
Community_NOMZ
investment_NOMZ
Supply_NN
arrangements_NOMZ
for_PIN
preferentially_RB
priced_VBN
anti-retrovirals_NN
ARVs_NN
124_CD
175_CD
Our_FPP1
philanthropic_JJ
work_NN
primarily_RB
Number_NN
of_PIN
countries_NN
supplied_VBN [WZPAST]
with_PIN
preferentially_RB
priced_VBN
ARVs_NN
50_CD
56_CD
focuses_VPRT
on_PIN
health_NN
and_PHC
education_NOMZ
._.
PAGE_NN
14_CD
Number_NN
of_PIN
Combivir_NN
tablets_NN
shipped_VBD
6.2_CD
m_NN [BEMA]
10.7_CD
m_NN
Number_NN
of_PIN
albendazole_JJ
tablets_NN
donated_VBN
66m_CD
94m_CD
Number_NN
of_PIN
countries_NN
supplied_VBN [WZPAST]
with_PIN
albendazole_JJ
31_CD
34_CD
Community_NOMZ
investment_NOMZ
Total_JJ
community_NOMZ
investment_NOMZ
expenditure_NN
239m_JJ
338m_CD
Total_JJ
value_NN
of_PIN
product_NN
donations_NOMZ
including_VBG [WZPRES]
albendazole_JJ
24m_JJ
116m_JJ
3_CD
Business_NOMZ
ethics_NN
and_PHC
integrity_NOMZ
Total_JJ
value_NN
of_PIN
products_NN
donated_VBN [WZPAST]
through_PIN
GSK_NN
Patient_NN
The_NN
standards_NN
of_PIN
behavior_NN
required_VBN [SUAV]
Assistance_NN
Program_NN
112m_CD
125m_CD
of_PIN
all_QUAN
our_FPP1
employees_NN
and_CC
the_DT
steps_NN
we_FPP1
Business_NOMZ
ethics_NN
and_PHC
integrity_NOMZ
are_VPRT
taking_VBG
to_TO
ensure_VB [SUAV] [PRIV] [THATD]
they_TPP3
are_VPRT [PASS]
achieved_VBN
._.
Number_NN
of_PIN
employees_NN
completing_VBG [WZPRES]
certification_NOMZ
to_PIN
700_CD
9,000_CD
PAGE_NN
18_CD
Code_NN
of_PIN
Conduct_NN
Environment_NOMZ
Number_NN
of_PIN
contract_NN
manufacturers_NN
audited_VBD
16_CD
28_CD
4_CD
Environment_NOMZ
,_,
health_NN
and_PHC
safety_NN
Energy_NN
consumption_NOMZ
million_CD
gigajoules_NN
20.1_CD
19.8_CD
Water_NN
consumption_NOMZ
million_CD
cubic_JJ
metres_NN
24.7_CD
23.5_CD
Using_VBG
resources_NN
efficiently_RB
and_CC
minimizing_VBG
the_DT
impact_NN
of_PIN
our_FPP1
products_NN
Ozone_NN
depletion_NOMZ
potential_NN
from_PIN
metered_VBN
dose_NN
inhalers_NN
and_PHC
operations_NOMZ
on_PIN
the_DT
environment_NOMZ
._.
tonnes_NN
CFC-11_NN
equivalent_JJ
1,500_CD
782_CD
Protecting_VBG
our_FPP1
employees_NN
and_PHC
Ozone_NN
depletion_NOMZ
potential_NN
from_PIN
production_NOMZ
tonnes_NN
CFC-11_NN
equivalent_JJ
120_CD
68_CD
contractors_NN
in_PIN
the_DT
workplace_NN
._.
Ozone_NN
depletion_NOMZ
potential_NN
from_PIN
refrigeration_NOMZ
and_CC
other_JJ
ancillary_JJ
uses_NN
PAGE_VPRT
20_CD
tonnes_NN
CFC-11_NN
equivalent_JJ
7.4_CD
2.2_CD
Volatile_JJ
organic_JJ
compound_NN
emissions_NN
thousand_CD
tonnes_NN
6.5_CD
6.6_CD
Global_JJ
warming_GER
potential_NN
from_PIN
energy_NN
sources_NN
thousand_CD
tonnes_VPRT
CO_NN
equivalent_JJ
1,842_CD
1,815_CD
2_CD
5_CD
Valuing_VBG
people_NN
Hazardous_JJ
waste_NN
disposed_VBD
thousand_CD
tonnes_NN
62.5_CD
61.4_CD
Our_FPP1
commitment_NOMZ
to_PIN
diversity_NOMZ
,_,
equal_JJ
Health_NN
and_PHC
safety_NN
opportunity_NOMZ
and_CC
creating_VBG
a_DT
working_VBG
Lost_VBN
time_NN
injury_NN
and_PHC
illness_NOMZ
rate_NN
cases_NN
per_PIN
100,000_CD
hours_NN
worked_VBD
0.34_CD
0.31_CD
environment_NOMZ
in_PIN
which_WDT [PIRE]
the_DT
talent_NN
of_PIN
all_QUAN
Lost_VBN
time_NN
injury_NN
and_PHC
illness_NOMZ
rate_NN
for_PIN
contractors_NN
working_VBG [WZPRES]
on_PIN
site_NN
our_FPP1
people_NN
will_PRMD
thrive_VB
._.
cases_NN
per_PIN
100,000_CD
hours_NN
worked_VBD
0.50_CD
0.33_CD
PAGE_NN
23_CD
Valuing_VBG
people_NN
Women_NN
in_PIN
management_NOMZ
grades_NN
%_NN
32_CD
34_CD
Research_NN
and_PHC
development_NOMZ
Ethnic_JJ
diversity_NOMZ
people_NN
of_PIN
color_NN
US_FPP1
only_DWNT
,_,
%_NN
19.0_CD
19.5_CD
6_CD
Research_NN
and_PHC
development_NOMZ
The_DT
conduct_NN
and_PHC
publication_NOMZ
of_PIN
clinical_JJ
trials_NN
._.
The_DT
need_NN
for_PIN
animal_NN
GSK_NN
animal_NN
research_NN
facilities_NOMZ
accredited_VBN [WZPAST]
by_PIN
the_DT
Association_NOMZ
for_PIN
testing_GER
and_PHC
safeguards_NN
for_PIN
their_TPP3
Assessment_NOMZ
and_PHC
Accreditation_NOMZ
of_PIN
Laboratory_NN
Animal_NN
Care_NN
7_CD
7_CD
treatment_NOMZ
._.
PAGE_NN
26_CD
We_FPP1
are_VPRT
assessing_VBG
the_DT
benefits_NN
of_PIN
developing_VBG
further_JJ
performance_NN
indicators_NN
._.
In_PIN
doing_VBG
so_RB
,_,
we_FPP1
will_PRMD
continue_VB
to_TO
take_VB
into_PIN
account_NN
the_DT
views_NN
of_PIN
our_FPP1
stakeholders_NN
._.
Corporate_JJ
Responsibility_NOMZ
Report_NN
2003_CD
05_CD
Each_QUAN
and_CC
ev_VB
GSK_NN
plays_VPRT
an_DT
important_JJ
role_NN
in_PIN
society_NN
through_PIN
research_NN
into_PIN
new_JJ
treatments_NOMZ
and_PHC
vaccines_NN
,_,
product_NN
donations_NOMZ
,_,
preferential_JJ
pricing_GER
for_PIN
developing_VBG
countries_NN
and_PHC
support_NN
for_PIN
patients_NN
who_WP [WHSUB]
can_POMD
not_XX0
afford_VB
medicines_NN
._.
Here_RB
are_VPRT [BEMA]
some_QUAN
examples_NN
of_PIN
how_RB
much_QUAN
we_FPP1
contribute_VPRT
each_QUAN
day_NN
._.
More_EMPH
than_PIN
555,000_CD
Americans_NN
have_VPRT
access_NN
to_PIN
our_FPP1
medicines_NN
free_JJ
of_PIN
charge_NN
or_CC
at_PIN
subsidised_JJ
rates_NN
These_DEMP
are_VPRT
people_NN
who_WP [WHSUB]
do_VPRT
not_XX0
have_VB
insurance_NN
and_CC
would_PRMD
otherwise_CONJ
not_XX0
be_VB [BEMA]
able_PRED
to_TO
afford_VB
medicines_NN
._.
7million_RB
invested_VBN
in_PIN
scientific_JJ
medical_JJ
research_NN
each_QUAN
day_NN
Society_NN
relies_VPRT
on_PIN
the_DT
pharmaceutical_JJ
industry_NN
to_TO
discover_VB [PRIV]
and_PHC
develop_VB
the_DT
medicines_NN
of_PIN
the_DT
future_NN
._.
06_CD
Corporate_JJ
Responsibility_NOMZ
Report_NN
2003_CD
every_QUAN
day_NN
Over_IN
2_CD
million_CD
GSK_NN
vaccines_NN
are_VPRT [PASS]
distributed_VBN
worldwide_JJ
These_DEMP
prevent_VPRT
disease_NN
and_PHC
help_NN
improve_VB
public_JJ
health_NN
._.
and_ANDC
over_IN
250,000_CD
albendazole_JJ
preventative_JJ
treatments_NOMZ
are_VPRT [PASS]
donated_VBN
to_PIN
people_NN
in_PIN
developing_VBG
countries_NN
Albendazole_NN
helps_VPRT
prevent_VB
transmission_NN
of_PIN
lymphatic_JJ
filariasis_NN
,_,
a_DT
debilitating_VBG
disease_NN
affecting_VBG [WZPRES]
120_CD
million_CD
people_NN
in_PIN
developing_VBG
countries_NN
._.
27,000_CD
tablets_NN
of_PIN
Combivir_NN
are_VPRT [PASS]
shipped_VBN
to_TO
treat_VB
HIV_NN
AIDS_NN
patients_NN
in_PIN
developing_VBG
countries_NN
Making_VBG [WZPRES]
anti-retrovirals_NN
more_EMPH
affordable_JJ
through_PIN
sustainable_JJ
preferential_JJ
pricing_GER
to_TO
help_VB
tackle_VB
the_DT
global_JJ
HIV_NN
AIDS_NN
epidemic_NN
._.
Corporate_JJ
Responsibility_NOMZ
Report_NN
2003_CD
07_CD
Our_FPP1
contributio_NN
Our_FPP1
business_NOMZ
is_VPRT
about_IN
developing_VBG
and_PHC
marketing_VBG
medicines_NN
and_PHC
vaccines_NN
that_TSUB
improve_VPRT
the_DT
health_NN
and_PHC
quality_NOMZ
of_PIN
life_NN
of_PIN
millions_NN
of_PIN
people_NN
around_PLACE
the_DT
world_NN
._.
We_FPP1
are_VPRT [BEMA]
a_DT
commercial_JJ
organization_NOMZ
that_TSUB
needs_VPRT
to_TO
make_VB
profits_NN
to_TO
fund_VB
future_JJ
investment_NOMZ
and_CC
to_TO
pay_VB
dividends_NN
to_PIN
our_FPP1
shareholders_NN
._.
Patient_NN
Assistance_NN
Program_NN
in_PIN
the_DT
US_FPP1
We_FPP1
believe_VPRT [PRIV]
governments_NOMZ
and_CC
Developing_VBG
world_NN
GSKs_NN
Patient_NN
Assistance_NN
Program_NN
PAP_NN
in_PIN
Many_QUAN
people_NN
in_PIN
the_DT
developing_VBG
world_NN
continue_VPRT
intergovernmental_JJ
bodies_NN
are_VPRT [BEMA]
primarily_RB
the_DT
US_FPP1
gives_VPRT
low-income_JJ
,_,
uninsured_JJ
patients_NN
to_TO
suffer_VB
and_PHC
die_VB
from_PIN
preventable_JJ
and_PHC
treatable_JJ
responsible_JJ
for_PIN
meeting_VBG
the_DT
worlds_NN
access_NN
to_PIN
the_DT
medicines_NN
they_TPP3
need_VPRT
but_CC
diseases_NN
._.
They_TPP3
do_VPRT
not_XX0
have_VB
access_NN
to_PIN
the_DT
health_NN
challenges_NN
,_,
including_VBG [PRESP]
those_DEMO
in_PIN
can_POMD
not_XX0
afford_VB
._.
medicines_NN
they_TPP3
need_VPRT
,_,
or_CC
to_PIN
adequate_JJ
healthcare_NN
the_DT
developing_VBG
world_NN
._.
We_FPP1
can_POMD
not_XX0
Commitment_VB
to_PIN
Access_NN
covers_VPRT
cancer_NN
facilities_NOMZ
._.
GSK_NN
makes_VPRT
a_DT
major_JJ
contribution_NOMZ
replace_VB
the_DT
functions_NOMZ
of_PIN
governments_NOMZ
treatments_NOMZ
while_OSUB
other_JJ
medicines_NN
are_VPRT [BEMA]
available_PRED
through_PIN
research_NN
into_PIN
treatments_NOMZ
and_PHC
vaccines_NN
or_CC
charities_NOMZ
but_CC
we_FPP1
support_VPRT
them_TPP3
in_PIN
through_PIN
another_DT
of_PIN
our_FPP1
programs_NN
,_,
Bridges_NN
for_PIN
diseases_NN
that_TSUB
are_VPRT [BEMA]
common_PRED
in_PIN
developing_VBG
some_QUAN
very_AMP
important_JJ
ways_NN
we_FPP1
have_VPRT
to_PIN
Access_NN
._.
countries_NN
,_,
providing_VBG
products_NN
at_PIN
preferential_JJ
a_DT
significant_JJ
role_NN
to_TO
play_VB
._.
In_PIN
2003_CD
,_,
over_IN
400,000_CD
people_NN
received_VBD
free_JJ
prices_NN
and_CC
investing_VBG
in_PIN
community_NOMZ
health_NN
and_PHC
GSK_NN
medicines_NN
through_PIN
these_DEMO
programs_NN
._.
These_DEMP
are_VPRT [PASS]
described_VBN
in_PIN
Pharmaceutical_NN
research_NN
Our_FPP1
total_JJ
commitment_NOMZ
to_PIN
PAP_NN
in_PIN
2003_CD
was_VBD
more_EMPH
detail_NN
on_PIN
page_NN
10_CD
._.
In_PIN
developed_JJ
countries_NN
we_FPP1
take_VPRT
medicines_NN
almost_DWNT
$_$
205_CD
million_CD
._.
Eligibility_NOMZ
criteria_NN
for_PIN
these_DEMO
for_PIN
granted_VBN [SUAV]
._.
We_FPP1
have_VPRT [PEAS]
benefited_VBN
from_PIN
advances_NN
programs_NN
are_VPRT [BEMA]
among_PIN
the_DT
most_EMPH
generous_JJ
Developed_VBN
world_NN
offered_VBN [WZPAST]
by_PIN
the_DT
pharmaceutical_JJ
industry_NN
._.
which_WDT [SERE]
mean_VPRT [PRIV]
that_THVC
most_EMPH
of_PIN
us_FPP1
are_VPRT
no_RB
longer_RB
at_PIN
risk_NN
Even_RB
in_PIN
developed_JJ
countries_NN
some_QUAN
sections_NOMZ
of_PIN
from_PIN
diseases_NN
such_JJ
as_IN
polio_NN
and_PHC
TB_NN
that_TSUB
were_VBD
Patient_NN
eligibility_NOMZ
is_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
through_PIN
one_CD
society_NN
do_VPRT
not_XX0
have_VB
sufficient_JJ
access_NN
to_PIN
medicines_NN
._.
major_JJ
threats_NN
less_RB
than_PIN
a_DT
century_NN
ago_RB
._.
But_CC
there_EX
phone_NN
call_NN
,_,
and_ANDC
once_TIME
enrolled_VBD
a_DT
patient_NN
can_POMD
This_DEMP
is_VPRT [BEMA]
a_DT
particular_JJ
concern_NN
in_PIN
the_DT
US_FPP1
,_,
where_RB
many_QUAN
are_VPRT [BEMA]
still_RB
many_QUAN
serious_JJ
illnesses_NOMZ
for_PIN
which_WDT [PIRE]
there_EX
receive_VPRT
the_DT
prescription_NOMZ
medicine_NN
immediately_TIME
people_NN
are_VPRT [BYPA]
not_XX0
covered_VBN
by_PIN
public_JJ
or_CC
private_JJ
health_NN
at_PIN
any_QUAN
local_JJ
pharmacy_NN
._.
In_CONJ
addition_NULL
patients_NN
are_VPRT
are_VPRT [BEMA]
few_QUAN
treatments_NOMZ
or_CC
where_RB
treatments_NOMZ
may_POMD
be_VB
insurance_NN
._.
We_FPP1
are_VPRT
helping_VBG
patients_NN
who_WP [WHSUB]
do_VPRT
not_XX0
helped_VBN
to_TO
find_VB [PRIV]
other_JJ
sources_NN
of_PIN
funding_VBG
such_JJ
improved_VBN
._.
have_VB
insurance_NN
coverage_NN
to_TO
gain_VB
access_NN
to_PIN
as_IN
Medicaid_NN
,_,
AIDS_NN
Drug_NN
Assistance_NN
Program_NN
,_,
State_NN
Childrens_NN
Health_NN
Insurance_NN
Programs_NN
prescription_NOMZ
medicines_NN
via_PIN
a_DT
number_NN
of_PIN
initiatives_NN
._.
Discovering_VBG [PRIV]
and_PHC
developing_VBG
a_DT
new_JJ
medicine_NN
and_PHC
State_NN
Elderly_NN
Drug_NN
Assistance_NN
Programs_NN
._.
to_TO
prevent_VB
or_CC
treat_VB
disease_NN
is_VPRT [BEMA]
expensive_PRED
the_DT
GSK_NN
was_VBD [BEMA]
the_DT
first_JJ
pharmaceutical_JJ
company_NN
in_PIN
the_DT
The_DT
company_NN
promotes_VPRT
the_DT
PAP_NN
on_PIN
two_CD
average_JJ
cost_NN
is_VPRT
over_IN
450_CD
million_CD
and_CC
it_PIT
takes_VPRT
6_CD
7_CD
,_,
websites_NN
which_WDT [WHSUB]
tell_VPRT
patients_NN
what_WDT
support_NN
US_FPP1
to_TO
offer_VB
a_DT
card_NN
providing_VBG [WZPRES]
savings_GER
on_PIN
medicines_NN
around_PLACE
12_CD
years_NN
._.
is_VPRT [BEMA]
available_PRED
and_CC
help_VB
to_TO
increase_VB
take-up_NN
._.
to_PIN
low_JJ
income_NN
senior_JJ
citizens_NN
and_CC
disabled_JJ
people_NN
._.
Our_FPP1
Orange_NN
Card_NN
is_VPRT [BEMA]
available_PRED
to_PIN
these_DEMO
groups_NN
,_,
GSK_NN
invested_VBD
almost_DWNT
providing_VBG
savings_GER
of_PIN
up_RB
to_PIN
40_CD
%_NN
on_PIN
GSKs_NN
4_CD
prescription_NOMZ
medicines_NN
._.
By_PIN
the_DT
end_NN
of_PIN
2003_CD
,_,
2.8_CD
billion_CD
in_PIN
research_NN
155,000_CD
patients_NN
had_VBD [PEAS]
enrolled_VBN
in_PIN
this_DEMO
program_NN
._.
GSK_NN
has_VPRT [SPAU] [PEAS]
also_RB
joined_VBN
with_PIN
six_CD
other_JJ
This_DEMP
enables_VPRT
us_FPP1
to_TO
employ_VB
the_DT
pharmaceutical_JJ
companies_NN
to_TO
offer_VB
the_DT
Together_RB
Rx_JJ
card_NN
to_PIN
low_JJ
income_NN
patients_NN
who_WP [WHSUB]
are_VPRT
leading_VBG
scientists_NN
and_CC
provide_VB
eligible_JJ
for_PIN
Medicare_NN
and_CC
would_PRMD
otherwise_CONJ
the_DT
technology_NN
they_TPP3
need_VPRT
5_CD
not_XX0
be_VB [BEMA]
able_PRED
to_TO
afford_VB
prescription_NOMZ
medicines_NN
._.
Together_RB
Rx_NN
provides_VPRT
a_DT
discount_NN
of_PIN
between_PIN
to_TO
push_VB
forward_RB
the_DT
frontiers_NN
20_CD
%_NN
and_CC
40_CD
%_NN
on_PIN
over_IN
150_CD
different_JJ
medicines_NN
._.
We_FPP1
also_RB
operate_VPRT
a_DT
Patient_NN
Assistance_NN
Program_NN
Society_NN
now_TIME
relies_VPRT
on_PIN
pharmaceutical_JJ
companies_NN
which_WDT [WHOBJ]
in_PIN
2003_CD
provided_VBN
medicines_NN
worth_JJ
to_TO
make_VB
this_DEMO
investment_NOMZ
and_PHC
fund_NN
research_NN
._.
These_DEMP
were_VBD [PASS]
provided_VBN
at_PIN
no_SYNE
cost_NN
,_,
or_CC
funding_GER
and_PHC
resources_NN
of_PIN
the_DT
industry_NN
are_VPRT [BEMA]
integral_JJ
minimal_JJ
cost_NN
,_,
to_PIN
more_EMPH
than_PIN
400,000_CD
patients_NN
in_PIN
to_PIN
the_DT
development_NOMZ
of_PIN
new_JJ
medicines_NN
._.
the_DT
US_FPP1
who_WP [WHSUB]
do_VPRT
not_XX0
have_VB
medical_JJ
insurance_NN
and_CC
may_POMD [SPAU]
otherwise_CONJ
have_VB [PEAS]
gone_VBN
without_PIN
their_TPP3
medicines_NN
._.
08_CD
Corporate_JJ
Responsibility_NOMZ
Report_NN
2003_CD
n_NN
to_PIN
society_NN
An_DT
important_JJ
part_NN
of_PIN
my_FPP1
job_NN
is_VPRT
helping_VBG
some_QUAN
of_PIN
the_DT
80,000_CD
people_NN
in_PIN
Baltimore_NN
County_NN
who_WP [WHSUB]
do_VPRT
not_XX0
have_VB
medical_JJ
insurance_NN
._.
GSKs_NN
program_NN
makes_VPRT
it_PIT
easy_JJ
for_PIN
me_FPP1
to_TO
help_VB
:_:
the_DT
process_NN
is_VPRT [BEMA]
so_EMPH
quick_PRED
I_FPP1
always_RB
hope_VPRT [PRIV]
its_PIT
a_DT
GSK_NN
medicine_NN
on_PIN
the_DT
prescription_NOMZ
._.
Patients_NN
pay_VPRT
just_EMPH
$_$
10_CD
for_PIN
two_CD
months_NN
supply_NN
of_PIN
medicine_NN
no_SYNE
matter_NN
what_WDT
drug_NN
is_VPRT [PASS]
required_VBN [SUAV]
._.
This_DEMP
is_VPRT [BEMA]
invaluable_PRED
to_PIN
uninsured_JJ
patients_NN
who_WP [WHSUB]
might_POMD [SPAU]
otherwise_CONJ
have_VB
to_TO
choose_VB
between_PIN
medicines_NN
or_CC
food_NN
._.
Wendy_NN
Freeman_NN
Case_NN
Manager_NN
,_,
Baltimore_NN
County_NN
Health_NN
Department_NOMZ
,_,
Maryland_NN
,_,
US_FPP1
Corporate_NN
Responsibility_NOMZ
Report_NN
2003_CD
09_CD
Medicines_NN
f_SYM
the_DT
develop_VB
Lack_NN
of_PIN
access_NN
to_TO
even_RB
basic_JJ
medication_NOMZ
and_PHC
healthcare_NN
facilities_NOMZ
has_VPRT [PEAS]
led_VBN
to_PIN
a_DT
healthcare_NN
crisis_NN
in_PIN
the_DT
developing_VBG
world_NN
._.
GSK_NN
is_VPRT [PASS]
committed_VBN
to_TO
playing_VBG
a_DT
leading_VBG
role_NN
in_PIN
addressing_VBG
this_DEMO
crisis_NN
._.
GSKs_NN
response_NN
to_PIN
this_DEMO
crisis_NN
has_VPRT
three_CD
elements_NOMZ
:_:
Progress_NN
in_PIN
2003_CD
half_NN
of_PIN
2002_CD
was_VBD [BEMA]
largely_RB
due_PRED
to_PIN
potential_JJ
Preferential_JJ
pricing_GER
offering_GER
anti-retrovirals_NN
Following_VBG [WZPRES]
improvements_NOMZ
in_PIN
manufacturing_GER
and_PHC
purchasers_NN
delaying_VBG [WZPRES]
placement_NOMZ
of_PIN
orders_NN
in_PIN
ARVs_NN
for_PIN
HIV_NN
AIDS_NN
and_PHC
anti-malarials_NN
on_PIN
a_DT
economies_NN
of_PIN
scale_NN
,_,
we_FPP1
cut_VBD
the_DT
not-for-profit_JJ
anticipation_NOMZ
of_PIN
new_JJ
funding_GER
sources_NN
._.
These_DEMO
not-for-profit_JJ
basis_NN
and_PHC
vaccines_NN
at_PIN
significant_JJ
prices_NN
of_PIN
ARVs_NN
in_PIN
April_NN
and_CC
again_TIME
in_PIN
October_NN
._.
became_VBD
available_JJ
early_TIME
in_PIN
2003_CD
,_,
hence_CONJ
the_DT
discounts_NN
to_PIN
the_DT
poorest_JJ
countries_NN
Combivir_NN
is_VPRT [BEMA]
now_TIME
available_PRED
at_PIN
$_$
0.65_CD
a_DT
day_NN
,_,
increase_NN
in_PIN
shipments_NOMZ
during_PIN
this_DEMO
year_NN
._.
Research_NN
and_PHC
development_NOMZ
investment_NOMZ
in_PIN
compared_VBN
to_TO
$_$
1.70_CD
in_PIN
December_NN
2002_CD
._.
the_DT
search_NN
for_PIN
new_JJ
treatments_NOMZ
and_PHC
vaccines_NN
It_PIT
is_VPRT [BEMA]
difficult_PRED
to_TO
quantify_VB
the_DT
number_NN
of_PIN
patients_NN
for_PIN
diseases_NN
of_PIN
the_DT
developing_VBG
world_NN
We_FPP1
now_TIME
have_VPRT
over_IN
175_CD
public_JJ
sector_NN
agreements_NOMZ
treated_VBN
as_CONJ
a_NULL
result_NULL
of_PIN
our_FPP1
programs_NN
because_CAUS
Community_NOMZ
investment_NOMZ
activities_NOMZ
and_CC
to_TO
supply_VB
ARVs_NN
in_PIN
56_CD
countries_NN
._.
This_DEMP
includes_VPRT
25_CD
we_FPP1
do_VPRT
not_XX0
control_VB
healthcare_NN
provision_NN
._.
However_CONJ
,_,
partnerships_NN
that_TSUB
support_VPRT
improving_VBG
health_NN
ARV_NN
supply_NN
agreements_NOMZ
with_PIN
employers_NN
in_PIN
suba_NN
study_NN
in_PIN
September_NN
2003_CD
by_PIN
the_DT
UN-led_JJ
in_PIN
under-served_JJ
communities_NOMZ
._.
Accelerating_VBG
Access_NN
Initiative_NN
AAI_NN
indicates_VPRT [PRIV]
that_THVC
in_PIN
sub-Saharan_JJ
Africa_NN
the_DT
number_NN
of_PIN
patients_NN
Preferential_JJ
pricing_GER
During_PIN
2003_CD
we_FPP1
shipped_VBD
almost_DWNT
11_CD
million_CD
treated_VBN
with_PIN
ARVs_NN
supplied_VBN [WZPAST]
by_PIN
the_DT
six_CD
companies_NN
All_QUAN
GSK_NN
ARVs_NN
and_CC
anti-malarial_JJ
medicines_NN
are_VPRT [SPAU] [PASS]
preferentially_RB
priced_VBN
Combivir_NN
tablets_NN
to_PIN
in_PIN
the_DT
AAI_NN
had_VBD
more_EMPH
than_PIN
doubled_VBN
in_PIN
a_DT
year_NN
to_TO
now_TIME
available_JJ
to_PIN
the_DT
public_JJ
sector_NN
at_PIN
not-fordeveloping_JJ
countries_NN
,_,
74_CD
%_NN
more_EMPH
than_PIN
in_PIN
2002_CD
._.
over_IN
75,000_CD
._.
This_DEMP
is_VPRT [BEMA]
still_RB
a_DT
very_AMP
small_JJ
proportion_NOMZ
profit_NN
prices_NN
in_PIN
63_CD
of_PIN
the_DT
worlds_NN
poorest_JJ
Shipment_NOMZ
figures_NN
for_PIN
2002_CD
exclude_VPRT
the_DT
product_NN
of_PIN
the_DT
patients_NN
who_WP [WHSUB]
need_VPRT
treatment_NOMZ
._.
Substantial_JJ
8_CD
countries_NN
,_,
including_VBG [PRESP]
all_QUAN
of_PIN
sub-Saharan_JJ
Africa_NN
._.
sold_VBN [PASTP]
at_PIN
not-for-profit_JJ
prices_NN
to_PIN
West_NN
Africa_NN
and_PHC
coverage_NN
requires_VPRT [SUAV]
more_EMPH
funding_GER
to_TO
pay_VB
for_PIN
better_JJ
Not-for-profit_JJ
prices_NN
for_PIN
ARVs_NN
are_VPRT [BEMA]
also_RB
available_JJ
illegally_RB
diverted_VBN
back_RB
to_PIN
Europe_NN
,_,
amounting_VBG [PRESP]
to_PIN
healthcare_NN
infrastructure_NN
and_CC
to_TO
ensure_VB [SUAV] [PRIV]
the_DT
safe_JJ
to_PIN
private_JJ
employers_NN
in_PIN
sub-Saharan_JJ
Africa_NN
who_WP
almost_DWNT
a_DT
quarter_NN
of_PIN
not-for-profit_JJ
Combivir_NN
sales_NN
delivery_NN
of_PIN
more_EMPH
medicines_NN
to_PIN
patients_NN
._.
provide_VB
care_NN
and_PHC
treatment_NOMZ
for_PIN
uninsured_JJ
staff_NN
._.
The_DT
decline_NN
in_PIN
shipments_NOMZ
in_PIN
the_DT
second_JJ
All_QUAN
projects_NN
fully_AMP
funded_VBN
by_PIN
the_DT
Global_NN
Fund_NN
to_PIN
9_CD
SUPPLY_NN
ARRANGEMENTS_NOMZ
BY_PIN
TYPE_NN
OF_PIN
CUSTOMER_NN
Fight_VPRT
AIDS_NN
,_,
TB_NN
and_PHC
Malaria_NN
are_VPRT [BEMA]
also_RB
eligible_PRED
,_,
so_OSUB
that_NULL
our_FPP1
not-for-profit_JJ
prices_NN
are_VPRT [BEMA]
now_TIME
available_PRED
in_PIN
over_IN
100_CD
countries_NN
._.
We_FPP1
negotiate_VPRT
preferential_JJ
200_CD
prices_NN
with_PIN
middle-income_JJ
countries_NN
on_PIN
a_DT
case-by-case_JJ
basis_NN
._.
150_CD
Our_FPP1
not-for-profit_JJ
prices_NN
are_VPRT [PASS]
set_VBN
to_TO
cover_VB
our_FPP1
manufacturing_GER
and_PHC
distribution_NOMZ
costs_NN
._.
This_DEMP
ensures_VPRT [SUAV] [PRIV] [THATD]
we_FPP1
can_POMD
sustain_VB
the_DT
supply_NN
of_PIN
these_DEMO
100_CD
products_NN
for_PIN
as_OSUB
long_NULL
as_NULL
patients_NN
need_VPRT
them_TPP3
._.
The_DT
World_NN
Health_NN
Organization_NOMZ
WHO_WP [WHSUB]
has_VPRT [PEAS]
set_VBN
a_DT
target_NN
to_TO
treat_VB
3_CD
million_CD
HIV_NN
positive_JJ
people_NN
in_PIN
50_CD
10_CD
developing_VBG
countries_NN
with_PIN
ARVs_NN
by_PIN
2005_CD
._.
We_FPP1
are_VPRT [PASS]
committed_VBN
to_TO
making_VBG
a_DT
strong_JJ
contribution_NOMZ
to_PIN
the_DT
achievement_NOMZ
of_PIN
this_DEMO
goal_NN
._.
0_CD
Q4_CD
Q1_NN
Q2_NN
Q3_NN
Q4_NN
Q1_NN
Q2_NN
Q3_NN
Q4_NN
Q1_NN
Q2_NN
Q3_NN
Q4_NN
2000 2001 2002 2003_CD
Employers_NN
Public_NN
Hospitals_NN
NGOs_NN
Govt_NN
Non_NN
AAI_NN
AAI_NN
10_CD
Corporate_JJ
Responsibility_NOMZ
Report_NN
2003_CD
1_CD
Medicines_NN
for_PIN
the_DT
developing_VBG
world_NN
for_PIN
oping_JJ
world_NN
In_PIN
2003_CD
we_FPP1
extended_VBD
the_DT
voluntary_JJ
licence_NN
Pilot_NN
projects_NN
are_VPRT [BEMA]
underway_PRED
to_TO
explore_VB
world_NN
._.
A_DT
similar_JJ
group_NN
also_RB
exists_VPRT
in_PIN
our_FPP1
vaccines_NN
granted_VBN [SUAV] [WZPAST]
to_PIN
the_DT
generics_NN
manufacturer_NN
,_,
Aspen_NN
opportunities_NOMZ
for_PIN
extending_VBG
preferential_JJ
pricing_GER
organization_NOMZ
based_VBN [WZPAST]
in_PIN
Belgium_NN
._.
Pharmacare_NN
,_,
to_TO
include_VB
sales_NN
to_PIN
the_DT
private_JJ
to_PIN
a_DT
wider_JJ
range_NN
of_PIN
medicines_NN
._.
Under_IN
this_DEMO
agreement_NOMZ
Aspen_NN
can_POMD [SPAU]
now_TIME
run_VB
in_PIN
partnership_NN
with_PIN
NGOs_NN
in_PIN
Zambia_NN
,_,
Malawi_NN
,_,
Progress_NN
in_PIN
2003_CD
manufacture_NN
and_CC
sell_VB
key_JJ
GSK_NN
ARVs_NN
across_PLACE
Uganda_NN
,_,
Tanzania_NN
and_PHC
Nigeria_NN
._.
Early_TIME
observations_NOMZ
In_PIN
February_NN
we_FPP1
launched_VBD
our_FPP1
new_JJ
meningitis_NN
sub-Saharan_JJ
Africa_NN
,_,
in_PIN
both_DT
the_DT
public_NN
and_CC
suggest_VPRT [SUAV] [PUBV]
that_THVC
the_DT
greatest_JJ
medical_JJ
need_NN
is_VPRT [BEMA]
for_PIN
vaccine_NN
for_PIN
Africa_NN
,_,
Mencevax_NN
ACW_NN
,_,
developed_VBD
private_JJ
sectors_NN
._.
Discussions_NN
are_VPRT [BEMA]
underway_PRED
with_PIN
basic_JJ
essential_JJ
medicines_NN
._.
Furthermore_CONJ
,_,
even_RB
with_PIN
the_DT
WHO_WP
._.
This_DEMP
is_VPRT [BEMA]
available_PRED
to_PIN
21_CD
African_NN
a_DT
second_JJ
generics_NN
manufacturer_NN
on_PIN
a_DT
similar_JJ
when_RB
medicines_NN
are_VPRT [PASS]
supplied_VBN
at_PIN
the_DT
lowest_JJ
prices_NN
,_,
countries_NN
at_PIN
the_DT
preferential_JJ
price_NN
of_PIN
one_CD
euro_NN
licence_NN
for_PIN
GSK_NN
ARVs_NN
across_PLACE
Africa_NN
._.
access_NN
to_PIN
treatment_NOMZ
may_POMD
not_XX0
significantly_RB
increase_VB
per_PIN
dose_NN
._.
Product_NN
diversion_NN
like_IN
that_DEMP
seen_VBN [PRIV]
in_PIN
2002_CD
denies_VPRT [PUBV]
Phase_NN
II_NN
clinical_JJ
trials_NN
of_PIN
our_FPP1
malaria_NN
vaccine_NN
for_PIN
treatment_NOMZ
to_PIN
patients_NN
in_PIN
developing_VBG
countries_NN
and_CC
The_DT
international_JJ
community_NOMZ
made_VBD
good_JJ
children_NN
began_VBD
in_PIN
Mozambique_NN
in_PIN
partnership_NN
undermines_VPRT
our_FPP1
preferential_JJ
price_NN
agreements_NOMZ
._.
To_TO
progress_VB
on_PIN
supporting_VBG
access_NN
to_PIN
medicines_NN
with_PIN
the_DT
Malaria_NN
Vaccine_NN
Initiative_NN
._.
We_FPP1
also_RB
help_VPRT
minimize_VB
diversion_NN
we_FPP1
are_VPRT
introducing_VBG
special_JJ
initiatives_NN
in_PIN
2003_CD
._.
In_CONJ
particular_NULL
we_FPP1
welcome_VPRT
started_VBD
Phase_NN
III_NN
clinical_JJ
trials_NN
in_PIN
Latin_NN
America_NN
access_NN
packs_VPRT
to_TO
differentiate_VB
preferentially_RB
priced_VBN
funding_GER
from_PIN
initiatives_NN
such_JJ
as_IN
the_DT
Global_NN
Fund_NN
for_PIN
our_FPP1
rotavirus_NN
vaccine_NN
,_,
for_PIN
protection_NOMZ
against_PIN
products_NN
._.
We_FPP1
are_VPRT [BEMA]
now_TIME
able_PRED
to_TO
supply_VB
58_CD
countries_NN
and_CC
the_DT
US_FPP1
Emergency_NN
Plan_NN
for_PIN
AIDS_NN
Relief_NN
,_,
a_DT
major_JJ
cause_NN
of_PIN
diarrhoea_NN
._.
The_DT
dehydration_NOMZ
with_PIN
Combivir_NN
in_PIN
a_DT
special_JJ
pack_NN
._.
as_RB
well_RB
as_IN
the_DT
G8_NN
Action_NOMZ
Plan_NN
on_PIN
Health_NN
that_TSUB
resulting_VBG
from_PIN
diarrhoea_NN
,_,
and_ANDC
the_DT
lack_NN
of_PIN
a_DT
clean_JJ
recognizes_VPRT [PRIV]
the_DT
importance_NN
of_PIN
preferential_JJ
pricing_GER
water_NN
supply_NN
,_,
causes_VPRT
the_DT
death_NN
of_PIN
over_IN
half_PDT
a_DT
11_CD
Similar_JJ
efforts_NN
are_VPRT [BEMA]
underway_PRED
to_TO
secure_VB
and_PHC
preventing_VBG
product_NN
diversion_NN
._.
However_CONJ
,_,
million_CD
children_NN
each_QUAN
year_NN
in_PIN
developing_VBG
countries_NN
._.
widespread_JJ
regulatory_JJ
approval_NN
for_PIN
Trizivir_NN
and_CC
much_QUAN
more_EMPH
still_RB
needs_VPRT
to_TO
be_VB [PASS]
done_VBN [PROD]
._.
Epivir_NN
tablet_NN
packs_NN
and_PHC
Retrovir_NN
and_PHC
Epivir_NN
Human_NN
clinical_JJ
trials_NN
of_PIN
our_FPP1
HIV_NN
vaccine_NN
continued_VBD
solution_NOMZ
packs_NN
._.
We_FPP1
will_PRMD [SPAU]
also_RB
be_VB
using_VBG
a_DT
different_JJ
Research_NN
and_PHC
development_NOMZ
this_DEMO
year_NN
and_CC
we_FPP1
are_VPRT
researching_VBG
several_QUAN
other_JJ
color_NN
for_PIN
some_QUAN
of_PIN
our_FPP1
ARV_NN
tablets_NN
._.
There_EX
is_VPRT
currently_RB
no_SYNE
cure_NN
for_PIN
many_QUAN
of_PIN
the_DT
potential_JJ
HIV_NN
vaccines_NN
._.
We_FPP1
anticipate_VPRT [PRIV]
taking_VBG
our_FPP1
diseases_NN
affecting_VBG [WZPRES]
developing_VBG
countries_NN
,_,
and_ANDC
TB_NN
vaccine_NN
into_PIN
Phase_NN
I_FPP1
development_NOMZ
in_PIN
early_TIME
2004_CD
._.
In_PIN
2003_CD
we_FPP1
applied_VBD
to_TO
register_VB
a_DT
number_NN
of_PIN
our_FPP1
some_QUAN
existing_VBG
treatments_NOMZ
are_VPRT
becoming_VBG
less_RB
ARVs_NN
under_IN
the_DT
EUs_NN
Anti-Diversion_NN
Regulation_NOMZ
effective_JJ
due_JJ
to_PIN
drug_NN
resistance_NN
._.
Investment_NOMZ
In_PIN
October_NN
we_FPP1
signed_VBD
a_DT
technology_NN
transfer_NN
,_,
designed_VBN
to_TO
prevent_VB
illegal_JJ
product_NN
diversion_NN
into_PIN
in_PIN
R&D_NN
for_PIN
new_JJ
treatments_NOMZ
and_PHC
vaccines_NN
is_VPRT
supply_NN
and_PHC
licence_NN
agreement_NOMZ
with_PIN
the_DT
Brazilian_JJ
Europe_NN
._.
Public_NN
private_JJ
partnerships_NN
PPP_NN
government_NOMZ
for_PIN
the_DT
production_NOMZ
of_PIN
the_DT
measles_NN
,_,
are_VPRT [BEMA]
essential_PRED
to_TO
fund_VB
research_NN
where_RB
there_EX
is_VPRT
mumps_NN
and_PHC
rubella_NN
vaccine_NN
._.
This_DEMP
will_PRMD
enable_VB
no_DT
commercially_RB
viable_JJ
market_NN
for_PIN
a_DT
potential_JJ
more_EMPH
than_PIN
100_CD
million_CD
children_NN
in_PIN
Brazil_NN
to_TO
be_VB
product_NN
._.
We_FPP1
are_VPRT
working_VBG
with_PIN
many_QUAN
vaccinated_VBN
over_IN
the_DT
next_JJ
five_CD
years_NN
._.
SHIPMENTS_NOMZ
OF_PIN
COMBIVIR_NN
TABLETS_NN
excluding_VBG [WZPRES]
diverted_VBN
product_NN
governments_NOMZ
,_,
UN_NN
agencies_NN
and_CC
other_JJ
global_JJ
funding_GER
bodies_NN
in_PIN
this_DEMO
area_NN
._.
In_PIN
July_NN
Lapdap_NN
,_,
an_DT
anti-malarial_JJ
treatment_NOMZ
5_CD
developed_VBN
by_PIN
GSK_NN
through_PIN
a_DT
PPP_NN
,_,
received_VBD
We_FPP1
believe_VPRT [PRIV] [THATD]
we_FPP1
are_VPRT [BEMA]
currently_RB
the_DT
only_DWNT
company_NN
approval_NN
from_PIN
the_DT
UK_NN
regulatory_JJ
agency_NN
see_VB [PRIV]
4_CD
researching_VBG
new_JJ
vaccines_NN
and_PHC
treatments_NOMZ
for_PIN
page_NN
13_CD
._.
We_FPP1
expanded_VBD
our_FPP1
research_NN
agreement_NOMZ
12_CD
all_QUAN
three_CD
of_PIN
the_DT
WHOs_NN
priority_NOMZ
diseases_NN
in_PIN
the_DT
with_PIN
the_DT
Medicines_NN
for_PIN
Malaria_NN
Venture_NN
._.
This_DEMP
developing_VBG
world_NN
HIV_NN
AIDS_NN
,_,
TB_NN
and_PHC
malaria_NN
._.
includes_VPRT
development_NOMZ
of_PIN
CDA_NN
,_,
a_DT
combination_NOMZ
of_PIN
3_CD
We_FPP1
have_VPRT
16_CD
clinical_JJ
development_NOMZ
programs_NN
Lapdap_NN
and_CC
artesunate_JJ
,_,
as_RB
well_RB
as_IN
two_CD
new_JJ
classes_NN
for_PIN
products_NN
of_PIN
relevance_NN
to_PIN
the_DT
developing_VBG
of_PIN
anti-malarial_JJ
in_PIN
drug_NN
discovery_NN
._.
Seven_CD
of_PIN
these_DEMP
are_VPRT [PASS]
aimed_VBN
specifically_RB
at_PIN
diseases_NN
that_TSUB
disproportionately_RB
affect_VPRT
developing_VBG
Phase_NN
II_NN
clinical_JJ
trials_NN
of_PIN
sitamaquine_NN
,_,
a_DT
new_JJ
oral_JJ
1_CD
countries_NN
see_VPRT [PRIV]
table_NN
,_,
page_NN
12_CD
._.
A_DT
number_NN
of_PIN
pretreatment_NOMZ
for_PIN
visceral_JJ
leishmaniasis_NN
,_,
were_VBD [PASS]
completed_VBN
clinical_JJ
projects_NN
are_VPRT [BEMA]
also_RB
underway_PRED
._.
in_PIN
Kenya_NN
and_PHC
India_NN
and_CC
demonstrated_VBD [PRIV]
promising_JJ
efficacy_NN
._.
Further_JJ
clinical_JJ
studies_NN
are_VPRT [PASS]
planned_VBN
for_PIN
0_CD
Q1_CD
Q2_NN
Q3_NN
Q4_NN
Q1_NN
Q2_NN
Q3_NN
Q4_NN
Q1_NN
Q2_NN
Q3_NN
Q4_NN
A_NN
team_NN
of_PIN
researchers_NN
in_PIN
the_DT
UK_NN
and_PHC
Tres_NN
Cantos_NN
,_,
2004_CD
._.
We_FPP1
discontinued_VBD
development_NOMZ
of_PIN
2001 2002 2003_CD
Spain_NN
has_VPRT [PEAS]
been_VBN [PASS]
established_VBN [PRIV]
specifically_RB
to_TO
focus_VB
oxibendazole_NN
for_PIN
intestinal_JJ
worms_NN
as_IN
the_DT
treatment_NOMZ
preferentially_RB
priced_VBN
on_PIN
research_NN
into_PIN
diseases_NN
of_PIN
the_DT
developing_VBG
offered_VBN
no_SYNE
advantage_NN
over_IN
existing_VBG
medicines_NN
._.
Corporate_JJ
Responsibility_NOMZ
Report_NN
2003_CD
11_CD
tablets_NN
shipped_VBN
millions_NN
DEVELOPMENT_NOMZ
PIPELINE_NN
AT_PIN
END_NN
OF_PIN
2003_CD
FOR_PIN
DISEASES_NN
RELEVANT_NN
TO_PIN
THE_DT
DEVELOPING_VBG
WORLD_NN
Pre_NN
clinical_JJ
Focus_NN
PHASE_NN
I_FPP1
PHASE_VPRT
II_NN
PHASE_NN
III_NN
MARKETED_VBD
activity_NOMZ
HIV_NN
Non-NRTI_NN
Ziagen_NN
Epivir_NN
Epivir_NN
Retrovir_NN
CCR5_NN
antagonist_NN
Ziagen_NN
Combivir_NN
Aspartyl_NN
protease_NN
inhibitor_NN
Agenerase_NN
Trizivir_NN
NRTI_NN
Lexiva_NN
Telzir_NN
Vaccines_NN
HIV_NN
Hepatitis_NN
E_NN
Rotarix_NN
rotavirus_VPRT
Havrix_NN
hepatitis_NN
A_NN
Engerix_NN
B_NN
hepatitis_NN
B_NN
Dengue_NN
fever_NN
Malaria_NN
Streptorix_NN
Twinrix_NN
hep_NN
A_NN
&_CC
B_NN
Infanrix_NN
diptheria_NN
,_,
tetanus_NN
,_,
N._NN
meningitidis_NN
S._NN
pneumoniae_NN
paediatric_NN
acellular_JJ
pertussis_NN
Cervarix_NN
HPV_NN
Tritanrix_NN
diptheria_NN
,_,
tetanus_NN
,_,
Polio_NN
Sabin_NN
polio_NN
whole_JJ
cell_NN
pertussis_NN
Priorix_NN
measles_NN
,_,
mumps_NN
Typherix_NN
typhoid_NN
and_PHC
rubella_NN
Hiberix_NN
hemophilus_VPRT
Mencevax_NN
ACW_NN
meningitis_VPRT
influenzae_NN
type_NN
b_NN
Malaria_NN
CDA_NN
chlorproguanil_NN
,_,
tafenoquine_NN
Malarone_NN
Halfan_NN
dapsone_NN
artesunate_NN
Lapdap_NN
TB_NN
Other_JJ
sitamaquine_NN
Zentel_NN
fide-worming_JJ
agent_NN
visceral_NN
leishmaniasis_NN
Pentostam_NN
visceral_JJ
leishmaniasis_NN
submitted_VBN [PUBV] [WZPAST]
for_PIN
approval_NN
more_EMPH
detailed_JJ
information_NOMZ
on_PIN
our_FPP1
product_NN
pipeline_NN
can_POMD
be_VB [PASS]
found_VBN [PRIV]
in_PIN
the_DT
Annual_JJ
Report_NN
Against_PIN
AIDS_NN
in_PIN
Africa_NN
KENWA_NN
believes_VPRT [PRIV]
that_THVC
a_DT
In_PIN
2003_CD
our_FPP1
ten-year_JJ
partnership_NN
program_NN
,_,
Community_NOMZ
investment_NOMZ
in_PIN
Positive_NN
Action_NOMZ
workshop_NN
on_PIN
writing_VBG [PUBV]
effective_JJ
Action_NOMZ
TB_NN
,_,
was_VBD [PASS]
completed_VBN
._.
This_DEMO
research_NN
developing_VBG [WZPRES]
countries_NN
fundraising_VBG [WZPRES]
proposals_NN
helped_VBD
it_PIT
secure_VB
a_DT
grant_NN
of_PIN
program_NN
improved_VBN
our_FPP1
understanding_GER
of_PIN
We_FPP1
manage_VPRT
a_DT
large_JJ
community_NOMZ
investment_NOMZ
$_$
220,000_CD
from_PIN
the_DT
Global_NN
Fund_NN
to_TO
Fight_VB
AIDS_NN
,_,
TB_NN
and_CC
should_NEMD
help_VB
the_DT
in-house_JJ
development_NOMZ
program_NN
in_PIN
developing_VBG
countries_NN
._.
This_DEMP
includes_VPRT
TB_NN
and_PHC
Malaria_NN
._.
of_PIN
more_EMPH
targeted_JJ
and_PHC
effective_JJ
treatments_NOMZ
donations_NOMZ
of_PIN
medicines_NN
,_,
as_RB
well_RB
as_IN
financial_JJ
and_CC
against_PIN
the_DT
disease_NN
._.
practical_JJ
support_NN
for_PIN
public_JJ
health_NN
initiatives_NN
14_CD
The_DT
GSK_NN
France_NN
Foundation_NOMZ
,_,
a_DT
GSK-endowed_JJ
and_CC
education_NOMZ
programs_NN
._.
The_DT
largest_JJ
charitable_JJ
foundation_NOMZ
,_,
supports_VPRT
a_DT
range_NN
of_PIN
We_FPP1
are_VPRT
supporting_VBG
27_CD
clinical_JJ
trials_NN
in_PIN
developing_VBG
programs_NN
include_VPRT
those_DEMP
tackling_VBG
three_CD
major_JJ
programs_NN
to_TO
improve_VB
access_NN
to_PIN
healthcare_NN
countries_NN
to_TO
assess_VB
the_DT
use_NN
of_PIN
ARVs_NN
in_PIN
resourcediseases_NN
lymphatic_JJ
filariasis_NN
LF_NN
,_,
commonly_RB
for_PIN
HIV-positive_JJ
people_NN
in_PIN
Africa_NN
,_,
particularly_RB
poor_JJ
settings_GER
._.
Seven_CD
new_JJ
studies_NN
began_VBD
in_PIN
subknown_JJ
elephantiasis_NN
,_,
HIV_NN
AIDS_NN
and_PHC
malaria_NN
._.
Over_IN
the_DT
last_JJ
five_CD
years_NN
,_,
Saharan_NN
Africa_NN
in_PIN
2003_CD
,_,
bringing_VBG [PRESP]
the_DT
total_NN
in_PIN
this_DEMO
the_DT
Foundation_NOMZ
has_VPRT [PEAS]
provided_VBN
2_CD
million_CD
to_PIN
region_NN
to_PIN
20_CD
._.
This_DEMP
includes_VPRT
the_DT
DART_NN
study_NN
,_,
the_DT
Elimination_NOMZ
of_PIN
lymphatic_JJ
filariasis_NN
LF_NN
support_NN
32_CD
programs_NN
in_PIN
13_CD
African_JJ
countries_NN
._.
largest_JJ
adult_NN
HIV_NN
treatment_NOMZ
study_NN
in_PIN
Africa_NN
LF_NN
affects_VPRT
120_CD
million_CD
people_NN
,_,
mostly_RB
in_PIN
involving_VBG
3,000_CD
patients_NN
in_PIN
Uganda_NN
and_CC
developing_VBG
countries_NN
,_,
and_ANDC
is_VPRT [BEMA]
one_CD
of_PIN
the_DT
worlds_NN
Progress_NN
in_PIN
2003_CD
Zimbabwe_NN
._.
We_FPP1
are_VPRT
supplying_VBG
drugs_NN
for_PIN
eight_CD
leading_VBG
causes_NN
of_PIN
permanent_JJ
disability_NOMZ
._.
Over_IN
one_CD
Positive_NN
Action_NOMZ
supported_VBD
38_CD
programs_NN
studies_NN
of_PIN
prevention_NOMZ
of_PIN
mother-to-child_JJ
HIV_NN
billion_CD
people_NN
,_,
almost_DWNT
one-fifth_NN
of_PIN
the_DT
worlds_NN
in_PIN
partnership_NN
with_PIN
28_CD
organizations_NOMZ
in_PIN
34_CD
transmission_NN
,_,
involving_VBG [PRESP]
8,000_CD
patients_NN
in_PIN
population_NOMZ
,_,
are_VPRT [BEMA]
at_PIN
risk_NN
of_PIN
LF_NN
infection_NOMZ
._.
Also_RB
during_PIN
2003_CD
,_,
the_DT
GSK_NN
France_NN
developing_VBG [WZPRES]
countries_NN
._.
albendazole_RB
prevents_VPRT
transmission_NN
of_PIN
LF_NN
when_RB
Foundation_NOMZ
supported_VBD
17_CD
initiatives_NN
and_CC
pledged_VBD [SUAV]
taken_VBN
together_RB
with_PIN
another_DT
medicine_NN
._.
As_IN
a_DT
to_TO
renew_VB
its_PIT
commitment_NOMZ
for_PIN
a_DT
further_JJ
five_CD
years_NN
._.
HIV_NN
treatment_NOMZ
regimens_VPRT
can_POMD
be_VB [BEMA]
very_AMP
complex_PRED
,_,
founding_JJ
partner_NN
in_PIN
the_DT
WHOs_NN
Global_NN
Program_NN
15_CD
GSK_NN
also_RB
granted_VBD [SUAV]
$_$
1.6_CD
million_CD
over_IN
two_CD
years_NN
to_TO
requiring_VBG [SUAV]
patients_NN
to_TO
take_VB
a_DT
combination_NOMZ
of_PIN
to_TO
Eliminate_VB
LF_NN
,_,
we_FPP1
expect_VPRT [PRIV]
to_TO
donate_VB
6_CD
billion_CD
support_NN
the_DT
work_NN
of_PIN
two_CD
HIV_NN
AIDS_NN
clinics_NN
in_PIN
several_QUAN
different_JJ
tablets_NN
at_PIN
different_JJ
times_NN
of_PIN
the_DT
treatments_NOMZ
by_PIN
2020_CD
,_,
worth_IN
an_DT
estimated_VBN [PRIV]
Malawi_NN
and_PHC
Uganda_NN
._.
This_DEMP
increases_VPRT
the_DT
risk_NN
of_PIN
patients_NN
missing_VBG [WZPRES]
$_$
1_CD
billion_CD
valued_VBN
at_PIN
wholesale_JJ
prices_NN
._.
a_DT
dose_NN
or_CC
taking_VBG
their_TPP3
medicine_NN
at_PIN
the_DT
wrong_JJ
GSK_NN
African_NN
Malaria_NN
Partnership_NN
time_NN
._.
This_DEMP
can_POMD
reduce_VB
the_DT
effectiveness_NOMZ
of_PIN
Progress_NN
in_PIN
2003_CD
This_DEMO
partnership_NN
is_VPRT
providing_VBG
$_$
1.5_CD
million_CD
treatment_NOMZ
and_PHC
lead_NN
to_PIN
drug_NN
resistance_NN
._.
We_FPP1
are_VPRT [PASS]
GSK_NN
donated_VBD
94_CD
million_CD
treatments_NOMZ
of_PIN
kick-start_JJ
funding_GER
over_IN
three_CD
years_NN
to_TO
support_VB
looking_VBG
at_PIN
ways_NN
to_TO
simplify_VB
treatment_NOMZ
regimens_NN
._.
We_FPP1
have_VPRT [PEAS]
donated_VBN
18_CD
malaria_NN
education_NOMZ
programs_NN
._.
The_DT
initiatives_NN
In_PIN
2003_CD
we_FPP1
sought_VBD
regulatory_JJ
approval_NN
in_PIN
the_DT
240_CD
million_CD
preventative_JJ
treatments_NOMZ
since_OSUB
1998_CD
are_VPRT [PASS]
designed_VBN
to_TO
improve_VB
the_DT
prevention_NOMZ
and_PHC
US_FPP1
and_PHC
Europe_NN
for_PIN
a_DT
new_JJ
fixed-dose_JJ
combination_NOMZ
to_PIN
over_IN
80_CD
million_CD
people_NN
._.
The_DT
program_NN
is_VPRT
management_NOMZ
of_PIN
malaria_NN
in_PIN
seven_CD
African_JJ
countries_NN
._.
of_PIN
Epivir_NN
and_PHC
Ziagen_NN
which_WDT [WHSUB]
are_VPRT [SPAU] [PASS]
currently_RB
used_VBN
expected_VBN [PRIV]
to_TO [SPIN]
eventually_TIME
reach_VB
one_CD
billion_CD
people_NN
._.
For_CONJ
example_NULL
,_,
our_FPP1
support_NN
will_PRMD
help_VB
Freedom_NN
From_PIN
as_IN
separate_JJ
tablets_NN
in_PIN
recommended_JJ
treatment_NOMZ
Hunger_NN
develop_VB
a_DT
malaria_NN
education_NOMZ
module_NN
for_PIN
its_PIT
regimens_NN
._.
If_COND
approved_VBN
,_,
this_DEMO
one-tablet_JJ
Programmes_NN
for_PIN
HIV_NN
AIDS_NN
`_``
Credit_NN
with_PIN
Education_NOMZ
'_POS
program_NN
._.
This_DEMP
provides_VPRT
combination_NOMZ
would_PRMD
be_VB [PASS]
taken_VBN
once_TIME
a_DT
day_NN
and_CC
For_PIN
11_CD
years_NN
our_FPP1
HIV_NN
AIDS_NN
program_NN
,_,
Positive_NN
16_CD
a_DT
package_NN
of_PIN
financial_JJ
services_NN
,_,
and_ANDC
health_NN
and_CC
would_PRMD
replace_VB
the_DT
two_CD
tablets_NN
currently_RB
taken_VBN
Action_NOMZ
,_,
has_VPRT [PEAS]
worked_VBN
at_PIN
the_DT
community_NOMZ
level_NN
business_NOMZ
education_NOMZ
to_TO
help_VB
very_AMP
poor_JJ
women_NN
fight_VB
twice_RB
a_DT
day_NN
._.
to_TO
support_VB
HIV_NN
care_NN
,_,
education_NOMZ
and_PHC
prevention_NOMZ
against_PIN
chronic_JJ
hunger_NN
,_,
illness_NOMZ
and_PHC
poverty_NN
._.
Positive_JJ
Action_NOMZ
partnerships_NN
with_PIN
In_PIN
October_NN
,_,
US_FPP1
FDA_NN
approval_NN
was_VBD [PASS]
secured_VBN
for_PIN
organizations_NOMZ
such_JJ
as_IN
the_DT
Centre_NN
for_PIN
African_NN
Family_NN
Progress_NN
in_PIN
2003_CD
Lexiva_NN
,_,
a_DT
new_JJ
HIV_NN
protease_NN
inhibitor_NN
,_,
currently_RB
Studies_NN
CAFS_NN
tackle_VB
issues_NN
such_JJ
as_IN
stigma_NN
and_CC
We_FPP1
contributed_VBD
the_DT
first_JJ
grants_NN
to_PIN
our_FPP1
partners_NN
,_,
the_DT
only_DWNT
protease_NN
inhibitor_NN
to_TO
offer_VB
flexible_JJ
dosing_NN
discrimination_NOMZ
,_,
a_DT
significant_JJ
barrier_NN
to_PIN
healthcare_NN
Freedom_NN
From_PIN
Hunger_NN
,_,
AMREF_NN
and_PHC
Plan_NN
with_PIN
no_SYNE
food_NN
or_CC
water_NN
restrictions_NOMZ
._.
We_FPP1
hope_VPRT [PRIV]
to_PIN
in_PIN
many_QUAN
communities_NOMZ
affected_VBN [WZPAST]
by_PIN
HIV_NN
AIDS_NN
._.
We_FPP1
also_RB
donated_VBD
$_$
25,000_CD
to_PIN
Plan_NN
start_VB
launching_VBG
Lexiva_NN
also_RB
known_VBN [PRIV]
as_IN
Telzir_NN
in_PIN
International_NN
to_TO
assist_VB
with_PIN
relief_NN
operations_NOMZ
and_CC
developing_VBG
countries_NN
in_PIN
2004_CD
2005_CD
._.
CAFS_NN
provides_VPRT
training_GER
courses_NN
to_PIN
community_NOMZ
an_DT
increase_NN
in_PIN
malaria_NN
cases_NN
in_PIN
Sudan_NN
following_VBG [WZPRES]
organizations_NOMZ
working_VBG [WZPRES]
with_PIN
people_NN
affected_VBN [WZPAST]
by_PIN
severe_JJ
flooding_GER
._.
In_PIN
December_NN
GSK_NN
was_VBD [PASS]
recognized_VBN [PRIV]
for_PIN
its_PIT
HIV_NN
._.
It_PIT
has_VPRT [PEAS]
trained_VBN
over_IN
250_CD
key_JJ
workers_NN
from_PIN
leadership_NN
in_PIN
alleviating_VBG
tropical_JJ
infectious_JJ
diseases_NN
65_CD
NGOs_NN
to_TO
build_VB
and_PHC
run_VB
effective_JJ
organizations_NOMZ
and_CC
improving_VBG
global_JJ
health_NN
,_,
by_PIN
the_DT
American_JJ
helping_VBG
people_NN
affected_VBN [WZPAST]
by_PIN
HIV_NN
._.
Such_JJ
well-placed_JJ
13_CD
Society_NN
of_PIN
Tropical_NN
Medicine_NN
and_PHC
Hygiene_NN
._.
support_NN
can_POMD
have_VB
a_DT
powerful_JJ
impact_NN
._.
For_CONJ
example_NULL
,_,
the_DT
Kenyan_NN
Network_NN
of_PIN
Women_NN
12_CD
Corporate_JJ
Responsibility_NOMZ
Report_NN
2003_CD
Lapdap_NN
can_POMD
help_VB
us_FPP1
meet_VB
the_DT
urgent_JJ
need_NN
for_PIN
an_DT
affordable_JJ
anti-malarial_JJ
treatment_NOMZ
for_PIN
use_NN
in_PIN
Africa_NN
,_,
as_IN
it_PIT
has_VPRT [PEAS]
been_VBN [PASS]
shown_VBN [PRIV]
to_TO
work_VB
in_PIN
cases_NN
where_RB
S_NN
P_NN
-LRB-_-LRB-
the_DT
standard_NN
treatment_NOMZ
-RRB-_-RRB-
has_VPRT [PEAS]
failed_VBN
._.
Professor_NN
Peter_NN
Winstanley_NN
University_NOMZ
of_PIN
Liverpool_NN
Lapdap_NN
a_DT
new_JJ
anti-malarial_JJ
for_PIN
subSaharan_NN
Africa_NN
Malaria_NN
affects_VPRT
more_EMPH
than_PIN
300_CD
million_CD
people_NN
every_QUAN
year_NN
._.
There_EX
is_VPRT
an_DT
urgent_JJ
need_NN
for_PIN
new_JJ
affordable_JJ
treatments_NOMZ
to_TO
combat_VB
the_DT
disease_NN
and_CC
to_TO
deal_VB
with_PIN
the_DT
problem_NN
of_PIN
resistance_NN
to_TO
existing_VBG
treatments_NOMZ
._.
The_DT
new_JJ
anti-malarial_JJ
treatment_NOMZ
,_,
Lapdap_NN
,_,
launched_VBN [PASTP]
in_PIN
2003_CD
,_,
is_VPRT [PASS]
designed_VBN
to_TO
tackle_VB
this_DEMO
deadly_JJ
disease_NN
._.
It_PIT
was_VBD [PASS]
developed_VBN
specifically_RB
for_PIN
use_NN
in_PIN
sub-Saharan_JJ
Africa_NN
,_,
where_RB
malaria_NN
kills_VPRT
more_EMPH
than_PIN
one_CD
million_CD
people_NN
every_QUAN
year_NN
,_,
the_DT
majority_NOMZ
of_PIN
whom_WP [PIRE]
are_VPRT
children_NN
under_IN
five_CD
._.
The_DT
initiative_NN
brought_VBN [WZPAST]
together_RB
GSK_NN
Drug_NN
Development_NOMZ
researchers_NN
with_PIN
scientists_NN
in_PIN
Africa_NN
,_,
and_ANDC
two_CD
leading_JJ
UK_NN
medical_JJ
schools_NN
the_DT
University_NOMZ
of_PIN
Liverpool_NN
and_CC
the_DT
London_NN
School_NN
of_PIN
Hygiene_NN
and_PHC
Tropical_NN
Medicine_NN
._.
GSK_NN
,_,
the_DT
WHO_WP
and_CC
the_DT
UK_NN
Government_NOMZ
Department_NOMZ
for_PIN
International_NN
Development_NOMZ
jointly_RB
funded_VBD
the_DT
development_NOMZ
project_NN
._.
Lapdap_NN
was_VBD [PASS]
approved_VBN
for_PIN
use_NN
by_PIN
the_DT
UK_NN
Medicines_NN
and_PHC
Healthcare_NN
Products_NN
Regulatory_NN
Agency_NN
and_CC
,_,
in_PIN
line_NN
with_PIN
best_JJ
medical_JJ
practice_NN
,_,
GSK_NN
is_VPRT
conducting_VBG
postmarketing_VBG
studies_NN
in_PIN
Africa_NN
to_TO
confirm_VB [PUBV]
the_DT
long-term_JJ
safety_NN
of_PIN
the_DT
treatment_NOMZ
._.
GSK_NN
is_VPRT
registering_VBG
Lapdap_NN
across_PLACE
sub-Saharan_NN
Africa_NN
,_,
where_RB
it_PIT
will_PRMD
be_VB [BEMA]
available_PRED
to_PIN
national_JJ
malaria_NN
control_NN
programs_NN
at_PIN
preferential_JJ
prices_NN
._.
The_DT
treatment_NOMZ
is_VPRT [SPAU] [PASS]
already_RB
registered_VBN
in_PIN
14_CD
African_JJ
countries_NN
._.
We_FPP1
are_VPRT [SPAU]
also_RB
developing_VBG
CDA_NN
,_,
a_DT
new_JJ
Lapdap_NN
plus_PIN
artesunate_JJ
combination_NOMZ
therapy_NN
,_,
with_PIN
the_DT
WHO_WP
and_CC
the_DT
Medicines_NN
for_PIN
Malaria_NN
Venture_NN
._.
Corporate_JJ
Responsibility_NOMZ
Report_NN
2003_CD
13_CD
Community_NOMZ
investment_NOMZ
The_DT
Childrens_NN
Health_NN
Fund_NN
's_POS
Referral_NN
Management_NOMZ
Initiative_NN
Homeless_NN
and_CC
disadvantaged_JJ
children_NN
are_VPRT [BEMA]
especially_RB
vulnerable_PRED
to_PIN
illness_NOMZ
and_CC
are_VPRT [BEMA]
more_EMPH
likely_PRED
to_TO
suffer_VB
from_PIN
acute_JJ
and_PHC
chronic_JJ
illnesses_NOMZ
such_JJ
as_IN
asthma_NN
._.
Many_QUAN
do_VPRT
not_XX0
receive_VB
vaccinations_NOMZ
._.
Despite_PIN
needing_VBG
more_EMPH
specialist_NN
care_NN
,_,
it_PIT
is_VPRT [BEMA]
difficult_PRED
for_PIN
these_DEMO
families_NN
to_TO
keep_VB
hospital_NN
appointments_NOMZ
._.
Millions_NN
of_PIN
children_NN
in_PIN
the_DT
US_FPP1
can_POMD
not_XX0
access_VB
the_DT
healthcare_NN
they_TPP3
need_VPRT
because_CAUS
of_PIN
a_DT
lack_NN
of_PIN
transport_NN
,_,
too_RB
few_QUAN
doctors_NN
in_PIN
disadvantaged_JJ
communities_NOMZ
,_,
or_CC
cultural_JJ
,_,
language_NN
and_CC
institutional_JJ
barriers_NN
._.
A_DT
transient_JJ
lifestyle_NN
often_RB
means_VPRT [PRIV] [THATD]
they_TPP3
lose_VPRT
contact_NN
with_PIN
their_TPP3
doctor_NN
._.
Over_IN
nine_CD
years_NN
,_,
GSK_NN
has_VPRT [PEAS]
provided_VBN
$_$
4.2_CD
million_CD
to_PIN
the_DT
Childrens_NN
Health_NN
Fund_NN
to_TO
set_VB
up_RP
and_CC
run_VB
a_DT
Referral_NN
Management_NOMZ
19_CD
Initiative_NN
RMI_NN
._.
This_DEMP
helps_VPRT
children_NN
,_,
referred_VBD
to_PIN
a_DT
specialist_NN
,_,
attend_VB
their_TPP3
appointments_NOMZ
and_CC
receive_VB
the_DT
care_NN
they_TPP3
need_VPRT
._.
The_DT
RMI_NN
reminds_VPRT
families_NN
about_IN
appointments_NOMZ
by_PIN
phone_NN
and_PHC
mail_NN
,_,
provides_VPRT
door-to-door_JJ
transport_NN
to_PIN
clinics_NN
and_CC
helps_VPRT
communications_NOMZ
,_,
including_VBG
providing_VBG
a_DT
translation_NOMZ
service_NN
where_RB
necessary_JJ
._.
GSK_NN
is_VPRT [BEMA]
sole_JJ
funder_NN
of_PIN
the_DT
RMI_NN
._.
In_PIN
2003_CD
we_FPP1
provided_VBD
additional_JJ
funding_GER
of_PIN
$_$
756,000_CD
to_TO
help_VB
extend_VB
the_DT
program_NN
and_CC
develop_VB
guidance_NN
for_PIN
introducing_VBG
similar_JJ
initiatives_NN
nationwide_JJ
._.
The_DT
RMI_NN
has_VPRT [SPAU] [PEAS]
dramatically_RB
increased_VBN
the_DT
number_NN
of_PIN
children_NN
who_WP [WHSUB]
see_VPRT [PRIV]
a_DT
medical_JJ
specialist_NN
after_IN
being_VBG [PASS]
referred_VBN
._.
Approximately_RB
75_CD
%_NN
of_PIN
the_DT
children_NN
in_PIN
the_DT
program_NN
are_VPRT [SPAU]
now_TIME
getting_VBG
the_DT
specialist_NN
care_NN
they_TPP3
need_VPRT
,_,
compared_VBN [PASTP]
with_PIN
just_EMPH
5_CD
%_NN
when_RB
the_DT
initiative_NN
began_VBD
._.
The_DT
Childrens_NN
Health_NN
Fund_NN
partnership_NN
with_PIN
GSK_NN
has_VPRT [PEAS]
been_VBN [BEMA]
responsible_PRED
for_PIN
positively_RB
transforming_VBG
the_DT
lives_NN
of_PIN
tens_NN
of_PIN
thousands_NN
of_PIN
medically_RB
under-served_JJ
children_NN
in_PIN
need_NN
of_PIN
specialist_NN
care_NN
._.
Irwin_NN
Redlener_NN
President_NN
,_,
Childrens_NN
Health_NN
Fund_NN
14_CD
Corporate_JJ
Responsibility_NOMZ
Report_NN
2003_CD
2_CD
Community_NOMZ
investment_NOMZ
We_FPP1
concentrate_VPRT
community_NOMZ
investment_NOMZ
on_PIN
improving_VBG
health_NN
and_PHC
education_NOMZ
in_PIN
under-served_JJ
and_PHC
vulnerable_JJ
communities_NOMZ
worldwide_NN
._.
Our_FPP1
contribution_NOMZ
is_VPRT [BEMA]
mainly_RB
through_PIN
donations_NOMZ
of_PIN
medicines_NN
,_,
financial_JJ
and_PHC
practical_JJ
support_NN
and_PHC
materials_NN
such_JJ
as_IN
laboratory_NN
and_PHC
office_NN
equipment_NOMZ
._.
We_FPP1
identify_VPRT
programs_NN
to_TO
support_VB
on_PIN
medicines_NN
were_VBD [BEMA]
among_PIN
the_DT
first_JJ
to_TO
reach_VB
Iraq_NN
the_DT
basis_NN
of_PIN
need_NN
,_,
not_XX0
for_PIN
their_TPP3
potential_JJ
after_IN
the_DT
conflict_NN
began_VBD
._.
We_FPP1
also_RB
provided_VBD
medicines_NN
following_VBG [WZPRES]
earthquakes_NN
in_PIN
India_NN
and_PHC
impact_NN
on_PIN
our_FPP1
commercial_JJ
business_NOMZ
._.
In_PIN
2003_CD
our_FPP1
global_JJ
community_NOMZ
investment_NOMZ
and_CC
Our_FPP1
humanitarian_JJ
donations_NOMZ
were_VBD [BEMA]
higher_PRED
than_PIN
in_PIN
charitable_JJ
donations_NOMZ
were_VBD [PASS]
valued_VBN
at_PIN
338_CD
million_CD
,_,
previous_JJ
years_NN
,_,
reflecting_VBG [PRIV] [PRESP]
the_DT
variability_NOMZ
in_PIN
both_DT
the_DT
equivalent_JJ
to_PIN
5.3_CD
%_NN
of_PIN
our_FPP1
pre-tax_JJ
profits_NN
statutory_JJ
supply_NN
and_PHC
demand_NN
for_PIN
donations_NOMZ
._.
This_DEMP
included_VBD
125_CD
million_CD
for_PIN
the_DT
Patient_NN
the_DT
need_NN
for_PIN
humanitarian_JJ
relief_NN
depends_VPRT
on_PIN
Assistance_NN
Program_NN
and_CC
other_JJ
medicine_NN
donations_NOMZ
events_NN
such_JJ
as_IN
conflict_NN
and_CC
natural_JJ
disasters_NN
._.
Also_RB
,_,
for_PIN
low_JJ
income_NN
groups_NN
in_PIN
the_DT
US_FPP1
,_,
and_ANDC
105_CD
million_CD
the_DT
supply_NN
of_PIN
product_NN
that_TOBJ
GSK_NN
has_VPRT
available_JJ
for_PIN
of_PIN
humanitarian_JJ
product_NN
donations_NOMZ
._.
It_PIT
also_RB
donation_NOMZ
can_POMD
vary_VB
._.
If_COND
we_FPP1
have_VPRT
excess_JJ
stock_NN
included_VBD
management_NOMZ
expenses_NN
of_PIN
17_CD
million_CD
,_,
available_JJ
this_DEMP
is_VPRT [PASS]
offered_VBN
to_PIN
charities_NOMZ
and_CC
will_PRMD
only_DWNT
the_DT
cost_NN
of_PIN
running_VBG
our_FPP1
community_NOMZ
investment_NOMZ
be_VB [PASS]
placed_VBN
when_RB
there_EX
is_VPRT
a_DT
clearly_RB
identified_VBN
programs_NN
._.
This_DEMP
is_VPRT [BEMA]
in_CONJ
addition_NULL
to_PIN
agreements_NOMZ
we_FPP1
have_VPRT
with_PIN
a_DT
number_NN
of_PIN
charities_NOMZ
which_WDT [WHSUB]
can_POMD
Our_FPP1
community_NOMZ
investment_NOMZ
programs_NN
select_VPRT
products_NN
from_PIN
GSK_NN
stock_NN
to_TO
fulfil_VB
their_TPP3
plans_NN
focus_VB
on_PIN
major_JJ
public_JJ
health_NN
initiatives_NN
on_PIN
HIV_NN
,_,
for_PIN
relief_NN
programs_NN
and_PHC
emergency_NN
aid_NN
._.
malaria_NN
and_CC
lymphatic_JJ
filariasis_NN
see_VPRT [PRIV]
page_NN
12_CD
,_,
humanitarian_JJ
aid_NN
,_,
supporting_VBG
communities_NOMZ
Supporting_VBG [WZPRES]
communities_NOMZ
around_PLACE
the_DT
world_NN
around_PLACE
the_DT
world_NN
,_,
and_ANDC
employee_NN
involvement_NOMZ
._.
Our_FPP1
programs_NN
support_VPRT
communities_NOMZ
in_PIN
need_NN
throughout_PIN
the_DT
world_NN
._.
Here_RB
are_VPRT [BEMA]
some_QUAN
examples_NN
Humanitarian_JJ
aid_NN
for_PIN
2003_CD
:_:
In_PIN
the_DT
aftermath_NN
of_PIN
a_DT
humanitarian_JJ
disaster_NN
it_PIT
is_VPRT [BEMA]
vital_PRED
to_TO
prevent_VB
the_DT
spread_NN
of_PIN
infectious_JJ
diseases_NN
._.
UK_NN
Our_FPP1
antibiotics_NN
can_POMD
play_VB
an_DT
essential_JJ
role_NN
._.
The_DT
GSK_NN
IMPACT_NN
Awards_NN
recognize_VPRT [PRIV]
and_PHC
reward_VPRT
the_DT
work_NN
of_PIN
smaller_JJ
voluntary_JJ
organizations_NOMZ
We_FPP1
donate_VPRT
antibiotics_NN
to_TO
support_VB
relief_NN
efforts_NN
in_PIN
dedicated_VBN
to_TO
improving_VBG
community_NOMZ
healthcare_NN
._.
countries_NN
affected_VBN [WZPAST]
by_PIN
natural_JJ
disasters_NN
or_CC
war_NN
._.
In_PIN
2003_CD
,_,
we_FPP1
awarded_VBD
260,000_CD
to_PIN
19_CD
Donations_NOMZ
are_VPRT [PASS]
made_VBN
through_PIN
our_FPP1
NGO_NN
partners_NN
organizations_NOMZ
dealing_VBG [WZPRES]
with_PIN
issues_NN
as_IN
diverse_JJ
as_IN
including_VBG
AmeriCares_NN
,_,
InterChurch_NN
Medical_NN
sexual_JJ
abuse_NN
,_,
mental_JJ
health_NN
problems_NN
and_PHC
day_NN
Assistance_NN
,_,
MAP_NN
International_NN
and_PHC
Project_NN
HOPE_NN
._.
New_NN
Life_NN
Counselling_GER
Service_NN
These_DEMO
organizations_NOMZ
can_POMD
request_VB [SUAV]
GSK_NN
medicines_NN
received_VBD
an_DT
award_NN
for_PIN
its_PIT
work_NN
counselling_VBG [WZPRES]
according_VBG
to_PIN
their_TPP3
needs_NN
._.
This_DEMP
enables_VPRT
them_TPP3
to_PIN
20_CD
families_NN
affected_VBN [WZPAST]
by_PIN
unrest_NN
in_PIN
Northern_NN
Ireland_NN
._.
respond_NN
quickly_RB
to_PIN
emergencies_NN
since_OSUB
they_TPP3
have_VPRT
the_DT
medicines_NN
in_PIN
their_TPP3
warehouses_NN
._.
In_PIN
2003_CD
we_FPP1
donated_VBD
medicines_NN
worth_IN
I_FPP1
am_VPRT [BEMA]
delighted_PRED
that_THAC
the_DT
105_CD
million_CD
valued_VBN
at_PIN
wholesale_JJ
prices_NN
to_PIN
excellent_JJ
work_NN
carried_VBD
out_PIN
by_PIN
New_NN
Life_NN
support_NN
relief_NN
efforts_NN
in_PIN
80_CD
countries_NN
._.
GSK_NN
's_POS
Counselling_GER
Service_NN
has_VPRT [PEAS]
been_VBN [BYPA]
recognized_VBN [PRIV]
by_PIN
this_DEMO
GSK_NN
IMPACT_NN
Award_NN
._.
To_TO
be_VB
METHOD_NN
OF_PIN
GIVING_GER
honored_VBD
at_PIN
a_DT
national_JJ
level_NN
,_,
with_PIN
such_JJ
including_VBG
US_FPP1
Patient_NN
Assistance_NN
Program_NN
a_DT
prestigious_JJ
award_NN
,_,
must_NEMD
be_VB [BEMA]
a_DT
source_NN
3_CD
1_CD
Product_NN
59_CD
%_NN
of_PIN
great_JJ
pride_NN
to_PIN
all_QUAN
concerned_VBN
._.
2_CD
Cash_NN
40_CD
%_NN
Des_NN
Brown_NN
MP_NN
Former_NN
Minister_NN
with_PIN
Responsibility_NOMZ
for_PIN
Health_NN
,_,
3_CD
In_PIN
kind_NN
1_CD
%_NN
Social_NN
Services_NN
and_PHC
Public_NN
Safety_NN
in_PIN
Northern_NN
Ireland_NN
2_CD
1_CD
Our_FPP1
product_NN
donations_NOMZ
are_VPRT [PASS]
valued_VBN
at_PIN
wholesale_JJ
acquisition_NOMZ
Corporate_JJ
Responsibility_NOMZ
Report_NN
2003_CD
15_CD
cost_NN
which_WDT [WHSUB]
relates_VPRT
to_PIN
the_DT
price_NN
GSK_NN
charges_NN
wholesalers_NN
and_PHC
warehousing_GER
chains_NN
,_,
not_XX0
the_DT
retail_JJ
price_NN
._.
This_DEMO
investment_NOMZ
by_PIN
GSK_NN
The_NN
Government_NOMZ
is_VPRT
to_TO
build_VB
basic_JJ
healthcare_NN
committed_VBN [WZPAST]
to_PIN
excellence_NN
in_PIN
science_NN
infrastructure_NN
will_PRMD
go_VB
some_QUAN
way_NN
education_NOMZ
and_CC
I_FPP1
am_VPRT [BEMA]
delighted_PRED
that_THAC
to_TO
ensuring_VBG [SUAV] [PRIV]
that_THVC
these_DEMO
vulnerable_JJ
GSK_NN
,_,
one_CD
of_PIN
our_FPP1
major_JJ
science-based_JJ
people_NN
do_VPRT
not_XX0
suffer_VB
further_JJ
due_JJ
companies_NN
,_,
and_ANDC
Imperial_NN
College_NN
,_,
are_VPRT [BEMA]
to_PIN
ill-health_NN
and_PHC
infant_NN
mortality_NOMZ
._.
Greta_NN
Beresford_NN
Safe_NN
Childbirth_NN
Coordinator_NN
,_,
HealthProm_NN
supporting_VBG [WZPRES]
this_DEMO
important_JJ
initiative_NN
._.
Rt_NN
Hon_NN
Tony_NN
Blair_NN
MP_NN
British_NN
Prime_NN
Minister_NN
,_,
speaking_VBG [PRESP]
at_PIN
the_DT
launch_NN
of_PIN
INSPIRE_NN
,_,
June_NN
2002_CD
GSK_NN
is_VPRT
helping_VBG
to_TO
improve_VB
school_NN
students_NN
Young_JJ
people_NN
with_PIN
HIV_NN
often_RB
face_VPRT
social_JJ
stigma_NN
North_NN
America_NN
interest_NN
and_PHC
achievement_NOMZ
in_PIN
science_NN
and_PHC
increase_NN
and_PHC
discrimination_NOMZ
that_TSUB
makes_VPRT
it_PIT
hard_RB
for_PIN
them_TPP3
The_DT
GSK_NN
IMPACT_NN
Awards_NN
recognize_VPRT [PRIV]
not-for-profit_JJ
the_DT
number_NN
of_PIN
science_NN
teachers_NN
through_PIN
the_DT
to_TO
continue_VB
living_VBG
normal_JJ
lives_NN
._.
GSK_NN
is_VPRT
supporting_VBG
organizations_NOMZ
in_PIN
Philadelphia_NN
that_TSUB
are_VPRT
helping_VBG
to_PIN
21_CD
INSPIRE_VPRT
INnovative_JJ
Scheme_NN
for_PIN
Post-docs_JJ
In_PIN
the_DT
SEYPA_NN
program_NN
that_TSUB
combats_VPRT
this_DEMO
social_JJ
improve_VB
healthcare_NN
._.
The_DT
awards_NN
have_VPRT [PEAS]
helped_VBN
Research_NN
and_PHC
Education_NOMZ
scheme_NN
._.
GSK_NN
is_VPRT
exclusion_NN
in_PIN
five_CD
European_JJ
countries_NN
with_PIN
a_DT
three_CD
-_:
58_CD
community_NOMZ
organizations_NOMZ
to_TO
raise_VB
funds_NN
,_,
providing_VBG
up_RP
to_PIN
1_CD
million_CD
over_IN
four_CD
years_NN
to_PIN
year_NN
grant_NN
of_PIN
400,000_CD
._.
Through_PIN
youth-led_JJ
focus_NN
recruit_VB
new_JJ
volunteers_NN
and_PHC
support_NN
greater_JJ
the_DT
scheme_NN
which_WDT [WHSUB]
was_VBD [PASS]
developed_VBN
in_PIN
partnership_NN
groups_NN
,_,
young_JJ
people_NN
find_VPRT [PRIV]
solutions_NOMZ
to_PIN
the_DT
numbers_NN
of_PIN
people_NN
._.
In_PIN
2003_CD
we_FPP1
awarded_VBD
with_PIN
Imperial_NN
College_NN
London_NN
and_CC
the_DT
Specialist_NN
problems_NN
they_TPP3
face_VPRT
._.
These_DEMP
include_VPRT
developing_VBG
$_$
367,000_CD
to_PIN
16_CD
organizations_NOMZ
dealing_VBG [WZPRES]
with_PIN
Schools_NN
Trust_NN
._.
INSPIRE_VB
places_NN
post-doctoral_JJ
training_GER
to_TO
help_VB
organizations_NOMZ
provide_VB
better_JJ
issues_NN
such_JJ
as_IN
child_NN
abuse_NN
,_,
breast_NN
cancer_NN
and_PHC
researchers_NN
into_PIN
specialist_NN
science_NN
schools_NN
to_TO
support_VB
to_PIN
young_JJ
people_NN
affected_VBN [WZPAST]
by_PIN
HIV_NN
._.
assist_VB
with_PIN
science_NN
teaching_GER
and_CC
to_TO
study_VB
towards_PIN
a_DT
teaching_GER
qualification_NOMZ
,_,
and_ANDC
provides_VPRT
Azerbaijan_NN
is_VPRT
home_NN
to_PIN
250,000_CD
refugees_NN
._.
GSK_NN
Our_FPP1
support_NN
for_PIN
the_DT
Childrens_NN
Health_NN
Fund_NN
has_VPRT
sponsorship_NN
to_TO
help_VB
schools_NN
gain_VB
specialist_NN
is_VPRT
providing_VBG
202,000_CD
over_IN
three_CD
years_NN
to_PIN
a_DT
Safe_NN
enabled_VBD
it_PIT
to_TO
improve_VB
access_NN
to_PIN
healthcare_NN
for_PIN
science_NN
status_NN
._.
Childbirth_NN
program_NN
to_TO
improve_VB
healthcare_NN
for_PIN
homeless_JJ
children_NN
page_NN
14_CD
._.
pregnant_JJ
women_NN
and_CC
reduce_VB
infant_NN
mortality_NOMZ
._.
Each_QUAN
year_NN
we_FPP1
support_VPRT
up_RP
to_PIN
five_CD
medical_JJ
research_NN
The_DT
program_NN
is_VPRT [PASS]
run_VBN
in_PIN
partnership_NN
with_PIN
the_DT
GSK_NN
is_VPRT [BEMA]
the_DT
major_JJ
supporter_NN
of_PIN
the_DT
University_NOMZ
charities_NOMZ
whose_WPS [WHOBJ]
work_NN
aims_VPRT
to_TO
benefit_VB
many_QUAN
charity_NOMZ
HealthProm_NN
and_CC
the_DT
Azerbaijan_NN
Ministry_NN
of_PIN
North_NN
Carolina_NN
's_POS
innovative_JJ
traveling_VBG
science_NN
people_NN
in_PIN
the_DT
future_NN
._.
It_PIT
uses_VPRT
qualified_VBN
doctors_NN
and_PHC
nurses_NN
laboratory_NN
,_,
DESTINY_NN
._.
The_DT
laboratory_NN
visited_VBD
73_CD
350,000_CD
to_TO
research_VB
projects_NN
run_VBN [WZPAST]
by_PIN
Tommys_NN
,_,
to_TO
train_VB
local_JJ
healthcare_NN
providers_NN
such_JJ
as_IN
under-served_JJ
secondary_JJ
schools_NN
and_CC
reached_VBD
the_DT
baby_NN
charity_NOMZ
,_,
International_NN
Spinal_NN
Research_NN
midwives_VPRT
,_,
and_ANDC
to_TO
develop_VB
healthcare_NN
training_GER
4,300_CD
students_NN
during_PIN
2003_CD
._.
The_DT
program_NN
Trust_NN
,_,
Epilepsy_NN
Research_NN
Foundation_NOMZ
materials_NN
._.
The_DT
local_JJ
GSK_NN
business_NOMZ
is_VPRT [SPAU]
also_RB
helping_VBG
encourages_VPRT
women_NN
and_PHC
minority_NOMZ
students_NN
to_TO
and_CC
the_DT
National_NN
Osteoporosis_NN
Society_NN
._.
to_TO
vaccinate_VB
refugee_NN
children_NN
against_PIN
measles_NN
,_,
pursue_VB
science_NN
careers_NN
._.
GSK_NN
's_POS
Positive_NN
Action_NOMZ
program_NN
is_VPRT
funding_VBG
Science_NN
in_PIN
the_DT
Summer_NN
is_VPRT [BEMA]
a_DT
free_JJ
science_NN
a_DT
UK-based_JJ
NGO_NN
called_VBD
five_CD
to_TO
develop_VB
a_DT
Zippys_NN
Friends_NN
,_,
a_DT
schools_NN
initiative_NN
run_VBN [WZPAST]
by_PIN
education_NOMZ
program_NN
that_TSUB
aims_VPRT
to_TO
inspire_VB
low-cost_JJ
health_NN
education_NOMZ
resource_NN
for_PIN
UK_NN
Partnership_NN
for_PIN
Children_NN
,_,
teaches_VPRT
very_AMP
young_JJ
children_NN
to_TO
pursue_VB
science_NN
careers_NN
._.
The_DT
Community_NOMZ
Health_NN
,_,
Advice_NN
,_,
Support_NN
children_NN
skills_NN
for_PIN
coping_VBG
with_PIN
adversities_NOMZ
such_JJ
fun_NN
,_,
hands-on_PIN
experiments_NOMZ
that_TSUB
relate_VPRT
science_NN
and_PHC
Education_NOMZ
CHASE_NN
program_NN
is_VPRT [PASS]
designed_VBN
as_IN
family_NN
changes_NN
,_,
bereavement_NOMZ
and_CC
bullying_VBG
._.
In_PIN
2003_CD
over_IN
6,000_CD
children_NN
to_TO
raise_VB
awareness_NOMZ
of_PIN
sexual_JJ
health_NN
issues_NN
and_CC
In_PIN
2003_CD
GSKs_NN
support_NN
helped_VBD
extend_VB
the_DT
participated_VBN
in_PIN
the_DT
program_NN
in_PIN
142_CD
libraries_NN
prevent_VPRT
the_DT
spread_NN
of_PIN
HIV_NN
,_,
TB_NN
,_,
and_ANDC
hepatitis_NN
._.
project_NN
from_PIN
Denmark_NN
and_PHC
Lithuania_NN
to_PIN
Goa_NN
,_,
in_PIN
the_DT
Philadelphia_NN
area_NN
._.
In_PIN
2003_CD
it_PIT
was_VBD [PASS]
piloted_VBN
in_PIN
150_CD
of_PIN
189_CD
UK_NN
prisons_NN
._.
We_FPP1
hope_VPRT [PRIV] [THATD]
the_DT
program_NN
will_PRMD
be_VB [PASS]
adapted_VBN
for_PIN
use_NN
in_PIN
other_JJ
resource-poor_JJ
settings_GER
._.
Europe_NN
Children_NN
coping_VBG [WZPRES]
with_PIN
cancer_NN
and_CC
life-threatening_JJ
illnesses_NOMZ
are_VPRT [PASS]
encouraged_VBN
to_TO
rediscover_VB
their_TPP3
childhood_NN
at_PIN
Barretstown_NN
in_PIN
Ireland_NN
and_PHC
LEnvol_NN
camp_NN
in_PIN
France_NN
._.
In_PIN
2003_CD
we_FPP1
donated_VBD
400,000_CD
to_TO
support_VB
these_DEMO
programs_NN
._.
Over_IN
60_CD
GSK_NN
employees_NN
also_RB
gave_VBD
their_TPP3
time_NN
to_TO
help_VB
run_VB
events_NN
for_PIN
children_NN
at_PIN
Barretstown_NN
while_OSUB
others_NN
The_DT
partnership_NN
provided_VBD
essential_JJ
business_NOMZ
expertise_NN
and_PHC
training_GER
to_PIN
the_DT
Barretstown_NN
team_NN
._.
we_FPP1
have_VPRT [PEAS]
forged_VBN
with_PIN
GSK_NN
to_TO
share_VB
skills_NN
and_PHC
resources_NN
has_VPRT [PEAS]
been_VBN [BEMA]
a_DT
great_JJ
example_NN
to_PIN
other_JJ
companies_NN
._.
I_FPP1
know_VPRT [PRIV]
that_THVC
many_QUAN
other_JJ
firms_NN
now_TIME
recognize_VPRT [PRIV]
the_DT
value_NN
of_PIN
partnering_VBG
with_PIN
a_DT
charity_NOMZ
rather_RB
than_PIN
merely_DWNT
donating_VBG
money_NN
._.
James_NN
Hill_NN
Chairman_NN
,_,
Barretstown_NN
16_CD
Corporate_JJ
Responsibility_NOMZ
Report_NN
2003_CD
10_CD
million_CD
people_NN
treated_VBN [WZPAST]
against_PIN
lymphatic_JJ
filariasis_NN
in_PIN
one_CD
day_NN
Using_VBG [WZPRES]
medicines_NN
donated_VBN [WZPAST]
by_PIN
GSK_NN
,_,
the_DT
Sri_NN
Lankan_NN
Ministry_NN
of_PIN
Health_NN
mobilised_VBD
50,000_CD
healthcare_NN
workers_NN
and_PHC
volunteers_NN
to_TO
treat_VB
half_NN
of_PIN
its_PIT
population_NOMZ
,_,
those_DEMO
at_PIN
risk_NN
of_PIN
LF_NN
,_,
in_PIN
one_CD
day_NN
10_CD
million_CD
people_NN
._.
Sri_NN
Lanka_NN
,_,
now_DPAR
halfway_NN
through_PIN
its_PIT
5-year_JJ
treatment_NOMZ
plan_NN
,_,
is_VPRT [BEMA]
just_EMPH
one_CD
of_PIN
36_CD
countries_NN
on_PIN
several_QUAN
continents_NN
working_VBG [WZPRES]
to_TO
eliminate_VB
LF_NN
forever_RB
._.
International_NN
In_PIN
China_NN
we_FPP1
are_VPRT
working_VBG
in_PIN
partnership_NN
with_PIN
the_DT
Our_FPP1
Rural_JJ
Nursing_GER
Excellence_NN
program_NN
in_PIN
British_JJ
and_PHC
Australian_JJ
Red_NN
Cross_NN
,_,
reaching_VBG
young_JJ
Thailand_NN
has_VPRT [PEAS]
helped_VBN
150_CD
nurses_NN
qualify_VPRT
since_OSUB
it_PIT
people_NN
and_PHC
drug_NN
users_NN
to_TO
prevent_VB
the_DT
spread_NN
of_PIN
was_VBD [PASS]
started_VBN
in_PIN
1997_CD
,_,
providing_VBG
support_NN
to_PIN
109_CD
HIV_NN
._.
During_PIN
2003_CD
8,000_CD
young_JJ
people_NN
took_VBD
part_NN
hospitals_NN
and_PHC
clinics_NN
._.
GSK_NN
has_VPRT [PEAS]
donated_VBN
500,000_CD
in_PIN
training_GER
and_CC
the_DT
program_NN
has_VPRT [PEAS]
reached_VBN
to_PIN
the_DT
program_NN
to_TO
provide_VB
training_GER
for_PIN
young_JJ
14,000_CD
people_NN
so_RB
far_PLACE
._.
The_DT
lack_NN
of_PIN
nurses_NN
is_VPRT [BEMA]
a_DT
major_JJ
barrier_NN
to_TO
improving_VBG
healthcare_NN
in_PIN
rural_JJ
areas_NN
and_CC
this_DEMO
Employee_NN
involvement_NOMZ
program_NN
encourages_VPRT
them_TPP3
to_TO
take_VB
their_TPP3
skills_NN
Many_QUAN
GSK_NN
employees_NN
volunteer_VPRT
their_TPP3
time_NN
back_RB
to_TO
benefit_VB
their_TPP3
villages_NN
._.
and_ANDC
expertise_NN
to_PIN
worthy_JJ
causes_NN
in_PIN
their_TPP3
local_JJ
communities_NOMZ
._.
This_DEMP
can_POMD
include_VB
participating_VBG
in_PIN
GSKs_NN
support_NN
has_VPRT
Our_FPP1
award-winning_JJ
Personal_JJ
Hygiene_NN
and_PHC
Days_NN
of_PIN
Caring_NN
at_PIN
not-for-profit_JJ
organizations_NOMZ
in_PIN
Sanitation_NOMZ
Education_NOMZ
PHASE_NN
program_NN
run_VBN [WZPAST]
in_PIN
the_DT
US_FPP1
and_CC
mentoring_VBG
school_NN
children_NN
through_PIN
helped_VBN
us_FPP1
to_TO
turn_VB
a_DT
simple_JJ
partnership_NN
with_PIN
AMREF_NN
and_PHC
Plan_NN
International_NN
our_FPP1
UK_NN
Science_NN
and_PHC
Engineering_GER
Ambassador_NN
idea_NN
for_PIN
promoting_VBG
childrens_NN
is_VPRT
reducing_VBG
diarrhoea-related_JJ
disease_NN
in_PIN
school_NN
Scheme_NN
and_CC
our_FPP1
US_FPP1
Partnership_NN
for_PIN
Educational_NN
children_NN
._.
In_PIN
2003_CD
this_DEMO
simple_JJ
hand-washing_JJ
Discovery_NN
._.
health_NN
into_PIN
an_DT
international_JJ
program_NN
was_VBD [PASS]
expanded_VBN
into_PIN
a_DT
fourth_JJ
country_NN
,_,
Zambia_NN
,_,
with_PIN
the_DT
Ministry_NN
of_PIN
Education_NOMZ
and_CC
In_PIN
2003_CD
in_PIN
the_DT
US_FPP1
,_,
GSK_NN
matched_VBD
donations_NOMZ
program_NN
we_FPP1
couldnt_VPRT
USAID_NN
,_,
and_ANDC
is_VPRT
being_VBG [PASS]
rolled_VBN
out_PIN
to_PIN
all_QUAN
schools_NN
in_PIN
of_PIN
$_$
3.8_CD
million_CD
made_VBN
by_PIN
GSK_NN
employees_NN
and_CC
have_VPRT [PEAS]
wished_VBN
for_PIN
better_JJ
Peru_NN
by_PIN
the_DT
Ministry_NN
of_PIN
Health_NN
._.
retirees_NN
through_PIN
our_FPP1
Matching_VBG
Gifts_NN
Program_NN
._.
In_CONJ
addition_NULL
,_,
the_DT
$_$
1.3_CD
million_CD
donated_VBN
by_PIN
GSK_NN
partners_NN
._.
We_FPP1
are_VPRT
helping_VBG
to_TO
give_VB
Africa_NN
's_POS
children_NN
employees_NN
to_PIN
the_DT
United_NN
Way_NN
campaign_NN
was_VBD
Chris_NN
Bale_NN
Director_NN
,_,
Partnership_NN
for_PIN
Children_NN
a_DT
healthier_RB
future_JJ
through_PIN
the_DT
Integrated_NN
matched_VBN [WZPAST]
by_PIN
GSK_NN
,_,
giving_VBG [PRESP]
a_DT
total_NN
of_PIN
$_$
2.6_CD
million_CD
._.
Management_NOMZ
of_PIN
Childhood_NN
Illness_NOMZ
IMCI_NN
strategy_NN
._.
The_DT
GSK_NN
Investment_NOMZ
in_PIN
Volunteer_NN
Excellence_NN
Developed_VBN [WZPAST]
by_PIN
the_DT
WHO_WP
and_CC
Unicef_NN
,_,
IMCI_NN
aims_VPRT
GIVE_VB
program_NN
makes_VPRT
donations_NOMZ
to_TO
registered_VBN
to_TO
reduce_VB
deaths_NN
from_PIN
treatable_JJ
and_PHC
preventable_JJ
charities_NOMZ
in_PIN
the_DT
US_FPP1
where_RB
GSK_NN
employees_NN
or_CC
diseases_NN
by_PIN
improving_VBG
the_DT
skills_NN
of_PIN
health_NN
workers_NN
their_TPP3
partners_NN
volunteer_NN
._.
and_ANDC
helping_VBG
families_NN
better_JJ
care_NN
for_PIN
sick_JJ
children_NN
._.
GSK_NN
has_VPRT [PEAS]
provided_VBN
funding_GER
of_PIN
$_$
300,000_CD
and_CC
In_PIN
the_DT
UK_NN
our_FPP1
Making_VBG
a_DT
Difference_NN
initiative_NN
technical_JJ
expertise_NN
._.
In_PIN
2003_CD
the_DT
initiative_NN
was_VBD
provides_VPRT
financial_JJ
support_NN
to_PIN
charities_NOMZ
where_RB
expanded_VBN
from_PIN
South_NN
Africa_NN
and_PHC
Ethiopia_NN
into_PIN
GSK_NN
employees_NN
are_VPRT [PASS]
involved_VBN
in_PIN
voluntary_JJ
work_NN
._.
GSKs_NN
product_NN
donations_NOMZ
for_PIN
humanitarian_JJ
relief_NN
efforts_NN
allow_VPRT [SUAV]
us_FPP1
to_TO
save_VB
lives_NN
and_CC
serve_VB
as_IN
a_DT
catalyst_NN
in_PIN
building_GER
sustainable_JJ
health_NN
programs_NN
throughout_PIN
the_DT
developing_VBG
world_NN
._.
Veronica_NN
Arroyave_NN
Director_NN
,_,
Corporate_NN
Relations_NOMZ
,_,
MAP_NN
International_NN
Corporate_NN
Responsibility_NOMZ
Report_NN
2003_CD
17_CD
GSK_NN
is_VPRT [PASS]
committed_VBN
to_TO
ensuring_VBG [SUAV] [PRIV]
that_THVC
all_QUAN
our_FPP1
business_NOMZ
practices_NN
meet_VPRT
high_JJ
standards_NN
and_CC
our_FPP1
employees_NN
behave_VPRT
ethically_RB
and_PHC
honestly_RB
,_,
compete_VB
fairly_RB
and_CC
avoid_VB
conflicts_NN
of_PIN
interest_NN
._.
This_DEMO
section_NOMZ
is_VPRT
about_IN
our_FPP1
business_NOMZ
Ensuring_VBG [SUAV] [PRIV] [WZPRES]
compliance_NN
Departments_NOMZ
such_JJ
as_IN
Finance_NN
,_,
Human_NN
Resources_NN
,_,
standards_NN
and_ANDC
in_CONJ
particular_NULL
those_DEMP
relating_VBG
All_QUAN
managers_NN
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
lead_VB
by_PIN
example_NN
in_PIN
Legal_NN
,_,
Compliance_NN
and_PHC
Internal_NN
Audit_NN
work_NN
complying_VBG [WZPRES]
with_PIN
our_FPP1
Code_NN
of_PIN
Conduct_NN
and_CC
other_JJ
together_RB
to_TO
monitor_VB
compliance_NN
with_PIN
our_FPP1
policies_NN
to_PIN
our_FPP1
marketing_GER
teams_NN
._.
GSK_NN
policies_NN
and_CC
supporting_VBG
their_TPP3
staff_NN
to_TO
do_VB [PROD]
the_DT
and_CC
applicable_JJ
laws_NN
._.
In_PIN
2002_CD
we_FPP1
introduced_VBD
an_DT
annual_JJ
practices_NN
are_VPRT [BYPA]
monitored_VBN
by_PIN
our_FPP1
Internal_NN
Audit_NN
Code_NN
of_PIN
conduct_NN
certification_NOMZ
process_NN
for_PIN
the_DT
700_CD
or_CC
so_RB
managers_NN
Department_NOMZ
during_PIN
audits_NN
of_PIN
our_FPP1
businesses_NOMZ
._.
GSKs_NN
Code_NN
of_PIN
Conduct_NN
sets_VPRT
out_PIN
the_DT
standards_NN
at_PIN
vice-president_NN
level_NN
and_CC
above_PLACE
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
We_FPP1
fully_AMP
investigate_VPRT
any_QUAN
suspected_VBN [PRIV]
breaches_NN
of_PIN
we_FPP1
expect_VPRT [PRIV]
employees_NN
to_TO
meet_VB
._.
It_PIT
requires_VPRT [SUAV]
all_QUAN
they_TPP3
understand_VPRT [PRIV]
this_DEMO
responsibility_NOMZ
._.
In_PIN
2003_CD
we_FPP1
policies_NN
and_CC
take_VB
appropriate_JJ
disciplinary_JJ
action_NOMZ
employees_NN
to_TO
behave_VB
honestly_RB
,_,
in_PIN
line_NN
with_PIN
extended_JJ
certification_NOMZ
to_TO
include_VB
all_QUAN
mid-level_JJ
where_RB
warranted_VBN
._.
company_NN
policy_NN
and_CC
with_PIN
the_DT
law_NN
,_,
to_TO
avoid_VB
management_NOMZ
in_PIN
the_DT
US_FPP1
and_PHC
UK_NN
so_OSUB
that_NULL
over_IN
conflicts_NN
of_PIN
interest_NN
and_CC
to_TO
report_VB [PUBV]
any_QUAN
violations_NOMZ
22_CD
9,000_CD
managers_NN
participated_VBD
in_PIN
the_DT
certification_NOMZ
._.
In_PIN
2002_CD
GSK_NN
provided_VBD
input_NN
into_PIN
the_DT
Compliance_NN
of_PIN
the_DT
Code_NN
or_CC
unethical_JJ
behavior_NN
._.
Program_NN
Guidance_NN
for_PIN
Pharmaceutical_NN
If_COND
employees_NN
have_VPRT
concerns_NN
they_TPP3
can_POMD
raise_VB
them_TPP3
Manufacturers_NN
developed_VBN [WZPAST]
by_PIN
the_DT
US_FPP1
Health_NN
and_CC
To_TO
help_VB
employees_NN
understand_VB [PRIV]
the_DT
Code_NN
and_CC
23_CD
with_PIN
the_DT
Corporate_JJ
Compliance_NN
Officer_NN
,_,
the_DT
Human_NN
Services_NN
Office_NN
of_PIN
Inspector_NN
General_NN
._.
what_WP
constitutes_VPRT
acceptable_JJ
and_PHC
unacceptable_JJ
business_NOMZ
unit_NN
Compliance_NN
Officers_NN
,_,
or_CC
through_PIN
The_DT
guidance_NN
,_,
published_VBN [PASTP]
in_PIN
April_NN
2003_CD
,_,
is_VPRT
behavior_NN
in_PIN
practice_NN
we_FPP1
have_VPRT [SPAU] [PEAS]
also_RB
issued_VBN
an_DT
our_FPP1
confidential_JJ
PO_NN
Box_NN
and_PHC
helplines_NN
._.
Other_JJ
designed_VBN
to_TO
help_VB
pharmaceutical_JJ
companies_NN
Employee_NN
Guide_NN
to_PIN
Business_NOMZ
Conduct_NN
._.
The_DT
Code_NN
stakeholders_NN
can_POMD
contact_VB
our_FPP1
customer_NN
response_NN
establish_VB [PRIV]
effective_JJ
compliance_NN
programs_NN
and_PHC
Guide_NN
are_VPRT [BEMA]
available_PRED
on_PIN
the_DT
company_NN
centres_VPRT
which_WDT
redirect_VPRT
calls_NN
to_PIN
appropriate_JJ
senior_JJ
to_TO
prevent_VB
unlawful_JJ
or_CC
unethical_JJ
conduct_NN
._.
are_VPRT
benchmarking_VBG
our_FPP1
programs_NN
against_PIN
the_DT
guidelines_NN
._.
Business_NOMZ
ethics_NN
and_PHC
integrity_NOMZ
18_CD
Corporate_JJ
Responsibility_NOMZ
Report_NN
2003_CD
3_CD
Business_NOMZ
ethics_NN
&_CC
integrity_NOMZ
Marketing_GER
practices_NN
These_DEMO
regional_JJ
codes_NN
are_VPRT
being_VBG [PASS]
introduced_VBN
across_PLACE
The_DT
advertising_GER
and_PHC
selling_GER
of_PIN
medicines_NN
are_VPRT [BEMA]
the_DT
company_NN
and_CC
we_FPP1
have_VPRT [PEAS]
designated_VBN
area_NN
subject_NN
to_PIN
regulations_NOMZ
set_VBN [WZPAST]
out_PIN
by_PIN
governments_NOMZ
champions_NN
to_TO
co-ordinate_VB
the_DT
distribution_NOMZ
of_PIN
the_DT
and_CC
medicines_NN
agencies_NN
._.
GSKs_NN
internal_JJ
policies_NN
codes_NN
and_PHC
training_GER
for_PIN
staff_NN
._.
Codes_NN
are_VPRT [PASS]
translated_VBN
encompass_VB
and_PHC
build_VB
on_PIN
these_DEMO
requirements_NOMZ
._.
into_PIN
local_JJ
languages_NN
and_CC
all_QUAN
sales_NN
and_PHC
marketing_GER
employees_NN
receive_VPRT
a_DT
copy_NN
._.
Most_EMPH
of_PIN
our_FPP1
products_NN
are_VPRT [BYPA]
marketed_VBN
by_PIN
sales_NN
representatives_NN
._.
They_TPP3
regularly_RB
meet_VPRT
doctors_NN
Training_VBG [WZPRES]
workshops_NN
and_CC
electronic_JJ
media_NN
and_PHC
pharmacists_NN
to_TO
inform_VB
them_TPP3
about_IN
our_FPP1
ensure_VB [SUAV] [PRIV] [THATD]
staff_NN
understand_VB [PRIV]
the_DT
codes_NN
and_ANDC
what_WP
medicines_NN
and_CC
their_TPP3
approved_VBN
uses_NN
._.
We_FPP1
also_RB
constitutes_VPRT
acceptable_JJ
promotional_JJ
activities_NOMZ
._.
Performance_NN
with_PIN
integrity_NOMZ
market_NN
some_QUAN
products_NN
directly_RB
to_PIN
consumers_NN
All_QUAN
employees_NN
involved_VBN [WZPAST]
in_PIN
sales_NN
and_PHC
marketing_GER
where_RB
this_DEMP
is_VPRT [PASS]
permitted_VBN
._.
receive_VB
regular_JJ
training_GER
on_PIN
our_FPP1
products_NN
so_IN
they_TPP3
in_PIN
all_QUAN
its_PIT
aspects_NN
is_VPRT
absolutely_AMP
non_NN
can_POMD
provide_VB
accurate_JJ
information_NOMZ
to_PIN
doctors_NN
._.
negotiable_JJ
,_,
and_ANDC
adherence_NN
to_PIN
the_DT
Specific_JJ
policies_NN
and_PHC
guidance_NN
for_PIN
sales_NN
and_CC
new_JJ
Code_NN
is_VPRT [BEMA]
a_DT
major_JJ
way_NN
in_PIN
which_WDT [PIRE]
marketing_GER
employees_NN
at_PIN
a_DT
national_JJ
level_NN
ensure_VB [SUAV] [PRIV]
that_THVC
all_QUAN
our_FPP1
marketing_GER
is_VPRT [BEMA]
accurate_PRED
,_,
based_VBN [PASTP]
on_PIN
valid_JJ
we_FPP1
show_VPRT [PRIV] [THATD]
that_DEMP
._.
scientific_JJ
evidence_NN
and_PHC
complies_NN
with_PIN
the_DT
law_NN
._.
Russell_NN
Greig_NN
President_NN
Pharmaceuticals_NN
International_NN
,_,
GSK_NN
We_FPP1
are_VPRT [PASS]
committed_VBN
to_PIN
GSK_NN
also_RB
has_VPRT
a_DT
company-wide_JJ
policy_NN
on_PIN
conducting_VBG
our_FPP1
business_NOMZ
with_PIN
Pharmaceutical_NN
Marketing_GER
and_PHC
Promotion_NOMZ
Activity_NOMZ
which_WDT [WHSUB]
applies_VPRT
to_PIN
all_QUAN
employees_NN
and_PHC
agents_NN
._.
It_PIT
sets_VPRT
integrity_NOMZ
and_CC
that_DEMP
means_VPRT [PRIV]
complying_VBG
out_PIN
our_FPP1
commitment_NOMZ
to_PIN
promotional_JJ
practices_NN
fully_AMP
,_,
not_XX0
only_DWNT
with_PIN
the_DT
letter_NN
of_PIN
the_DT
that_DEMP
are_VPRT [BEMA]
ethical_PRED
,_,
responsible_JJ
,_,
principled_JJ
and_PHC
patient-centred_JJ
._.
It_PIT
prohibits_VPRT
bribery_NN
or_CC
other_JJ
law_NN
,_,
but_CC
with_PIN
the_DT
spirit_NN
._.
It_PIT
is_VPRT [BEMA]
not_XX0
our_FPP1
inducements_NOMZ
to_PIN
doctors_NN
to_TO
prescribe_VB
a_DT
medicine_NN
._.
objective_NN
to_TO
look_VB
for_PIN
loop-holes_NN
or_CC
creative_JJ
interpretations_NOMZ
of_PIN
the_DT
law_NN
,_,
More_EMPH
detailed_JJ
guidance_NN
is_VPRT [BYPA]
provided_VBN
by_PIN
the_DT
international_JJ
and_PHC
regional_JJ
industry_NN
codes_NN
of_PIN
nor_SYNE
shall_PRMD
it_PIT
be_VB [BEMA]
our_FPP1
benchmark_NN
to_TO
practice_VB
that_DEMO
we_FPP1
adhere_VPRT
to_TO
,_,
including_VBG [PRESP]
the_DT
simply_RB
compare_VB
ourselves_FPP1
with_PIN
our_FPP1
International_NN
Federation_NOMZ
of_PIN
Pharmaceutical_NN
Manufacturers_NN
Associations_NOMZ
IFPMA_NN
Code_NN
of_PIN
competitors_NN
and_CC
be_VB [PASS]
satisfied_VBN
that_DEMO
24_CD
Pharmaceutical_NN
Marketing_GER
Practices_NN
._.
we_FPP1
are_VPRT [BEMA]
as_RB
good_PRED
as_IN
,_,
or_CC
no_SYNE
worse_JJ
than_PIN
them_TPP3
._.
In_CONJ
addition_NULL
GSK_NN
has_VPRT [PEAS]
developed_VBN
,_,
and_ANDC
keeps_VPRT
under_IN
review_NN
,_,
its_PIT
own_JJ
regional_JJ
marketing_GER
codes_NN
that_TOBJ
Andrew_NN
Witty_NN
President_NN
Pharmaceuticals_NN
Europe_NN
,_,
GSK_NN
ensure_VB [SUAV] [PRIV]
differences_NN
in_PIN
market_NN
structure_NN
,_,
national_JJ
healthcare_NN
systems_NN
and_CC
legal_JJ
framework_NN
are_VPRT [SPAU] [PASS]
appropriately_RB
reflected_VBN [PRIV]
._.
Enhancing_VBG [PRESP]
a_DT
compliance_NN
culture_NN
in_PIN
sales_NN
and_CC
A_DT
regular_JJ
High_JJ
Road_NN
newsletter_NN
and_CC
audio_JJ
program_NN
marketing_GER
help_NN
reinforce_VB
key_JJ
points_NN
from_PIN
training_GER
and_CC
keep_VB
employees_NN
up_RB
to_PIN
date_NN
on_PIN
new_JJ
developments_NOMZ
._.
Our_FPP1
pharmaceutical_JJ
sales_NN
and_PHC
marketing_GER
division_NN
in_PIN
the_DT
US_FPP1
has_VPRT [PEAS]
introduced_VBN
a_DT
program_NN
to_TO
make_VB
business_NOMZ
The_DT
company_NN
has_VPRT [SPAU] [PEAS]
also_RB
established_VBN [PRIV]
an_DT
advisory_JJ
board_NN
integrity_NOMZ
a_DT
key_JJ
requirement_NOMZ
._.
The_DT
initiative_NN
,_,
called_VBN
Take_VB
of_PIN
sales_NN
managers_NN
from_PIN
across_PLACE
the_DT
business_NOMZ
to_TO
provide_VB
the_DT
High_NN
Road_NN
on_PIN
Ethics_NN
and_PHC
Legal_NN
Compliance_NN
,_,
aims_VPRT
to_TO
feedback_VB
on_PIN
new_JJ
initiatives_NN
and_CC
help_VB
ensure_VB [SUAV] [PRIV] [THATD]
compliance_NN
ensure_VB [SUAV] [PRIV] [THATD]
employees_NN
understand_VB [PRIV]
and_PHC
comply_VB
with_PIN
our_FPP1
sales_NN
programs_NN
are_VPRT [BEMA]
practical_PRED
and_CC
user-friendly_RB
._.
The_DT
compliance_NN
department_NOMZ
and_CC
confidential_JJ
GSK_NN
Education_NOMZ
is_VPRT [BEMA]
an_DT
essential_JJ
element_NOMZ
._.
A_DT
comprehensive_JJ
Integrity_NOMZ
Helpline_NN
have_VPRT [PEAS]
been_VBN [PASS]
publicised_VBN
so_RB
employees_NN
paper_NN
and_CC
on-line_JJ
manual_NN
has_VPRT [PEAS]
been_VBN [PASS]
developed_VBN
,_,
know_VPRT [PRIV]
where_RB [WHCL]
to_TO
go_VB
if_COND
they_TPP3
have_VPRT
any_QUAN
questions_NOMZ
or_CC
containing_VBG
our_FPP1
sales_NN
and_PHC
marketing_GER
policies_NN
,_,
guidelines_NN
concerns_NN
._.
Sales_NN
employees_NN
used_VBN
this_DEMO
facility_NOMZ
to_TO
ask_VB [SUAV]
more_EMPH
for_PIN
employees_NN
and_PHC
Q&A_NN
s_VPRT [BEMA]
on_PIN
key_JJ
subjects_NN
._.
This_DEMP
is_VPRT [BEMA]
available_PRED
than_PIN
1,100_CD
questions_NOMZ
on_PIN
sales_NN
and_PHC
marketing_GER
policies_NN
to_PIN
over_IN
10,000_CD
employees_NN
across_PLACE
the_DT
US_FPP1
._.
All_QUAN
new_JJ
in_PIN
2003_CD
._.
and_ANDC
existing_VBG
sales_NN
and_PHC
marketing_GER
employees_NN
attend_VPRT
compliance_NN
training_GER
and_CC
11_CD
new_JJ
computer-based_JJ
training_GER
Monitoring_GER
behavior_NN
is_VPRT [BEMA]
an_DT
important_JJ
element_NOMZ
of_PIN
modules_NN
have_VPRT [PEAS]
been_VBN [PASS]
developed_VBN
._.
A_DT
full-time_JJ
project_NN
team_NN
looked_VBD
employees_NN
completed_VBN
compliance_NN
training_GER
in_PIN
2003_CD
._.
in_PIN
detail_NN
at_PIN
our_FPP1
monitoring_GER
processes_VPRT
for_PIN
sales_NN
and_CC
A_DT
video_NN
,_,
Performing_VBG [PRESP]
With_PIN
Integrity_NOMZ
,_,
supports_VPRT
the_DT
training_GER
marketing_GER
and_CC
introduced_VBN
improvements_NOMZ
where_RB
and_CC
includes_VPRT
perspectives_NN
from_PIN
GSK_NN
sales_NN
people_NN
._.
Audits_NN
have_VPRT [PEAS]
been_VBN [PASS]
conducted_VBN
in_PIN
key_JJ
compliance_NN
areas_NN
during_PIN
the_DT
past_JJ
two_CD
years_NN
._.
Corporate_JJ
Responsibility_NOMZ
Report_NN
2003_CD
19_CD
Environme_NN
health_NN
and_PHC
Environment_NOMZ
,_,
health_NN
and_PHC
safety_NN
EHS_NN
issues_NN
are_VPRT [PASS]
managed_VBN
through_PIN
an_DT
integrated_JJ
system_NN
that_TSUB
ensures_VPRT [SUAV] [PRIV]
issues_NN
and_PHC
risks_NN
are_VPRT [PASS]
identified_VBN
,_,
training_GER
is_VPRT [PASS]
provided_VBN
,_,
targets_NN
set_VBN
and_CC
audits_NN
conducted_VBN
._.
Our_FPP1
EHS_NN
standards_NN
apply_VB
throughout_PIN
our_FPP1
operations_NOMZ
and_CC
in_PIN
2002_CD
we_FPP1
developed_VBD
a_DT
ten-year_JJ
strategic_JJ
25_CD
plan_NN
our_FPP1
Plan_NN
for_PIN
Excellence_NN
._.
Environment_NOMZ
Important_NN
environmental_JJ
issues_NN
include_VPRT
:_:
We_FPP1
have_VPRT
a_DT
systematic_JJ
plan_NN
to_TO
improve_VB
Air_NN
quality_NOMZ
Volatile_NN
organic_JJ
compounds_NN
VOCs_NN
environment_NOMZ
,_,
health_NN
and_PHC
safety_NN
performance_NN
used_VBN
as_IN
solvents_NN
in_PIN
manufacturing_GER
can_POMD
contribute_VB
the_DT
EHS_NN
Plan_NN
for_PIN
Excellence_NN
._.
Our_FPP1
long-term_JJ
goal_NN
to_PIN
the_DT
formation_NOMZ
of_PIN
smog_NN
._.
is_VPRT
to_TO
drive_VB
down_RP
manufacturing_GER
impacts_NN
and_CC
switch_VB
to_TO
using_VBG
renewable_JJ
resources_NN
so_OSUB
that_NULL
our_FPP1
Climate_NN
Burning_GER
fossil_JJ
fuels_NN
for_PIN
energy_NN
operations_NOMZ
become_VPRT
increasingly_RB
compatible_JJ
with_PIN
produces_VPRT
carbon_NN
dioxide_NN
which_WDT [WHSUB]
contributes_VPRT
to_PIN
the_DT
principles_NN
of_PIN
sustainable_JJ
development_NOMZ
._.
global_JJ
warming_GER
and_PHC
climate_NN
change_NN
._.
We_FPP1
have_VPRT [PEAS]
identified_VBN
appropriate_JJ
parameters_NN
Ozone_NN
depletion_NOMZ
Some_QUAN
of_PIN
our_FPP1
products_NN
and_CC
to_TO
track_VB
progress_NN
in_PIN
each_QUAN
of_PIN
our_FPP1
main_JJ
impacts_NN
._.
These_DEMO
gases_NN
Following_VBG [WZPRES]
the_DT
formation_NOMZ
of_PIN
GSK_NN
we_FPP1
established_VBD [PRIV]
damage_NN
the_DT
ozone_NN
layer_NN
if_COND
released_VBN
into_PIN
the_DT
baseline_NN
values_NN
for_PIN
these_DEMO
parameters_NN
in_PIN
2001_CD
atmosphere_NN
._.
and_ANDC
set_VBN
improvement_NOMZ
targets_NN
to_TO
be_VB [BYPA]
achieved_VBN
by_PIN
the_DT
end_NN
of_PIN
2005_CD
see_VPRT [PRIV]
chart_NN
,_,
page_NN
22_CD
._.
Waste_NN
Some_QUAN
of_PIN
the_DT
raw_JJ
materials_NN
used_VBN [WZPAST]
in_PIN
pharmaceutical_JJ
production_NOMZ
processes_NN
are_VPRT [BEMA]
An_DT
important_JJ
element_NOMZ
of_PIN
our_FPP1
approach_NN
is_VPRT [BEMA]
hazardous_PRED
and_CC
require_VB [SUAV]
special_JJ
disposal_NN
methods_NN
._.
consultation_NOMZ
with_PIN
people_NN
outside_PLACE
GSK_NN
either_CC
experts_NN
or_CC
community_NOMZ
neighbors_NN
who_WP [WHSUB]
may_POMD
be_VB
Water_NN
Waste_NN
water_NN
discharges_VPRT
from_PIN
affected_VBN
by_PIN
our_FPP1
sites_NN
._.
We_FPP1
do_VPRT
this_DEMO
routinely_RB
and_CC
at_PIN
manufacturing_VBG
sites_NN
require_VPRT [SUAV]
treatment_NOMZ
before_IN
several_QUAN
levels_NN
._.
The_DT
aim_NN
is_VPRT [BEMA]
for_PIN
our_FPP1
stakeholders_NN
to_PIN
they_TPP3
are_VPRT [PASS]
released_VBN
._.
have_VB
access_NN
to_PIN
the_DT
information_NOMZ
they_TPP3
need_VPRT
and_CC
the_DT
opportunity_NOMZ
to_TO
tell_VB
us_FPP1
what_WP
they_TPP3
think_VPRT [PRIV]
and_ANDC
how_RB
they_TPP3
want_VPRT
us_FPP1
to_TO
improve_VB
._.
20_CD
Corporate_JJ
Responsibility_NOMZ
report_NN
2003_CD
4_CD
Environment_NOMZ
health_NN
&_CC
safety_NN
nt_NN
safety_NN
Technological_JJ
changes_NN
improve_VPRT
materials_NN
recovery_NN
New_NN
technology_NN
can_POMD
help_VB
improve_VB
our_FPP1
environmental_JJ
performance_NN
._.
GSKs_NN
manufacturing_VBG [WZPRES]
site_NN
at_PIN
Ulverston_NN
in_PIN
the_DT
UK_NN
has_VPRT [PEAS]
introduced_VBN
a_DT
new_JJ
membrane_NN
filtration_NOMZ
system_NN
that_TSUB
has_VPRT [PEAS]
reduced_VBN
hazardous_JJ
waste_NN
by_PIN
50_CD
tonnes_NN
and_PHC
emissions_NN
of_PIN
VOCs_NN
by_PIN
3_CD
tonnes_NN
per_PIN
annum_NN
._.
The_DT
new_JJ
system_NN
saves_VPRT
the_DT
site_NN
around_PLACE
1_CD
million_CD
a_DT
year_NN
._.
Ulverston_NN
is_VPRT [BEMA]
one_CD
of_PIN
our_FPP1
largest_JJ
primary_JJ
manufacturing_GER
plants_NN
with_PIN
over_IN
600_CD
staff_NN
on_PIN
a_DT
60-acre_JJ
site_NN
._.
It_PIT
is_VPRT [PASS]
situated_VBN
near_PLACE
the_DT
Lake_NN
District_NN
,_,
an_DT
area_NN
of_PIN
natural_JJ
beauty_NN
and_CC
ecological_JJ
importance_NN
._.
The_DT
plant_NN
makes_VPRT
active_JJ
ingredients_NN
for_PIN
many_QUAN
of_PIN
our_FPP1
antibiotics_NN
._.
Acetone_NN
,_,
a_DT
VOC_NN
,_,
is_VPRT [PASS]
used_VBN
as_IN
a_DT
solvent_JJ
during_PIN
manufacturing_VBG
when_RB
axetil_NN
,_,
an_DT
oral_JJ
antibiotic_JJ
,_,
is_VPRT [PASS]
spray_NN
dried_VBD
._.
This_DEMO
process_NN
ensures_VPRT [SUAV] [PRIV] [THATD]
the_DT
medicines_NN
can_POMD
be_VB [PASS]
absorbed_VBN
efficiently_RB
from_PIN
the_DT
stomach_NN
and_PHC
gut_NN
into_PIN
the_DT
patients_NN
bloodstream_NN
._.
Acetone_NN
is_VPRT [SPAU] [PASS]
also_RB
used_VBN
to_TO
wash_VB
the_DT
equipment_NOMZ
used_VBN [WZPAST]
in_PIN
processing_GER
._.
Antibiotic_JJ
residue_NN
in_PIN
the_DT
acetone_NN
is_VPRT [BEMA]
valuable_PRED
and_CC
needs_VPRT
to_TO
be_VB [PASS]
recovered_VBN
before_IN
disposal_NN
of_PIN
the_DT
acetone_NN
._.
Previously_TIME
this_DEMP
was_VBD [PASS]
done_VBN [PROD]
in_PIN
a_DT
remote_JJ
area_NN
of_PIN
the_DT
site_NN
but_CC
the_DT
system_NN
was_VBD [BEMA]
inefficient_PRED
so_IN
a_EMPH
lot_NULL
of_PIN
the_DT
product_NN
was_VBD [PASS]
wasted_VBN
._.
Acetone_NN
is_VPRT [BEMA]
highly_AMP
flammable_PRED
so_IN
pumping_VBG
it_PIT
across_PLACE
the_DT
site_NN
created_VBD
a_DT
potential_JJ
health_NN
and_PHC
safety_NN
risk_NN
._.
In_PIN
2002_CD
the_DT
site_NN
introduced_VBD
a_DT
new_JJ
membrane_NN
filtration_NOMZ
system_NN
._.
This_DEMP
separates_VPRT
antibiotic_JJ
from_PIN
other_JJ
residues_NN
in_PIN
the_DT
acetone_NN
,_,
allowing_VBG [SUAV] [PRESP]
it_PIT
to_TO
be_VB [PASS]
concentrated_VBN
for_PIN
more_EMPH
efficient_JJ
recovery_NN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
installing_VBG
the_DT
new_JJ
equipment_NOMZ
,_,
the_DT
overall_JJ
process_NN
has_VPRT [PEAS]
become_VBN
much_QUAN
more_EMPH
efficient_JJ
._.
Up_IN
to_PIN
97_CD
%_NN
of_PIN
the_DT
antibiotic_JJ
is_VPRT [SPAU] [PASS]
now_TIME
recovered_VBN
,_,
so_IN
there_EX
is_VPRT
less_JJ
waste_NN
._.
The_DT
filtration_NOMZ
system_NN
was_VBD [PASS]
installed_VBN
next_JJ
to_PIN
the_DT
production_NOMZ
building_GER
,_,
reducing_VBG [PRESP]
the_DT
amount_NN
of_PIN
solvent_JJ
transferred_VBN
across_PLACE
the_DT
site_NN
and_CC
the_DT
health_NN
and_PHC
safety_NN
risks_NN
._.
The_DT
site_NN
won_VBD
a_DT
GSK_NN
CEOs_NN
EHS_NN
Excellence_NN
Award_NN
in_PIN
2003_CD
for_PIN
its_PIT
work_NN
in_PIN
implementing_VBG
the_DT
new_JJ
system_NN
._.
Corporate_JJ
Responsibility_NOMZ
Report_NN
2003_CD
21_CD
Progress_NN
in_PIN
2003_CD
emissions_NN
from_PIN
the_DT
use_NN
of_PIN
inhalers_NN
and_CC
from_PIN
CAUSES_NN
OF_PIN
LOST_NN
INJURY_NN
TIME_CD
%_NN
Our_FPP1
performance_NN
relating_VBG [WZPRES]
to_PIN
resources_NN
,_,
waste_NN
manufacturing_GER
,_,
resulting_VBG [PRESP]
in_PIN
48_CD
%_NN
less_JJ
ozone_NN
disposal_NN
,_,
climate_NN
change_NN
and_PHC
air_NN
quality_NOMZ
depleting_VBG [WZPRES]
potential_JJ
overall_JJ
._.
Some_QUAN
of_PIN
our_FPP1
targets_NN
2_CD
2_CD
Caught_NN
in_PIN
on_PIN
between_PIN
8_CD
%_NN
6_CD
and_CC
the_DT
percentage_NN
reductions_NOMZ
achieved_VBN [WZPAST]
are_VPRT
Health_NN
and_PHC
safety_NN
3_CD
Motor_NN
vehicle_NN
accidents_NN
20_CD
%_NN
shown_VBN [PRIV] [WZPAST]
in_PIN
the_DT
chart_NN
._.
The_DT
health_NN
and_PHC
safety_NN
of_PIN
our_FPP1
employees_NN
and_CC
4_CD
Over-exertions_NOMZ
strains_NN
23_CD
%_NN
3_CD
5_CD
Slips_VPRT
trips_NN
falls_VPRT
26_CD
%_NN
contractors_NN
is_VPRT [BEMA]
a_DT
high_JJ
priority_NOMZ
for_PIN
GSK_NN
._.
The_DT
risks_NN
6_CD
Striking_VBG
against_PIN
struck_VBN
10_CD
%_NN
5_CD
During_PIN
2003_CD
we_FPP1
made_VBD
particularly_RB
good_JJ
progress_NN
and_PHC
hazards_NN
associated_VBN [WZPAST]
with_PIN
our_FPP1
products_NN
and_CC
7_CD
Other_JJ
7_CD
%_NN
toward_PIN
our_FPP1
targets_NN
in_PIN
six_CD
areas_NN
._.
Comparing_VBG [PRESP]
with_PIN
operations_NOMZ
are_VPRT [SPAU] [PASS]
systematically_RB
assessed_VBN
and_PHC
includes_VPRT
contact_NN
with_PIN
sharps_NN
,_,
animal_NN
insect_NN
,_,
electric_JJ
fire_NN
explosion_NN
,_,
foreign_JJ
2001_CD
figures_NN
,_,
the_DT
year_NN
we_FPP1
set_VBD
our_FPP1
targets_NN
,_,
and_ANDC
measures_NN
are_VPRT [PASS]
taken_VBN
to_TO
protect_VB
employees_NN
and_CC
4_CD
bodies_NN
objects_NN
,_,
workplace_NN
violence_NN
with_PIN
all_QUAN
measures_NN
normalised_VBN [WZPAST]
against_PIN
sales_NN
,_,
others_NN
coming_VBG [WZPRES]
into_PIN
contact_NN
with_PIN
the_DT
hazards_NN
._.
energy_NN
consumption_NOMZ
was_VBD [BEMA]
down_RB
8_CD
%_NN
,_,
associated_VBN
global_JJ
warming_GER
potential_NN
was_VBD [BEMA]
down_RB
8_CD
%_NN
,_,
water_NN
We_FPP1
track_VPRT
the_DT
number_NN
of_PIN
cases_NN
of_PIN
injury_NN
or_CC
illness_NOMZ
consumption_NOMZ
was_VBD [BEMA]
down_RB
17_CD
%_NN
,_,
ozone_NN
depletion_NOMZ
resulting_VBG [WZPRES]
in_PIN
time_NN
off_PIN
work_NN
and_CC
have_VPRT [PEAS]
set_VBN
a_DT
potential_NN
from_PIN
production_NOMZ
was_VBD [BEMA]
down_RB
64_CD
%_NN
,_,
challenging_VBG
target_NN
of_PIN
reducing_VBG
this_DEMO
by_PIN
15_CD
%_NN
every_QUAN
ozone_NN
depletion_NOMZ
potential_NN
from_PIN
ancillary_JJ
sources_NN
year_NN
until_IN
2005_CD
._.
In_PIN
2002_CD
we_FPP1
cut_VBD
our_FPP1
injury_NN
and_CC
was_VBD [BEMA]
down_RB
66_CD
%_NN
and_CC
hazardous_JJ
waste_NN
disposed_VBD
illness_NOMZ
rate_NN
by_PIN
21_CD
%_NN
,_,
and_ANDC
in_PIN
2003_CD
we_FPP1
reduced_VBD
it_PIT
was_VBD [BEMA]
down_RB
8_CD
%_NN
._.
CFCs_NN
are_VPRT [PASS]
used_VBN
as_IN
propellants_NN
in_PIN
metered_JJ
dose_NN
We_FPP1
also_RB
monitor_VPRT
the_DT
causes_NN
of_PIN
incidents_NN
and_PHC
inhalers_NN
MDIs_NN
and_CC
we_FPP1
also_RB
use_VPRT
ozone_NN
depleting_GER
assess_VPRT
what_WP
can_POMD
be_VB [PASS]
learned_VBN [PRIV]
to_TO
avoid_VB
similar_JJ
substances_NN
for_PIN
refrigeration_NOMZ
._.
When_RB
a_DT
patient_NN
uses_VPRT
injuries_NN
again_TIME
._.
The_DT
main_JJ
causes_NN
of_PIN
injury_NN
are_VPRT
slips_VPRT
,_,
an_DT
MDI_NN
the_DT
propellant_NN
is_VPRT [PASS]
released_VBN
into_PIN
the_DT
trips_NN
,_,
falls_VPRT
,_,
strains_NN
from_PIN
over-exertion_NOMZ
and_PHC
motor_NN
atmosphere_NN
._.
This_DEMP
is_VPRT [BEMA]
our_FPP1
largest_JJ
source_NN
of_PIN
CFC_NN
vehicle_NN
accidents_NN
._.
We_FPP1
deeply_RB
regret_VPRT
that_DEMO
during_PIN
emissions_NN
,_,
amounting_VBG [PRESP]
to_PIN
782_CD
metric_JJ
tonnes_NN
,_,
2003_CD
there_EX
were_VBD
five_CD
work-related_JJ
fatalities_NOMZ
about_IN
92_CD
%_NN
of_PIN
the_DT
total_NN
._.
Releases_NN
from_PIN
our_FPP1
among_PIN
GSK_NN
employees_NN
._.
Four_CD
died_VBD
in_PIN
driving_VBG
factories_NN
that_TSUB
manufacture_VPRT
MDIs_NN
are_VPRT [BEMA]
our_FPP1
second_JJ
accidents_NN
and_CC
one_CD
from_PIN
mesothelioma_NN
due_JJ
to_TO
most_EMPH
significant_JJ
source_NN
and_PHC
refrigeration_NOMZ
is_VPRT [BEMA]
the_DT
asbestos_NN
exposure_NN
in_PIN
the_DT
1950s_CD
._.
Replacement_NOMZ
of_PIN
MDIs_NN
using_VBG [WZPRES]
CFC_NN
as_IN
a_DT
one_CD
contractor_NN
died_VBD
in_PIN
a_DT
fork-lift_JJ
truck_NN
accident_NN
._.
propellant_NN
with_PIN
alternative_JJ
technologies_NN
has_VPRT [PEAS]
cut_VBN
2003_CD
PROGRESS_NN
AGAINST_PIN
TARGETS_NN
-15_CD
%_NN
Lost_VBD
time_NN
injury_NN
and_PHC
illness_NOMZ
rate_NN
-9_CD
%_NN
-8_CD
%_NN
Energy_NN
-8_CD
%_NN
consumption_NOMZ
-10_CD
%_NN
Water_NN
consumption_NOMZ
-17_CD
%_NN
ODP_NN
refrigeration_NOMZ
and_CC
-100_CD
%_NN
ancillary_JJ
CFC_NN
emissions_NN
-66_CD
%_NN
-50_CD
%_NN
ODP_NN
production_NOMZ
CFC-11_NN
equivalent_JJ
emissions_NN
-64_CD
%_NN
-30_CD
%_NN
Volatile_JJ
organic_JJ
compound_NN
emissions_NN
-7_CD
%_NN
-8_CD
%_NN
Global_JJ
warming_VBG
potential_JJ
-8_CD
%_NN
from_PIN
energy_NN
sources_NN
-15_CD
%_NN
Hazardous_JJ
waste_NN
disposed_VBD
-8_CD
%_NN
2005_CD
Targets_NN
except_PIN
for_PIN
lost_VBN
time_NN
injury_NN
and_PHC
illness_NOMZ
rate_NN
which_WDT [WHSUB]
is_VPRT [BEMA]
an_DT
annual_JJ
target_NN
2003_CD
Improvements_NOMZ
against_PIN
2001_CD
baseline_NN
Environmental_NN
measures_NN
are_VPRT [BYPA]
normalised_VBN
by_PIN
sales_NN
ODP_NN
is_VPRT
ozone_NN
depletion_NOMZ
potential_NN
Global_JJ
warming_GER
potential_NN
is_VPRT [PASS]
measured_VBN
as_IN
CO_NN
equivalents_NN
2_CD
An_DT
explanation_NOMZ
of_PIN
all_QUAN
EHS_NN
data_NN
is_VPRT [BEMA]
in_PIN
the_DT
full_JJ
EHS_NN
report_NN
on_PIN
our_FPP1
website_NN
,_,
www_NN
._.
com_NN
EHS_NN
data_NN
for_PIN
2003_CD
not_XX0
yet_RB
verified_VBN
22_CD
Corporate_JJ
Responsibility_NOMZ
Report_NN
2003_CD
5_CD
Valuing_VBG
people_NN
Valuing_VBG [WZPRES]
people_NN
GSK_NN
employs_VPRT
over_IN
100,000_CD
people_NN
in_PIN
117_CD
countries_NN
._.
Getting_VBG [PRESP]
the_DT
best_JJ
from_PIN
our_FPP1
people_NN
is_VPRT [BEMA]
vital_PRED
to_PIN
the_DT
success_NN
of_PIN
our_FPP1
business_NOMZ
and_CC
a_DT
key_JJ
source_NN
of_PIN
competitive_JJ
advantage_NN
._.
Below_PLACE
we_FPP1
report_VPRT [PUBV]
on_PIN
:_:
More_EMPH
than_PIN
two-thirds_NN
of_PIN
GSK_NN
employees_NN
our_FPP1
work_NN
to_TO
embed_VB
the_DT
GSK_NN
Spirit_NN
and_PHC
culture_NN
participate_VB
in_PIN
our_FPP1
individual_JJ
appraisal_NN
process_NN
,_,
across_PLACE
our_FPP1
operations_NOMZ
worldwide_VPRT
Performance_NN
and_PHC
Development_NOMZ
Planning_GER
PDP_NN
._.
the_DT
development_NOMZ
of_PIN
our_FPP1
diversity_NOMZ
initiatives_VPRT
This_DEMP
helps_VPRT
employees_NN
set_VBN
objectives_NN
,_,
rewards_NN
introducing_VBG [WZPRES]
human_JJ
rights_NN
standards_NN
into_PIN
our_FPP1
strong_JJ
performance_NN
and_CC
helps_VPRT
them_TPP3
identify_VB
procurement_NOMZ
processes_NN
._.
the_DT
training_GER
they_TPP3
need_VPRT
to_TO
develop_VB
their_TPP3
careers_NN
._.
As_IN
part_NN
of_PIN
the_DT
PDP_NN
process_NN
,_,
employees_NN
and_CC
The_DT
GSK_NN
Spirit_NN
their_TPP3
managers_NN
assess_VPRT
how_RB
well_RB
they_TPP3
have_VPRT
This_DEMP
sets_VPRT
out_PIN
the_DT
values_NN
and_PHC
qualities_NOMZ
we_FPP1
expect_VPRT [PRIV]
implemented_VBD
the_DT
GSK_NN
Spirit_NN
in_PIN
their_TPP3
work_NN
,_,
and_ANDC
employees_NN
to_TO
embrace_VB
in_PIN
their_TPP3
work_NN
._.
this_DEMP
can_POMD
have_VB
a_DT
significant_JJ
impact_NN
on_PIN
the_DT
bonus_NN
Its_PIT
principles_NN
are_VPRT
:_:
payments_NOMZ
awarded_VBD
to_PIN
eligible_JJ
employees_NN
._.
performance_NN
with_PIN
integrity_NOMZ
entrepreneurial_JJ
spirit_NN
We_FPP1
use_VPRT
a_DT
global_JJ
survey_NN
of_PIN
11,000_CD
managers_NN
to_TO
focus_VB
on_PIN
innovation_NOMZ
help_VPRT
us_FPP1
analyze_VB
how_RB
effectively_RB
we_FPP1
are_VPRT
building_VBG
a_DT
sense_NN
of_PIN
urgency_NN
the_DT
GSK_NN
Spirit_NN
._.
Last_JJ
year_NN
we_FPP1
reported_VBD [PUBV]
on_PIN
the_DT
passion_NN
for_PIN
achievement_NOMZ
._.
2002_CD
results_NN
,_,
which_WDT [SERE]
were_VBD [BEMA]
generally_RB
positive_PRED
._.
Since_OSUB
then_RB
,_,
work_NN
has_VPRT [PEAS]
been_VBN
taking_VBG
place_NN
to_TO
Getting_VBG
our_FPP1
culture_NN
right_NN
address_NN
areas_NN
identified_VBN [WZPAST]
for_PIN
development_NOMZ
._.
``_``
We_FPP1
aim_VPRT
to_TO
build_VB
a_DT
culture_NN
in_PIN
which_WDT [PIRE]
our_FPP1
people_NN
Progress_NN
will_PRMD
be_VB [PASS]
measured_VBN
when_RB
the_DT
next_JJ
are_VPRT [BEMA]
clear_PRED
about_IN
the_DT
companys_NN
expectations_NOMZ
and_PHC
survey_NN
takes_VPRT
place_NN
during_PIN
2004_CD
._.
instinctively_RB
''_''
``_``
do_VPRT
the_DT
right_JJ
thing_NN
''_''
''_''
._.
''_''
Each_QUAN
of_PIN
our_FPP1
operations_NOMZ
has_VPRT [PEAS]
been_VBN
working_VBG
with_PIN
employees_NN
to_PIN
Diversity_NOMZ
ensure_VB [SUAV] [PRIV] [THATD]
they_TPP3
understand_VPRT [PRIV]
and_PHC
adopt_VPRT
the_DT
principles_NN
GSK_NN
is_VPRT [PASS]
committed_VBN
to_TO
employing_VBG
a_DT
diverse_JJ
of_PIN
the_DT
GSK_NN
Spirit_NN
._.
Our_FPP1
approach_NN
is_VPRT [PASS]
tailored_VBN
to_PIN
workforce_NN
._.
Both_DT
individual_JJ
employees_NN
and_CC
reflect_VB [PRIV]
local_JJ
circumstances_NN
,_,
with_PIN
events_NN
including_VBG [WZPRES]
GSK_NN
benefit_NN
from_PIN
a_DT
workplace_NN
where_RB
talented_VBN
workshops_NN
,_,
team_NN
meetings_GER
,_,
presentations_NOMZ
and_PHC
people_NN
can_POMD
thrive_VB
,_,
and_ANDC
where_RB
their_TPP3
diversity_NOMZ
of_PIN
awards_NN
._.
For_CONJ
example_NULL
,_,
GSK_NN
in_PIN
Nigeria_NN
used_VBD
a_DT
background_NN
,_,
culture_NN
and_PHC
outlook_NN
helps_VPRT
us_FPP1
better_JJ
costumed_VBD
storyteller_NN
to_TO
introduce_VB
the_DT
Spirit_NN
understand_VPRT [PRIV]
the_DT
needs_NN
of_PIN
patients_NN
and_PHC
customers_NN
to_PIN
employees_NN
._.
In_PIN
Argentina_NN
every_QUAN
employee_NN
worldwide_NN
._.
Our_FPP1
aim_NN
is_VPRT
to_TO
create_VB
an_DT
inclusive_JJ
work_NN
attended_VBD
a_DT
half-day_JJ
culture_NN
awareness_NOMZ
workshop_NN
._.
environment_NOMZ
free_JJ
from_PIN
discrimination_NOMZ
on_PIN
grounds_NN
of_PIN
race_NN
,_,
ethnicity_NOMZ
,_,
gender_NN
,_,
religion_NN
,_,
sexual_JJ
Our_FPP1
leadership_NN
development_NOMZ
programs_NN
are_VPRT
orientation_NOMZ
,_,
disability_NOMZ
or_CC
age_NN
._.
designed_VBN
to_TO
encourage_VB
employees_NN
to_TO
apply_VB
the_DT
GSK_NN
Spirit_NN
._.
These_DEMO
programs_NN
are_VPRT [BEMA]
available_PRED
to_PIN
We_FPP1
held_VBD [PRIV]
our_FPP1
first_JJ
Diversity_NOMZ
&_CC
Multi-Cultural_NN
managers_NN
globally_RB
at_PIN
all_QUAN
levels_NN
._.
This_DEMO
year_NN
286_CD
Marketing_GER
Awards_NN
in_PIN
Philadelphia_NN
in_PIN
May_POMD
2003_CD
._.
people_NN
attended_VBD
Leadership_NN
Edge_NN
,_,
our_FPP1
global_JJ
The_DT
awards_NN
,_,
which_WDT [SERE]
will_PRMD
be_VB [PASS]
made_VBN
annually_RB
,_,
have_VPRT
program_NN
for_PIN
senior_JJ
managers_NN
,_,
and_ANDC
235_CD
been_VBN [PASS]
set_VBN
up_RP
to_TO
demonstrate_VB [PRIV]
the_DT
impact_NN
diversity_NOMZ
attended_VBD
Leadership@GSK,_NN
the_DT
program_NN
for_PIN
can_POMD
have_VB
on_PIN
improving_VBG
business_NOMZ
performance_NN
,_,
middle_JJ
managers_NN
._.
The_DT
programs_NN
are_VPRT [PASS]
designed_VBN
and_CC
to_TO
share_VB
best_JJ
practices_NN
around_PLACE
the_DT
company_NN
._.
to_TO
help_VB
managers_NN
to_TO
achieve_VB
performance_NN
through_PIN
others_NN
and_CC
to_TO
increase_VB
their_TPP3
insight_NN
into_PIN
differing_VBG
work_NN
styles_NN
,_,
strengths_NN
and_PHC
motivations_NOMZ
._.
Corporate_JJ
Responsibility_NOMZ
Report_NN
2003_CD
23_CD
Current_JJ
diversity_NOMZ
initiatives_NN
include_VPRT
our_FPP1
Women_NN
Human_JJ
rights_NN
in_PIN
Leadership_NN
program_NN
in_PIN
the_DT
US_FPP1
to_TO
support_VB
Compliance_NN
with_PIN
our_FPP1
human_JJ
rights_NN
requirements_NOMZ
career_NN
development_NOMZ
._.
Additionally_RB
in_PIN
2004_CD
we_FPP1
will_PRMD
has_VPRT [PEAS]
been_VBN [PASS]
included_VBN
as_IN
one_CD
of_PIN
our_FPP1
criteria_NN
for_PIN
be_VB
holding_VBG [PRIV]
a_DT
Women_NN
in_PIN
Science_NN
day_NN
in_PIN
the_DT
UK_NN
to_TO
selecting_VBG
suppliers_NN
._.
We_FPP1
are_VPRT [SPAU]
also_RB
introducing_VBG
attract_VB
more_EMPH
female_JJ
science_NN
graduates_VPRT
into_PIN
the_DT
binding_JJ
clauses_NN
into_PIN
our_FPP1
procurement_NOMZ
contracts_NN
industry_NN
._.
We_FPP1
are_VPRT [SPAU]
also_RB
undertaking_VBG
a_DT
review_NN
in_PIN
which_WDT [PIRE]
require_VPRT [SUAV]
suppliers_NN
to_TO
meet_VB
our_FPP1
standards_NN
on_PIN
the_DT
UK_NN
of_PIN
how_RB
we_FPP1
can_POMD
improve_VB
the_DT
working_VBG
human_JJ
rights_NN
._.
environment_NOMZ
and_PHC
access_NN
to_PIN
our_FPP1
facilities_NOMZ
and_PHC
websites_NN
for_PIN
disabled_JJ
employees_NN
,_,
potential_JJ
In_PIN
2003_CD
we_FPP1
began_VBD
incorporating_VBG
human_JJ
rights_NN
employees_NN
and_PHC
visitors_NN
._.
This_DEMP
will_PRMD
conclude_VB [PRIV]
in_PIN
clauses_NN
into_PIN
our_FPP1
central_JJ
contract_NN
templates_NN
for_PIN
use_NN
early_TIME
2004_CD
._.
with_PIN
new_JJ
suppliers_NN
._.
This_DEMO
process_NN
will_PRMD
be_VB [PASS]
completed_VBN
in_PIN
2004_CD
._.
We_FPP1
are_VPRT [SPAU]
also_RB
adding_VBG [PUBV]
these_DEMO
clauses_NN
to_PIN
In_PIN
2003_CD
we_FPP1
widened_VBD
the_DT
scope_NN
of_PIN
our_FPP1
employee_NN
contract_NN
templates_NN
used_VBN [WZPAST]
by_PIN
local_JJ
operations_NOMZ
._.
networks_NN
in_PIN
the_DT
US_FPP1
,_,
with_PIN
new_JJ
groups_NN
for_PIN
sales_NN
staff_NN
and_CC
in_PIN
the_DT
Delaware_NN
Valley_NN
._.
Our_FPP1
broad_JJ
Risk_NN
of_PIN
human_JJ
rights_NN
issues_NN
varies_VPRT
around_PLACE
the_DT
spread_NN
of_PIN
existing_VBG
network_NN
activities_NOMZ
includes_VPRT
world_NN
,_,
and_ANDC
where_RB
appropriate_JJ
we_FPP1
are_VPRT
contacting_VBG
career_NN
development_NOMZ
programs_NN
for_PIN
Asian_JJ
,_,
major_JJ
existing_VBG
suppliers_NN
to_TO
assess_VB
whether_IN
they_TPP3
African_JJ
American_NN
,_,
Hispanic_NN
and_CC
gay_JJ
and_PHC
lesbian_JJ
meet_VB
our_FPP1
standards_NN
._.
Key_NN
suppliers_NN
have_VPRT [PEAS]
been_VBN
employees_NN
._.
asked_VBD [SUAV]
to_TO
confirm_VB [PUBV]
in_PIN
writing_VBG [PUBV]
that_THVC
they_TPP3
comply_VPRT
,_,
and_ANDC
the_DT
requirements_NOMZ
are_VPRT
being_VBG [PASS]
introduced_VBN
into_PIN
GLOBAL_NN
MANAGEMENT_NOMZ
POPULATION_NOMZ
existing_VBG [WZPRES]
contracts_NN
when_RB
they_TPP3
are_VPRT [PASS]
reviewed_VBN
._.
BY_PIN
GENDER_NN
2003_CD
Implementing_VBG
the_DT
GSK_NN
Spirit_NN
in_PIN
MEN_NN
WOMEN_NN
TOTAL_NN
Consumer_NN
Healthcare_NN
India_NN
We_FPP1
have_VPRT [PEAS]
contacted_VBN
over_IN
400_CD
suppliers_NN
so_RB
far_PLACE
to_PIN
In_PIN
a_DT
country_NN
as_IN
diverse_JJ
as_IN
India_NN
,_,
creating_VBG [PRESP]
a_DT
gain_NN
their_TPP3
agreement_NOMZ
to_PIN
the_DT
standards_NN
._.
To_PIN
date_NN
Bands_NN
A_NN
&_CC
B_NN
550_CD
80_CD
%_NN
135_CD
20_CD
%_NN
685_CD
unified_VBN
spirit_NN
and_PHC
culture_NN
is_VPRT [BEMA]
critical_PRED
to_PIN
the_DT
success_NN
no_SYNE
companies_NN
have_VPRT [PEAS]
declined_VBN
to_TO
co-operate_VB
,_,
and_ANDC
Bands_NN
C_NN
1-3_JJ
2,557_CD
69_CD
%_NN
1,158_CD
31_CD
%_NN
3,715_CD
of_PIN
GSKs_NN
Consumer_NN
Healthcare_NN
business_NOMZ
._.
Bands_NN
C_$
4-5_CD
4,221_CD
63_CD
%_NN
2,432_CD
37_CD
%_NN
6,653_CD
we_FPP1
are_VPRT
following_VBG
up_RP
with_PIN
those_DEMO
that_DEMP
have_VPRT
not_XX0
yet_RB
The_DT
main_JJ
product_NN
is_VPRT
Horlicks_NN
which_WDT [WHSUB]
is_VPRT [BEMA]
a_DT
major_JJ
responded_VBD
to_PIN
our_FPP1
request_NN
._.
The_DT
business_NOMZ
employs_VPRT
3,000_CD
people_NN
at_PIN
ten_NN
sites_NN
._.
Employees_NN
are_VPRT
Questions_NOMZ
on_PIN
human_JJ
rights_NN
issues_NN
have_VPRT [PEAS]
been_VBN [BEMA]
Corporate_JJ
Executive_NN
Team_NN
,_,
Vice_NN
Presidents_NN
and_PHC
Senior_NN
drawn_VBN [WZPAST]
from_PIN
across_PLACE
India_NN
so_IN
there_EX
are_VPRT
huge_JJ
Vice_NN
Presidents_NN
added_VBD [PUBV]
to_PIN
the_DT
standard_JJ
list_NN
of_PIN
topics_NN
discussed_VBN
differences_NN
of_PIN
background_NN
,_,
religion_NN
and_PHC
Director_NN
Level_NN
at_PIN
supplier_NN
visits_NN
by_PIN
our_FPP1
procurement_NOMZ
and_PHC
EHS_NN
culture_NN
._.
At_PIN
least_JJ
four_CD
different_JJ
languages_NN
are_VPRT
Manager_NN
Level_NN
commonly_RB
spoken_VBD
in_PIN
the_DT
workplace_NN
._.
This_DEMO
year_NN
we_FPP1
have_VPRT [PEAS]
seen_VBN [PRIV]
an_DT
increase_NN
in_PIN
the_DT
Each_QUAN
site_NN
has_VPRT [PEAS]
developed_VBN
initiatives_NN
to_TO
bring_VB
the_DT
number_NN
of_PIN
women_NN
in_PIN
management_NOMZ
positions_NOMZ
If_COND
a_DT
supplier_NN
is_VPRT [PASS]
found_VBN [PRIV]
not_XX0
to_TO
meet_VB
our_FPP1
standards_NN
GSK_NN
Spirit_NN
to_PIN
life_NN
and_CC
enable_VB
employees_NN
to_PIN
in_PIN
the_DT
company_NN
from_PIN
32_CD
%_NN
in_PIN
2002_CD
to_PIN
34_CD
%_NN
we_FPP1
will_PRMD
work_VB
with_PIN
them_TPP3
to_TO
achieve_VB
compliance_NN
._.
understand_VB [PRIV]
its_PIT
relevance_NN
in_PIN
an_DT
Indian_JJ
working_GER
environment_NOMZ
._.
These_DEMP
are_VPRT [BYPA]
supported_VBN
by_PIN
businessin_NN
2003_CD
._.
We_FPP1
will_PRMD
conduct_VB
regular_JJ
audits_NN
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
wide_JJ
tools_NN
such_JJ
as_IN
a_DT
Spirit_NN
website_NN
with_PIN
they_TPP3
have_VPRT [PEAS]
improved_VBN
their_TPP3
performance_NN
so_IN
it_PIT
is_VPRT [BEMA]
in_PIN
regularly_RB
updated_VBN
games_NN
and_CC
quizzes_VPRT
on_PIN
how_RB
We_FPP1
report_VPRT [PUBV]
ethnicity_NOMZ
data_NN
for_PIN
US_FPP1
employees_NN
._.
We_FPP1
will_PRMD
terminate_VB
a_DT
to_TO
apply_VB
the_DT
Spirit_NN
in_PIN
practice_NN
._.
In_PIN
2002_CD
people_NN
of_PIN
color_NN
accounted_VBD
for_PIN
19.0_CD
%_NN
._.
contract_NN
if_COND
a_DT
supplier_NN
will_PRMD
not_XX0
or_CC
can_POMD
not_XX0
work_VB
The_DT
companys_NN
Nabha_NN
manufacturing_VBG [WZPRES]
site_NN
in_PIN
This_DEMP
increased_VBN
very_AMP
slightly_DWNT
in_PIN
2003_CD
to_PIN
19.5_CD
%_NN
towards_PIN
compliance_NN
._.
the_DT
rural_JJ
Punjab_NN
area_NN
,_,
where_RB
literacy_NN
rates_NN
are_VPRT [BEMA]
of_PIN
the_DT
US_FPP1
workforce_NN
of_PIN
24,000_CD
._.
We_FPP1
intend_VPRT [SUAV]
to_PIN
low_JJ
,_,
uses_VPRT
posters_NN
with_PIN
cricket_NN
cartoons_NN
to_TO
collect_VB
and_PHC
report_VB [PUBV]
ethnicity_NOMZ
data_NN
for_PIN
our_FPP1
UK_NN
illustrate_VPRT
the_DT
Spirits_NN
principles_NN
._.
Employees_NN
have_VPRT
operations_NOMZ
for_PIN
2004_CD
._.
also_RB
made_VBN
their_TPP3
own_JJ
motivational_JJ
film_NN
for_PIN
use_NN
in_PIN
team_NN
meetings_GER
._.
ETHNICITY_NOMZ
OF_PIN
US_FPP1
EMPLOYEE_NN
POPULATION_NOMZ
2003_CD
Employees_NN
at_PIN
manufacturing_VBG
sites_NN
are_VPRT [PASS]
encouraged_VBN
to_TO
get_VB
involved_VBN
in_PIN
our_FPP1
global_JJ
Operational_NN
Excellence_NN
campaign_NN
and_CC
Total_JJ
US_FPP1
demonstrate_VPRT [PRIV]
passion_NN
in_PIN
their_TPP3
work_NN
,_,
by_PIN
employees_NN
24,000_CD
19.5_CD
%_NN
developing_VBG [WZPRES]
a_DT
Just_EMPH
do_VB [PROD]
it_PIT
JDI_NN
concept_NN
._.
These_DEMP
are_VPRT [BEMA]
simple_JJ
ideas_NN
to_TO
improve_VB
efficiency_NN
and_PHC
People_NN
of_PIN
color_NN
effectiveness_NOMZ
._.
In_PIN
2003_CD
every_QUAN
one_CD
of_PIN
over_IN
1,000_CD
employees_NN
at_PIN
Nabha_NN
contributed_VBD
at_PIN
least_JJ
one_CD
JDI_NN
,_,
including_VBG
ideas_NN
to_TO
improve_VB
health_NN
and_PHC
safety_NN
and_CC
reduce_VB
waste_NN
at_PIN
the_DT
site_NN
._.
JDIs_NN
developed_VBD
at_PIN
our_FPP1
Sonepat_NN
plant_NN
helped_VBD
save_VB
over_IN
30,000_CD
during_PIN
2003_CD
._.
Employees_NN
are_VPRT [PASS]
rewarded_VBN
for_PIN
their_TPP3
ideas_NN
through_PIN
Spirit_NN
recognition_NOMZ
awards_NN
._.
The_DT
companys_NN
focus_VB
on_PIN
getting_VBG
its_PIT
culture_NN
right_NN
has_VPRT [PEAS]
helped_VBN
it_PIT
gain_VB
recognition_NOMZ
as_IN
one_CD
of_PIN
Indias_NN
top_JJ
employers_NN
._.
In_PIN
2003_CD
it_PIT
was_VBD [PASS]
declared_VBN [PUBV]
fifth_JJ
best_JJ
employer_NN
in_PIN
the_DT
annual_JJ
Business_NOMZ
Today_TIME
Hewitt_NN
awards_NN
,_,
which_WDT [SERE]
are_VPRT [SPAU] [BYPA]
partly_DWNT
determined_VBN [SUAV] [PRIV]
by_PIN
employee_NN
feedback_NN
._.
24_CD
Corporate_JJ
Responsibility_NOMZ
Report_NN
2003_CD
Corporate_JJ
Responsibility_NOMZ
Report_NN
2003_CD
25_CD
Research_NN
a_DT
developme_NN
Medical_JJ
research_NN
can_POMD
give_VB
rise_VB
to_PIN
ethical_JJ
concerns_NN
and_CC
we_FPP1
engage_VPRT
openly_RB
in_PIN
constructive_JJ
debate_NN
on_PIN
these_DEMO
matters_NN
._.
Here_RB
we_FPP1
discuss_VPRT
the_DT
disclosure_NN
of_PIN
clinical_JJ
trial_NN
information_NOMZ
and_CC
the_DT
use_NN
of_PIN
animals_NN
in_PIN
research_NN
._.
Evaluating_VBG
potential_JJ
new_JJ
medicines_NN
in_PIN
We_FPP1
believe_VPRT [PRIV]
that_THVC
healthcare_NN
decisions_NN
should_NEMD
clinical_JJ
trials_NN
is_VPRT [BEMA]
an_DT
essential_JJ
and_PHC
mandatory_JJ
be_VB [PASS]
made_VBN
in_PIN
the_DT
knowledge_NN
of_PIN
all_QUAN
relevant_JJ
information_NOMZ
._.
GSK_NN
supports_VPRT
scientific_JJ
and_PHC
medical_JJ
step_NN
in_PIN
developing_VBG
new_JJ
treatments_NOMZ
._.
Trials_NN
progress_NN
by_PIN
making_VBG
the_DT
results_NN
of_PIN
clinical_JJ
trials_NN
may_POMD [SPAU]
also_RB
be_VB [PASS]
conducted_VBN
once_TIME
a_DT
medicine_NN
more_EMPH
widely_RB
available_JJ
._.
Whenever_NN
possible_JJ
,_,
we_FPP1
is_VPRT [BEMA]
on_PIN
the_DT
market_NN
to_PIN
further_JJ
investigate_VB
its_PIT
publish_VB
our_FPP1
clinical_JJ
trial_NN
results_NN
in_PIN
peer-reviewed_JJ
role_NN
in_PIN
the_DT
treatment_NOMZ
of_PIN
patients_NN
._.
In_PIN
all_QUAN
scientific_JJ
and_PHC
medical_JJ
journals_NN
and_CC
in_PIN
conference_NN
studies_NN
,_,
our_FPP1
first_JJ
concern_NN
is_VPRT [BEMA]
the_DT
safety_NN
abstracts_NN
and_PHC
proceedings_GER
._.
The_DT
research_NN
and_CC
and_CC
well-being_NN [BEMA]
of_PIN
trial_NN
participants_NN
and_PHC
healthcare_NN
communities_NOMZ
look_VPRT
to_PIN
these_DEMO
sources_NN
future_JJ
patients_NN
._.
Our_FPP1
clinical_JJ
trials_NN
are_VPRT [PASS]
conducted_VBN
in_PIN
accordance_NN
We_FPP1
worked_VBD
with_PIN
other_JJ
pharmaceutical_JJ
with_PIN
all_QUAN
applicable_JJ
laws_NN
and_PHC
regulations_NOMZ
,_,
as_RB
well_RB
companies_NN
in_PIN
2002_CD
to_TO
help_VB
clarify_VB
the_DT
industrys_NN
as_IN
recognized_VBN [PRIV]
principles_NN
of_PIN
good_JJ
clinical_JJ
practice_NN
._.
approach_NN
to_PIN
the_DT
communication_NOMZ
of_PIN
clinical_JJ
trial_NN
We_FPP1
are_VPRT [SPAU] [PASS]
legally_RB
obliged_VBN
to_TO
disclose_VB [PUBV]
all_QUAN
data_NN
from_PIN
results_NN
and_CC
to_TO
develop_VB
the_DT
PhRMA_NN
Principles_NN
on_PIN
clinical_JJ
trials_NN
to_PIN
the_DT
regulatory_JJ
authorities_NOMZ
when_RB
the_DT
Conduct_NN
of_PIN
Clinical_NN
Trials_NN
&_CC
Communication_NOMZ
we_FPP1
seek_VPRT
approval_NN
for_PIN
a_DT
new_JJ
product_NN
._.
We_FPP1
fully_AMP
support_VPRT
these_DEMO
principles_NN
and_CC
apply_VB
them_TPP3
to_PIN
all_QUAN
our_FPP1
clinical_JJ
Approval_NN
to_TO
market_VB
a_DT
product_NN
is_VPRT [SPAU] [PASS]
only_DWNT
given_VBN
if_COND
studies_NN
worldwide_VPRT
._.
the_DT
regulators_NN
are_VPRT [PASS]
satisfied_VBN
that_DEMO
the_DT
product_NN
is_VPRT [BEMA]
safe_PRED
and_PHC
effective_PRED
,_,
and_ANDC
can_POMD
be_VB [PASS]
manufactured_VBN
to_PIN
high_JJ
In_CONJ
particular_NULL
we_FPP1
reaffirm_VPRT
our_FPP1
commitment_NOMZ
to_TO
:_:
and_ANDC
consistent_JJ
quality_NOMZ
standards_NN
._.
After_IN
a_DT
medicine_NN
The_DT
timely_JJ
communication_NOMZ
of_PIN
all_QUAN
meaningful_JJ
or_CC
vaccine_NN
has_VPRT [PEAS]
been_VBN [PASS]
approved_VBN
for_PIN
marketing_GER
,_,
we_FPP1
results_NN
of_PIN
controlled_JJ
clinical_JJ
trials_NN
of_PIN
marketed_VBN
continue_VPRT
to_TO
provide_VB
regulatory_JJ
authorities_NOMZ
with_PIN
products_NN
or_CC
investigational_JJ
products_NN
that_TSUB
are_VPRT [BEMA]
further_JJ
safety_NN
information_NOMZ
._.
approved_VBN [PASTP]
for_PIN
marketing_GER
,_,
whether_IN
the_DT
results_NN
are_VPRT [BEMA]
positive_PRED
or_CC
negative_JJ
26_CD
Corporate_JJ
Responsibility_NOMZ
Report_NN
2003_CD
6_CD
Research_NN
and_PHC
development_NOMZ
nd_NN
nt_NN
Advancing_VBG [WZPRES]
management_NOMZ
of_PIN
Review_NN
and_CC
discuss_VB
manuscripts_NN
with_PIN
the_DT
NUMBER_NN
OF_PIN
PUBLICATIONS_NOMZ
OF_PIN
GSK_NN
CLINICAL_NN
TRIALS_VPRT
heart_NN
disease_NN
clinical_JJ
investigators_NN
who_WP [WHSUB]
conducted_VBD
GSKHeart_NN
failure_NN
is_VPRT [BEMA]
a_DT
serious_JJ
condition_NOMZ
,_,
with_PIN
five_CD
sponsored_VBN
studies_NN
before_IN
they_TPP3
are_VPRT [PASS]
submitted_VBN [PUBV] [THATD]
million_CD
people_NN
affected_VBN [WZPAST]
in_PIN
the_DT
US_FPP1
alone_RB
._.
Half_NN
to_PIN
a_DT
journal_NN
or_CC
conference_NN
for_PIN
publication_NOMZ
600_CD
of_PIN
these_DEMO
patients_NN
will_PRMD
die_VB
within_PIN
five_CD
years_NN
of_PIN
549_CD
Ensure_NN
that_DEMO
anyone_QUPR
who_WP
contributes_VPRT
diagnosis_NN
and_CC
new_JJ
treatments_NOMZ
are_VPRT
urgently_RB
significantly_RB
to_PIN
the_DT
study_NN
and_CC
writing_VBG [PUBV]
or_CC
500_CD
required_VBN [SUAV]
._.
437_CD
revising_VBG
of_PIN
the_DT
manuscript_NN
receives_VPRT
appropriate_JJ
GSK_NN
,_,
partnering_VBG [PRESP]
with_PIN
another_DT
company_NN
,_,
rose_VBD
364_CD
recognition_NOMZ
as_IN
an_DT
author_NN
or_CC
contributor_NN
when_RB
400_CD
to_PIN
this_DEMO
challenge_NN
by_PIN
investigating_VBG
new_JJ
uses_NN
the_DT
manuscript_NN
is_VPRT [PASS]
published_VBN
for_PIN
Coreg_NN
,_,
a_DT
GSK_NN
beta-blocker_NN
medicine_NN
for_PIN
300_CD
Publish_JJ
results_NN
gathered_VBN [PRIV] [WZPAST]
from_PIN
all_QUAN
the_DT
centres_NN
treating_VBG [WZPRES]
high_JJ
blood_NN
pressure_NN
._.
involved_VBN [PASTP]
in_PIN
a_DT
multi-centre_JJ
trial_NN
before_IN
those_DEMO
Clinical_JJ
trial_NN
results_NN
were_VBD [BEMA]
positive_PRED
,_,
200_CD
from_PIN
individual_JJ
centres_NN
._.
demonstrating_VBG [PRIV] [THATD] [PRESP]
that_DEMP
adding_VBG [PUBV]
Coreg_NN
to_PIN
current_JJ
medication_NOMZ
reduced_VBD
the_DT
mortality_NOMZ
rate_NN
among_PIN
100_CD
Publication_NOMZ
in_PIN
journals_NN
and_CC
at_PIN
many_QUAN
conferences_NN
patients_NN
with_PIN
heart_NN
failure_NN
by_PIN
35_CD
%_NN
and_CC
slowed_VBD
progression_NN
of_PIN
the_DT
disease_NN
._.
This_DEMP
can_POMD
help_VB
is_VPRT [BEMA]
subject_PRED
to_TO
peer_VB
review_NN
and_CC
is_VPRT [BEMA]
at_PIN
the_DT
discretion_NOMZ
0_CD
patients_NN
to_TO
live_VB
longer_JJ
and_CC
to_TO
feel_VB [PRIV]
better_RB
._.
of_PIN
journal_NN
editors_NN
and_PHC
conference_NN
organisers_NN
._.
2001 2002 2003_CD
This_DEMP
means_VPRT [PRIV]
that_THVC
GSK_NN
can_POMD
not_XX0
guarantee_VB [PUBV]
that_THVC
The_DT
product_NN
licence_NN
was_VBD [PASS]
expanded_VBN
so_EMPH
clinical_JJ
trial_NN
information_NOMZ
will_PRMD
be_VB [PASS]
published_VBN
in_PIN
Coreg_NN
can_POMD [SPAU]
now_TIME
be_VB [BYPA]
prescribed_VBN
by_PIN
doctors_NN
for_PIN
treatment_NOMZ
of_PIN
heart_NN
failure_NN
as_RB
well_RB
as_IN
these_DEMO
ways_NN
._.
We_FPP1
are_VPRT [SPAU]
therefore_CONJ
assessing_VBG
additional_JJ
The_DT
number_NN
of_PIN
publications_NOMZ
each_QUAN
year_NN
depends_VPRT
hypertension_NN
._.
options_NOMZ
to_TO
communicate_VB
clinical_JJ
trial_NN
information_NOMZ
._.
on_PIN
the_DT
number_NN
of_PIN
trials_NN
completed_VBN
and_CC
the_DT
This_DEMP
was_VBD [BEMA]
the_DT
first_JJ
time_NN
a_DT
beta-blocker_NN
was_VBD [PASS]
number_NN
accepted_VBN [PRIV] [WZPAST]
for_PIN
publication_NOMZ
._.
shown_VBN [PRIV]
to_TO
be_VB [BEMA]
effective_PRED
and_PHC
safe_PRED
in_PIN
treating_VBG
heart_NN
failure_NN
._.
Previously_TIME
it_PIT
was_VBD [PASS]
believed_VBN [PRIV]
that_THVC
In_PIN
2003_CD
437_CD
papers_NN
describing_VBG [WZPRES]
the_DT
results_NN
of_PIN
beta-blockers_NN
were_VBD [BEMA]
unsafe_PRED
in_PIN
heart_NN
failure_NN
GSKs_NN
clinical_JJ
trials_NN
were_VBD [PASS]
published_VBN
in_PIN
journals_NN
patients_NN
._.
Corporate_JJ
Responsibility_NOMZ
Report_NN
2003_CD
27_CD
Animal_NN
research_NN
We_FPP1
are_VPRT [PASS]
committed_VBN
to_PIN
the_DT
3_CD
Rs_NN
:_:
reducing_VBG [PRESP]
the_DT
The_DT
number_NN
of_PIN
animals_NN
used_VBN
may_POMD
fluctuate_VB
Animal_NN
research_NN
is_VPRT [BEMA]
essential_PRED
to_TO
understand_VB [PRIV]
number_NN
of_PIN
animals_NN
used_VBN [WZPAST]
in_PIN
each_QUAN
study_NN
:_:
refining_GER
from_PIN
year_NN
to_PIN
year_NN
and_CC
depends_VPRT
on_PIN
several_QUAN
factors_NN
disease_NN
._.
It_PIT
enables_VPRT
us_FPP1
to_TO
evaluate_VB
the_DT
studies_NN
to_TO
minimize_VB
pain_NN
and_CC
maximize_VB
the_DT
such_JJ
as_IN
the_DT
number_NN
of_PIN
compounds_NN
in_PIN
research_NN
effectiveness_NOMZ
and_PHC
safety_NN
of_PIN
new_JJ
medicines_NN
before_IN
information_NOMZ
obtained_VBN [WZPAST]
from_PIN
each_QUAN
animal_NN
:_:
and_ANDC
and_CC
development_NOMZ
,_,
regulatory_JJ
requirements_NOMZ
and_CC
they_TPP3
are_VPRT [PASS]
given_VBN
to_PIN
people_NN
._.
Regulations_NOMZ
require_VPRT [SUAV]
the_DT
replacing_VBG
animal_NN
studies_NN
with_PIN
alternative_JJ
methods_NN
the_DT
introduction_NOMZ
of_PIN
new_JJ
non-animal_JJ
research_NN
use_NN
of_PIN
animals_NN
to_TO
establish_VB [PRIV]
that_THVC
new_JJ
medicines_NN
wherever_RB
possible_JJ
._.
are_VPRT [BEMA]
safe_PRED
and_CC
to_TO
test_VB
some_QUAN
types_NN
of_PIN
vaccines_NN
after_IN
27_CD
each_QUAN
batch_NN
is_VPRT [PASS]
produced_VBN
._.
For_CONJ
example_NULL
,_,
we_FPP1
have_VPRT [PEAS]
replaced_VBN
many_QUAN
animal_NN
Our_FPP1
laboratories_NN
comply_VPRT
with_PIN
strict_JJ
national_JJ
studies_NN
with_PIN
new_JJ
research_NN
methods_NN
such_JJ
as_IN
laws_NN
,_,
guidelines_NN
and_PHC
codes_NN
of_PIN
conduct_NN
and_CC
are_VPRT [BEMA]
We_FPP1
believe_VB [PRIV] [THATD]
it_PIT
is_VPRT [BEMA]
important_PRED
to_TO
explain_VB [PUBV]
the_DT
need_NN
for_PIN
computer_NN
modelling_GER
and_PHC
tests_NN
on_PIN
isolated_JJ
cells_NN
regularly_RB
inspected_VBN
by_PIN
government_NOMZ
agencies_NN
._.
Our_FPP1
animal_NN
research_NN
and_CC
to_TO
be_VB [BEMA]
open_PRED
about_IN
what_WP
we_FPP1
and_CC
tissues_NN
._.
We_FPP1
have_VPRT [PEAS]
refined_VBN
many_QUAN
procedures_NN
employees_NN
and_CC
any_QUAN
laboratories_NN
working_VBG [WZPRES]
on_PIN
our_FPP1
do_VPRT
._.
We_FPP1
host_VPRT
visits_NN
from_PIN
schools_NN
and_PHC
colleges_NN
,_,
to_TO
use_VB
non-invasive_JJ
techniques_NN
such_JJ
as_IN
magnetic_JJ
behalf_NN
must_NEMD [SPAU]
also_RB
follow_VB
a_DT
GSK_NN
code_NN
of_PIN
practice_NN
._.
animal_NN
welfare_NN
organizations_NOMZ
such_JJ
as_IN
the_DT
RSPCA_NN
resonance_NN
imaging_GER
,_,
which_WDT [SERE]
have_VPRT [PEAS]
helped_VBN
to_TO
reduce_VB
Research_NN
teams_NN
ensure_VB [SUAV] [PRIV]
that_THVC
studies_NN
are_VPRT [PASS]
refined_VBN
and_CC
other_JJ
stakeholders_NN
to_PIN
our_FPP1
laboratories_NN
in_PIN
the_DT
the_DT
number_NN
of_PIN
animals_NN
used_VBN [WZPAST]
in_PIN
each_QUAN
study_NN
._.
to_TO
minimize_VB
any_QUAN
animal_NN
suffering_GER
._.
In_PIN
2003_CD
we_FPP1
also_RB
made_VBD
over_IN
70_CD
visits_NN
to_PIN
UK_NN
schools_NN
to_TO
discuss_VB
issues_NN
arising_VBG [WZPRES]
from_PIN
animal_NN
We_FPP1
run_VPRT
award_NN
programs_NN
to_TO
encourage_VB
We_FPP1
also_RB
obtain_VB
additional_JJ
independent_JJ
research_NN
._.
We_FPP1
consult_VPRT
with_PIN
other_JJ
organizations_NOMZ
researchers_NN
to_TO
find_VB [PRIV]
alternative_JJ
approaches_NN
evaluation_NOMZ
from_PIN
the_DT
Association_NOMZ
for_PIN
Assessment_NOMZ
such_JJ
as_IN
the_DT
Nuffield_NN
Council_NN
on_PIN
Bioethics_NN
and_CC
to_PIN
the_DT
use_NN
of_PIN
animals_NN
._.
GSKs_NN
R&D_NN
Chairman_NN
&_CC
Accreditation_NOMZ
of_PIN
Laboratory_NN
Animal_NN
Care_NN
the_DT
Universities_NOMZ
Federation_NOMZ
for_PIN
Animal_NN
Welfare_NN
._.
presents_NN
several_QUAN
Animal_NN
Welfare_NN
Awards_NN
each_QUAN
AAALAC_NN
International_NN
,_,
which_WDT [SERE]
gives_VPRT
year_NN
to_PIN
employees_NN
who_WP [WHSUB]
have_VPRT [PEAS]
made_VBN
outstanding_JJ
accreditation_NOMZ
to_PIN
sites_NN
that_TSUB
meet_VPRT
the_DT
highest_JJ
29_CD
GSK_NN
has_VPRT
12_CD
animal_JJ
research_NN
facilities_NOMZ
in_PIN
the_DT
US_FPP1
,_,
advances_NN
in_PIN
implementing_VBG
the_DT
3_CD
Rs_NN
._.
All_QUAN
seven_CD
of_PIN
GSKs_NN
animal_JJ
28_CD
Europe_NN
and_PHC
Japan_NN
._.
Some_QUAN
research_NN
approximately_RB
European_JJ
GSK_NN
Laboratory_NN
Animal_NN
Welfare_NN
Prize_NN
laboratories_NN
in_PIN
the_DT
US_FPP1
and_PHC
UK_NN
are_VPRT [PASS]
accredited_VBN
._.
4_CD
%_NN
is_VPRT [BYPA]
conducted_VBN
by_PIN
external_JJ
contractors_NN
on_PIN
for_PIN
external_JJ
laboratories_NN
is_VPRT [PASS]
awarded_VBN
to_PIN
We_FPP1
have_VPRT [PEAS]
made_VBN
good_JJ
progress_NN
working_VBG [WZPRES]
towards_PIN
our_FPP1
behalf_NN
._.
individuals_NN
or_CC
groups_NN
who_WP [WHSUB]
have_VPRT [PEAS]
developed_VBN
new_JJ
accreditation_NOMZ
of_PIN
sites_NN
in_PIN
continental_JJ
Europe_NN
and_PHC
techniques_NN
that_TSUB
enhance_VPRT
our_FPP1
ability_NOMZ
to_TO
implement_VB
Japan_NN
and_PHC
plan_NN
to_TO
complete_VB
this_DEMO
process_NN
as_RB
soon_TIME
Over_IN
99_CD
%_NN
of_PIN
the_DT
animals_NN
we_FPP1
use_VPRT
are_VPRT
rodents_NN
._.
This_DEMO
years_NN
winner_NN
was_VBD [BEMA]
the_DT
Norwegian_JJ
as_IN
possible_JJ
._.
The_DT
remaining_VBG
1_CD
%_NN
includes_VPRT
fish_NN
,_,
amphibians_NN
,_,
Reference_NN
Centre_NN
for_PIN
Laboratory_NN
Animal_NN
Science_NN
rabbits_NN
,_,
pigs_NN
,_,
dogs_NN
,_,
cats_NN
and_PHC
primates_NN
._.
This_DEMO
approach_NN
is_VPRT
achieving_VBG
results_NN
._.
The_DT
number_NN
of_PIN
animals_NN
used_VBN [WZPAST]
by_PIN
GSK_NN
is_VPRT [BEMA]
broadly_RB
the_DT
same_JJ
as_IN
nine_CD
years_NN
ago_RB
despite_PIN
a_DT
significant_JJ
increase_NN
in_PIN
R&D_NN
activity_NOMZ
._.
ANIMALS_NN
USED_VBD
IN_PIN
RESEARCH_NN
CHANGE_NN
IN_PIN
R&D_NN
ACTIVITY_NOMZ
COMPARED_VBD
WITH_PIN
NUMBER_NN
OF_PIN
ANIMALS_NN
USED_NN
BY_PIN
GSK_NN
200_CD
Mice_NN
65_CD
%_NN
150_CD
Rats_NN
26_CD
%_NN
Guinea_NN
pigs_NN
7_CD
%_NN
100_CD
Other_JJ
rodents_NN
1_CD
%_NN
Others_NN
1_CD
%_NN
50_CD
0_CD
1994 1995 1996 1997_CD
1998 1999 2000 2001_CD
2002_CD
Year_NN
R&D_NN
activity_NOMZ
Animals_NN
used_VBN
Figures_NN
normalised_VBD
to_PIN
1994_CD
levels_NN
28_CD
Corporate_JJ
Responsibility_NOMZ
Report_NN
2003_CD
%_NN
change_NN
since_OSUB
1994_CD
Discussion_NN
with_PIN
others_NN
Engaging_VBG [WZPRES]
with_PIN
stakeholders_NN
is_VPRT [BEMA]
an_DT
important_JJ
aspect_NN
of_PIN
our_FPP1
approach_NN
to_PIN
corporate_JJ
responsibility_NOMZ
._.
We_FPP1
believe_VPRT [PRIV] [THATD]
it_PIT
is_VPRT [BEMA]
essential_PRED
to_TO
listen_VB
to_PIN
other_JJ
peoples_NN
views_NN
and_CC
to_TO
communicate_VB
our_FPP1
own_JJ
opinions_NN
externally_RB
._.
Communication_NOMZ
with_PIN
employees_NN
Employee_NN
satisfaction_NOMZ
surveys_NN
give_VPRT
us_FPP1
feedback_VB
We_FPP1
interact_VB
with_PIN
many_QUAN
different_JJ
people_NN
Internal_NN
communication_NOMZ
is_VPRT [BEMA]
particularly_RB
important_PRED
._.
on_PIN
our_FPP1
company_NN
programs_NN
and_CC
identify_VB
and_CC
groups_NN
who_WP [WHSUB]
are_VPRT [BEMA]
interested_PRED
in_PIN
our_FPP1
We_FPP1
aim_VPRT
to_TO
keep_VB
everyone_QUPR
well_RB
informed_VBN
and_CC
areas_NN
where_RB
we_FPP1
can_POMD
do_VB [PROD]
better_JJ
._.
Our_FPP1
global_JJ
survey_NN
business_NOMZ
or_CC
affected_VBN
by_PIN
our_FPP1
products_NN
and_CC
involved_VBN
in_PIN
company_NN
activities_NOMZ
,_,
and_ANDC
we_FPP1
seek_VPRT
in_PIN
2002_CD
involved_JJ
11,000_CD
managers_NN
from_PIN
around_PLACE
operations_NOMZ
:_:
employees_NN
,_,
investors_NN
,_,
doctors_NN
,_,
their_TPP3
feedback_NN
._.
We_FPP1
have_VPRT
a_DT
range_NN
of_PIN
initiatives_NN
to_PIN
the_DT
world_NN
._.
The_DT
next_JJ
management_NOMZ
survey_NN
will_PRMD
patients_NN
,_,
suppliers_NN
,_,
non-governmental_JJ
ensure_VB [SUAV] [PRIV]
that_THVC
we_FPP1
reach_VPRT
employees_NN
right_JJ
across_PLACE
the_DT
take_NN
place_NN
in_PIN
2004_CD
._.
organizations_NOMZ
NGOs_NN
,_,
multilateral_JJ
company_NN
._.
These_DEMP
include_VPRT
:_:
At_PIN
a_DT
local_JJ
level_NN
,_,
many_QUAN
sites_NN
produce_VPRT
regular_JJ
agencies_NN
,_,
governments_NOMZ
and_CC
local_JJ
newsletters_NN
for_PIN
staff_NN
,_,
often_RB
spotlighting_VBG
communities_NOMZ
._.
Much_QUAN
of_PIN
this_DEMO
discussion_NN
myGSK_NN
,_,
our_FPP1
global_JJ
intranet_NN
site_NN
,_,
with_PIN
updates_NN
environment_NOMZ
,_,
health_NN
or_CC
safety_NN
issues_NN
and_CC
takes_VPRT
place_NN
as_IN
part_NN
of_PIN
the_DT
normal_JJ
course_NN
on_PIN
company_NN
and_PHC
industry_NN
news_NN
and_CC
a_DT
Q&A_NN
programs_NN
._.
We_FPP1
also_RB
have_VPRT
meetings_GER
page_NN
where_RB
employees_NN
can_POMD
put_VB
questions_NOMZ
Confidential_NN
feedback_NN
mechanisms_NN
enable_VPRT
specifically_RB
to_TO
review_VB
corporate_JJ
directly_RB
to_PIN
the_DT
CEO_NN
._.
Up_IN
to_PIN
100_CD
questions_NOMZ
are_VPRT
employees_NN
to_TO
raise_VB
concerns_NN
._.
These_DEMP
include_VPRT
responsibility_NOMZ
issues_NN
,_,
for_CONJ
example_NULL
with_PIN
answered_VBN
each_QUAN
month_NN
._.
integrity_NOMZ
helplines_NN
in_PIN
the_DT
UK_NN
and_PHC
US_FPP1
._.
socially_RB
responsible_JJ
investors_NN
and_PHC
NGOs_NN
._.
Behind_PLACE
the_DT
News_NN
,_,
a_DT
section_NOMZ
of_PIN
the_DT
GSK_NN
In_PIN
Europe_NN
our_FPP1
Works_NN
Councils_NN
and_CC
European_JJ
intranet_NN
,_,
giving_VBG [PRESP]
the_DT
companys_NN
position_NOMZ
on_PIN
Employee_NN
Consultation_NOMZ
Forum_NN
provide_VPRT
regular_JJ
important_JJ
issues_NN
linked_VBN
to_TO
press_VB
clippings_GER
opportunities_NOMZ
for_PIN
employees_NN
and_PHC
company_NN
about_IN
GSK_NN
._.
Spirit_NN
,_,
our_FPP1
internal_JJ
magazine_NN
,_,
is_VPRT [BEMA]
available_PRED
to_PIN
employees_NN
company-wide_JJ
four_CD
times_NN
a_DT
year_NN
._.
An_DT
events_NN
program_NN
with_PIN
more_EMPH
than_PIN
100_CD
meetings_GER
in_PIN
2003_CD
._.
Events_NN
enable_VPRT
employees_NN
at_PIN
all_QUAN
levels_NN
to_TO
meet_VB
the_DT
CEO_NN
and_CC
senior_JJ
management_NOMZ
and_CC
discuss_VB
the_DT
progress_NN
of_PIN
the_DT
business_NOMZ
,_,
to_TO
raise_VB
questions_NOMZ
and_CC
to_TO
give_VB
feedback_NN
._.
Corporate_JJ
Responsibility_NOMZ
Report_NN
2003_CD
29_CD
Discussion_NN
with_PIN
external_JJ
stakeholders_NN
The_DT
way_NN
we_FPP1
interact_VPRT
with_PIN
these_DEMO
groups_NN
depends_VPRT
very_AMP
much_QUAN
on_PIN
their_TPP3
needs_NN
and_CC
the_DT
type_NN
of_PIN
work_NN
we_FPP1
are_VPRT
doing_VBG [PROD]
with_PIN
them_TPP3
._.
Here_RB
are_VPRT [BEMA]
some_QUAN
of_PIN
the_DT
ways_NN
we_FPP1
interact_VPRT
:_:
Type_NN
of_PIN
communication_NOMZ
Stakeholder_NN
Healthcare_NN
We_FPP1
meet_VPRT
regularly_RB
with_PIN
doctors_NN
and_PHC
pharmacists_NN
to_TO
tell_VB
them_TPP3
about_IN
our_FPP1
products_NN
and_CC
discuss_VB
any_QUAN
issues_NN
professionals_NN
and_PHC
concerns_NN
they_TPP3
may_POMD
have_VB
._.
We_FPP1
also_RB
conduct_VPRT
market_NN
research_NN
among_PIN
doctors_NN
and_CC
other_JJ
healthcare_NN
for_CONJ
example_NULL
,_,
doctors_NN
professionals_NN
to_TO
get_VB
feedback_NN
._.
and_ANDC
pharmacists_NN
We_FPP1
work_VPRT
with_PIN
medical_JJ
organizations_NOMZ
to_TO
develop_VB
and_PHC
sponsor_VB
continuing_VBG
medical_JJ
education_NOMZ
for_PIN
doctors_NN
and_CC
other_JJ
healthcare_NN
professionals_NN
such_JJ
as_IN
accredited_JJ
training_GER
courses_NN
in_PIN
asthma_NN
care_NN
for_PIN
nurses_NN
._.
We_FPP1
partner_NN
with_PIN
healthcare_NN
professionals_NN
to_TO
design_VB
and_PHC
conduct_VB
clinical_JJ
trials_NN
and_PHC
research_NN
projects_NN
._.
Research_NN
results_NN
,_,
including_VBG [PRESP]
those_DEMO
from_PIN
our_FPP1
clinical_JJ
trials_NN
,_,
are_VPRT [BEMA]
peer-reviewed_PRED
and_CC
published_VBN
in_PIN
medical_JJ
journals_NN
._.
Governments_NOMZ
and_CC
We_FPP1
have_VPRT
regular_JJ
dialogue_NN
with_PIN
regulators_NN
to_TO
share_VB
information_NOMZ
on_PIN
new_JJ
science_NN
and_PHC
technologies_NN
._.
regulators_NN
For_CONJ
example_NULL
,_,
we_FPP1
have_VPRT [PEAS]
supported_VBN
a_DT
genetic_JJ
research_NN
education_NOMZ
program_NN
to_TO
discuss_VB
issues_NN
raised_VBN [WZPAST]
by_PIN
genetics_NN
and_CC
its_PIT
potential_JJ
applications_NOMZ
in_PIN
healthcare_NN
._.
Our_FPP1
operations_NOMZ
liaise_VPRT
regularly_RB
with_PIN
environment_NOMZ
,_,
health_NN
and_PHC
safety_NN
authorities_NOMZ
to_TO
ensure_VB [SUAV] [PRIV] [THATD]
we_FPP1
are_VPRT
complying_VBG
fully_AMP
with_PIN
our_FPP1
legal_JJ
obligations_NOMZ
._.
Many_QUAN
of_PIN
our_FPP1
specialist_NN
environment_NOMZ
,_,
health_NN
and_PHC
safety_NN
employees_NN
also_RB
participate_VB
in_PIN
government_NOMZ
committees_NN
and_PHC
consultations_NOMZ
to_TO
help_VB
develop_VB
better_JJ
regulation_NOMZ
for_PIN
the_DT
future_NN
._.
In_PIN
2003_CD
we_FPP1
sponsored_VBD
the_DT
annual_JJ
conference_NN
of_PIN
the_DT
UK_NN
Environment_NOMZ
Agency_NN
,_,
where_RB
GSKs_NN
work_VPRT
on_PIN
green_JJ
chemistry_NN
was_VBD [PASS]
acknowledged_VBN [PUBV]
in_PIN
a_DT
presentation_NOMZ
by_PIN
Baroness_NOMZ
Young_NN
,_,
Chief_NN
Executive_NN
of_PIN
the_DT
agency_NN
._.
Investors_NN
Senior_JJ
managers_NN
present_JJ
final_JJ
year-end_NN
results_NN
to_PIN
institutional_JJ
investors_NN
and_PHC
analysts_NN
in_PIN
London_NN
and_PHC
New_NN
York_NN
._.
There_EX
are_VPRT
also_RB
teleconferences_NN
after_IN
the_DT
release_NN
of_PIN
quarterly_JJ
results_NN
._.
These_DEMO
presentations_NOMZ
can_POMD
be_VB [PASS]
accessed_VBN
via_PIN
our_FPP1
website_NN
._.
The_DT
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
takes_VPRT
place_NN
in_PIN
London_NN
._.
This_DEMP
includes_VPRT
a_DT
business_NOMZ
presentation_NOMZ
to_PIN
shareholders_NN
,_,
and_ANDC
Directors_NN
are_VPRT [BEMA]
available_PRED
to_TO
answer_VB
questions_NOMZ
._.
Senior_JJ
managers_NN
discuss_VPRT
the_DT
companys_NN
plans_NN
,_,
objectives_NN
and_PHC
governance_NN
with_PIN
institutional_JJ
shareholders_NN
._.
This_DEMP
includes_VPRT
regular_JJ
meetings_GER
and_PHC
participation_NOMZ
in_PIN
external_JJ
investor_NN
conferences_NN
._.
We_FPP1
held_VBD [PRIV]
an_DT
R&D_NN
day_NN
in_PIN
December_NN
2003_CD
to_TO
inform_VB
investors_NN
about_IN
products_NN
in_PIN
our_FPP1
development_NOMZ
pipeline_NN
._.
Our_FPP1
annual_JJ
Corporate_JJ
Responsibility_NOMZ
forum_NN
for_PIN
investors_NN
was_VBD [PASS]
held_VBN [PRIV]
in_PIN
July_NN
._.
Senior_JJ
GSK_NN
managers_NN
with_PIN
expertise_NN
in_PIN
relevant_JJ
areas_NN
met_VBD
representatives_NN
of_PIN
more_EMPH
than_PIN
30_CD
investment_NOMZ
funds_NN
and_PHC
rating_NN
agencies_NN
and_CC
responded_VBD
to_PIN
their_TPP3
questions_NOMZ
._.
We_FPP1
also_RB
meet_VPRT
regularly_RB
with_PIN
investors_NN
to_TO
discuss_VB
our_FPP1
corporate_JJ
responsibility_NOMZ
policies_NN
and_PHC
performance_NN
._.
Meetings_GER
held_VBN [PRIV] [WZPAST]
in_PIN
2003_CD
included_VBD
discussions_NN
on_PIN
all_QUAN
the_DT
key_JJ
impact_NN
areas_NN
addressed_VBD
in_PIN
this_DEMO
report_NN
._.
30_CD
Corporate_JJ
Responsibility_NOMZ
Report_NN
2003_CD
Type_NN
of_PIN
communication_NOMZ
Stakeholder_NN
Non-governmental_JJ
We_FPP1
discuss_VPRT
approaches_NN
to_PIN
the_DT
healthcare_NN
needs_NN
of_PIN
developing_VBG
countries_NN
with_PIN
NGOs_NN
such_JJ
as_IN
Mdecins_NN
Sans_NN
organizations_NOMZ
and_PHC
Frontires_NN
,_,
Freedom_NN
from_PIN
Hunger_NN
and_PHC
Oxfam_NN
._.
communities_NOMZ
We_FPP1
work_VPRT
with_PIN
NGOs_NN
,_,
patient_JJ
groups_NN
and_PHC
consumer_NN
groups_NN
,_,
for_CONJ
example_NULL
on_PIN
smoking_GER
cessation_NOMZ
,_,
asthma_NN
and_PHC
vaccination_NOMZ
campaigns_NN
._.
Through_PIN
our_FPP1
community_NOMZ
investment_NOMZ
programs_NN
we_FPP1
work_VPRT
in_PIN
partnership_NN
with_PIN
organizations_NOMZ
and_PHC
community_NOMZ
groups_NN
._.
We_FPP1
meet_VPRT
together_RB
regularly_RB
around_PLACE
the_DT
world_NN
to_TO
evaluate_VB
progress_NN
in_PIN
meeting_GER
local_JJ
community_NOMZ
needs_NN
._.
Our_FPP1
Environment_NOMZ
,_,
Health_NN
and_PHC
Safety_NN
EHS_NN
Workshop_NN
in_PIN
September_NN
2003_CD
brought_VBD
together_RB
key_JJ
NGOs_NN
,_,
trade_NN
unions_NN
and_PHC
government_NOMZ
representatives_NN
to_TO
discuss_VB
our_FPP1
environmental_JJ
performance_NN
and_CC
our_FPP1
long-term_JJ
strategy_NN
for_PIN
achieving_VBG
leadership_NN
and_PHC
excellence_NN
in_PIN
EHS_NN
._.
The_DT
key_JJ
issues_NN
highlighted_VBN [WZPAST]
by_PIN
this_DEMO
discussion_NN
will_PRMD
form_VB
part_NN
of_PIN
our_FPP1
improvement_NOMZ
program_NN
in_PIN
2004_CD
._.
We_FPP1
partner_NN
with_PIN
a_DT
number_NN
of_PIN
environmental_JJ
NGOs_NN
._.
Examples_NN
include_VPRT
sponsoring_VBG
Green_NN
Alliance_NN
in_PIN
a_DT
project_NN
to_TO
raise_VB
awareness_NOMZ
of_PIN
the_DT
links_NN
between_PIN
environment_NOMZ
and_PHC
health_NN
and_PHC
funding_GER
Earthwatch_NN
to_TO
send_VB
school_NN
teachers_NN
on_PIN
conservation_NOMZ
projects_NN
._.
We_FPP1
host_VPRT
tours_NN
of_PIN
our_FPP1
laboratories_NN
and_PHC
visit_NN
schools_NN
to_TO
help_VB
improve_VB
understanding_GER
of_PIN
scientific_JJ
research_NN
,_,
for_CONJ
example_NULL
the_DT
use_NN
of_PIN
animals_NN
._.
Many_QUAN
of_PIN
our_FPP1
operations_NOMZ
produce_VPRT
newsletters_NN
to_TO
keep_VB
local_JJ
communities_NOMZ
informed_VBN [WZPAST]
of_PIN
their_TPP3
work_NN
,_,
and_ANDC
each_QUAN
year_NN
several_QUAN
sites_NN
host_NN
open_JJ
days_NN
._.
At_PIN
many_QUAN
GSK_NN
sites_NN
,_,
employees_NN
undertake_VPRT
projects_NN
to_TO
improve_VB
the_DT
environment_NOMZ
in_PIN
their_TPP3
local_JJ
area_NN
._.
A_DT
number_NN
of_PIN
our_FPP1
operations_NOMZ
also_RB
have_VPRT
outreach_JJ
projects_NN
._.
For_CONJ
example_NULL
,_,
in_PIN
2003_CD
,_,
a_DT
Horlicks_NN
plant_NN
in_PIN
Rajahmundry_NN
,_,
India_NN
,_,
was_VBD [PASS]
recognized_VBN [PRIV]
with_PIN
the_DT
CEOs_NN
EHS_NN
Excellence_NN
Award_NN
in_PIN
Community_NOMZ
Partnership_NN
for_PIN
local_JJ
projects_NN
including_VBG [WZPRES]
the_DT
provision_NN
of_PIN
drinking_GER
water_NN
to_PIN
villages_NN
experiencing_VBG [WZPRES]
drought_NN
,_,
donation_NOMZ
of_PIN
desks_NN
and_PHC
chairs_NN
to_PIN
schools_NN
,_,
building_VBG [PRESP]
a_DT
bridge_NN
to_TO
improve_VB
access_NN
to_PIN
a_DT
school_NN
,_,
and_ANDC
organising_VBG
a_DT
fide-worming_JJ
program_NN
for_PIN
children_NN
._.
We_FPP1
collaborate_VPRT
with_PIN
academics_NN
,_,
researchers_NN
and_CC
other_JJ
pharmaceutical_JJ
companies_NN
to_PIN
research_NN
and_CC
develop_VB
Scientific_NN
community_NOMZ
new_JJ
treatments_NOMZ
and_CC
encourage_VB
the_DT
transfer_NN
of_PIN
expertise_NN
and_PHC
skills_NN
._.
We_FPP1
work_VPRT
with_PIN
education_NOMZ
authorities_NOMZ
to_TO
develop_VB
and_PHC
sponsor_VB
initiatives_NN
that_DEMO
further_RB
science_NN
education_NOMZ
in_PIN
schools_NN
,_,
for_CONJ
example_NULL
through_PIN
our_FPP1
INSPIRE_NN
program_NN
._.
We_FPP1
hold_VPRT [PRIV]
a_DT
regular_JJ
science_NN
policy_NN
conference_NN
in_PIN
the_DT
UK_NN
,_,
in_PIN
partnership_NN
with_PIN
government_NOMZ
and_CC
non_JJ
government_NOMZ
stakeholders_NN
,_,
to_TO
discuss_VB
issues_NN
of_PIN
common_JJ
interest_NN
._.
The_DT
2004_CD
meeting_GER
will_PRMD
discuss_VB
clinical_JJ
sciences_NN
in_PIN
the_DT
UK_NN
._.
We_FPP1
sponsor_VPRT
university_NOMZ
research_NN
in_PIN
environment_NOMZ
,_,
health_NN
and_PHC
safety_NN
issues_NN
,_,
including_VBG
projects_NN
in_PIN
green_JJ
chemistry_NN
,_,
eco-efficiency_NN
and_PHC
alternative_NN
technologies_NN
to_TO
reduce_VB
environmental_JJ
impacts_NN
._.
We_FPP1
regularly_RB
meet_VPRT
with_PIN
UN_NN
agencies_NN
,_,
including_VBG [PRESP]
the_DT
WHO_WP
,_,
UNAAI_NN
,_,
Unicef_NN
and_CC
the_DT
Global_NN
Fund_NN
to_TO
Fight_VB
AIDS_NN
,_,
TB_NN
and_PHC
Malaria_NN
,_,
to_TO
discuss_VB
a_DT
wide_JJ
range_NN
of_PIN
issues_NN
._.
These_DEMP
include_VPRT
addressing_VBG
the_DT
HIV_NN
AIDS_NN
epidemic_JJ
Multilateral_NN
agencies_NN
through_PIN
preferential_JJ
pricing_GER
arrangements_NOMZ
,_,
creating_VBG
public_JJ
private_JJ
partnerships_NN
for_PIN
R&D_NN
into_PIN
diseases_NN
of_PIN
the_DT
developing_VBG
world_NN
and_CC
targeting_VBG
our_FPP1
product_NN
donations_NOMZ
._.
We_FPP1
collaborate_VPRT
with_PIN
the_DT
WHO_WP
,_,
Ministries_NN
of_PIN
Health_NN
and_CC
40_CD
other_JJ
partners_NN
as_IN
part_NN
of_PIN
the_DT
Global_JJ
Alliance_NN
to_TO
Eliminate_VB
LF_NN
._.
We_FPP1
take_VPRT
part_NN
in_PIN
the_DT
annual_JJ
WHO-IFPMA_NN
round_NN
tables_NN
at_PIN
which_WDT [PIRE]
the_DT
WHO_WP
and_CC
industry_NN
discuss_VPRT
partnership_NN
opportunities_NOMZ
to_TO
improve_VB
global_JJ
health_NN
._.
Corporate_JJ
Responsibility_NOMZ
Report_NN
2003_CD
31_CD
Web_NN
references_NN
Our_FPP1
corporate_JJ
website_NN
can_POMD
be_VB [PASS]
found_VBN [PRIV]
at_PIN
www_NN
._.
com_NN
Websites_NN
cited_VBD
in_PIN
this_DEMO
report_NN
:_:
1_CD
www_NN
._.
org_RB
public_JJ
english_NN
standards_NN
norm_NN
index_NN
._.
com_NN
community_NOMZ
impact_NN
awards_NN
uk_VPRT
._.
com_NN
community_NOMZ
impact_NN
awards_NN
us_FPP1
._.
org_NN
publications_NOMZ
policy_NN
2003-11-20_CD
.871_CD
._.
pdf_NN
27_CD
www_NN
._.
org_NN
32_CD
Corporate_JJ
Responsibility_NOMZ
Report_NN
2003_CD
Internet_NN
Information_NOMZ
about_IN
the_DT
company_NN
is_VPRT [BEMA]
available_PRED
on_PIN
GlaxoSmithKlines_NN
corporate_JJ
website_NN
at_PIN
www_NN
._.
com_NN
Head_NN
Office_NN
and_PHC
Registered_NN
Office_NN
GlaxoSmithKline_NN
plc_NN
980_CD
Great_NN
West_NN
Road_NN
Brentford_NN
Middlesex_NN
TW8_NN
9GS_NN
UK_NN
Tel_NN
:_:
44_CD
0_CD
20 8047 5000_CD
You_SPP2
can_POMD
contact_VB
the_DT
company_NN
directly_RB
about_IN
corporate_JJ
responsibility_NOMZ
issues_NN
on_PIN
csr_NN
._.
com_NN
Our_FPP1
Reports_NN
ANNUAL_JJ
REVIEW_NN
Do_VPRT
more_EMPH
,_,
feel_VB [PRIV]
better_RB
,_,
live_VPRT
longer_RB
A_DT
review_NN
of_PIN
major_JJ
themes_NN
for_PIN
2003_CD
and_CC
an_DT
abridged_JJ
version_NN
of_PIN
the_DT
financial_JJ
results_NN
._.
Improving_GER
health_NN
every_QUAN
day_NN
ANNUAL_NN
REVIEW_NN
2003_CD
ANNUAL_NN
REPORT_NN
Do_VPRT
more_EMPH
,_,
feel_VB [PRIV]
better_RB
,_,
live_VPRT
longer_RB
The_DT
full_JJ
financial_JJ
statements_NOMZ
for_PIN
2003_CD
._.
Improving_GER
performance_NN
every_QUAN
day_NN
ANNUAL_NN
REPORT_NN
2003_CD
Produced_VBN
by_PIN
Corporate_NN
Communications_NOMZ
,_,
GlaxoSmithKline_NN
._.
CORPORATE_JJ
Do_VPRT
more_EMPH
,_,
feel_VB [PRIV]
better_RB
,_,
live_VPRT
longer_JJ
Design_NN
consultancy_NN
by_PIN
salterbaxter_NN
._.
RESPONSIBILITY_NOMZ
REPORT_NN
A_DT
review_NN
of_PIN
our_FPP1
Corporate_JJ
responsibility_NOMZ
consultancy_NN
by_PIN
Context_NN
._.
commitment_NOMZ
to_PIN
society_NN
and_CC
the_DT
environment_NOMZ
._.
Photograph_NN
on_PIN
page_NN
14_CD
,_,
courtesy_NN
of_PIN
Monika_NN
Graff_NN
._.
Printed_NN
in_PIN
the_DT
UK_NN
by_PIN
The_DT
Colourhouse_NN
._.
The_DT
paper_NN
used_VBN [WZPAST]
in_PIN
the_DT
production_NOMZ
of_PIN
this_DEMO
document_NOMZ
is_VPRT [PASS]
made_VBN
Making_VBG
a_DT
difference_NN
from_PIN
pulps_NN
harvested_VBN [WZPAST]
from_PIN
sustainable_JJ
forests_NN
,_,
also_RB
every_QUAN
day_NN
using_VBG [WZPRES]
sawmill_NN
residues_NN
and_PHC
forest_NN
thinnings_GER
._.
It_PIT
is_VPRT [BEMA]
CORPORATE_JJ
RESPONSIBILITY_NOMZ
REPORT_NN
2003_CD
elemental_JJ
chlorine-free_NN
._.
Making_VBG [PRESP]
a_DT
dif_NN
Improving_GER
health_NN
,_,
every_QUAN
day_NN
ference_NN
,_,
every_QUAN
day_NN
101_CD
101_CD
Product_NN
names_NN
throughout_PIN
this_DEMO
publication_NOMZ
are_VPRT [PASS]
indicated_VBN [PRIV]
in_PIN
italics_NN
and_CC
are_VPRT
trademarks_NN
of_PIN
GlaxoSmithKline_NN
plc_NN
,_,
its_PIT
subsidiaries_NN
or_CC
associated_VBN
Every_QUAN
day_NN
,_,
all_QUAN
around_PLACE
the_DT
world_NN
,_,
GlaxoSmithKline_NN
is_VPRT
companies_NN
,_,
with_PIN
the_DT
exception_NOMZ
of_PIN
Levitra_NN
,_,
a_DT
trying_VBG
to_TO
improve_VB
peoples_NN
lives_NN
and_CC
have_VPRT
a_DT
positive_JJ
trademark_NN
of_PIN
Bayer_NN
AG_NN
and_PHC
Nicoderm_NN
,_,
a_DT
trademark_NN
impact_NN
on_PIN
all_QUAN
its_PIT
stakeholders_NN
._.
This_DEMO
years_NN
reports_NN
of_PIN
Aventis_NN
SA_NN
,_,
both_DT
of_PIN
which_WDT [PIRE]
are_VPRT [PASS]
used_VBN
under_IN
licence_NN
emphasise_NN
this_DEMO
far-reaching_JJ
commitment_NOMZ
._.
